Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
Karzinomen, Rachenhinterwand, Kehlkopfentfernung, Patienten, Rachenhinterwandkarzinom, Hypopharynx, Tumorausdehnung, kehlkopferhaltendes, Patienten, Karzinomen, Rachenhinterwand, Unterarmlappen, Duenndarmtransplantat, Tumorausdehnungen, Patienten, Schluckfunktion, Ernaehrung, Patient, Patient, Aspirationen, Nahrungsaufnahme, Patienten, Laryngektomie, Komplikationen, Patienten, Rehabilitation, Rachenhinterwandkarzinome, Patienten
HNO.80460135.ger.abstr_task2
Sentence: Bei der chirurgischen Entfernung von ausgedehnten Karzinomen der hypopharyngealen Rachenhinterwand stellt sich die Frage der Kehlkopfentfernung in erster Linie aus funktionellen Gruenden . Zwischen 1994 und 1997 wurde allen Patienten mit einem Rachenhinterwandkarzinom des Hypopharynx und einer geschaetzten Tumorausdehnung von mehr als 6 cm ein kehlkopferhaltendes chirurgisches Behandlungskonzept vorgeschlagen . Bei 9 Patienten mit T2 ( n=2) und T4 ( n=7) Karzinomen erfolgte nach lateraler Pharyngotomie eine Rekonstruktion der Rachenhinterwand mit freien Lappen ( 8 Unterarmlappen und 1 Duenndarmtransplantat ) . Die maximalen Tumorausdehnungen reichten von 6,5-12,5 cm . Bei der Praeparation wurde versucht , den N. laryngeus superior zu erhalten und bei der Einnaht der freien Lappen fand die exakte Anpassung des Lappens an den Defekt besondere Beachtung . Bei 7 Patienten war innerhalb von 3 Monaten die Schluckfunktion so wiederhergestellt , dass die Ernaehrung oral erfolgen konnte . Ein Patient benoetigte hierzu 4 Monate und ein Patient war 12 Monate postoperativ aufgrund von Aspirationen weiterhin nicht zur ausreichenden oralen Nahrungsaufnahme faehig , 6 Patienten wurden bisher dekanueliert und in keinem Fall war in der Beobachtungszeit eine Laryngektomie aufgrund von Komplikationen oder auf Wunsch des Patienten erforderlich . Die funktionelle Rehabilitation nach der Entfernung ausgedehnter Rachenhinterwandkarzinome gelingt mit Hilfe von freien Lappen bei einem Grossteil der Patienten . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Bei der chirurgischen Entfernung von ausgedehnten Karzinomen der hypopharyngealen Rachenhinterwand stellt sich die Frage der Kehlkopfentfernung in erster Linie aus funktionellen Gruenden . Zwischen 1994 und 1997 wurde allen Patienten mit einem Rachenhinterwandkarzinom des Hypopharynx und einer geschaetzten Tumorausdehnung von mehr als 6 cm ein kehlkopferhaltendes chirurgisches Behandlungskonzept vorgeschlagen . Bei 9 Patienten mit T2 ( n=2) und T4 ( n=7) Karzinomen erfolgte nach lateraler Pharyngotomie eine Rekonstruktion der Rachenhinterwand mit freien Lappen ( 8 Unterarmlappen und 1 Duenndarmtransplantat ) . Die maximalen Tumorausdehnungen reichten von 6,5-12,5 cm . Bei der Praeparation wurde versucht , den N. laryngeus superior zu erhalten und bei der Einnaht der freien Lappen fand die exakte Anpassung des Lappens an den Defekt besondere Beachtung . Bei 7 Patienten war innerhalb von 3 Monaten die Schluckfunktion so wiederhergestellt , dass die Ernaehrung oral erfolgen konnte . Ein Patient benoetigte hierzu 4 Monate und ein Patient war 12 Monate postoperativ aufgrund von Aspirationen weiterhin nicht zur ausreichenden oralen Nahrungsaufnahme faehig , 6 Patienten wurden bisher dekanueliert und in keinem Fall war in der Beobachtungszeit eine Laryngektomie aufgrund von Komplikationen oder auf Wunsch des Patienten erforderlich . Die funktionelle Rehabilitation nach der Entfernung ausgedehnter Rachenhinterwandkarzinome gelingt mit Hilfe von freien Lappen bei einem Grossteil der Patienten .
[ "Bei", "der", "chirurgischen", "Entfernung", "von", "ausgedehnten", "Karzinomen", "der", "hypopharyngealen", "Rachenhinterwand", "stellt", "sich", "die", "Frage", "der", "Kehlkopfentfernung", "in", "erster", "Linie", "aus", "funktionellen", "Gruenden", ".", "Zwischen", "1994", "und", "1997", "wurde", "allen", "Patienten", "mit", "einem", "Rachenhinterwandkarzinom", "des", "Hypopharynx", "und", "einer", "geschaetzten", "Tumorausdehnung", "von", "mehr", "als", "6", "cm", "ein", "kehlkopferhaltendes", "chirurgisches", "Behandlungskonzept", "vorgeschlagen", ".", "Bei", "9", "Patienten", "mit", "T2", "(", "n=2", ")", "und", "T4", "(", "n=7", ")", "Karzinomen", "erfolgte", "nach", "lateraler", "Pharyngotomie", "eine", "Rekonstruktion", "der", "Rachenhinterwand", "mit", "freien", "Lappen", "(", "8", "Unterarmlappen", "und", "1", "Duenndarmtransplantat", ")", ".", "Die", "maximalen", "Tumorausdehnungen", "reichten", "von", "6,5", "-", "12,5", "cm", ".", "Bei", "der", "Praeparation", "wurde", "versucht", ",", "den", "N.", "laryngeus", "superior", "zu", "erhalten", "und", "bei", "der", "Einnaht", "der", "freien", "Lappen", "fand", "die", "exakte", "Anpassung", "des", "Lappens", "an", "den", "Defekt", "besondere", "Beachtung", ".", "Bei", "7", "Patienten", "war", "innerhalb", "von", "3", "Monaten", "die", "Schluckfunktion", "so", "wiederhergestellt", ",", "dass", "die", "Ernaehrung", "oral", "erfolgen", "konnte", ".", "Ein", "Patient", "benoetigte", "hierzu", "4", "Monate", "und", "ein", "Patient", "war", "12", "Monate", "postoperativ", "aufgrund", "von", "Aspirationen", "weiterhin", "nicht", "zur", "ausreichenden", "oralen", "Nahrungsaufnahme", "faehig", ",", "6", "Patienten", "wurden", "bisher", "dekanueliert", "und", "in", "keinem", "Fall", "war", "in", "der", "Beobachtungszeit", "eine", "Laryngektomie", "aufgrund", "von", "Komplikationen", "oder", "auf", "Wunsch", "des", "Patienten", "erforderlich", ".", "Die", "funktionelle", "Rehabilitation", "nach", "der", "Entfernung", "ausgedehnter", "Rachenhinterwandkarzinome", "gelingt", "mit", "Hilfe", "von", "freien", "Lappen", "bei", "einem", "Grossteil", "der", "Patienten", "." ]
[ "umlsterm" ]
titanium is an umlsterm, canula is an umlsterm, stem is an umlsterm
DerUnfallchirurg.01030956.eng.abstr_task0
Sentence: Up to now there are no facts concerning the loosening rate of the cemented titanium stem ( Trios ) . The central guiding canula and the longitudinal drilled stem shall ensure a symmetric cement mantle . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Up to now there are no facts concerning the loosening rate of the cemented titanium stem ( Trios ) . The central guiding canula and the longitudinal drilled stem shall ensure a symmetric cement mantle .
[ "Up", "to", "now", "there", "are", "no", "facts", "concerning", "the", "loosening", "rate", "of", "the", "cemented", "titanium", "stem", "(", "Trios", ")", ".", "The", "central", "guiding", "canula", "and", "the", "longitudinal", "drilled", "stem", "shall", "ensure", "a", "symmetric", "cement", "mantle", "." ]
[ "umlsterm" ]
titanium is an umlsterm, canula is an umlsterm, stem is an umlsterm
DerUnfallchirurg.01030956.eng.abstr_task1
Sentence: Up to now there are no facts concerning the loosening rate of the cemented titanium stem ( Trios ) . The central guiding canula and the longitudinal drilled stem shall ensure a symmetric cement mantle . Instructions: please typing these entity words according to sentence: titanium, canula, stem Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Up to now there are no facts concerning the loosening rate of the cemented titanium stem ( Trios ) . The central guiding canula and the longitudinal drilled stem shall ensure a symmetric cement mantle .
[ "Up", "to", "now", "there", "are", "no", "facts", "concerning", "the", "loosening", "rate", "of", "the", "cemented", "titanium", "stem", "(", "Trios", ")", ".", "The", "central", "guiding", "canula", "and", "the", "longitudinal", "drilled", "stem", "shall", "ensure", "a", "symmetric", "cement", "mantle", "." ]
[ "umlsterm" ]
titanium, canula, stem
DerUnfallchirurg.01030956.eng.abstr_task2
Sentence: Up to now there are no facts concerning the loosening rate of the cemented titanium stem ( Trios ) . The central guiding canula and the longitudinal drilled stem shall ensure a symmetric cement mantle . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]
Up to now there are no facts concerning the loosening rate of the cemented titanium stem ( Trios ) . The central guiding canula and the longitudinal drilled stem shall ensure a symmetric cement mantle .
[ "Up", "to", "now", "there", "are", "no", "facts", "concerning", "the", "loosening", "rate", "of", "the", "cemented", "titanium", "stem", "(", "Trios", ")", ".", "The", "central", "guiding", "canula", "and", "the", "longitudinal", "drilled", "stem", "shall", "ensure", "a", "symmetric", "cement", "mantle", "." ]
[ "umlsterm" ]
profilin is a Individual_protein, actin is a Individual_protein
188_task0
Sentence: Characterization of a mutant profilin with reduced actin-binding capacity: effects in vitro and in vivo. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein
[ "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Characterization of a mutant profilin with reduced actin-binding capacity: effects in vitro and in vivo.
[ "Characterization", "of", "a", "mutant", "profilin", "with", "reduced", "actin", "-", "binding", "capacity", ":", "effects", "in", "vitro", "and", "in", "vivo", "." ]
[ "Individual_protein" ]
profilin is a Individual_protein, actin is a Individual_protein
188_task1
Sentence: Characterization of a mutant profilin with reduced actin-binding capacity: effects in vitro and in vivo. Instructions: please typing these entity words according to sentence: profilin, actin Options: Individual_protein
[ "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Characterization of a mutant profilin with reduced actin-binding capacity: effects in vitro and in vivo.
[ "Characterization", "of", "a", "mutant", "profilin", "with", "reduced", "actin", "-", "binding", "capacity", ":", "effects", "in", "vitro", "and", "in", "vivo", "." ]
[ "Individual_protein" ]
profilin, actin
188_task2
Sentence: Characterization of a mutant profilin with reduced actin-binding capacity: effects in vitro and in vivo. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Characterization of a mutant profilin with reduced actin-binding capacity: effects in vitro and in vivo.
[ "Characterization", "of", "a", "mutant", "profilin", "with", "reduced", "actin", "-", "binding", "capacity", ":", "effects", "in", "vitro", "and", "in", "vivo", "." ]
[ "Individual_protein" ]
human is an umlsterm, heart is an umlsterm, ventricles is an umlsterm, arteries is an umlsterm, surgical is an umlsterm, efforts is an umlsterm, myocardium is an umlsterm, aorta is an umlsterm, aorto - coronary bypass is an umlsterm, grafts is an umlsterm, myocardium is an umlsterm, laser is an umlsterm, blood is an umlsterm, ventricle is an umlsterm, myocardium is an umlsterm, human is an umlsterm, heart is an umlsterm, hearts is an umlsterm, nutrition is an umlsterm, myocardium is an umlsterm, diffusion is an umlsterm
ZfuerKardiologie.70860149.eng.abstr_task0
Sentence: Under normal conditions the coronary system of the human heart is not hermetically isolated from the surrounding structures nor the ventricles , but is in various ways connected to the adjacent arteries and the cardiac chambers . These natural connections have been models for most surgical efforts to revascularize the myocardium . Numerous anastomoses between the aorta and the coronary branches functionally resemble aorto-coronary bypass grafts . Coronaro-ventricular anastomoses do also exist in the myocardium and therefore transmyocardial laser revascularization should allow blood to penetrate from the ventricle into the myocardium . This process should not be called " reptilization " of the human heart , as in large reptilian hearts the nutrition of an extensive amount of myocardium only by diffusion is highly unlikely . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Under normal conditions the coronary system of the human heart is not hermetically isolated from the surrounding structures nor the ventricles , but is in various ways connected to the adjacent arteries and the cardiac chambers . These natural connections have been models for most surgical efforts to revascularize the myocardium . Numerous anastomoses between the aorta and the coronary branches functionally resemble aorto-coronary bypass grafts . Coronaro-ventricular anastomoses do also exist in the myocardium and therefore transmyocardial laser revascularization should allow blood to penetrate from the ventricle into the myocardium . This process should not be called " reptilization " of the human heart , as in large reptilian hearts the nutrition of an extensive amount of myocardium only by diffusion is highly unlikely .
[ "Under", "normal", "conditions", "the", "coronary", "system", "of", "the", "human", "heart", "is", "not", "hermetically", "isolated", "from", "the", "surrounding", "structures", "nor", "the", "ventricles", ",", "but", "is", "in", "various", "ways", "connected", "to", "the", "adjacent", "arteries", "and", "the", "cardiac", "chambers", ".", "These", "natural", "connections", "have", "been", "models", "for", "most", "surgical", "efforts", "to", "revascularize", "the", "myocardium", ".", "Numerous", "anastomoses", "between", "the", "aorta", "and", "the", "coronary", "branches", "functionally", "resemble", "aorto", "-", "coronary", "bypass", "grafts", ".", "Coronaro", "-", "ventricular", "anastomoses", "do", "also", "exist", "in", "the", "myocardium", "and", "therefore", "transmyocardial", "laser", "revascularization", "should", "allow", "blood", "to", "penetrate", "from", "the", "ventricle", "into", "the", "myocardium", ".", "This", "process", "should", "not", "be", "called", "\"", "reptilization", "\"", "of", "the", "human", "heart", ",", "as", "in", "large", "reptilian", "hearts", "the", "nutrition", "of", "an", "extensive", "amount", "of", "myocardium", "only", "by", "diffusion", "is", "highly", "unlikely", "." ]
[ "umlsterm" ]
human is an umlsterm, heart is an umlsterm, ventricles is an umlsterm, arteries is an umlsterm, surgical is an umlsterm, efforts is an umlsterm, myocardium is an umlsterm, aorta is an umlsterm, aorto - coronary bypass is an umlsterm, grafts is an umlsterm, myocardium is an umlsterm, laser is an umlsterm, blood is an umlsterm, ventricle is an umlsterm, myocardium is an umlsterm, human is an umlsterm, heart is an umlsterm, hearts is an umlsterm, nutrition is an umlsterm, myocardium is an umlsterm, diffusion is an umlsterm
ZfuerKardiologie.70860149.eng.abstr_task1
Sentence: Under normal conditions the coronary system of the human heart is not hermetically isolated from the surrounding structures nor the ventricles , but is in various ways connected to the adjacent arteries and the cardiac chambers . These natural connections have been models for most surgical efforts to revascularize the myocardium . Numerous anastomoses between the aorta and the coronary branches functionally resemble aorto-coronary bypass grafts . Coronaro-ventricular anastomoses do also exist in the myocardium and therefore transmyocardial laser revascularization should allow blood to penetrate from the ventricle into the myocardium . This process should not be called " reptilization " of the human heart , as in large reptilian hearts the nutrition of an extensive amount of myocardium only by diffusion is highly unlikely . Instructions: please typing these entity words according to sentence: human, heart, ventricles, arteries, surgical, efforts, myocardium, aorta, aorto - coronary bypass, grafts, myocardium, laser, blood, ventricle, myocardium, human, heart, hearts, nutrition, myocardium, diffusion Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Under normal conditions the coronary system of the human heart is not hermetically isolated from the surrounding structures nor the ventricles , but is in various ways connected to the adjacent arteries and the cardiac chambers . These natural connections have been models for most surgical efforts to revascularize the myocardium . Numerous anastomoses between the aorta and the coronary branches functionally resemble aorto-coronary bypass grafts . Coronaro-ventricular anastomoses do also exist in the myocardium and therefore transmyocardial laser revascularization should allow blood to penetrate from the ventricle into the myocardium . This process should not be called " reptilization " of the human heart , as in large reptilian hearts the nutrition of an extensive amount of myocardium only by diffusion is highly unlikely .
[ "Under", "normal", "conditions", "the", "coronary", "system", "of", "the", "human", "heart", "is", "not", "hermetically", "isolated", "from", "the", "surrounding", "structures", "nor", "the", "ventricles", ",", "but", "is", "in", "various", "ways", "connected", "to", "the", "adjacent", "arteries", "and", "the", "cardiac", "chambers", ".", "These", "natural", "connections", "have", "been", "models", "for", "most", "surgical", "efforts", "to", "revascularize", "the", "myocardium", ".", "Numerous", "anastomoses", "between", "the", "aorta", "and", "the", "coronary", "branches", "functionally", "resemble", "aorto", "-", "coronary", "bypass", "grafts", ".", "Coronaro", "-", "ventricular", "anastomoses", "do", "also", "exist", "in", "the", "myocardium", "and", "therefore", "transmyocardial", "laser", "revascularization", "should", "allow", "blood", "to", "penetrate", "from", "the", "ventricle", "into", "the", "myocardium", ".", "This", "process", "should", "not", "be", "called", "\"", "reptilization", "\"", "of", "the", "human", "heart", ",", "as", "in", "large", "reptilian", "hearts", "the", "nutrition", "of", "an", "extensive", "amount", "of", "myocardium", "only", "by", "diffusion", "is", "highly", "unlikely", "." ]
[ "umlsterm" ]
human, heart, ventricles, arteries, surgical, efforts, myocardium, aorta, aorto - coronary bypass, grafts, myocardium, laser, blood, ventricle, myocardium, human, heart, hearts, nutrition, myocardium, diffusion
ZfuerKardiologie.70860149.eng.abstr_task2
Sentence: Under normal conditions the coronary system of the human heart is not hermetically isolated from the surrounding structures nor the ventricles , but is in various ways connected to the adjacent arteries and the cardiac chambers . These natural connections have been models for most surgical efforts to revascularize the myocardium . Numerous anastomoses between the aorta and the coronary branches functionally resemble aorto-coronary bypass grafts . Coronaro-ventricular anastomoses do also exist in the myocardium and therefore transmyocardial laser revascularization should allow blood to penetrate from the ventricle into the myocardium . This process should not be called " reptilization " of the human heart , as in large reptilian hearts the nutrition of an extensive amount of myocardium only by diffusion is highly unlikely . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Under normal conditions the coronary system of the human heart is not hermetically isolated from the surrounding structures nor the ventricles , but is in various ways connected to the adjacent arteries and the cardiac chambers . These natural connections have been models for most surgical efforts to revascularize the myocardium . Numerous anastomoses between the aorta and the coronary branches functionally resemble aorto-coronary bypass grafts . Coronaro-ventricular anastomoses do also exist in the myocardium and therefore transmyocardial laser revascularization should allow blood to penetrate from the ventricle into the myocardium . This process should not be called " reptilization " of the human heart , as in large reptilian hearts the nutrition of an extensive amount of myocardium only by diffusion is highly unlikely .
[ "Under", "normal", "conditions", "the", "coronary", "system", "of", "the", "human", "heart", "is", "not", "hermetically", "isolated", "from", "the", "surrounding", "structures", "nor", "the", "ventricles", ",", "but", "is", "in", "various", "ways", "connected", "to", "the", "adjacent", "arteries", "and", "the", "cardiac", "chambers", ".", "These", "natural", "connections", "have", "been", "models", "for", "most", "surgical", "efforts", "to", "revascularize", "the", "myocardium", ".", "Numerous", "anastomoses", "between", "the", "aorta", "and", "the", "coronary", "branches", "functionally", "resemble", "aorto", "-", "coronary", "bypass", "grafts", ".", "Coronaro", "-", "ventricular", "anastomoses", "do", "also", "exist", "in", "the", "myocardium", "and", "therefore", "transmyocardial", "laser", "revascularization", "should", "allow", "blood", "to", "penetrate", "from", "the", "ventricle", "into", "the", "myocardium", ".", "This", "process", "should", "not", "be", "called", "\"", "reptilization", "\"", "of", "the", "human", "heart", ",", "as", "in", "large", "reptilian", "hearts", "the", "nutrition", "of", "an", "extensive", "amount", "of", "myocardium", "only", "by", "diffusion", "is", "highly", "unlikely", "." ]
[ "umlsterm" ]
autologous fibroblasts is a Intervention_Pharmacological, placebo - controlled is a Intervention_Control, autologous fibroblasts ( human dermal ) injections is a Intervention_Pharmacological, wrinkle and acne scar appearance is a Outcome_Physical, vehicle control is a Intervention_Control, acne scarring is a Outcome_Physical, 2 mL of autologous fibroblast suspension is a Intervention_Pharmacological, Autologous fibroblast treatment is a Intervention_Pharmacological, Autologous fibroblast injections is a Intervention_Pharmacological, appearance of depressed distensible acne scars is a Outcome_Physical
59026_task0
Sentence: Successful treatment of depressed , distensible acne scars using autologous fibroblasts : a multi-site , prospective , double blind , placebo-controlled clinical trial . BACKGROUND A previous clinical trial evaluating autologous fibroblasts ( human dermal ) injections for the treatment of facial contour deformities found significantly greater improvements in wrinkle and acne scar appearance than with placebo treatment . OBJECTIVE To compare the efficacy and safety of autologous fibroblast treatment of moderate to severe , depressed , distensible facial acne scars with that of vehicle control . METHODS This was a randomized multicenter , double-blind , placebo-controlled trial in subjects with bilateral moderate to severe acne scarring ; subjects served as their own controls . Skin biopsies were obtained from randomized subjects for fibroblast production . Subjects ( n = 99 ) underwent three intradermal injection sessions with 2 mL of autologous fibroblast suspension ( 10-20 million cells/mL ) on one cheek and vehicle control ( cell culture medium ) on the other at 14-day intervals . Efficacy was based on the blinded subject 's , evaluator 's , and independent photographic viewer 's ( IPR ) assessment of acne scarring 1 to 4 months after the last treatment . RESULTS Autologous fibroblast treatment was associated with significantly greater treatment success than vehicle control for the subject ( 43 % vs.18 % ) , evaluator ( 59 % vs. 2 % ) , and IPR assessments . Autologous fibroblast injections were well tolerated , without permanent adverse effects . CONCLUSIONS Autologous fibroblast injections safely and effectively improved the appearance of depressed distensible acne scars . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Intervention_Control
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O" ]
Successful treatment of depressed , distensible acne scars using autologous fibroblasts : a multi-site , prospective , double blind , placebo-controlled clinical trial . BACKGROUND A previous clinical trial evaluating autologous fibroblasts ( human dermal ) injections for the treatment of facial contour deformities found significantly greater improvements in wrinkle and acne scar appearance than with placebo treatment . OBJECTIVE To compare the efficacy and safety of autologous fibroblast treatment of moderate to severe , depressed , distensible facial acne scars with that of vehicle control . METHODS This was a randomized multicenter , double-blind , placebo-controlled trial in subjects with bilateral moderate to severe acne scarring ; subjects served as their own controls . Skin biopsies were obtained from randomized subjects for fibroblast production . Subjects ( n = 99 ) underwent three intradermal injection sessions with 2 mL of autologous fibroblast suspension ( 10-20 million cells/mL ) on one cheek and vehicle control ( cell culture medium ) on the other at 14-day intervals . Efficacy was based on the blinded subject 's , evaluator 's , and independent photographic viewer 's ( IPR ) assessment of acne scarring 1 to 4 months after the last treatment . RESULTS Autologous fibroblast treatment was associated with significantly greater treatment success than vehicle control for the subject ( 43 % vs.18 % ) , evaluator ( 59 % vs. 2 % ) , and IPR assessments . Autologous fibroblast injections were well tolerated , without permanent adverse effects . CONCLUSIONS Autologous fibroblast injections safely and effectively improved the appearance of depressed distensible acne scars .
[ "Successful", "treatment", "of", "depressed", ",", "distensible", "acne", "scars", "using", "autologous", "fibroblasts", ":", "a", "multi", "-", "site", ",", "prospective", ",", "double", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "A", "previous", "clinical", "trial", "evaluating", "autologous", "fibroblasts", "(", "human", "dermal", ")", "injections", "for", "the", "treatment", "of", "facial", "contour", "deformities", "found", "significantly", "greater", "improvements", "in", "wrinkle", "and", "acne", "scar", "appearance", "than", "with", "placebo", "treatment", ".", "OBJECTIVE", "To", "compare", "the", "efficacy", "and", "safety", "of", "autologous", "fibroblast", "treatment", "of", "moderate", "to", "severe", ",", "depressed", ",", "distensible", "facial", "acne", "scars", "with", "that", "of", "vehicle", "control", ".", "METHODS", "This", "was", "a", "randomized", "multicenter", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "in", "subjects", "with", "bilateral", "moderate", "to", "severe", "acne", "scarring", ";", "subjects", "served", "as", "their", "own", "controls", ".", "Skin", "biopsies", "were", "obtained", "from", "randomized", "subjects", "for", "fibroblast", "production", ".", "Subjects", "(", "n", "=", "99", ")", "underwent", "three", "intradermal", "injection", "sessions", "with", "2", "mL", "of", "autologous", "fibroblast", "suspension", "(", "10", "-", "20", "million", "cells", "/", "mL", ")", "on", "one", "cheek", "and", "vehicle", "control", "(", "cell", "culture", "medium", ")", "on", "the", "other", "at", "14-day", "intervals", ".", "Efficacy", "was", "based", "on", "the", "blinded", "subject", "'", "s", ",", "evaluator", "'", "s", ",", "and", "independent", "photographic", "viewer", "'", "s", "(", "IPR", ")", "assessment", "of", "acne", "scarring", "1", "to", "4", "months", "after", "the", "last", "treatment", ".", "RESULTS", "Autologous", "fibroblast", "treatment", "was", "associated", "with", "significantly", "greater", "treatment", "success", "than", "vehicle", "control", "for", "the", "subject", "(", "43", "%", "vs.18", "%", ")", ",", "evaluator", "(", "59", "%", "vs", ".", "2", "%", ")", ",", "and", "IPR", "assessments", ".", "Autologous", "fibroblast", "injections", "were", "well", "tolerated", ",", "without", "permanent", "adverse", "effects", ".", "CONCLUSIONS", "Autologous", "fibroblast", "injections", "safely", "and", "effectively", "improved", "the", "appearance", "of", "depressed", "distensible", "acne", "scars", "." ]
[ "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control" ]
autologous fibroblasts is a Intervention_Pharmacological, placebo - controlled is a Intervention_Control, autologous fibroblasts ( human dermal ) injections is a Intervention_Pharmacological, wrinkle and acne scar appearance is a Outcome_Physical, vehicle control is a Intervention_Control, acne scarring is a Outcome_Physical, 2 mL of autologous fibroblast suspension is a Intervention_Pharmacological, Autologous fibroblast treatment is a Intervention_Pharmacological, Autologous fibroblast injections is a Intervention_Pharmacological, appearance of depressed distensible acne scars is a Outcome_Physical
59026_task1
Sentence: Successful treatment of depressed , distensible acne scars using autologous fibroblasts : a multi-site , prospective , double blind , placebo-controlled clinical trial . BACKGROUND A previous clinical trial evaluating autologous fibroblasts ( human dermal ) injections for the treatment of facial contour deformities found significantly greater improvements in wrinkle and acne scar appearance than with placebo treatment . OBJECTIVE To compare the efficacy and safety of autologous fibroblast treatment of moderate to severe , depressed , distensible facial acne scars with that of vehicle control . METHODS This was a randomized multicenter , double-blind , placebo-controlled trial in subjects with bilateral moderate to severe acne scarring ; subjects served as their own controls . Skin biopsies were obtained from randomized subjects for fibroblast production . Subjects ( n = 99 ) underwent three intradermal injection sessions with 2 mL of autologous fibroblast suspension ( 10-20 million cells/mL ) on one cheek and vehicle control ( cell culture medium ) on the other at 14-day intervals . Efficacy was based on the blinded subject 's , evaluator 's , and independent photographic viewer 's ( IPR ) assessment of acne scarring 1 to 4 months after the last treatment . RESULTS Autologous fibroblast treatment was associated with significantly greater treatment success than vehicle control for the subject ( 43 % vs.18 % ) , evaluator ( 59 % vs. 2 % ) , and IPR assessments . Autologous fibroblast injections were well tolerated , without permanent adverse effects . CONCLUSIONS Autologous fibroblast injections safely and effectively improved the appearance of depressed distensible acne scars . Instructions: please typing these entity words according to sentence: autologous fibroblasts, placebo - controlled, autologous fibroblasts ( human dermal ) injections, wrinkle and acne scar appearance, vehicle control, acne scarring, 2 mL of autologous fibroblast suspension, Autologous fibroblast treatment, Autologous fibroblast injections, appearance of depressed distensible acne scars Options: Intervention_Pharmacological, Outcome_Physical, Intervention_Control
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O" ]
Successful treatment of depressed , distensible acne scars using autologous fibroblasts : a multi-site , prospective , double blind , placebo-controlled clinical trial . BACKGROUND A previous clinical trial evaluating autologous fibroblasts ( human dermal ) injections for the treatment of facial contour deformities found significantly greater improvements in wrinkle and acne scar appearance than with placebo treatment . OBJECTIVE To compare the efficacy and safety of autologous fibroblast treatment of moderate to severe , depressed , distensible facial acne scars with that of vehicle control . METHODS This was a randomized multicenter , double-blind , placebo-controlled trial in subjects with bilateral moderate to severe acne scarring ; subjects served as their own controls . Skin biopsies were obtained from randomized subjects for fibroblast production . Subjects ( n = 99 ) underwent three intradermal injection sessions with 2 mL of autologous fibroblast suspension ( 10-20 million cells/mL ) on one cheek and vehicle control ( cell culture medium ) on the other at 14-day intervals . Efficacy was based on the blinded subject 's , evaluator 's , and independent photographic viewer 's ( IPR ) assessment of acne scarring 1 to 4 months after the last treatment . RESULTS Autologous fibroblast treatment was associated with significantly greater treatment success than vehicle control for the subject ( 43 % vs.18 % ) , evaluator ( 59 % vs. 2 % ) , and IPR assessments . Autologous fibroblast injections were well tolerated , without permanent adverse effects . CONCLUSIONS Autologous fibroblast injections safely and effectively improved the appearance of depressed distensible acne scars .
[ "Successful", "treatment", "of", "depressed", ",", "distensible", "acne", "scars", "using", "autologous", "fibroblasts", ":", "a", "multi", "-", "site", ",", "prospective", ",", "double", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "A", "previous", "clinical", "trial", "evaluating", "autologous", "fibroblasts", "(", "human", "dermal", ")", "injections", "for", "the", "treatment", "of", "facial", "contour", "deformities", "found", "significantly", "greater", "improvements", "in", "wrinkle", "and", "acne", "scar", "appearance", "than", "with", "placebo", "treatment", ".", "OBJECTIVE", "To", "compare", "the", "efficacy", "and", "safety", "of", "autologous", "fibroblast", "treatment", "of", "moderate", "to", "severe", ",", "depressed", ",", "distensible", "facial", "acne", "scars", "with", "that", "of", "vehicle", "control", ".", "METHODS", "This", "was", "a", "randomized", "multicenter", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "in", "subjects", "with", "bilateral", "moderate", "to", "severe", "acne", "scarring", ";", "subjects", "served", "as", "their", "own", "controls", ".", "Skin", "biopsies", "were", "obtained", "from", "randomized", "subjects", "for", "fibroblast", "production", ".", "Subjects", "(", "n", "=", "99", ")", "underwent", "three", "intradermal", "injection", "sessions", "with", "2", "mL", "of", "autologous", "fibroblast", "suspension", "(", "10", "-", "20", "million", "cells", "/", "mL", ")", "on", "one", "cheek", "and", "vehicle", "control", "(", "cell", "culture", "medium", ")", "on", "the", "other", "at", "14-day", "intervals", ".", "Efficacy", "was", "based", "on", "the", "blinded", "subject", "'", "s", ",", "evaluator", "'", "s", ",", "and", "independent", "photographic", "viewer", "'", "s", "(", "IPR", ")", "assessment", "of", "acne", "scarring", "1", "to", "4", "months", "after", "the", "last", "treatment", ".", "RESULTS", "Autologous", "fibroblast", "treatment", "was", "associated", "with", "significantly", "greater", "treatment", "success", "than", "vehicle", "control", "for", "the", "subject", "(", "43", "%", "vs.18", "%", ")", ",", "evaluator", "(", "59", "%", "vs", ".", "2", "%", ")", ",", "and", "IPR", "assessments", ".", "Autologous", "fibroblast", "injections", "were", "well", "tolerated", ",", "without", "permanent", "adverse", "effects", ".", "CONCLUSIONS", "Autologous", "fibroblast", "injections", "safely", "and", "effectively", "improved", "the", "appearance", "of", "depressed", "distensible", "acne", "scars", "." ]
[ "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control" ]
autologous fibroblasts, placebo - controlled, autologous fibroblasts ( human dermal ) injections, wrinkle and acne scar appearance, vehicle control, acne scarring, 2 mL of autologous fibroblast suspension, Autologous fibroblast treatment, Autologous fibroblast injections, appearance of depressed distensible acne scars
59026_task2
Sentence: Successful treatment of depressed , distensible acne scars using autologous fibroblasts : a multi-site , prospective , double blind , placebo-controlled clinical trial . BACKGROUND A previous clinical trial evaluating autologous fibroblasts ( human dermal ) injections for the treatment of facial contour deformities found significantly greater improvements in wrinkle and acne scar appearance than with placebo treatment . OBJECTIVE To compare the efficacy and safety of autologous fibroblast treatment of moderate to severe , depressed , distensible facial acne scars with that of vehicle control . METHODS This was a randomized multicenter , double-blind , placebo-controlled trial in subjects with bilateral moderate to severe acne scarring ; subjects served as their own controls . Skin biopsies were obtained from randomized subjects for fibroblast production . Subjects ( n = 99 ) underwent three intradermal injection sessions with 2 mL of autologous fibroblast suspension ( 10-20 million cells/mL ) on one cheek and vehicle control ( cell culture medium ) on the other at 14-day intervals . Efficacy was based on the blinded subject 's , evaluator 's , and independent photographic viewer 's ( IPR ) assessment of acne scarring 1 to 4 months after the last treatment . RESULTS Autologous fibroblast treatment was associated with significantly greater treatment success than vehicle control for the subject ( 43 % vs.18 % ) , evaluator ( 59 % vs. 2 % ) , and IPR assessments . Autologous fibroblast injections were well tolerated , without permanent adverse effects . CONCLUSIONS Autologous fibroblast injections safely and effectively improved the appearance of depressed distensible acne scars . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O" ]
Successful treatment of depressed , distensible acne scars using autologous fibroblasts : a multi-site , prospective , double blind , placebo-controlled clinical trial . BACKGROUND A previous clinical trial evaluating autologous fibroblasts ( human dermal ) injections for the treatment of facial contour deformities found significantly greater improvements in wrinkle and acne scar appearance than with placebo treatment . OBJECTIVE To compare the efficacy and safety of autologous fibroblast treatment of moderate to severe , depressed , distensible facial acne scars with that of vehicle control . METHODS This was a randomized multicenter , double-blind , placebo-controlled trial in subjects with bilateral moderate to severe acne scarring ; subjects served as their own controls . Skin biopsies were obtained from randomized subjects for fibroblast production . Subjects ( n = 99 ) underwent three intradermal injection sessions with 2 mL of autologous fibroblast suspension ( 10-20 million cells/mL ) on one cheek and vehicle control ( cell culture medium ) on the other at 14-day intervals . Efficacy was based on the blinded subject 's , evaluator 's , and independent photographic viewer 's ( IPR ) assessment of acne scarring 1 to 4 months after the last treatment . RESULTS Autologous fibroblast treatment was associated with significantly greater treatment success than vehicle control for the subject ( 43 % vs.18 % ) , evaluator ( 59 % vs. 2 % ) , and IPR assessments . Autologous fibroblast injections were well tolerated , without permanent adverse effects . CONCLUSIONS Autologous fibroblast injections safely and effectively improved the appearance of depressed distensible acne scars .
[ "Successful", "treatment", "of", "depressed", ",", "distensible", "acne", "scars", "using", "autologous", "fibroblasts", ":", "a", "multi", "-", "site", ",", "prospective", ",", "double", "blind", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "A", "previous", "clinical", "trial", "evaluating", "autologous", "fibroblasts", "(", "human", "dermal", ")", "injections", "for", "the", "treatment", "of", "facial", "contour", "deformities", "found", "significantly", "greater", "improvements", "in", "wrinkle", "and", "acne", "scar", "appearance", "than", "with", "placebo", "treatment", ".", "OBJECTIVE", "To", "compare", "the", "efficacy", "and", "safety", "of", "autologous", "fibroblast", "treatment", "of", "moderate", "to", "severe", ",", "depressed", ",", "distensible", "facial", "acne", "scars", "with", "that", "of", "vehicle", "control", ".", "METHODS", "This", "was", "a", "randomized", "multicenter", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "in", "subjects", "with", "bilateral", "moderate", "to", "severe", "acne", "scarring", ";", "subjects", "served", "as", "their", "own", "controls", ".", "Skin", "biopsies", "were", "obtained", "from", "randomized", "subjects", "for", "fibroblast", "production", ".", "Subjects", "(", "n", "=", "99", ")", "underwent", "three", "intradermal", "injection", "sessions", "with", "2", "mL", "of", "autologous", "fibroblast", "suspension", "(", "10", "-", "20", "million", "cells", "/", "mL", ")", "on", "one", "cheek", "and", "vehicle", "control", "(", "cell", "culture", "medium", ")", "on", "the", "other", "at", "14-day", "intervals", ".", "Efficacy", "was", "based", "on", "the", "blinded", "subject", "'", "s", ",", "evaluator", "'", "s", ",", "and", "independent", "photographic", "viewer", "'", "s", "(", "IPR", ")", "assessment", "of", "acne", "scarring", "1", "to", "4", "months", "after", "the", "last", "treatment", ".", "RESULTS", "Autologous", "fibroblast", "treatment", "was", "associated", "with", "significantly", "greater", "treatment", "success", "than", "vehicle", "control", "for", "the", "subject", "(", "43", "%", "vs.18", "%", ")", ",", "evaluator", "(", "59", "%", "vs", ".", "2", "%", ")", ",", "and", "IPR", "assessments", ".", "Autologous", "fibroblast", "injections", "were", "well", "tolerated", ",", "without", "permanent", "adverse", "effects", ".", "CONCLUSIONS", "Autologous", "fibroblast", "injections", "safely", "and", "effectively", "improved", "the", "appearance", "of", "depressed", "distensible", "acne", "scars", "." ]
[ "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control" ]
Oxytocin receptor is a GENE-Y, carbetocin is a CHEMICAL
9760035_task0
Sentence: Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation.
[ "Oxytocin", "receptor", "binding", "and", "uterotonic", "activity", "of", "carbetocin", "and", "its", "metabolites", "following", "enzymatic", "degradation", "." ]
[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Oxytocin receptor is a GENE-Y, carbetocin is a CHEMICAL
9760035_task1
Sentence: Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Instructions: please typing these entity words according to sentence: Oxytocin receptor, carbetocin Options: GENE-Y, CHEMICAL
[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation.
[ "Oxytocin", "receptor", "binding", "and", "uterotonic", "activity", "of", "carbetocin", "and", "its", "metabolites", "following", "enzymatic", "degradation", "." ]
[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Oxytocin receptor, carbetocin
9760035_task2
Sentence: Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]
Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation.
[ "Oxytocin", "receptor", "binding", "and", "uterotonic", "activity", "of", "carbetocin", "and", "its", "metabolites", "following", "enzymatic", "degradation", "." ]
[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Niederlande is an umlsterm, westlichen Welt is an umlsterm, Produktivitaet is an umlsterm, Arbeit is an umlsterm, Methode is an umlsterm, Schweiz is an umlsterm, Methodik is an umlsterm, Deutschland is an umlsterm, Italien is an umlsterm, Frankreich is an umlsterm, Spanien is an umlsterm, Zeitschriften is an umlsterm, Gewohnheit is an umlsterm, Literatur is an umlsterm, Produktivitaet is an umlsterm, Chirurgengesellschaft is an umlsterm, Chirurgengesellschaft is an umlsterm, Niederlande is an umlsterm, Forschung is an umlsterm, Publikationen is an umlsterm, Klima is an umlsterm, Niederlanden is an umlsterm, Organisation is an umlsterm
DerChirurg.00710676.ger.abstr_task0
Sentence: Zusammenfassung . Die Schlussfolgerung der hier gezeigten Daten koennte sein , dass die Niederlande eine grosse Anzahl guter chirurgischer Studien publiziert und damit in der Spitze der westlichen Welt rangiert . Es ist auffallend , dass die hoechste Produktivitaet in kleinen Laendern und in Laendern mit niedriger Einwohnerzahl gefunden wurde . Die meisten grossen europaeischen Laender haben einen geringen wissenschaftlichen " output " nach der in der hier vorliegenden Arbeit benutzten Methode . Die skandinavischen Laender , Holland und die Schweiz haben den besten wissenschaftlichen Index nach der hier benutzten Methodik . Es koennte sein , dass die grossen europaeischen Laender wie Deutschland , Italien , Frankreich und Spanien dazu tendieren , in lokalen Zeitschriften zu publizieren . In manchen Laendern oder Landesteilen gehoert es vielleicht auch nicht zur Gewohnheit , Daten in der englischsprachigen Literatur zu publizieren , was sicherlich den wissenschafltichen Index dieses Landes negativ beeinflusst . Die hohe Produktivitaet hollaendischer Chirurgen koennte dadurch erklaert werden , dass die 700 Chirurgen in einem kleinen Land mit einer relativ grossen Anzahl an Einwohnern gut organisiert sind . Die hollaendischen Chirurgen sind in einer nationalen Chirurgengesellschaft organisiert , in welcher fast jeder Chirurg aktives Mitglied ist . Alle sprechen und schreiben Englisch sehr gut . Die von der nationalen Chirurgengesellschaft organisierten Aktivitaeten sind sehr gut besucht und beinhalten 2 mal im Jahr wissenschaftliche Treffen , bei dem Assistenten und Chirurgen fuer einen oder 2 Tage zusammenkommen . Zusaetzlich werden in allen Ausbildungs- und nicht Ausbildungskliniken Qualitaetskontrollen durchgefuehrt . Durch all diese Massnahmen kennen sich die Chirurgen in diesem relativ kleinen Land untereinander sehr gut , welches die Kooperation bei der Durchfuehrung von Studien foerdert . Die Groesse der Niederlande ist gerade ausreichend , um relevante klinische Studien durchzufuehren und es mag sein , dass wir relativ viele solcher Studien kreieren . Holland ist ein demokratisches Land , welches dem Chirurgen und Forscher die freie Gelegenheit bietet Forschung und Publikationen , nach eigenem Gusto durchzufuehren ohne von hierachischen Strukturen behindert zu werden . Alle diese Faktoren zusammen schaffen ein wissenschaftliches Klima in den Niederlanden , das zur Organisation von Multizenter-Studien und klinischen Studien anregt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Die Schlussfolgerung der hier gezeigten Daten koennte sein , dass die Niederlande eine grosse Anzahl guter chirurgischer Studien publiziert und damit in der Spitze der westlichen Welt rangiert . Es ist auffallend , dass die hoechste Produktivitaet in kleinen Laendern und in Laendern mit niedriger Einwohnerzahl gefunden wurde . Die meisten grossen europaeischen Laender haben einen geringen wissenschaftlichen " output " nach der in der hier vorliegenden Arbeit benutzten Methode . Die skandinavischen Laender , Holland und die Schweiz haben den besten wissenschaftlichen Index nach der hier benutzten Methodik . Es koennte sein , dass die grossen europaeischen Laender wie Deutschland , Italien , Frankreich und Spanien dazu tendieren , in lokalen Zeitschriften zu publizieren . In manchen Laendern oder Landesteilen gehoert es vielleicht auch nicht zur Gewohnheit , Daten in der englischsprachigen Literatur zu publizieren , was sicherlich den wissenschafltichen Index dieses Landes negativ beeinflusst . Die hohe Produktivitaet hollaendischer Chirurgen koennte dadurch erklaert werden , dass die 700 Chirurgen in einem kleinen Land mit einer relativ grossen Anzahl an Einwohnern gut organisiert sind . Die hollaendischen Chirurgen sind in einer nationalen Chirurgengesellschaft organisiert , in welcher fast jeder Chirurg aktives Mitglied ist . Alle sprechen und schreiben Englisch sehr gut . Die von der nationalen Chirurgengesellschaft organisierten Aktivitaeten sind sehr gut besucht und beinhalten 2 mal im Jahr wissenschaftliche Treffen , bei dem Assistenten und Chirurgen fuer einen oder 2 Tage zusammenkommen . Zusaetzlich werden in allen Ausbildungs- und nicht Ausbildungskliniken Qualitaetskontrollen durchgefuehrt . Durch all diese Massnahmen kennen sich die Chirurgen in diesem relativ kleinen Land untereinander sehr gut , welches die Kooperation bei der Durchfuehrung von Studien foerdert . Die Groesse der Niederlande ist gerade ausreichend , um relevante klinische Studien durchzufuehren und es mag sein , dass wir relativ viele solcher Studien kreieren . Holland ist ein demokratisches Land , welches dem Chirurgen und Forscher die freie Gelegenheit bietet Forschung und Publikationen , nach eigenem Gusto durchzufuehren ohne von hierachischen Strukturen behindert zu werden . Alle diese Faktoren zusammen schaffen ein wissenschaftliches Klima in den Niederlanden , das zur Organisation von Multizenter-Studien und klinischen Studien anregt .
[ "Zusammenfassung", ".", "Die", "Schlussfolgerung", "der", "hier", "gezeigten", "Daten", "koennte", "sein", ",", "dass", "die", "Niederlande", "eine", "grosse", "Anzahl", "guter", "chirurgischer", "Studien", "publiziert", "und", "damit", "in", "der", "Spitze", "der", "westlichen", "Welt", "rangiert", ".", "Es", "ist", "auffallend", ",", "dass", "die", "hoechste", "Produktivitaet", "in", "kleinen", "Laendern", "und", "in", "Laendern", "mit", "niedriger", "Einwohnerzahl", "gefunden", "wurde", ".", "Die", "meisten", "grossen", "europaeischen", "Laender", "haben", "einen", "geringen", "wissenschaftlichen", "\"", "output", "\"", "nach", "der", "in", "der", "hier", "vorliegenden", "Arbeit", "benutzten", "Methode", ".", "Die", "skandinavischen", "Laender", ",", "Holland", "und", "die", "Schweiz", "haben", "den", "besten", "wissenschaftlichen", "Index", "nach", "der", "hier", "benutzten", "Methodik", ".", "Es", "koennte", "sein", ",", "dass", "die", "grossen", "europaeischen", "Laender", "wie", "Deutschland", ",", "Italien", ",", "Frankreich", "und", "Spanien", "dazu", "tendieren", ",", "in", "lokalen", "Zeitschriften", "zu", "publizieren", ".", "In", "manchen", "Laendern", "oder", "Landesteilen", "gehoert", "es", "vielleicht", "auch", "nicht", "zur", "Gewohnheit", ",", "Daten", "in", "der", "englischsprachigen", "Literatur", "zu", "publizieren", ",", "was", "sicherlich", "den", "wissenschafltichen", "Index", "dieses", "Landes", "negativ", "beeinflusst", ".", "Die", "hohe", "Produktivitaet", "hollaendischer", "Chirurgen", "koennte", "dadurch", "erklaert", "werden", ",", "dass", "die", "700", "Chirurgen", "in", "einem", "kleinen", "Land", "mit", "einer", "relativ", "grossen", "Anzahl", "an", "Einwohnern", "gut", "organisiert", "sind", ".", "Die", "hollaendischen", "Chirurgen", "sind", "in", "einer", "nationalen", "Chirurgengesellschaft", "organisiert", ",", "in", "welcher", "fast", "jeder", "Chirurg", "aktives", "Mitglied", "ist", ".", "Alle", "sprechen", "und", "schreiben", "Englisch", "sehr", "gut", ".", "Die", "von", "der", "nationalen", "Chirurgengesellschaft", "organisierten", "Aktivitaeten", "sind", "sehr", "gut", "besucht", "und", "beinhalten", "2", "mal", "im", "Jahr", "wissenschaftliche", "Treffen", ",", "bei", "dem", "Assistenten", "und", "Chirurgen", "fuer", "einen", "oder", "2", "Tage", "zusammenkommen", ".", "Zusaetzlich", "werden", "in", "allen", "Ausbildungs-", "und", "nicht", "Ausbildungskliniken", "Qualitaetskontrollen", "durchgefuehrt", ".", "Durch", "all", "diese", "Massnahmen", "kennen", "sich", "die", "Chirurgen", "in", "diesem", "relativ", "kleinen", "Land", "untereinander", "sehr", "gut", ",", "welches", "die", "Kooperation", "bei", "der", "Durchfuehrung", "von", "Studien", "foerdert", ".", "Die", "Groesse", "der", "Niederlande", "ist", "gerade", "ausreichend", ",", "um", "relevante", "klinische", "Studien", "durchzufuehren", "und", "es", "mag", "sein", ",", "dass", "wir", "relativ", "viele", "solcher", "Studien", "kreieren", ".", "Holland", "ist", "ein", "demokratisches", "Land", ",", "welches", "dem", "Chirurgen", "und", "Forscher", "die", "freie", "Gelegenheit", "bietet", "Forschung", "und", "Publikationen", ",", "nach", "eigenem", "Gusto", "durchzufuehren", "ohne", "von", "hierachischen", "Strukturen", "behindert", "zu", "werden", ".", "Alle", "diese", "Faktoren", "zusammen", "schaffen", "ein", "wissenschaftliches", "Klima", "in", "den", "Niederlanden", ",", "das", "zur", "Organisation", "von", "Multizenter", "-", "Studien", "und", "klinischen", "Studien", "anregt", "." ]
[ "umlsterm" ]
Niederlande is an umlsterm, westlichen Welt is an umlsterm, Produktivitaet is an umlsterm, Arbeit is an umlsterm, Methode is an umlsterm, Schweiz is an umlsterm, Methodik is an umlsterm, Deutschland is an umlsterm, Italien is an umlsterm, Frankreich is an umlsterm, Spanien is an umlsterm, Zeitschriften is an umlsterm, Gewohnheit is an umlsterm, Literatur is an umlsterm, Produktivitaet is an umlsterm, Chirurgengesellschaft is an umlsterm, Chirurgengesellschaft is an umlsterm, Niederlande is an umlsterm, Forschung is an umlsterm, Publikationen is an umlsterm, Klima is an umlsterm, Niederlanden is an umlsterm, Organisation is an umlsterm
DerChirurg.00710676.ger.abstr_task1
Sentence: Zusammenfassung . Die Schlussfolgerung der hier gezeigten Daten koennte sein , dass die Niederlande eine grosse Anzahl guter chirurgischer Studien publiziert und damit in der Spitze der westlichen Welt rangiert . Es ist auffallend , dass die hoechste Produktivitaet in kleinen Laendern und in Laendern mit niedriger Einwohnerzahl gefunden wurde . Die meisten grossen europaeischen Laender haben einen geringen wissenschaftlichen " output " nach der in der hier vorliegenden Arbeit benutzten Methode . Die skandinavischen Laender , Holland und die Schweiz haben den besten wissenschaftlichen Index nach der hier benutzten Methodik . Es koennte sein , dass die grossen europaeischen Laender wie Deutschland , Italien , Frankreich und Spanien dazu tendieren , in lokalen Zeitschriften zu publizieren . In manchen Laendern oder Landesteilen gehoert es vielleicht auch nicht zur Gewohnheit , Daten in der englischsprachigen Literatur zu publizieren , was sicherlich den wissenschafltichen Index dieses Landes negativ beeinflusst . Die hohe Produktivitaet hollaendischer Chirurgen koennte dadurch erklaert werden , dass die 700 Chirurgen in einem kleinen Land mit einer relativ grossen Anzahl an Einwohnern gut organisiert sind . Die hollaendischen Chirurgen sind in einer nationalen Chirurgengesellschaft organisiert , in welcher fast jeder Chirurg aktives Mitglied ist . Alle sprechen und schreiben Englisch sehr gut . Die von der nationalen Chirurgengesellschaft organisierten Aktivitaeten sind sehr gut besucht und beinhalten 2 mal im Jahr wissenschaftliche Treffen , bei dem Assistenten und Chirurgen fuer einen oder 2 Tage zusammenkommen . Zusaetzlich werden in allen Ausbildungs- und nicht Ausbildungskliniken Qualitaetskontrollen durchgefuehrt . Durch all diese Massnahmen kennen sich die Chirurgen in diesem relativ kleinen Land untereinander sehr gut , welches die Kooperation bei der Durchfuehrung von Studien foerdert . Die Groesse der Niederlande ist gerade ausreichend , um relevante klinische Studien durchzufuehren und es mag sein , dass wir relativ viele solcher Studien kreieren . Holland ist ein demokratisches Land , welches dem Chirurgen und Forscher die freie Gelegenheit bietet Forschung und Publikationen , nach eigenem Gusto durchzufuehren ohne von hierachischen Strukturen behindert zu werden . Alle diese Faktoren zusammen schaffen ein wissenschaftliches Klima in den Niederlanden , das zur Organisation von Multizenter-Studien und klinischen Studien anregt . Instructions: please typing these entity words according to sentence: Niederlande, westlichen Welt, Produktivitaet, Arbeit, Methode, Schweiz, Methodik, Deutschland, Italien, Frankreich, Spanien, Zeitschriften, Gewohnheit, Literatur, Produktivitaet, Chirurgengesellschaft, Chirurgengesellschaft, Niederlande, Forschung, Publikationen, Klima, Niederlanden, Organisation Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Die Schlussfolgerung der hier gezeigten Daten koennte sein , dass die Niederlande eine grosse Anzahl guter chirurgischer Studien publiziert und damit in der Spitze der westlichen Welt rangiert . Es ist auffallend , dass die hoechste Produktivitaet in kleinen Laendern und in Laendern mit niedriger Einwohnerzahl gefunden wurde . Die meisten grossen europaeischen Laender haben einen geringen wissenschaftlichen " output " nach der in der hier vorliegenden Arbeit benutzten Methode . Die skandinavischen Laender , Holland und die Schweiz haben den besten wissenschaftlichen Index nach der hier benutzten Methodik . Es koennte sein , dass die grossen europaeischen Laender wie Deutschland , Italien , Frankreich und Spanien dazu tendieren , in lokalen Zeitschriften zu publizieren . In manchen Laendern oder Landesteilen gehoert es vielleicht auch nicht zur Gewohnheit , Daten in der englischsprachigen Literatur zu publizieren , was sicherlich den wissenschafltichen Index dieses Landes negativ beeinflusst . Die hohe Produktivitaet hollaendischer Chirurgen koennte dadurch erklaert werden , dass die 700 Chirurgen in einem kleinen Land mit einer relativ grossen Anzahl an Einwohnern gut organisiert sind . Die hollaendischen Chirurgen sind in einer nationalen Chirurgengesellschaft organisiert , in welcher fast jeder Chirurg aktives Mitglied ist . Alle sprechen und schreiben Englisch sehr gut . Die von der nationalen Chirurgengesellschaft organisierten Aktivitaeten sind sehr gut besucht und beinhalten 2 mal im Jahr wissenschaftliche Treffen , bei dem Assistenten und Chirurgen fuer einen oder 2 Tage zusammenkommen . Zusaetzlich werden in allen Ausbildungs- und nicht Ausbildungskliniken Qualitaetskontrollen durchgefuehrt . Durch all diese Massnahmen kennen sich die Chirurgen in diesem relativ kleinen Land untereinander sehr gut , welches die Kooperation bei der Durchfuehrung von Studien foerdert . Die Groesse der Niederlande ist gerade ausreichend , um relevante klinische Studien durchzufuehren und es mag sein , dass wir relativ viele solcher Studien kreieren . Holland ist ein demokratisches Land , welches dem Chirurgen und Forscher die freie Gelegenheit bietet Forschung und Publikationen , nach eigenem Gusto durchzufuehren ohne von hierachischen Strukturen behindert zu werden . Alle diese Faktoren zusammen schaffen ein wissenschaftliches Klima in den Niederlanden , das zur Organisation von Multizenter-Studien und klinischen Studien anregt .
[ "Zusammenfassung", ".", "Die", "Schlussfolgerung", "der", "hier", "gezeigten", "Daten", "koennte", "sein", ",", "dass", "die", "Niederlande", "eine", "grosse", "Anzahl", "guter", "chirurgischer", "Studien", "publiziert", "und", "damit", "in", "der", "Spitze", "der", "westlichen", "Welt", "rangiert", ".", "Es", "ist", "auffallend", ",", "dass", "die", "hoechste", "Produktivitaet", "in", "kleinen", "Laendern", "und", "in", "Laendern", "mit", "niedriger", "Einwohnerzahl", "gefunden", "wurde", ".", "Die", "meisten", "grossen", "europaeischen", "Laender", "haben", "einen", "geringen", "wissenschaftlichen", "\"", "output", "\"", "nach", "der", "in", "der", "hier", "vorliegenden", "Arbeit", "benutzten", "Methode", ".", "Die", "skandinavischen", "Laender", ",", "Holland", "und", "die", "Schweiz", "haben", "den", "besten", "wissenschaftlichen", "Index", "nach", "der", "hier", "benutzten", "Methodik", ".", "Es", "koennte", "sein", ",", "dass", "die", "grossen", "europaeischen", "Laender", "wie", "Deutschland", ",", "Italien", ",", "Frankreich", "und", "Spanien", "dazu", "tendieren", ",", "in", "lokalen", "Zeitschriften", "zu", "publizieren", ".", "In", "manchen", "Laendern", "oder", "Landesteilen", "gehoert", "es", "vielleicht", "auch", "nicht", "zur", "Gewohnheit", ",", "Daten", "in", "der", "englischsprachigen", "Literatur", "zu", "publizieren", ",", "was", "sicherlich", "den", "wissenschafltichen", "Index", "dieses", "Landes", "negativ", "beeinflusst", ".", "Die", "hohe", "Produktivitaet", "hollaendischer", "Chirurgen", "koennte", "dadurch", "erklaert", "werden", ",", "dass", "die", "700", "Chirurgen", "in", "einem", "kleinen", "Land", "mit", "einer", "relativ", "grossen", "Anzahl", "an", "Einwohnern", "gut", "organisiert", "sind", ".", "Die", "hollaendischen", "Chirurgen", "sind", "in", "einer", "nationalen", "Chirurgengesellschaft", "organisiert", ",", "in", "welcher", "fast", "jeder", "Chirurg", "aktives", "Mitglied", "ist", ".", "Alle", "sprechen", "und", "schreiben", "Englisch", "sehr", "gut", ".", "Die", "von", "der", "nationalen", "Chirurgengesellschaft", "organisierten", "Aktivitaeten", "sind", "sehr", "gut", "besucht", "und", "beinhalten", "2", "mal", "im", "Jahr", "wissenschaftliche", "Treffen", ",", "bei", "dem", "Assistenten", "und", "Chirurgen", "fuer", "einen", "oder", "2", "Tage", "zusammenkommen", ".", "Zusaetzlich", "werden", "in", "allen", "Ausbildungs-", "und", "nicht", "Ausbildungskliniken", "Qualitaetskontrollen", "durchgefuehrt", ".", "Durch", "all", "diese", "Massnahmen", "kennen", "sich", "die", "Chirurgen", "in", "diesem", "relativ", "kleinen", "Land", "untereinander", "sehr", "gut", ",", "welches", "die", "Kooperation", "bei", "der", "Durchfuehrung", "von", "Studien", "foerdert", ".", "Die", "Groesse", "der", "Niederlande", "ist", "gerade", "ausreichend", ",", "um", "relevante", "klinische", "Studien", "durchzufuehren", "und", "es", "mag", "sein", ",", "dass", "wir", "relativ", "viele", "solcher", "Studien", "kreieren", ".", "Holland", "ist", "ein", "demokratisches", "Land", ",", "welches", "dem", "Chirurgen", "und", "Forscher", "die", "freie", "Gelegenheit", "bietet", "Forschung", "und", "Publikationen", ",", "nach", "eigenem", "Gusto", "durchzufuehren", "ohne", "von", "hierachischen", "Strukturen", "behindert", "zu", "werden", ".", "Alle", "diese", "Faktoren", "zusammen", "schaffen", "ein", "wissenschaftliches", "Klima", "in", "den", "Niederlanden", ",", "das", "zur", "Organisation", "von", "Multizenter", "-", "Studien", "und", "klinischen", "Studien", "anregt", "." ]
[ "umlsterm" ]
Niederlande, westlichen Welt, Produktivitaet, Arbeit, Methode, Schweiz, Methodik, Deutschland, Italien, Frankreich, Spanien, Zeitschriften, Gewohnheit, Literatur, Produktivitaet, Chirurgengesellschaft, Chirurgengesellschaft, Niederlande, Forschung, Publikationen, Klima, Niederlanden, Organisation
DerChirurg.00710676.ger.abstr_task2
Sentence: Zusammenfassung . Die Schlussfolgerung der hier gezeigten Daten koennte sein , dass die Niederlande eine grosse Anzahl guter chirurgischer Studien publiziert und damit in der Spitze der westlichen Welt rangiert . Es ist auffallend , dass die hoechste Produktivitaet in kleinen Laendern und in Laendern mit niedriger Einwohnerzahl gefunden wurde . Die meisten grossen europaeischen Laender haben einen geringen wissenschaftlichen " output " nach der in der hier vorliegenden Arbeit benutzten Methode . Die skandinavischen Laender , Holland und die Schweiz haben den besten wissenschaftlichen Index nach der hier benutzten Methodik . Es koennte sein , dass die grossen europaeischen Laender wie Deutschland , Italien , Frankreich und Spanien dazu tendieren , in lokalen Zeitschriften zu publizieren . In manchen Laendern oder Landesteilen gehoert es vielleicht auch nicht zur Gewohnheit , Daten in der englischsprachigen Literatur zu publizieren , was sicherlich den wissenschafltichen Index dieses Landes negativ beeinflusst . Die hohe Produktivitaet hollaendischer Chirurgen koennte dadurch erklaert werden , dass die 700 Chirurgen in einem kleinen Land mit einer relativ grossen Anzahl an Einwohnern gut organisiert sind . Die hollaendischen Chirurgen sind in einer nationalen Chirurgengesellschaft organisiert , in welcher fast jeder Chirurg aktives Mitglied ist . Alle sprechen und schreiben Englisch sehr gut . Die von der nationalen Chirurgengesellschaft organisierten Aktivitaeten sind sehr gut besucht und beinhalten 2 mal im Jahr wissenschaftliche Treffen , bei dem Assistenten und Chirurgen fuer einen oder 2 Tage zusammenkommen . Zusaetzlich werden in allen Ausbildungs- und nicht Ausbildungskliniken Qualitaetskontrollen durchgefuehrt . Durch all diese Massnahmen kennen sich die Chirurgen in diesem relativ kleinen Land untereinander sehr gut , welches die Kooperation bei der Durchfuehrung von Studien foerdert . Die Groesse der Niederlande ist gerade ausreichend , um relevante klinische Studien durchzufuehren und es mag sein , dass wir relativ viele solcher Studien kreieren . Holland ist ein demokratisches Land , welches dem Chirurgen und Forscher die freie Gelegenheit bietet Forschung und Publikationen , nach eigenem Gusto durchzufuehren ohne von hierachischen Strukturen behindert zu werden . Alle diese Faktoren zusammen schaffen ein wissenschaftliches Klima in den Niederlanden , das zur Organisation von Multizenter-Studien und klinischen Studien anregt . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Die Schlussfolgerung der hier gezeigten Daten koennte sein , dass die Niederlande eine grosse Anzahl guter chirurgischer Studien publiziert und damit in der Spitze der westlichen Welt rangiert . Es ist auffallend , dass die hoechste Produktivitaet in kleinen Laendern und in Laendern mit niedriger Einwohnerzahl gefunden wurde . Die meisten grossen europaeischen Laender haben einen geringen wissenschaftlichen " output " nach der in der hier vorliegenden Arbeit benutzten Methode . Die skandinavischen Laender , Holland und die Schweiz haben den besten wissenschaftlichen Index nach der hier benutzten Methodik . Es koennte sein , dass die grossen europaeischen Laender wie Deutschland , Italien , Frankreich und Spanien dazu tendieren , in lokalen Zeitschriften zu publizieren . In manchen Laendern oder Landesteilen gehoert es vielleicht auch nicht zur Gewohnheit , Daten in der englischsprachigen Literatur zu publizieren , was sicherlich den wissenschafltichen Index dieses Landes negativ beeinflusst . Die hohe Produktivitaet hollaendischer Chirurgen koennte dadurch erklaert werden , dass die 700 Chirurgen in einem kleinen Land mit einer relativ grossen Anzahl an Einwohnern gut organisiert sind . Die hollaendischen Chirurgen sind in einer nationalen Chirurgengesellschaft organisiert , in welcher fast jeder Chirurg aktives Mitglied ist . Alle sprechen und schreiben Englisch sehr gut . Die von der nationalen Chirurgengesellschaft organisierten Aktivitaeten sind sehr gut besucht und beinhalten 2 mal im Jahr wissenschaftliche Treffen , bei dem Assistenten und Chirurgen fuer einen oder 2 Tage zusammenkommen . Zusaetzlich werden in allen Ausbildungs- und nicht Ausbildungskliniken Qualitaetskontrollen durchgefuehrt . Durch all diese Massnahmen kennen sich die Chirurgen in diesem relativ kleinen Land untereinander sehr gut , welches die Kooperation bei der Durchfuehrung von Studien foerdert . Die Groesse der Niederlande ist gerade ausreichend , um relevante klinische Studien durchzufuehren und es mag sein , dass wir relativ viele solcher Studien kreieren . Holland ist ein demokratisches Land , welches dem Chirurgen und Forscher die freie Gelegenheit bietet Forschung und Publikationen , nach eigenem Gusto durchzufuehren ohne von hierachischen Strukturen behindert zu werden . Alle diese Faktoren zusammen schaffen ein wissenschaftliches Klima in den Niederlanden , das zur Organisation von Multizenter-Studien und klinischen Studien anregt .
[ "Zusammenfassung", ".", "Die", "Schlussfolgerung", "der", "hier", "gezeigten", "Daten", "koennte", "sein", ",", "dass", "die", "Niederlande", "eine", "grosse", "Anzahl", "guter", "chirurgischer", "Studien", "publiziert", "und", "damit", "in", "der", "Spitze", "der", "westlichen", "Welt", "rangiert", ".", "Es", "ist", "auffallend", ",", "dass", "die", "hoechste", "Produktivitaet", "in", "kleinen", "Laendern", "und", "in", "Laendern", "mit", "niedriger", "Einwohnerzahl", "gefunden", "wurde", ".", "Die", "meisten", "grossen", "europaeischen", "Laender", "haben", "einen", "geringen", "wissenschaftlichen", "\"", "output", "\"", "nach", "der", "in", "der", "hier", "vorliegenden", "Arbeit", "benutzten", "Methode", ".", "Die", "skandinavischen", "Laender", ",", "Holland", "und", "die", "Schweiz", "haben", "den", "besten", "wissenschaftlichen", "Index", "nach", "der", "hier", "benutzten", "Methodik", ".", "Es", "koennte", "sein", ",", "dass", "die", "grossen", "europaeischen", "Laender", "wie", "Deutschland", ",", "Italien", ",", "Frankreich", "und", "Spanien", "dazu", "tendieren", ",", "in", "lokalen", "Zeitschriften", "zu", "publizieren", ".", "In", "manchen", "Laendern", "oder", "Landesteilen", "gehoert", "es", "vielleicht", "auch", "nicht", "zur", "Gewohnheit", ",", "Daten", "in", "der", "englischsprachigen", "Literatur", "zu", "publizieren", ",", "was", "sicherlich", "den", "wissenschafltichen", "Index", "dieses", "Landes", "negativ", "beeinflusst", ".", "Die", "hohe", "Produktivitaet", "hollaendischer", "Chirurgen", "koennte", "dadurch", "erklaert", "werden", ",", "dass", "die", "700", "Chirurgen", "in", "einem", "kleinen", "Land", "mit", "einer", "relativ", "grossen", "Anzahl", "an", "Einwohnern", "gut", "organisiert", "sind", ".", "Die", "hollaendischen", "Chirurgen", "sind", "in", "einer", "nationalen", "Chirurgengesellschaft", "organisiert", ",", "in", "welcher", "fast", "jeder", "Chirurg", "aktives", "Mitglied", "ist", ".", "Alle", "sprechen", "und", "schreiben", "Englisch", "sehr", "gut", ".", "Die", "von", "der", "nationalen", "Chirurgengesellschaft", "organisierten", "Aktivitaeten", "sind", "sehr", "gut", "besucht", "und", "beinhalten", "2", "mal", "im", "Jahr", "wissenschaftliche", "Treffen", ",", "bei", "dem", "Assistenten", "und", "Chirurgen", "fuer", "einen", "oder", "2", "Tage", "zusammenkommen", ".", "Zusaetzlich", "werden", "in", "allen", "Ausbildungs-", "und", "nicht", "Ausbildungskliniken", "Qualitaetskontrollen", "durchgefuehrt", ".", "Durch", "all", "diese", "Massnahmen", "kennen", "sich", "die", "Chirurgen", "in", "diesem", "relativ", "kleinen", "Land", "untereinander", "sehr", "gut", ",", "welches", "die", "Kooperation", "bei", "der", "Durchfuehrung", "von", "Studien", "foerdert", ".", "Die", "Groesse", "der", "Niederlande", "ist", "gerade", "ausreichend", ",", "um", "relevante", "klinische", "Studien", "durchzufuehren", "und", "es", "mag", "sein", ",", "dass", "wir", "relativ", "viele", "solcher", "Studien", "kreieren", ".", "Holland", "ist", "ein", "demokratisches", "Land", ",", "welches", "dem", "Chirurgen", "und", "Forscher", "die", "freie", "Gelegenheit", "bietet", "Forschung", "und", "Publikationen", ",", "nach", "eigenem", "Gusto", "durchzufuehren", "ohne", "von", "hierachischen", "Strukturen", "behindert", "zu", "werden", ".", "Alle", "diese", "Faktoren", "zusammen", "schaffen", "ein", "wissenschaftliches", "Klima", "in", "den", "Niederlanden", ",", "das", "zur", "Organisation", "von", "Multizenter", "-", "Studien", "und", "klinischen", "Studien", "anregt", "." ]
[ "umlsterm" ]
Heterogeneous expression is an other_name, Epstein - Barr virus latent proteins is a protein_family_or_group, Burkitt 's lymphoma is an other_name
4655_task0
Sentence: Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, other_name
[ "B-other_name", "I-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]
Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
[ "Heterogeneous", "expression", "of", "Epstein", "-", "Barr", "virus", "latent", "proteins", "in", "endemic", "Burkitt", "'s", "lymphoma", "." ]
[ "other_name", "cell_type", "protein_family_or_group", "protein_molecule", "cell_line", "(AND protein_molecule protein_molecule protein_molecule protein_molecule protein_molecule protein_molecule)", "virus", "multi_cell", "RNA_family_or_group", "tissue", "" ]
Heterogeneous expression is an other_name, Epstein - Barr virus latent proteins is a protein_family_or_group, Burkitt 's lymphoma is an other_name
4655_task1
Sentence: Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Instructions: please typing these entity words according to sentence: Heterogeneous expression, Epstein - Barr virus latent proteins, Burkitt 's lymphoma Options: protein_family_or_group, other_name
[ "B-other_name", "I-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]
Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
[ "Heterogeneous", "expression", "of", "Epstein", "-", "Barr", "virus", "latent", "proteins", "in", "endemic", "Burkitt", "'s", "lymphoma", "." ]
[ "other_name", "cell_type", "protein_family_or_group", "protein_molecule", "cell_line", "(AND protein_molecule protein_molecule protein_molecule protein_molecule protein_molecule protein_molecule)", "virus", "multi_cell", "RNA_family_or_group", "tissue", "" ]
Heterogeneous expression, Epstein - Barr virus latent proteins, Burkitt 's lymphoma
4655_task2
Sentence: Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Instructions: please extract entity words from the input sentence
[ "B-other_name", "I-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]
Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
[ "Heterogeneous", "expression", "of", "Epstein", "-", "Barr", "virus", "latent", "proteins", "in", "endemic", "Burkitt", "'s", "lymphoma", "." ]
[ "other_name", "cell_type", "protein_family_or_group", "protein_molecule", "cell_line", "(AND protein_molecule protein_molecule protein_molecule protein_molecule protein_molecule protein_molecule)", "virus", "multi_cell", "RNA_family_or_group", "tissue", "" ]
Kind is an umlsterm, Aniridie is an umlsterm, Glaukom is an umlsterm, drucksenkender is an umlsterm, drucksenkende is an umlsterm, Schweissabsonderung is an umlsterm, Aufmerksamkeit is an umlsterm
DerOpthalmologe.80950633.ger.abstr_task0
Sentence: Bei einem Kind mit Aniridie und Glaukom wurde wegen ungenuegend drucksenkender Wirkung anderer Antiglaukomatosa-Kombinationen ein Betablocker in Kombination mit Latanoprost eingesetzt . Die drucksenkende Wirkung war sehr gut . Als Nebenwirkung trat ca. 1-2 h nach Gabe der Latanoprosttropfen eine starke Schweissabsonderung am gesamten Koerper auf . Diese Nebenwirkung wurde bisher noch nicht beschrieben und spricht fuer eine systemische Nebenwirkung von Latanoprost-Augentropfen . Da die systemischen Nebenwirkungen dieser Substanz auch bei sachgerechter lokaler Anwendung staerker sind als bisher vermutet , sollte man bei der Anwendung besondere Aufmerksamkeit walten lassen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Bei einem Kind mit Aniridie und Glaukom wurde wegen ungenuegend drucksenkender Wirkung anderer Antiglaukomatosa-Kombinationen ein Betablocker in Kombination mit Latanoprost eingesetzt . Die drucksenkende Wirkung war sehr gut . Als Nebenwirkung trat ca. 1-2 h nach Gabe der Latanoprosttropfen eine starke Schweissabsonderung am gesamten Koerper auf . Diese Nebenwirkung wurde bisher noch nicht beschrieben und spricht fuer eine systemische Nebenwirkung von Latanoprost-Augentropfen . Da die systemischen Nebenwirkungen dieser Substanz auch bei sachgerechter lokaler Anwendung staerker sind als bisher vermutet , sollte man bei der Anwendung besondere Aufmerksamkeit walten lassen .
[ "Bei", "einem", "Kind", "mit", "Aniridie", "und", "Glaukom", "wurde", "wegen", "ungenuegend", "drucksenkender", "Wirkung", "anderer", "Antiglaukomatosa", "-", "Kombinationen", "ein", "Betablocker", "in", "Kombination", "mit", "Latanoprost", "eingesetzt", ".", "Die", "drucksenkende", "Wirkung", "war", "sehr", "gut", ".", "Als", "Nebenwirkung", "trat", "ca", ".", "1", "-", "2", "h", "nach", "Gabe", "der", "Latanoprosttropfen", "eine", "starke", "Schweissabsonderung", "am", "gesamten", "Koerper", "auf", ".", "Diese", "Nebenwirkung", "wurde", "bisher", "noch", "nicht", "beschrieben", "und", "spricht", "fuer", "eine", "systemische", "Nebenwirkung", "von", "Latanoprost", "-", "Augentropfen", ".", "Da", "die", "systemischen", "Nebenwirkungen", "dieser", "Substanz", "auch", "bei", "sachgerechter", "lokaler", "Anwendung", "staerker", "sind", "als", "bisher", "vermutet", ",", "sollte", "man", "bei", "der", "Anwendung", "besondere", "Aufmerksamkeit", "walten", "lassen", "." ]
[ "umlsterm" ]
Kind is an umlsterm, Aniridie is an umlsterm, Glaukom is an umlsterm, drucksenkender is an umlsterm, drucksenkende is an umlsterm, Schweissabsonderung is an umlsterm, Aufmerksamkeit is an umlsterm
DerOpthalmologe.80950633.ger.abstr_task1
Sentence: Bei einem Kind mit Aniridie und Glaukom wurde wegen ungenuegend drucksenkender Wirkung anderer Antiglaukomatosa-Kombinationen ein Betablocker in Kombination mit Latanoprost eingesetzt . Die drucksenkende Wirkung war sehr gut . Als Nebenwirkung trat ca. 1-2 h nach Gabe der Latanoprosttropfen eine starke Schweissabsonderung am gesamten Koerper auf . Diese Nebenwirkung wurde bisher noch nicht beschrieben und spricht fuer eine systemische Nebenwirkung von Latanoprost-Augentropfen . Da die systemischen Nebenwirkungen dieser Substanz auch bei sachgerechter lokaler Anwendung staerker sind als bisher vermutet , sollte man bei der Anwendung besondere Aufmerksamkeit walten lassen . Instructions: please typing these entity words according to sentence: Kind, Aniridie, Glaukom, drucksenkender, drucksenkende, Schweissabsonderung, Aufmerksamkeit Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Bei einem Kind mit Aniridie und Glaukom wurde wegen ungenuegend drucksenkender Wirkung anderer Antiglaukomatosa-Kombinationen ein Betablocker in Kombination mit Latanoprost eingesetzt . Die drucksenkende Wirkung war sehr gut . Als Nebenwirkung trat ca. 1-2 h nach Gabe der Latanoprosttropfen eine starke Schweissabsonderung am gesamten Koerper auf . Diese Nebenwirkung wurde bisher noch nicht beschrieben und spricht fuer eine systemische Nebenwirkung von Latanoprost-Augentropfen . Da die systemischen Nebenwirkungen dieser Substanz auch bei sachgerechter lokaler Anwendung staerker sind als bisher vermutet , sollte man bei der Anwendung besondere Aufmerksamkeit walten lassen .
[ "Bei", "einem", "Kind", "mit", "Aniridie", "und", "Glaukom", "wurde", "wegen", "ungenuegend", "drucksenkender", "Wirkung", "anderer", "Antiglaukomatosa", "-", "Kombinationen", "ein", "Betablocker", "in", "Kombination", "mit", "Latanoprost", "eingesetzt", ".", "Die", "drucksenkende", "Wirkung", "war", "sehr", "gut", ".", "Als", "Nebenwirkung", "trat", "ca", ".", "1", "-", "2", "h", "nach", "Gabe", "der", "Latanoprosttropfen", "eine", "starke", "Schweissabsonderung", "am", "gesamten", "Koerper", "auf", ".", "Diese", "Nebenwirkung", "wurde", "bisher", "noch", "nicht", "beschrieben", "und", "spricht", "fuer", "eine", "systemische", "Nebenwirkung", "von", "Latanoprost", "-", "Augentropfen", ".", "Da", "die", "systemischen", "Nebenwirkungen", "dieser", "Substanz", "auch", "bei", "sachgerechter", "lokaler", "Anwendung", "staerker", "sind", "als", "bisher", "vermutet", ",", "sollte", "man", "bei", "der", "Anwendung", "besondere", "Aufmerksamkeit", "walten", "lassen", "." ]
[ "umlsterm" ]
Kind, Aniridie, Glaukom, drucksenkender, drucksenkende, Schweissabsonderung, Aufmerksamkeit
DerOpthalmologe.80950633.ger.abstr_task2
Sentence: Bei einem Kind mit Aniridie und Glaukom wurde wegen ungenuegend drucksenkender Wirkung anderer Antiglaukomatosa-Kombinationen ein Betablocker in Kombination mit Latanoprost eingesetzt . Die drucksenkende Wirkung war sehr gut . Als Nebenwirkung trat ca. 1-2 h nach Gabe der Latanoprosttropfen eine starke Schweissabsonderung am gesamten Koerper auf . Diese Nebenwirkung wurde bisher noch nicht beschrieben und spricht fuer eine systemische Nebenwirkung von Latanoprost-Augentropfen . Da die systemischen Nebenwirkungen dieser Substanz auch bei sachgerechter lokaler Anwendung staerker sind als bisher vermutet , sollte man bei der Anwendung besondere Aufmerksamkeit walten lassen . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]
Bei einem Kind mit Aniridie und Glaukom wurde wegen ungenuegend drucksenkender Wirkung anderer Antiglaukomatosa-Kombinationen ein Betablocker in Kombination mit Latanoprost eingesetzt . Die drucksenkende Wirkung war sehr gut . Als Nebenwirkung trat ca. 1-2 h nach Gabe der Latanoprosttropfen eine starke Schweissabsonderung am gesamten Koerper auf . Diese Nebenwirkung wurde bisher noch nicht beschrieben und spricht fuer eine systemische Nebenwirkung von Latanoprost-Augentropfen . Da die systemischen Nebenwirkungen dieser Substanz auch bei sachgerechter lokaler Anwendung staerker sind als bisher vermutet , sollte man bei der Anwendung besondere Aufmerksamkeit walten lassen .
[ "Bei", "einem", "Kind", "mit", "Aniridie", "und", "Glaukom", "wurde", "wegen", "ungenuegend", "drucksenkender", "Wirkung", "anderer", "Antiglaukomatosa", "-", "Kombinationen", "ein", "Betablocker", "in", "Kombination", "mit", "Latanoprost", "eingesetzt", ".", "Die", "drucksenkende", "Wirkung", "war", "sehr", "gut", ".", "Als", "Nebenwirkung", "trat", "ca", ".", "1", "-", "2", "h", "nach", "Gabe", "der", "Latanoprosttropfen", "eine", "starke", "Schweissabsonderung", "am", "gesamten", "Koerper", "auf", ".", "Diese", "Nebenwirkung", "wurde", "bisher", "noch", "nicht", "beschrieben", "und", "spricht", "fuer", "eine", "systemische", "Nebenwirkung", "von", "Latanoprost", "-", "Augentropfen", ".", "Da", "die", "systemischen", "Nebenwirkungen", "dieser", "Substanz", "auch", "bei", "sachgerechter", "lokaler", "Anwendung", "staerker", "sind", "als", "bisher", "vermutet", ",", "sollte", "man", "bei", "der", "Anwendung", "besondere", "Aufmerksamkeit", "walten", "lassen", "." ]
[ "umlsterm" ]
X2 box is a DNA_domain_or_region, DRA promoter is a DNA_domain_or_region, B cells is a cell_type
70966_task0
Sentence: Role of the X2 box in activated transcription from the DRA promoter in B cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, DNA_domain_or_region
[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "O" ]
Role of the X2 box in activated transcription from the DRA promoter in B cells.
[ "Role", "of", "the", "X2", "box", "in", "activated", "transcription", "from", "the", "DRA", "promoter", "in", "B", "cells", "." ]
[ "protein_family_or_group", "other_organic_compound", "polynucleotide", "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule" ]
X2 box is a DNA_domain_or_region, DRA promoter is a DNA_domain_or_region, B cells is a cell_type
70966_task1
Sentence: Role of the X2 box in activated transcription from the DRA promoter in B cells. Instructions: please typing these entity words according to sentence: X2 box, DRA promoter, B cells Options: cell_type, DNA_domain_or_region
[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "O" ]
Role of the X2 box in activated transcription from the DRA promoter in B cells.
[ "Role", "of", "the", "X2", "box", "in", "activated", "transcription", "from", "the", "DRA", "promoter", "in", "B", "cells", "." ]
[ "protein_family_or_group", "other_organic_compound", "polynucleotide", "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule" ]
X2 box, DRA promoter, B cells
70966_task2
Sentence: Role of the X2 box in activated transcription from the DRA promoter in B cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "B-cell_type", "I-cell_type", "O" ]
Role of the X2 box in activated transcription from the DRA promoter in B cells.
[ "Role", "of", "the", "X2", "box", "in", "activated", "transcription", "from", "the", "DRA", "promoter", "in", "B", "cells", "." ]
[ "protein_family_or_group", "other_organic_compound", "polynucleotide", "DNA_domain_or_region", "cell_line", "cell_type", "protein_molecule" ]
intraocular pressure is an umlsterm, blood supply is an umlsterm, pathogenesis is an umlsterm, open - angle glaucoma is an umlsterm
DerOpthalmologe.00970663.eng.abstr_task0
Sentence: Background . In addition to elevated intraocular pressure , a compromised ocular blood supply has been implicated in the pathogenesis of primary open-angle glaucoma ( PCOG ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]
Background . In addition to elevated intraocular pressure , a compromised ocular blood supply has been implicated in the pathogenesis of primary open-angle glaucoma ( PCOG ) .
[ "Background", ".", "In", "addition", "to", "elevated", "intraocular", "pressure", ",", "a", "compromised", "ocular", "blood", "supply", "has", "been", "implicated", "in", "the", "pathogenesis", "of", "primary", "open", "-", "angle", "glaucoma", "(", "PCOG", ")", "." ]
[ "umlsterm" ]
intraocular pressure is an umlsterm, blood supply is an umlsterm, pathogenesis is an umlsterm, open - angle glaucoma is an umlsterm
DerOpthalmologe.00970663.eng.abstr_task1
Sentence: Background . In addition to elevated intraocular pressure , a compromised ocular blood supply has been implicated in the pathogenesis of primary open-angle glaucoma ( PCOG ) . Instructions: please typing these entity words according to sentence: intraocular pressure, blood supply, pathogenesis, open - angle glaucoma Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]
Background . In addition to elevated intraocular pressure , a compromised ocular blood supply has been implicated in the pathogenesis of primary open-angle glaucoma ( PCOG ) .
[ "Background", ".", "In", "addition", "to", "elevated", "intraocular", "pressure", ",", "a", "compromised", "ocular", "blood", "supply", "has", "been", "implicated", "in", "the", "pathogenesis", "of", "primary", "open", "-", "angle", "glaucoma", "(", "PCOG", ")", "." ]
[ "umlsterm" ]
intraocular pressure, blood supply, pathogenesis, open - angle glaucoma
DerOpthalmologe.00970663.eng.abstr_task2
Sentence: Background . In addition to elevated intraocular pressure , a compromised ocular blood supply has been implicated in the pathogenesis of primary open-angle glaucoma ( PCOG ) . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]
Background . In addition to elevated intraocular pressure , a compromised ocular blood supply has been implicated in the pathogenesis of primary open-angle glaucoma ( PCOG ) .
[ "Background", ".", "In", "addition", "to", "elevated", "intraocular", "pressure", ",", "a", "compromised", "ocular", "blood", "supply", "has", "been", "implicated", "in", "the", "pathogenesis", "of", "primary", "open", "-", "angle", "glaucoma", "(", "PCOG", ")", "." ]
[ "umlsterm" ]
17 beta - hydroxysteroid dehydrogenase type XI is a GENE-Y
12697717_task0
Sentence: 17 beta-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y
[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]
17 beta-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells.
[ "17", "beta", "-", "hydroxysteroid", "dehydrogenase", "type", "XI", "localizes", "to", "human", "steroidogenic", "cells", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
17 beta - hydroxysteroid dehydrogenase type XI is a GENE-Y
12697717_task1
Sentence: 17 beta-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells. Instructions: please typing these entity words according to sentence: 17 beta - hydroxysteroid dehydrogenase type XI Options: GENE-Y
[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]
17 beta-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells.
[ "17", "beta", "-", "hydroxysteroid", "dehydrogenase", "type", "XI", "localizes", "to", "human", "steroidogenic", "cells", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
17 beta - hydroxysteroid dehydrogenase type XI
12697717_task2
Sentence: 17 beta-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]
17 beta-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells.
[ "17", "beta", "-", "hydroxysteroid", "dehydrogenase", "type", "XI", "localizes", "to", "human", "steroidogenic", "cells", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
Sprains is an umlsterm, lateral ligaments is an umlsterm, ankle is an umlsterm, injuries is an umlsterm, human body is an umlsterm, injury is an umlsterm, supination is an umlsterm, foot is an umlsterm, movement is an umlsterm, ankle is an umlsterm, ligament is an umlsterm, injuries is an umlsterm, sprains is an umlsterm, ruptures is an umlsterm, trauma is an umlsterm, lateral ligaments is an umlsterm, ALRI is an umlsterm, retrospective is an umlsterm, clinical study is an umlsterm, patients is an umlsterm, anterior is an umlsterm, ligaments is an umlsterm, injuries is an umlsterm, ankle is an umlsterm, sprains is an umlsterm, ligaments is an umlsterm, ankle is an umlsterm, leads is an umlsterm, injuries is an umlsterm, foot is an umlsterm, supination is an umlsterm, fracture is an umlsterm, line is an umlsterm, injuries is an umlsterm, clinical examination is an umlsterm, ankle is an umlsterm, sprains is an umlsterm, tip is an umlsterm, fibula is an umlsterm, metatarsal is an umlsterm, ligament is an umlsterm, ligaments is an umlsterm, anterior is an umlsterm, talus is an umlsterm, ligaments is an umlsterm, pain is an umlsterm, clinical examination is an umlsterm, radiographs is an umlsterm, ankle is an umlsterm, sprains is an umlsterm, therapy is an umlsterm
DerOrthopaede.90280469.eng.abstr_task0
Sentence: Sprains in the lateral ligaments of the ankle produce the most common ligamentous injuries of the human body . The mechanism of injury is complex , while supination represents the main component of foot movement . Classifying lateral ankle ligament injuries , many authors use a system of three degrees , which includes mild , moderate and severe sprains . Despite this scientific categories , in our opinion is the differentiation between elongation and complete ruptures of practical relevance . Under a biomechanical point of view , ligamentous trauma of the lateral ligaments lead to acute antero-lateral rotational instability ( ALRI ) . Following the retrospective clinical study of Zwipp with 1235 patients , in 70 % of complete disruptions , the anterior talo-naviculare and fibulo-calcanear ligaments are involved together . Syndesmotic injuries have been reported at a rate up to 10 % of ankle sprains with deltoid ligaments at 2,5 % . Rarely , the classic ankle sprain leads to injuries which affect the foot on a so called " supination fracture line " . A rate of 7,4 % is reported for these accompanying injuries . Therefore , clinical examination of ankle sprains should not only address on the distal tip of the fibula . Critical bony and ligamentous structures like the fifth metatarsal base , the calcaneo-cuboideal ligament , the ligaments of the anterior calcaneal process , the talus and syndesmotic ligaments have to be screened for pain and swelling . In our opinion , careful clinical examination and plain radiographs in two plains are sufficient for diagnosing ankle sprains and functional therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Sprains in the lateral ligaments of the ankle produce the most common ligamentous injuries of the human body . The mechanism of injury is complex , while supination represents the main component of foot movement . Classifying lateral ankle ligament injuries , many authors use a system of three degrees , which includes mild , moderate and severe sprains . Despite this scientific categories , in our opinion is the differentiation between elongation and complete ruptures of practical relevance . Under a biomechanical point of view , ligamentous trauma of the lateral ligaments lead to acute antero-lateral rotational instability ( ALRI ) . Following the retrospective clinical study of Zwipp with 1235 patients , in 70 % of complete disruptions , the anterior talo-naviculare and fibulo-calcanear ligaments are involved together . Syndesmotic injuries have been reported at a rate up to 10 % of ankle sprains with deltoid ligaments at 2,5 % . Rarely , the classic ankle sprain leads to injuries which affect the foot on a so called " supination fracture line " . A rate of 7,4 % is reported for these accompanying injuries . Therefore , clinical examination of ankle sprains should not only address on the distal tip of the fibula . Critical bony and ligamentous structures like the fifth metatarsal base , the calcaneo-cuboideal ligament , the ligaments of the anterior calcaneal process , the talus and syndesmotic ligaments have to be screened for pain and swelling . In our opinion , careful clinical examination and plain radiographs in two plains are sufficient for diagnosing ankle sprains and functional therapy .
[ "Sprains", "in", "the", "lateral", "ligaments", "of", "the", "ankle", "produce", "the", "most", "common", "ligamentous", "injuries", "of", "the", "human", "body", ".", "The", "mechanism", "of", "injury", "is", "complex", ",", "while", "supination", "represents", "the", "main", "component", "of", "foot", "movement", ".", "Classifying", "lateral", "ankle", "ligament", "injuries", ",", "many", "authors", "use", "a", "system", "of", "three", "degrees", ",", "which", "includes", "mild", ",", "moderate", "and", "severe", "sprains", ".", "Despite", "this", "scientific", "categories", ",", "in", "our", "opinion", "is", "the", "differentiation", "between", "elongation", "and", "complete", "ruptures", "of", "practical", "relevance", ".", "Under", "a", "biomechanical", "point", "of", "view", ",", "ligamentous", "trauma", "of", "the", "lateral", "ligaments", "lead", "to", "acute", "antero", "-", "lateral", "rotational", "instability", "(", "ALRI", ")", ".", "Following", "the", "retrospective", "clinical", "study", "of", "Zwipp", "with", "1235", "patients", ",", "in", "70", "%", "of", "complete", "disruptions", ",", "the", "anterior", "talo", "-", "naviculare", "and", "fibulo", "-", "calcanear", "ligaments", "are", "involved", "together", ".", "Syndesmotic", "injuries", "have", "been", "reported", "at", "a", "rate", "up", "to", "10", "%", "of", "ankle", "sprains", "with", "deltoid", "ligaments", "at", "2,5", "%", ".", "Rarely", ",", "the", "classic", "ankle", "sprain", "leads", "to", "injuries", "which", "affect", "the", "foot", "on", "a", "so", "called", "\"", "supination", "fracture", "line", "\"", ".", "A", "rate", "of", "7,4", "%", "is", "reported", "for", "these", "accompanying", "injuries", ".", "Therefore", ",", "clinical", "examination", "of", "ankle", "sprains", "should", "not", "only", "address", "on", "the", "distal", "tip", "of", "the", "fibula", ".", "Critical", "bony", "and", "ligamentous", "structures", "like", "the", "fifth", "metatarsal", "base", ",", "the", "calcaneo", "-", "cuboideal", "ligament", ",", "the", "ligaments", "of", "the", "anterior", "calcaneal", "process", ",", "the", "talus", "and", "syndesmotic", "ligaments", "have", "to", "be", "screened", "for", "pain", "and", "swelling", ".", "In", "our", "opinion", ",", "careful", "clinical", "examination", "and", "plain", "radiographs", "in", "two", "plains", "are", "sufficient", "for", "diagnosing", "ankle", "sprains", "and", "functional", "therapy", "." ]
[ "umlsterm" ]
Sprains is an umlsterm, lateral ligaments is an umlsterm, ankle is an umlsterm, injuries is an umlsterm, human body is an umlsterm, injury is an umlsterm, supination is an umlsterm, foot is an umlsterm, movement is an umlsterm, ankle is an umlsterm, ligament is an umlsterm, injuries is an umlsterm, sprains is an umlsterm, ruptures is an umlsterm, trauma is an umlsterm, lateral ligaments is an umlsterm, ALRI is an umlsterm, retrospective is an umlsterm, clinical study is an umlsterm, patients is an umlsterm, anterior is an umlsterm, ligaments is an umlsterm, injuries is an umlsterm, ankle is an umlsterm, sprains is an umlsterm, ligaments is an umlsterm, ankle is an umlsterm, leads is an umlsterm, injuries is an umlsterm, foot is an umlsterm, supination is an umlsterm, fracture is an umlsterm, line is an umlsterm, injuries is an umlsterm, clinical examination is an umlsterm, ankle is an umlsterm, sprains is an umlsterm, tip is an umlsterm, fibula is an umlsterm, metatarsal is an umlsterm, ligament is an umlsterm, ligaments is an umlsterm, anterior is an umlsterm, talus is an umlsterm, ligaments is an umlsterm, pain is an umlsterm, clinical examination is an umlsterm, radiographs is an umlsterm, ankle is an umlsterm, sprains is an umlsterm, therapy is an umlsterm
DerOrthopaede.90280469.eng.abstr_task1
Sentence: Sprains in the lateral ligaments of the ankle produce the most common ligamentous injuries of the human body . The mechanism of injury is complex , while supination represents the main component of foot movement . Classifying lateral ankle ligament injuries , many authors use a system of three degrees , which includes mild , moderate and severe sprains . Despite this scientific categories , in our opinion is the differentiation between elongation and complete ruptures of practical relevance . Under a biomechanical point of view , ligamentous trauma of the lateral ligaments lead to acute antero-lateral rotational instability ( ALRI ) . Following the retrospective clinical study of Zwipp with 1235 patients , in 70 % of complete disruptions , the anterior talo-naviculare and fibulo-calcanear ligaments are involved together . Syndesmotic injuries have been reported at a rate up to 10 % of ankle sprains with deltoid ligaments at 2,5 % . Rarely , the classic ankle sprain leads to injuries which affect the foot on a so called " supination fracture line " . A rate of 7,4 % is reported for these accompanying injuries . Therefore , clinical examination of ankle sprains should not only address on the distal tip of the fibula . Critical bony and ligamentous structures like the fifth metatarsal base , the calcaneo-cuboideal ligament , the ligaments of the anterior calcaneal process , the talus and syndesmotic ligaments have to be screened for pain and swelling . In our opinion , careful clinical examination and plain radiographs in two plains are sufficient for diagnosing ankle sprains and functional therapy . Instructions: please typing these entity words according to sentence: Sprains, lateral ligaments, ankle, injuries, human body, injury, supination, foot, movement, ankle, ligament, injuries, sprains, ruptures, trauma, lateral ligaments, ALRI, retrospective, clinical study, patients, anterior, ligaments, injuries, ankle, sprains, ligaments, ankle, leads, injuries, foot, supination, fracture, line, injuries, clinical examination, ankle, sprains, tip, fibula, metatarsal, ligament, ligaments, anterior, talus, ligaments, pain, clinical examination, radiographs, ankle, sprains, therapy Options: umlsterm
[ "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Sprains in the lateral ligaments of the ankle produce the most common ligamentous injuries of the human body . The mechanism of injury is complex , while supination represents the main component of foot movement . Classifying lateral ankle ligament injuries , many authors use a system of three degrees , which includes mild , moderate and severe sprains . Despite this scientific categories , in our opinion is the differentiation between elongation and complete ruptures of practical relevance . Under a biomechanical point of view , ligamentous trauma of the lateral ligaments lead to acute antero-lateral rotational instability ( ALRI ) . Following the retrospective clinical study of Zwipp with 1235 patients , in 70 % of complete disruptions , the anterior talo-naviculare and fibulo-calcanear ligaments are involved together . Syndesmotic injuries have been reported at a rate up to 10 % of ankle sprains with deltoid ligaments at 2,5 % . Rarely , the classic ankle sprain leads to injuries which affect the foot on a so called " supination fracture line " . A rate of 7,4 % is reported for these accompanying injuries . Therefore , clinical examination of ankle sprains should not only address on the distal tip of the fibula . Critical bony and ligamentous structures like the fifth metatarsal base , the calcaneo-cuboideal ligament , the ligaments of the anterior calcaneal process , the talus and syndesmotic ligaments have to be screened for pain and swelling . In our opinion , careful clinical examination and plain radiographs in two plains are sufficient for diagnosing ankle sprains and functional therapy .
[ "Sprains", "in", "the", "lateral", "ligaments", "of", "the", "ankle", "produce", "the", "most", "common", "ligamentous", "injuries", "of", "the", "human", "body", ".", "The", "mechanism", "of", "injury", "is", "complex", ",", "while", "supination", "represents", "the", "main", "component", "of", "foot", "movement", ".", "Classifying", "lateral", "ankle", "ligament", "injuries", ",", "many", "authors", "use", "a", "system", "of", "three", "degrees", ",", "which", "includes", "mild", ",", "moderate", "and", "severe", "sprains", ".", "Despite", "this", "scientific", "categories", ",", "in", "our", "opinion", "is", "the", "differentiation", "between", "elongation", "and", "complete", "ruptures", "of", "practical", "relevance", ".", "Under", "a", "biomechanical", "point", "of", "view", ",", "ligamentous", "trauma", "of", "the", "lateral", "ligaments", "lead", "to", "acute", "antero", "-", "lateral", "rotational", "instability", "(", "ALRI", ")", ".", "Following", "the", "retrospective", "clinical", "study", "of", "Zwipp", "with", "1235", "patients", ",", "in", "70", "%", "of", "complete", "disruptions", ",", "the", "anterior", "talo", "-", "naviculare", "and", "fibulo", "-", "calcanear", "ligaments", "are", "involved", "together", ".", "Syndesmotic", "injuries", "have", "been", "reported", "at", "a", "rate", "up", "to", "10", "%", "of", "ankle", "sprains", "with", "deltoid", "ligaments", "at", "2,5", "%", ".", "Rarely", ",", "the", "classic", "ankle", "sprain", "leads", "to", "injuries", "which", "affect", "the", "foot", "on", "a", "so", "called", "\"", "supination", "fracture", "line", "\"", ".", "A", "rate", "of", "7,4", "%", "is", "reported", "for", "these", "accompanying", "injuries", ".", "Therefore", ",", "clinical", "examination", "of", "ankle", "sprains", "should", "not", "only", "address", "on", "the", "distal", "tip", "of", "the", "fibula", ".", "Critical", "bony", "and", "ligamentous", "structures", "like", "the", "fifth", "metatarsal", "base", ",", "the", "calcaneo", "-", "cuboideal", "ligament", ",", "the", "ligaments", "of", "the", "anterior", "calcaneal", "process", ",", "the", "talus", "and", "syndesmotic", "ligaments", "have", "to", "be", "screened", "for", "pain", "and", "swelling", ".", "In", "our", "opinion", ",", "careful", "clinical", "examination", "and", "plain", "radiographs", "in", "two", "plains", "are", "sufficient", "for", "diagnosing", "ankle", "sprains", "and", "functional", "therapy", "." ]
[ "umlsterm" ]
Sprains, lateral ligaments, ankle, injuries, human body, injury, supination, foot, movement, ankle, ligament, injuries, sprains, ruptures, trauma, lateral ligaments, ALRI, retrospective, clinical study, patients, anterior, ligaments, injuries, ankle, sprains, ligaments, ankle, leads, injuries, foot, supination, fracture, line, injuries, clinical examination, ankle, sprains, tip, fibula, metatarsal, ligament, ligaments, anterior, talus, ligaments, pain, clinical examination, radiographs, ankle, sprains, therapy
DerOrthopaede.90280469.eng.abstr_task2
Sentence: Sprains in the lateral ligaments of the ankle produce the most common ligamentous injuries of the human body . The mechanism of injury is complex , while supination represents the main component of foot movement . Classifying lateral ankle ligament injuries , many authors use a system of three degrees , which includes mild , moderate and severe sprains . Despite this scientific categories , in our opinion is the differentiation between elongation and complete ruptures of practical relevance . Under a biomechanical point of view , ligamentous trauma of the lateral ligaments lead to acute antero-lateral rotational instability ( ALRI ) . Following the retrospective clinical study of Zwipp with 1235 patients , in 70 % of complete disruptions , the anterior talo-naviculare and fibulo-calcanear ligaments are involved together . Syndesmotic injuries have been reported at a rate up to 10 % of ankle sprains with deltoid ligaments at 2,5 % . Rarely , the classic ankle sprain leads to injuries which affect the foot on a so called " supination fracture line " . A rate of 7,4 % is reported for these accompanying injuries . Therefore , clinical examination of ankle sprains should not only address on the distal tip of the fibula . Critical bony and ligamentous structures like the fifth metatarsal base , the calcaneo-cuboideal ligament , the ligaments of the anterior calcaneal process , the talus and syndesmotic ligaments have to be screened for pain and swelling . In our opinion , careful clinical examination and plain radiographs in two plains are sufficient for diagnosing ankle sprains and functional therapy . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Sprains in the lateral ligaments of the ankle produce the most common ligamentous injuries of the human body . The mechanism of injury is complex , while supination represents the main component of foot movement . Classifying lateral ankle ligament injuries , many authors use a system of three degrees , which includes mild , moderate and severe sprains . Despite this scientific categories , in our opinion is the differentiation between elongation and complete ruptures of practical relevance . Under a biomechanical point of view , ligamentous trauma of the lateral ligaments lead to acute antero-lateral rotational instability ( ALRI ) . Following the retrospective clinical study of Zwipp with 1235 patients , in 70 % of complete disruptions , the anterior talo-naviculare and fibulo-calcanear ligaments are involved together . Syndesmotic injuries have been reported at a rate up to 10 % of ankle sprains with deltoid ligaments at 2,5 % . Rarely , the classic ankle sprain leads to injuries which affect the foot on a so called " supination fracture line " . A rate of 7,4 % is reported for these accompanying injuries . Therefore , clinical examination of ankle sprains should not only address on the distal tip of the fibula . Critical bony and ligamentous structures like the fifth metatarsal base , the calcaneo-cuboideal ligament , the ligaments of the anterior calcaneal process , the talus and syndesmotic ligaments have to be screened for pain and swelling . In our opinion , careful clinical examination and plain radiographs in two plains are sufficient for diagnosing ankle sprains and functional therapy .
[ "Sprains", "in", "the", "lateral", "ligaments", "of", "the", "ankle", "produce", "the", "most", "common", "ligamentous", "injuries", "of", "the", "human", "body", ".", "The", "mechanism", "of", "injury", "is", "complex", ",", "while", "supination", "represents", "the", "main", "component", "of", "foot", "movement", ".", "Classifying", "lateral", "ankle", "ligament", "injuries", ",", "many", "authors", "use", "a", "system", "of", "three", "degrees", ",", "which", "includes", "mild", ",", "moderate", "and", "severe", "sprains", ".", "Despite", "this", "scientific", "categories", ",", "in", "our", "opinion", "is", "the", "differentiation", "between", "elongation", "and", "complete", "ruptures", "of", "practical", "relevance", ".", "Under", "a", "biomechanical", "point", "of", "view", ",", "ligamentous", "trauma", "of", "the", "lateral", "ligaments", "lead", "to", "acute", "antero", "-", "lateral", "rotational", "instability", "(", "ALRI", ")", ".", "Following", "the", "retrospective", "clinical", "study", "of", "Zwipp", "with", "1235", "patients", ",", "in", "70", "%", "of", "complete", "disruptions", ",", "the", "anterior", "talo", "-", "naviculare", "and", "fibulo", "-", "calcanear", "ligaments", "are", "involved", "together", ".", "Syndesmotic", "injuries", "have", "been", "reported", "at", "a", "rate", "up", "to", "10", "%", "of", "ankle", "sprains", "with", "deltoid", "ligaments", "at", "2,5", "%", ".", "Rarely", ",", "the", "classic", "ankle", "sprain", "leads", "to", "injuries", "which", "affect", "the", "foot", "on", "a", "so", "called", "\"", "supination", "fracture", "line", "\"", ".", "A", "rate", "of", "7,4", "%", "is", "reported", "for", "these", "accompanying", "injuries", ".", "Therefore", ",", "clinical", "examination", "of", "ankle", "sprains", "should", "not", "only", "address", "on", "the", "distal", "tip", "of", "the", "fibula", ".", "Critical", "bony", "and", "ligamentous", "structures", "like", "the", "fifth", "metatarsal", "base", ",", "the", "calcaneo", "-", "cuboideal", "ligament", ",", "the", "ligaments", "of", "the", "anterior", "calcaneal", "process", ",", "the", "talus", "and", "syndesmotic", "ligaments", "have", "to", "be", "screened", "for", "pain", "and", "swelling", ".", "In", "our", "opinion", ",", "careful", "clinical", "examination", "and", "plain", "radiographs", "in", "two", "plains", "are", "sufficient", "for", "diagnosing", "ankle", "sprains", "and", "functional", "therapy", "." ]
[ "umlsterm" ]
cerebral veins is an umlsterm, frequency is an umlsterm, autopsy is an umlsterm, hematological disorders is an umlsterm, neoplasms is an umlsterm, brain is an umlsterm, colitis is an umlsterm, life is an umlsterm, headache is an umlsterm, vertigo is an umlsterm, abnormality is an umlsterm, physician is an umlsterm, hospital is an umlsterm, comatose is an umlsterm, neurological examination is an umlsterm, decerebrate state is an umlsterm, pupils is an umlsterm, light is an umlsterm, bulbi is an umlsterm, extensor plantar responses is an umlsterm, computer is an umlsterm, cerebral edema is an umlsterm, hemorrhage is an umlsterm, basal ganglia is an umlsterm, cerebral ventricles is an umlsterm, right is an umlsterm, ganglia is an umlsterm, corpus callosum is an umlsterm, right is an umlsterm, therapy is an umlsterm, thrombosis is an umlsterm, sinus is an umlsterm, cerebral veins is an umlsterm, infarction is an umlsterm, thalamus is an umlsterm, basal ganglia is an umlsterm, hemorrhage is an umlsterm, thrombus is an umlsterm, sinus is an umlsterm, signs is an umlsterm, origin is an umlsterm, disorder is an umlsterm, colitis is an umlsterm, cause is an umlsterm
Rechtsmedizin.90090148.eng.abstr_task0
Sentence: Thromboses of the cerebral veins which occur at a frequency of 3.75 to 9.3% in autopsy material are caused by local or systemic inflammatory processes , hematological disorders , neoplasms or traumatic brain damage . We report on a 14-year-old girl who suffered from colitis ulcerosa during the last 4 years of life . Immediately after a brawl with a schoolboy she complained of headache and vertigo , but no physical abnormality was detected by the physician . She was admitted to the hospital after becoming comatose during the following night . On neurological examination she was comatous with a decerebrate state , the pupils were small and non-reactive to light , divergent ocular bulbi and bilateral extensor plantar responses . A cerebral computer tomogramm showed a cerebral edema and a hemorrhage in the left basal ganglia and both cerebral ventricles which subsequently increased to the right cerebral ganglia , the corpus callosum and the right cerebral hemisphere . Despite antiedematous therapy the girl died on the second day after the brawl . A neuropathology examination revealed thrombosis of the superior sagittal sinus extending to the internal cerebral veins and a bilateral hemorrhagic infarction of the thalamus and the basal ganglia with intraventricular hemorrhage . As the thrombus in the sagittal sinus showed signs of organisation , a postraumatic origin alone is improbable and a hemorrheological disorder due to colitis ulcerosa seemed to be the main cause . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Thromboses of the cerebral veins which occur at a frequency of 3.75 to 9.3% in autopsy material are caused by local or systemic inflammatory processes , hematological disorders , neoplasms or traumatic brain damage . We report on a 14-year-old girl who suffered from colitis ulcerosa during the last 4 years of life . Immediately after a brawl with a schoolboy she complained of headache and vertigo , but no physical abnormality was detected by the physician . She was admitted to the hospital after becoming comatose during the following night . On neurological examination she was comatous with a decerebrate state , the pupils were small and non-reactive to light , divergent ocular bulbi and bilateral extensor plantar responses . A cerebral computer tomogramm showed a cerebral edema and a hemorrhage in the left basal ganglia and both cerebral ventricles which subsequently increased to the right cerebral ganglia , the corpus callosum and the right cerebral hemisphere . Despite antiedematous therapy the girl died on the second day after the brawl . A neuropathology examination revealed thrombosis of the superior sagittal sinus extending to the internal cerebral veins and a bilateral hemorrhagic infarction of the thalamus and the basal ganglia with intraventricular hemorrhage . As the thrombus in the sagittal sinus showed signs of organisation , a postraumatic origin alone is improbable and a hemorrheological disorder due to colitis ulcerosa seemed to be the main cause .
[ "Thromboses", "of", "the", "cerebral", "veins", "which", "occur", "at", "a", "frequency", "of", "3.75", "to", "9.3", "%", "in", "autopsy", "material", "are", "caused", "by", "local", "or", "systemic", "inflammatory", "processes", ",", "hematological", "disorders", ",", "neoplasms", "or", "traumatic", "brain", "damage", ".", "We", "report", "on", "a", "14-year", "-", "old", "girl", "who", "suffered", "from", "colitis", "ulcerosa", "during", "the", "last", "4", "years", "of", "life", ".", "Immediately", "after", "a", "brawl", "with", "a", "schoolboy", "she", "complained", "of", "headache", "and", "vertigo", ",", "but", "no", "physical", "abnormality", "was", "detected", "by", "the", "physician", ".", "She", "was", "admitted", "to", "the", "hospital", "after", "becoming", "comatose", "during", "the", "following", "night", ".", "On", "neurological", "examination", "she", "was", "comatous", "with", "a", "decerebrate", "state", ",", "the", "pupils", "were", "small", "and", "non", "-", "reactive", "to", "light", ",", "divergent", "ocular", "bulbi", "and", "bilateral", "extensor", "plantar", "responses", ".", "A", "cerebral", "computer", "tomogramm", "showed", "a", "cerebral", "edema", "and", "a", "hemorrhage", "in", "the", "left", "basal", "ganglia", "and", "both", "cerebral", "ventricles", "which", "subsequently", "increased", "to", "the", "right", "cerebral", "ganglia", ",", "the", "corpus", "callosum", "and", "the", "right", "cerebral", "hemisphere", ".", "Despite", "antiedematous", "therapy", "the", "girl", "died", "on", "the", "second", "day", "after", "the", "brawl", ".", "A", "neuropathology", "examination", "revealed", "thrombosis", "of", "the", "superior", "sagittal", "sinus", "extending", "to", "the", "internal", "cerebral", "veins", "and", "a", "bilateral", "hemorrhagic", "infarction", "of", "the", "thalamus", "and", "the", "basal", "ganglia", "with", "intraventricular", "hemorrhage", ".", "As", "the", "thrombus", "in", "the", "sagittal", "sinus", "showed", "signs", "of", "organisation", ",", "a", "postraumatic", "origin", "alone", "is", "improbable", "and", "a", "hemorrheological", "disorder", "due", "to", "colitis", "ulcerosa", "seemed", "to", "be", "the", "main", "cause", "." ]
[ "umlsterm" ]
cerebral veins is an umlsterm, frequency is an umlsterm, autopsy is an umlsterm, hematological disorders is an umlsterm, neoplasms is an umlsterm, brain is an umlsterm, colitis is an umlsterm, life is an umlsterm, headache is an umlsterm, vertigo is an umlsterm, abnormality is an umlsterm, physician is an umlsterm, hospital is an umlsterm, comatose is an umlsterm, neurological examination is an umlsterm, decerebrate state is an umlsterm, pupils is an umlsterm, light is an umlsterm, bulbi is an umlsterm, extensor plantar responses is an umlsterm, computer is an umlsterm, cerebral edema is an umlsterm, hemorrhage is an umlsterm, basal ganglia is an umlsterm, cerebral ventricles is an umlsterm, right is an umlsterm, ganglia is an umlsterm, corpus callosum is an umlsterm, right is an umlsterm, therapy is an umlsterm, thrombosis is an umlsterm, sinus is an umlsterm, cerebral veins is an umlsterm, infarction is an umlsterm, thalamus is an umlsterm, basal ganglia is an umlsterm, hemorrhage is an umlsterm, thrombus is an umlsterm, sinus is an umlsterm, signs is an umlsterm, origin is an umlsterm, disorder is an umlsterm, colitis is an umlsterm, cause is an umlsterm
Rechtsmedizin.90090148.eng.abstr_task1
Sentence: Thromboses of the cerebral veins which occur at a frequency of 3.75 to 9.3% in autopsy material are caused by local or systemic inflammatory processes , hematological disorders , neoplasms or traumatic brain damage . We report on a 14-year-old girl who suffered from colitis ulcerosa during the last 4 years of life . Immediately after a brawl with a schoolboy she complained of headache and vertigo , but no physical abnormality was detected by the physician . She was admitted to the hospital after becoming comatose during the following night . On neurological examination she was comatous with a decerebrate state , the pupils were small and non-reactive to light , divergent ocular bulbi and bilateral extensor plantar responses . A cerebral computer tomogramm showed a cerebral edema and a hemorrhage in the left basal ganglia and both cerebral ventricles which subsequently increased to the right cerebral ganglia , the corpus callosum and the right cerebral hemisphere . Despite antiedematous therapy the girl died on the second day after the brawl . A neuropathology examination revealed thrombosis of the superior sagittal sinus extending to the internal cerebral veins and a bilateral hemorrhagic infarction of the thalamus and the basal ganglia with intraventricular hemorrhage . As the thrombus in the sagittal sinus showed signs of organisation , a postraumatic origin alone is improbable and a hemorrheological disorder due to colitis ulcerosa seemed to be the main cause . Instructions: please typing these entity words according to sentence: cerebral veins, frequency, autopsy, hematological disorders, neoplasms, brain, colitis, life, headache, vertigo, abnormality, physician, hospital, comatose, neurological examination, decerebrate state, pupils, light, bulbi, extensor plantar responses, computer, cerebral edema, hemorrhage, basal ganglia, cerebral ventricles, right, ganglia, corpus callosum, right, therapy, thrombosis, sinus, cerebral veins, infarction, thalamus, basal ganglia, hemorrhage, thrombus, sinus, signs, origin, disorder, colitis, cause Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Thromboses of the cerebral veins which occur at a frequency of 3.75 to 9.3% in autopsy material are caused by local or systemic inflammatory processes , hematological disorders , neoplasms or traumatic brain damage . We report on a 14-year-old girl who suffered from colitis ulcerosa during the last 4 years of life . Immediately after a brawl with a schoolboy she complained of headache and vertigo , but no physical abnormality was detected by the physician . She was admitted to the hospital after becoming comatose during the following night . On neurological examination she was comatous with a decerebrate state , the pupils were small and non-reactive to light , divergent ocular bulbi and bilateral extensor plantar responses . A cerebral computer tomogramm showed a cerebral edema and a hemorrhage in the left basal ganglia and both cerebral ventricles which subsequently increased to the right cerebral ganglia , the corpus callosum and the right cerebral hemisphere . Despite antiedematous therapy the girl died on the second day after the brawl . A neuropathology examination revealed thrombosis of the superior sagittal sinus extending to the internal cerebral veins and a bilateral hemorrhagic infarction of the thalamus and the basal ganglia with intraventricular hemorrhage . As the thrombus in the sagittal sinus showed signs of organisation , a postraumatic origin alone is improbable and a hemorrheological disorder due to colitis ulcerosa seemed to be the main cause .
[ "Thromboses", "of", "the", "cerebral", "veins", "which", "occur", "at", "a", "frequency", "of", "3.75", "to", "9.3", "%", "in", "autopsy", "material", "are", "caused", "by", "local", "or", "systemic", "inflammatory", "processes", ",", "hematological", "disorders", ",", "neoplasms", "or", "traumatic", "brain", "damage", ".", "We", "report", "on", "a", "14-year", "-", "old", "girl", "who", "suffered", "from", "colitis", "ulcerosa", "during", "the", "last", "4", "years", "of", "life", ".", "Immediately", "after", "a", "brawl", "with", "a", "schoolboy", "she", "complained", "of", "headache", "and", "vertigo", ",", "but", "no", "physical", "abnormality", "was", "detected", "by", "the", "physician", ".", "She", "was", "admitted", "to", "the", "hospital", "after", "becoming", "comatose", "during", "the", "following", "night", ".", "On", "neurological", "examination", "she", "was", "comatous", "with", "a", "decerebrate", "state", ",", "the", "pupils", "were", "small", "and", "non", "-", "reactive", "to", "light", ",", "divergent", "ocular", "bulbi", "and", "bilateral", "extensor", "plantar", "responses", ".", "A", "cerebral", "computer", "tomogramm", "showed", "a", "cerebral", "edema", "and", "a", "hemorrhage", "in", "the", "left", "basal", "ganglia", "and", "both", "cerebral", "ventricles", "which", "subsequently", "increased", "to", "the", "right", "cerebral", "ganglia", ",", "the", "corpus", "callosum", "and", "the", "right", "cerebral", "hemisphere", ".", "Despite", "antiedematous", "therapy", "the", "girl", "died", "on", "the", "second", "day", "after", "the", "brawl", ".", "A", "neuropathology", "examination", "revealed", "thrombosis", "of", "the", "superior", "sagittal", "sinus", "extending", "to", "the", "internal", "cerebral", "veins", "and", "a", "bilateral", "hemorrhagic", "infarction", "of", "the", "thalamus", "and", "the", "basal", "ganglia", "with", "intraventricular", "hemorrhage", ".", "As", "the", "thrombus", "in", "the", "sagittal", "sinus", "showed", "signs", "of", "organisation", ",", "a", "postraumatic", "origin", "alone", "is", "improbable", "and", "a", "hemorrheological", "disorder", "due", "to", "colitis", "ulcerosa", "seemed", "to", "be", "the", "main", "cause", "." ]
[ "umlsterm" ]
cerebral veins, frequency, autopsy, hematological disorders, neoplasms, brain, colitis, life, headache, vertigo, abnormality, physician, hospital, comatose, neurological examination, decerebrate state, pupils, light, bulbi, extensor plantar responses, computer, cerebral edema, hemorrhage, basal ganglia, cerebral ventricles, right, ganglia, corpus callosum, right, therapy, thrombosis, sinus, cerebral veins, infarction, thalamus, basal ganglia, hemorrhage, thrombus, sinus, signs, origin, disorder, colitis, cause
Rechtsmedizin.90090148.eng.abstr_task2
Sentence: Thromboses of the cerebral veins which occur at a frequency of 3.75 to 9.3% in autopsy material are caused by local or systemic inflammatory processes , hematological disorders , neoplasms or traumatic brain damage . We report on a 14-year-old girl who suffered from colitis ulcerosa during the last 4 years of life . Immediately after a brawl with a schoolboy she complained of headache and vertigo , but no physical abnormality was detected by the physician . She was admitted to the hospital after becoming comatose during the following night . On neurological examination she was comatous with a decerebrate state , the pupils were small and non-reactive to light , divergent ocular bulbi and bilateral extensor plantar responses . A cerebral computer tomogramm showed a cerebral edema and a hemorrhage in the left basal ganglia and both cerebral ventricles which subsequently increased to the right cerebral ganglia , the corpus callosum and the right cerebral hemisphere . Despite antiedematous therapy the girl died on the second day after the brawl . A neuropathology examination revealed thrombosis of the superior sagittal sinus extending to the internal cerebral veins and a bilateral hemorrhagic infarction of the thalamus and the basal ganglia with intraventricular hemorrhage . As the thrombus in the sagittal sinus showed signs of organisation , a postraumatic origin alone is improbable and a hemorrheological disorder due to colitis ulcerosa seemed to be the main cause . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Thromboses of the cerebral veins which occur at a frequency of 3.75 to 9.3% in autopsy material are caused by local or systemic inflammatory processes , hematological disorders , neoplasms or traumatic brain damage . We report on a 14-year-old girl who suffered from colitis ulcerosa during the last 4 years of life . Immediately after a brawl with a schoolboy she complained of headache and vertigo , but no physical abnormality was detected by the physician . She was admitted to the hospital after becoming comatose during the following night . On neurological examination she was comatous with a decerebrate state , the pupils were small and non-reactive to light , divergent ocular bulbi and bilateral extensor plantar responses . A cerebral computer tomogramm showed a cerebral edema and a hemorrhage in the left basal ganglia and both cerebral ventricles which subsequently increased to the right cerebral ganglia , the corpus callosum and the right cerebral hemisphere . Despite antiedematous therapy the girl died on the second day after the brawl . A neuropathology examination revealed thrombosis of the superior sagittal sinus extending to the internal cerebral veins and a bilateral hemorrhagic infarction of the thalamus and the basal ganglia with intraventricular hemorrhage . As the thrombus in the sagittal sinus showed signs of organisation , a postraumatic origin alone is improbable and a hemorrheological disorder due to colitis ulcerosa seemed to be the main cause .
[ "Thromboses", "of", "the", "cerebral", "veins", "which", "occur", "at", "a", "frequency", "of", "3.75", "to", "9.3", "%", "in", "autopsy", "material", "are", "caused", "by", "local", "or", "systemic", "inflammatory", "processes", ",", "hematological", "disorders", ",", "neoplasms", "or", "traumatic", "brain", "damage", ".", "We", "report", "on", "a", "14-year", "-", "old", "girl", "who", "suffered", "from", "colitis", "ulcerosa", "during", "the", "last", "4", "years", "of", "life", ".", "Immediately", "after", "a", "brawl", "with", "a", "schoolboy", "she", "complained", "of", "headache", "and", "vertigo", ",", "but", "no", "physical", "abnormality", "was", "detected", "by", "the", "physician", ".", "She", "was", "admitted", "to", "the", "hospital", "after", "becoming", "comatose", "during", "the", "following", "night", ".", "On", "neurological", "examination", "she", "was", "comatous", "with", "a", "decerebrate", "state", ",", "the", "pupils", "were", "small", "and", "non", "-", "reactive", "to", "light", ",", "divergent", "ocular", "bulbi", "and", "bilateral", "extensor", "plantar", "responses", ".", "A", "cerebral", "computer", "tomogramm", "showed", "a", "cerebral", "edema", "and", "a", "hemorrhage", "in", "the", "left", "basal", "ganglia", "and", "both", "cerebral", "ventricles", "which", "subsequently", "increased", "to", "the", "right", "cerebral", "ganglia", ",", "the", "corpus", "callosum", "and", "the", "right", "cerebral", "hemisphere", ".", "Despite", "antiedematous", "therapy", "the", "girl", "died", "on", "the", "second", "day", "after", "the", "brawl", ".", "A", "neuropathology", "examination", "revealed", "thrombosis", "of", "the", "superior", "sagittal", "sinus", "extending", "to", "the", "internal", "cerebral", "veins", "and", "a", "bilateral", "hemorrhagic", "infarction", "of", "the", "thalamus", "and", "the", "basal", "ganglia", "with", "intraventricular", "hemorrhage", ".", "As", "the", "thrombus", "in", "the", "sagittal", "sinus", "showed", "signs", "of", "organisation", ",", "a", "postraumatic", "origin", "alone", "is", "improbable", "and", "a", "hemorrheological", "disorder", "due", "to", "colitis", "ulcerosa", "seemed", "to", "be", "the", "main", "cause", "." ]
[ "umlsterm" ]
standard wound care is a Intervention_Physical, adjunctive hyperbaric oxygen therapy ( HBOT ) is a Intervention_Physical, chronic , non - healing ulcers of the lower limb is a Participant_Condition, diabetes mellitus is a Participant_Condition, diabetic foot ulcers is a Outcome_Physical, lower extremity amputations is a Outcome_Physical, hyperbaric oxygen therapy plus standard wound care is a Intervention_Physical, major amputation is a Outcome_Other, chronic ulcers is a Participant_Condition, One hundred and eighteen is a Participant_Sample-size, 59 is a Participant_Sample-size, non - healing diabetic ulcers of the lower limb is a Participant_Condition, 18 years of age is a Participant_Age, Type 1 or 2 diabetes is a Participant_Condition, Wagner grading of foot lesions 2 , 3 or 4 on lower limb not healing for at least 4 weeks is a Participant_Condition, freedom from having , or meeting the criteria for , a major amputation ( below knee amputation , or metatarsal level ) is a Outcome_Physical, wound healing is a Outcome_Physical, effectiveness is a Outcome_Other, safety is a Outcome_Other, healthcare resource utilization is a Outcome_Other, quality of life is a Outcome_Mental, cost - effectiveness is a Outcome_Physical
49438_task0
Sentence: A prospective , double-blind , randomized , controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy ( HBOT ) to standard wound care only for the treatment of chronic , non-healing ulcers of the lower limb in patients with diabetes mellitus : a study protocol . BACKGROUND It has been suggested that the use of adjunctive hyperbaric oxygen therapy improves the healing of diabetic foot ulcers , and decreases the risk of lower extremity amputations . A limited number of studies have used a double blind approach to evaluate the efficacy of hyperbaric oxygen therapy in the treatment of diabetic ulcers . The primary aim of this study is to assess the efficacy of hyperbaric oxygen therapy plus standard wound care compared with standard wound care alone in preventing the need for major amputation in patients with diabetes mellitus and chronic ulcers of the lower limb . METHODS/DESIGN One hundred and eighteen ( 59 patients per arm ) patients with non-healing diabetic ulcers of the lower limb , referred to the Judy Dan Research and Treatment Centre are being recruited if they are at least 18 years of age , have either Type 1 or 2 diabetes with a Wagner grading of foot lesions 2 , 3 or 4 on lower limb not healing for at least 4 weeks . Patients receive hyperbaric oxygen therapy every day for 6 weeks during the treatment phase and are provided ongoing wound care and weekly assessments . Patients are required to return to the study centre every week for an additional 6 weeks of follow-up for wound evaluation and management . The primary outcome is freedom from having , or meeting the criteria for , a major amputation ( below knee amputation , or metatarsal level ) up to 12 weeks after randomization . The decision to amputate is made by a vascular surgeon . Other outcomes include wound healing , effectiveness , safety , healthcare resource utilization , quality of life , and cost-effectiveness . The study will run for a total of about 3 years . DISCUSSION The results of this study will provide detailed information on the efficacy of hyperbaric oxygen therapy for the treatment of non-healing ulcers of the lower limb . This will be the first double-blind randomized controlled trial for this health technology which evaluates the efficacy of hyperbaric oxygen therapy in prevention of amputations in diabetic patients . TRIAL REGISTRATION ClinicalTrials.gov Identifier : NCT00621608 . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A prospective , double-blind , randomized , controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy ( HBOT ) to standard wound care only for the treatment of chronic , non-healing ulcers of the lower limb in patients with diabetes mellitus : a study protocol . BACKGROUND It has been suggested that the use of adjunctive hyperbaric oxygen therapy improves the healing of diabetic foot ulcers , and decreases the risk of lower extremity amputations . A limited number of studies have used a double blind approach to evaluate the efficacy of hyperbaric oxygen therapy in the treatment of diabetic ulcers . The primary aim of this study is to assess the efficacy of hyperbaric oxygen therapy plus standard wound care compared with standard wound care alone in preventing the need for major amputation in patients with diabetes mellitus and chronic ulcers of the lower limb . METHODS/DESIGN One hundred and eighteen ( 59 patients per arm ) patients with non-healing diabetic ulcers of the lower limb , referred to the Judy Dan Research and Treatment Centre are being recruited if they are at least 18 years of age , have either Type 1 or 2 diabetes with a Wagner grading of foot lesions 2 , 3 or 4 on lower limb not healing for at least 4 weeks . Patients receive hyperbaric oxygen therapy every day for 6 weeks during the treatment phase and are provided ongoing wound care and weekly assessments . Patients are required to return to the study centre every week for an additional 6 weeks of follow-up for wound evaluation and management . The primary outcome is freedom from having , or meeting the criteria for , a major amputation ( below knee amputation , or metatarsal level ) up to 12 weeks after randomization . The decision to amputate is made by a vascular surgeon . Other outcomes include wound healing , effectiveness , safety , healthcare resource utilization , quality of life , and cost-effectiveness . The study will run for a total of about 3 years . DISCUSSION The results of this study will provide detailed information on the efficacy of hyperbaric oxygen therapy for the treatment of non-healing ulcers of the lower limb . This will be the first double-blind randomized controlled trial for this health technology which evaluates the efficacy of hyperbaric oxygen therapy in prevention of amputations in diabetic patients . TRIAL REGISTRATION ClinicalTrials.gov Identifier : NCT00621608 .
[ "A", "prospective", ",", "double", "-", "blind", ",", "randomized", ",", "controlled", "clinical", "trial", "comparing", "standard", "wound", "care", "with", "adjunctive", "hyperbaric", "oxygen", "therapy", "(", "HBOT", ")", "to", "standard", "wound", "care", "only", "for", "the", "treatment", "of", "chronic", ",", "non", "-", "healing", "ulcers", "of", "the", "lower", "limb", "in", "patients", "with", "diabetes", "mellitus", ":", "a", "study", "protocol", ".", "BACKGROUND", "It", "has", "been", "suggested", "that", "the", "use", "of", "adjunctive", "hyperbaric", "oxygen", "therapy", "improves", "the", "healing", "of", "diabetic", "foot", "ulcers", ",", "and", "decreases", "the", "risk", "of", "lower", "extremity", "amputations", ".", "A", "limited", "number", "of", "studies", "have", "used", "a", "double", "blind", "approach", "to", "evaluate", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "in", "the", "treatment", "of", "diabetic", "ulcers", ".", "The", "primary", "aim", "of", "this", "study", "is", "to", "assess", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "plus", "standard", "wound", "care", "compared", "with", "standard", "wound", "care", "alone", "in", "preventing", "the", "need", "for", "major", "amputation", "in", "patients", "with", "diabetes", "mellitus", "and", "chronic", "ulcers", "of", "the", "lower", "limb", ".", "METHODS", "/", "DESIGN", "One", "hundred", "and", "eighteen", "(", "59", "patients", "per", "arm", ")", "patients", "with", "non", "-", "healing", "diabetic", "ulcers", "of", "the", "lower", "limb", ",", "referred", "to", "the", "Judy", "Dan", "Research", "and", "Treatment", "Centre", "are", "being", "recruited", "if", "they", "are", "at", "least", "18", "years", "of", "age", ",", "have", "either", "Type", "1", "or", "2", "diabetes", "with", "a", "Wagner", "grading", "of", "foot", "lesions", "2", ",", "3", "or", "4", "on", "lower", "limb", "not", "healing", "for", "at", "least", "4", "weeks", ".", "Patients", "receive", "hyperbaric", "oxygen", "therapy", "every", "day", "for", "6", "weeks", "during", "the", "treatment", "phase", "and", "are", "provided", "ongoing", "wound", "care", "and", "weekly", "assessments", ".", "Patients", "are", "required", "to", "return", "to", "the", "study", "centre", "every", "week", "for", "an", "additional", "6", "weeks", "of", "follow", "-", "up", "for", "wound", "evaluation", "and", "management", ".", "The", "primary", "outcome", "is", "freedom", "from", "having", ",", "or", "meeting", "the", "criteria", "for", ",", "a", "major", "amputation", "(", "below", "knee", "amputation", ",", "or", "metatarsal", "level", ")", "up", "to", "12", "weeks", "after", "randomization", ".", "The", "decision", "to", "amputate", "is", "made", "by", "a", "vascular", "surgeon", ".", "Other", "outcomes", "include", "wound", "healing", ",", "effectiveness", ",", "safety", ",", "healthcare", "resource", "utilization", ",", "quality", "of", "life", ",", "and", "cost", "-", "effectiveness", ".", "The", "study", "will", "run", "for", "a", "total", "of", "about", "3", "years", ".", "DISCUSSION", "The", "results", "of", "this", "study", "will", "provide", "detailed", "information", "on", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "for", "the", "treatment", "of", "non", "-", "healing", "ulcers", "of", "the", "lower", "limb", ".", "This", "will", "be", "the", "first", "double", "-", "blind", "randomized", "controlled", "trial", "for", "this", "health", "technology", "which", "evaluates", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "in", "prevention", "of", "amputations", "in", "diabetic", "patients", ".", "TRIAL", "REGISTRATION", "ClinicalTrials.gov", "Identifier", ":", "NCT00621608", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Physical", "Outcome_Other", "Participant_Sample-size", "Outcome_Mental", "Participant_Age", "Outcome_Adverse-effects" ]
standard wound care is a Intervention_Physical, adjunctive hyperbaric oxygen therapy ( HBOT ) is a Intervention_Physical, chronic , non - healing ulcers of the lower limb is a Participant_Condition, diabetes mellitus is a Participant_Condition, diabetic foot ulcers is a Outcome_Physical, lower extremity amputations is a Outcome_Physical, hyperbaric oxygen therapy plus standard wound care is a Intervention_Physical, major amputation is a Outcome_Other, chronic ulcers is a Participant_Condition, One hundred and eighteen is a Participant_Sample-size, 59 is a Participant_Sample-size, non - healing diabetic ulcers of the lower limb is a Participant_Condition, 18 years of age is a Participant_Age, Type 1 or 2 diabetes is a Participant_Condition, Wagner grading of foot lesions 2 , 3 or 4 on lower limb not healing for at least 4 weeks is a Participant_Condition, freedom from having , or meeting the criteria for , a major amputation ( below knee amputation , or metatarsal level ) is a Outcome_Physical, wound healing is a Outcome_Physical, effectiveness is a Outcome_Other, safety is a Outcome_Other, healthcare resource utilization is a Outcome_Other, quality of life is a Outcome_Mental, cost - effectiveness is a Outcome_Physical
49438_task1
Sentence: A prospective , double-blind , randomized , controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy ( HBOT ) to standard wound care only for the treatment of chronic , non-healing ulcers of the lower limb in patients with diabetes mellitus : a study protocol . BACKGROUND It has been suggested that the use of adjunctive hyperbaric oxygen therapy improves the healing of diabetic foot ulcers , and decreases the risk of lower extremity amputations . A limited number of studies have used a double blind approach to evaluate the efficacy of hyperbaric oxygen therapy in the treatment of diabetic ulcers . The primary aim of this study is to assess the efficacy of hyperbaric oxygen therapy plus standard wound care compared with standard wound care alone in preventing the need for major amputation in patients with diabetes mellitus and chronic ulcers of the lower limb . METHODS/DESIGN One hundred and eighteen ( 59 patients per arm ) patients with non-healing diabetic ulcers of the lower limb , referred to the Judy Dan Research and Treatment Centre are being recruited if they are at least 18 years of age , have either Type 1 or 2 diabetes with a Wagner grading of foot lesions 2 , 3 or 4 on lower limb not healing for at least 4 weeks . Patients receive hyperbaric oxygen therapy every day for 6 weeks during the treatment phase and are provided ongoing wound care and weekly assessments . Patients are required to return to the study centre every week for an additional 6 weeks of follow-up for wound evaluation and management . The primary outcome is freedom from having , or meeting the criteria for , a major amputation ( below knee amputation , or metatarsal level ) up to 12 weeks after randomization . The decision to amputate is made by a vascular surgeon . Other outcomes include wound healing , effectiveness , safety , healthcare resource utilization , quality of life , and cost-effectiveness . The study will run for a total of about 3 years . DISCUSSION The results of this study will provide detailed information on the efficacy of hyperbaric oxygen therapy for the treatment of non-healing ulcers of the lower limb . This will be the first double-blind randomized controlled trial for this health technology which evaluates the efficacy of hyperbaric oxygen therapy in prevention of amputations in diabetic patients . TRIAL REGISTRATION ClinicalTrials.gov Identifier : NCT00621608 . Instructions: please typing these entity words according to sentence: standard wound care, adjunctive hyperbaric oxygen therapy ( HBOT ), chronic , non - healing ulcers of the lower limb, diabetes mellitus, diabetic foot ulcers, lower extremity amputations, hyperbaric oxygen therapy plus standard wound care, major amputation, chronic ulcers, One hundred and eighteen, 59, non - healing diabetic ulcers of the lower limb, 18 years of age, Type 1 or 2 diabetes, Wagner grading of foot lesions 2 , 3 or 4 on lower limb not healing for at least 4 weeks, freedom from having , or meeting the criteria for , a major amputation ( below knee amputation , or metatarsal level ), wound healing, effectiveness, safety, healthcare resource utilization, quality of life, cost - effectiveness Options: Intervention_Physical, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A prospective , double-blind , randomized , controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy ( HBOT ) to standard wound care only for the treatment of chronic , non-healing ulcers of the lower limb in patients with diabetes mellitus : a study protocol . BACKGROUND It has been suggested that the use of adjunctive hyperbaric oxygen therapy improves the healing of diabetic foot ulcers , and decreases the risk of lower extremity amputations . A limited number of studies have used a double blind approach to evaluate the efficacy of hyperbaric oxygen therapy in the treatment of diabetic ulcers . The primary aim of this study is to assess the efficacy of hyperbaric oxygen therapy plus standard wound care compared with standard wound care alone in preventing the need for major amputation in patients with diabetes mellitus and chronic ulcers of the lower limb . METHODS/DESIGN One hundred and eighteen ( 59 patients per arm ) patients with non-healing diabetic ulcers of the lower limb , referred to the Judy Dan Research and Treatment Centre are being recruited if they are at least 18 years of age , have either Type 1 or 2 diabetes with a Wagner grading of foot lesions 2 , 3 or 4 on lower limb not healing for at least 4 weeks . Patients receive hyperbaric oxygen therapy every day for 6 weeks during the treatment phase and are provided ongoing wound care and weekly assessments . Patients are required to return to the study centre every week for an additional 6 weeks of follow-up for wound evaluation and management . The primary outcome is freedom from having , or meeting the criteria for , a major amputation ( below knee amputation , or metatarsal level ) up to 12 weeks after randomization . The decision to amputate is made by a vascular surgeon . Other outcomes include wound healing , effectiveness , safety , healthcare resource utilization , quality of life , and cost-effectiveness . The study will run for a total of about 3 years . DISCUSSION The results of this study will provide detailed information on the efficacy of hyperbaric oxygen therapy for the treatment of non-healing ulcers of the lower limb . This will be the first double-blind randomized controlled trial for this health technology which evaluates the efficacy of hyperbaric oxygen therapy in prevention of amputations in diabetic patients . TRIAL REGISTRATION ClinicalTrials.gov Identifier : NCT00621608 .
[ "A", "prospective", ",", "double", "-", "blind", ",", "randomized", ",", "controlled", "clinical", "trial", "comparing", "standard", "wound", "care", "with", "adjunctive", "hyperbaric", "oxygen", "therapy", "(", "HBOT", ")", "to", "standard", "wound", "care", "only", "for", "the", "treatment", "of", "chronic", ",", "non", "-", "healing", "ulcers", "of", "the", "lower", "limb", "in", "patients", "with", "diabetes", "mellitus", ":", "a", "study", "protocol", ".", "BACKGROUND", "It", "has", "been", "suggested", "that", "the", "use", "of", "adjunctive", "hyperbaric", "oxygen", "therapy", "improves", "the", "healing", "of", "diabetic", "foot", "ulcers", ",", "and", "decreases", "the", "risk", "of", "lower", "extremity", "amputations", ".", "A", "limited", "number", "of", "studies", "have", "used", "a", "double", "blind", "approach", "to", "evaluate", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "in", "the", "treatment", "of", "diabetic", "ulcers", ".", "The", "primary", "aim", "of", "this", "study", "is", "to", "assess", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "plus", "standard", "wound", "care", "compared", "with", "standard", "wound", "care", "alone", "in", "preventing", "the", "need", "for", "major", "amputation", "in", "patients", "with", "diabetes", "mellitus", "and", "chronic", "ulcers", "of", "the", "lower", "limb", ".", "METHODS", "/", "DESIGN", "One", "hundred", "and", "eighteen", "(", "59", "patients", "per", "arm", ")", "patients", "with", "non", "-", "healing", "diabetic", "ulcers", "of", "the", "lower", "limb", ",", "referred", "to", "the", "Judy", "Dan", "Research", "and", "Treatment", "Centre", "are", "being", "recruited", "if", "they", "are", "at", "least", "18", "years", "of", "age", ",", "have", "either", "Type", "1", "or", "2", "diabetes", "with", "a", "Wagner", "grading", "of", "foot", "lesions", "2", ",", "3", "or", "4", "on", "lower", "limb", "not", "healing", "for", "at", "least", "4", "weeks", ".", "Patients", "receive", "hyperbaric", "oxygen", "therapy", "every", "day", "for", "6", "weeks", "during", "the", "treatment", "phase", "and", "are", "provided", "ongoing", "wound", "care", "and", "weekly", "assessments", ".", "Patients", "are", "required", "to", "return", "to", "the", "study", "centre", "every", "week", "for", "an", "additional", "6", "weeks", "of", "follow", "-", "up", "for", "wound", "evaluation", "and", "management", ".", "The", "primary", "outcome", "is", "freedom", "from", "having", ",", "or", "meeting", "the", "criteria", "for", ",", "a", "major", "amputation", "(", "below", "knee", "amputation", ",", "or", "metatarsal", "level", ")", "up", "to", "12", "weeks", "after", "randomization", ".", "The", "decision", "to", "amputate", "is", "made", "by", "a", "vascular", "surgeon", ".", "Other", "outcomes", "include", "wound", "healing", ",", "effectiveness", ",", "safety", ",", "healthcare", "resource", "utilization", ",", "quality", "of", "life", ",", "and", "cost", "-", "effectiveness", ".", "The", "study", "will", "run", "for", "a", "total", "of", "about", "3", "years", ".", "DISCUSSION", "The", "results", "of", "this", "study", "will", "provide", "detailed", "information", "on", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "for", "the", "treatment", "of", "non", "-", "healing", "ulcers", "of", "the", "lower", "limb", ".", "This", "will", "be", "the", "first", "double", "-", "blind", "randomized", "controlled", "trial", "for", "this", "health", "technology", "which", "evaluates", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "in", "prevention", "of", "amputations", "in", "diabetic", "patients", ".", "TRIAL", "REGISTRATION", "ClinicalTrials.gov", "Identifier", ":", "NCT00621608", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Physical", "Outcome_Other", "Participant_Sample-size", "Outcome_Mental", "Participant_Age", "Outcome_Adverse-effects" ]
standard wound care, adjunctive hyperbaric oxygen therapy ( HBOT ), chronic , non - healing ulcers of the lower limb, diabetes mellitus, diabetic foot ulcers, lower extremity amputations, hyperbaric oxygen therapy plus standard wound care, major amputation, chronic ulcers, One hundred and eighteen, 59, non - healing diabetic ulcers of the lower limb, 18 years of age, Type 1 or 2 diabetes, Wagner grading of foot lesions 2 , 3 or 4 on lower limb not healing for at least 4 weeks, freedom from having , or meeting the criteria for , a major amputation ( below knee amputation , or metatarsal level ), wound healing, effectiveness, safety, healthcare resource utilization, quality of life, cost - effectiveness
49438_task2
Sentence: A prospective , double-blind , randomized , controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy ( HBOT ) to standard wound care only for the treatment of chronic , non-healing ulcers of the lower limb in patients with diabetes mellitus : a study protocol . BACKGROUND It has been suggested that the use of adjunctive hyperbaric oxygen therapy improves the healing of diabetic foot ulcers , and decreases the risk of lower extremity amputations . A limited number of studies have used a double blind approach to evaluate the efficacy of hyperbaric oxygen therapy in the treatment of diabetic ulcers . The primary aim of this study is to assess the efficacy of hyperbaric oxygen therapy plus standard wound care compared with standard wound care alone in preventing the need for major amputation in patients with diabetes mellitus and chronic ulcers of the lower limb . METHODS/DESIGN One hundred and eighteen ( 59 patients per arm ) patients with non-healing diabetic ulcers of the lower limb , referred to the Judy Dan Research and Treatment Centre are being recruited if they are at least 18 years of age , have either Type 1 or 2 diabetes with a Wagner grading of foot lesions 2 , 3 or 4 on lower limb not healing for at least 4 weeks . Patients receive hyperbaric oxygen therapy every day for 6 weeks during the treatment phase and are provided ongoing wound care and weekly assessments . Patients are required to return to the study centre every week for an additional 6 weeks of follow-up for wound evaluation and management . The primary outcome is freedom from having , or meeting the criteria for , a major amputation ( below knee amputation , or metatarsal level ) up to 12 weeks after randomization . The decision to amputate is made by a vascular surgeon . Other outcomes include wound healing , effectiveness , safety , healthcare resource utilization , quality of life , and cost-effectiveness . The study will run for a total of about 3 years . DISCUSSION The results of this study will provide detailed information on the efficacy of hyperbaric oxygen therapy for the treatment of non-healing ulcers of the lower limb . This will be the first double-blind randomized controlled trial for this health technology which evaluates the efficacy of hyperbaric oxygen therapy in prevention of amputations in diabetic patients . TRIAL REGISTRATION ClinicalTrials.gov Identifier : NCT00621608 . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A prospective , double-blind , randomized , controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy ( HBOT ) to standard wound care only for the treatment of chronic , non-healing ulcers of the lower limb in patients with diabetes mellitus : a study protocol . BACKGROUND It has been suggested that the use of adjunctive hyperbaric oxygen therapy improves the healing of diabetic foot ulcers , and decreases the risk of lower extremity amputations . A limited number of studies have used a double blind approach to evaluate the efficacy of hyperbaric oxygen therapy in the treatment of diabetic ulcers . The primary aim of this study is to assess the efficacy of hyperbaric oxygen therapy plus standard wound care compared with standard wound care alone in preventing the need for major amputation in patients with diabetes mellitus and chronic ulcers of the lower limb . METHODS/DESIGN One hundred and eighteen ( 59 patients per arm ) patients with non-healing diabetic ulcers of the lower limb , referred to the Judy Dan Research and Treatment Centre are being recruited if they are at least 18 years of age , have either Type 1 or 2 diabetes with a Wagner grading of foot lesions 2 , 3 or 4 on lower limb not healing for at least 4 weeks . Patients receive hyperbaric oxygen therapy every day for 6 weeks during the treatment phase and are provided ongoing wound care and weekly assessments . Patients are required to return to the study centre every week for an additional 6 weeks of follow-up for wound evaluation and management . The primary outcome is freedom from having , or meeting the criteria for , a major amputation ( below knee amputation , or metatarsal level ) up to 12 weeks after randomization . The decision to amputate is made by a vascular surgeon . Other outcomes include wound healing , effectiveness , safety , healthcare resource utilization , quality of life , and cost-effectiveness . The study will run for a total of about 3 years . DISCUSSION The results of this study will provide detailed information on the efficacy of hyperbaric oxygen therapy for the treatment of non-healing ulcers of the lower limb . This will be the first double-blind randomized controlled trial for this health technology which evaluates the efficacy of hyperbaric oxygen therapy in prevention of amputations in diabetic patients . TRIAL REGISTRATION ClinicalTrials.gov Identifier : NCT00621608 .
[ "A", "prospective", ",", "double", "-", "blind", ",", "randomized", ",", "controlled", "clinical", "trial", "comparing", "standard", "wound", "care", "with", "adjunctive", "hyperbaric", "oxygen", "therapy", "(", "HBOT", ")", "to", "standard", "wound", "care", "only", "for", "the", "treatment", "of", "chronic", ",", "non", "-", "healing", "ulcers", "of", "the", "lower", "limb", "in", "patients", "with", "diabetes", "mellitus", ":", "a", "study", "protocol", ".", "BACKGROUND", "It", "has", "been", "suggested", "that", "the", "use", "of", "adjunctive", "hyperbaric", "oxygen", "therapy", "improves", "the", "healing", "of", "diabetic", "foot", "ulcers", ",", "and", "decreases", "the", "risk", "of", "lower", "extremity", "amputations", ".", "A", "limited", "number", "of", "studies", "have", "used", "a", "double", "blind", "approach", "to", "evaluate", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "in", "the", "treatment", "of", "diabetic", "ulcers", ".", "The", "primary", "aim", "of", "this", "study", "is", "to", "assess", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "plus", "standard", "wound", "care", "compared", "with", "standard", "wound", "care", "alone", "in", "preventing", "the", "need", "for", "major", "amputation", "in", "patients", "with", "diabetes", "mellitus", "and", "chronic", "ulcers", "of", "the", "lower", "limb", ".", "METHODS", "/", "DESIGN", "One", "hundred", "and", "eighteen", "(", "59", "patients", "per", "arm", ")", "patients", "with", "non", "-", "healing", "diabetic", "ulcers", "of", "the", "lower", "limb", ",", "referred", "to", "the", "Judy", "Dan", "Research", "and", "Treatment", "Centre", "are", "being", "recruited", "if", "they", "are", "at", "least", "18", "years", "of", "age", ",", "have", "either", "Type", "1", "or", "2", "diabetes", "with", "a", "Wagner", "grading", "of", "foot", "lesions", "2", ",", "3", "or", "4", "on", "lower", "limb", "not", "healing", "for", "at", "least", "4", "weeks", ".", "Patients", "receive", "hyperbaric", "oxygen", "therapy", "every", "day", "for", "6", "weeks", "during", "the", "treatment", "phase", "and", "are", "provided", "ongoing", "wound", "care", "and", "weekly", "assessments", ".", "Patients", "are", "required", "to", "return", "to", "the", "study", "centre", "every", "week", "for", "an", "additional", "6", "weeks", "of", "follow", "-", "up", "for", "wound", "evaluation", "and", "management", ".", "The", "primary", "outcome", "is", "freedom", "from", "having", ",", "or", "meeting", "the", "criteria", "for", ",", "a", "major", "amputation", "(", "below", "knee", "amputation", ",", "or", "metatarsal", "level", ")", "up", "to", "12", "weeks", "after", "randomization", ".", "The", "decision", "to", "amputate", "is", "made", "by", "a", "vascular", "surgeon", ".", "Other", "outcomes", "include", "wound", "healing", ",", "effectiveness", ",", "safety", ",", "healthcare", "resource", "utilization", ",", "quality", "of", "life", ",", "and", "cost", "-", "effectiveness", ".", "The", "study", "will", "run", "for", "a", "total", "of", "about", "3", "years", ".", "DISCUSSION", "The", "results", "of", "this", "study", "will", "provide", "detailed", "information", "on", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "for", "the", "treatment", "of", "non", "-", "healing", "ulcers", "of", "the", "lower", "limb", ".", "This", "will", "be", "the", "first", "double", "-", "blind", "randomized", "controlled", "trial", "for", "this", "health", "technology", "which", "evaluates", "the", "efficacy", "of", "hyperbaric", "oxygen", "therapy", "in", "prevention", "of", "amputations", "in", "diabetic", "patients", ".", "TRIAL", "REGISTRATION", "ClinicalTrials.gov", "Identifier", ":", "NCT00621608", "." ]
[ "Outcome_Physical", "Participant_Condition", "Intervention_Physical", "Outcome_Other", "Participant_Sample-size", "Outcome_Mental", "Participant_Age", "Outcome_Adverse-effects" ]
kinsenoside is a CHEMICAL, glucose is a CHEMICAL, kinsenoside is a CHEMICAL, glucose is a CHEMICAL, kinsenoside is a CHEMICAL, glucose is a CHEMICAL, cholesterol is a CHEMICAL, streptozotocin is a CHEMICAL, kinsenoside is a CHEMICAL, nitric oxide is a CHEMICAL, NO is a CHEMICAL, lactic dehydrogenase is a GENE-N, LDH is a GENE-N, superoxide dismutase is a GENE-N, SOD is a GENE-N, catalase is a GENE-Y, CAT is a GENE-Y, glucose is a CHEMICAL, matrix metalloproteinases is a GENE-N, tissue inhibitors of matrix metalloproteinases is a GENE-N, MMP is a GENE-N, kinsenoside is a CHEMICAL, nuclear factor kappa B is a GENE-N, NF - κB is a GENE-N, glucose is a CHEMICAL, hematoxylin is a CHEMICAL, eosin is a CHEMICAL, methenamine is a CHEMICAL, kinsenoside is a CHEMICAL, kinsenoside is a CHEMICAL
12417_task0
Sentence: The vascular protective properties of kinsenoside isolated from Anoectochilus roxburghii under high glucose condition. Anoectochilus roxburghii is a traditional Chinese herb used for the treatment of diabetes and some other diseases. The vascular protective effect of its major active ingredient, kinsenoside, in high glucose conditions was investigated in in vivo and in vitro experiments. In in vivo tests, kinsenoside (50 and 100mg/kg) efficiently lowered blood glucose and cholesterol levels and it enhanced the oxidation resistance of diabetic mice induced by streptozotocin. In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system. The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-κB) mRNA expression levels in high glucose conditions. Moreover, histological examination, including hematoxylin-eosin (H&E) staining, masson trichrome (Masson) staining, and periodic Schiff-methenamine (PASM) staining, greatly supported the morphological and functional amelioration of diabetes-related changes in mice aortas after kinsenoside (20 and 50μg/mL) treatment. These results indicated that kinsenoside might be a promising agent for the treatment of diabetic vascular disease. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The vascular protective properties of kinsenoside isolated from Anoectochilus roxburghii under high glucose condition. Anoectochilus roxburghii is a traditional Chinese herb used for the treatment of diabetes and some other diseases. The vascular protective effect of its major active ingredient, kinsenoside, in high glucose conditions was investigated in in vivo and in vitro experiments. In in vivo tests, kinsenoside (50 and 100mg/kg) efficiently lowered blood glucose and cholesterol levels and it enhanced the oxidation resistance of diabetic mice induced by streptozotocin. In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system. The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-κB) mRNA expression levels in high glucose conditions. Moreover, histological examination, including hematoxylin-eosin (H&E) staining, masson trichrome (Masson) staining, and periodic Schiff-methenamine (PASM) staining, greatly supported the morphological and functional amelioration of diabetes-related changes in mice aortas after kinsenoside (20 and 50μg/mL) treatment. These results indicated that kinsenoside might be a promising agent for the treatment of diabetic vascular disease.
[ "The", "vascular", "protective", "properties", "of", "kinsenoside", "isolated", "from", "Anoectochilus", "roxburghii", "under", "high", "glucose", "condition", ".", "\n", "Anoectochilus", "roxburghii", "is", "a", "traditional", "Chinese", "herb", "used", "for", "the", "treatment", "of", "diabetes", "and", "some", "other", "diseases", ".", "The", "vascular", "protective", "effect", "of", "its", "major", "active", "ingredient", ",", "kinsenoside", ",", "in", "high", "glucose", "conditions", "was", "investigated", "in", "in", "vivo", "and", "in", "vitro", "experiments", ".", "In", "in", "vivo", "tests", ",", "kinsenoside", "(", "50", "and", "100mg", "/", "kg", ")", "efficiently", "lowered", "blood", "glucose", "and", "cholesterol", "levels", "and", "it", "enhanced", "the", "oxidation", "resistance", "of", "diabetic", "mice", "induced", "by", "streptozotocin", ".", "In", "the", "in", "vitro", "assay", ",", "kinsenoside", "(", "20", "and", "50μg", "/", "mL", ")", "markedly", "inhibited", "changes", "in", "various", "biochemical", "substances", "(", "nitric", "oxide", "(", "NO", ")", ",", "lactic", "dehydrogenase", "(", "LDH", ")", ",", "superoxide", "dismutase", "(", "SOD", ")", ",", "and", "catalase", "(", "CAT", ")", ")", "in", "human", "umbilical", "vein", "endothelial", "cells", "(", "HUVECs", ")", "damaged", "by", "high", "glucose", "(", "35mM", ")", "and", "restored", "vascular", "endothelial", "structure", "by", "balancing", "the", "matrix", "metalloproteinases", "-", "the", "tissue", "inhibitors", "of", "matrix", "metalloproteinases", "(", "MMP", "-", "TIMP", ")", "system", ".", "The", "vascular", "protective", "effects", "of", "kinsenoside", "were", "speculated", "to", "be", "attributed", "to", "oxidative", "stress", "inhibition", "and", "the", "reduction", "of", "nuclear", "factor", "kappa", "B", "(", "NF", "-", "κB", ")", "mRNA", "expression", "levels", "in", "high", "glucose", "conditions", ".", "Moreover", ",", "histological", "examination", ",", "including", "hematoxylin", "-", "eosin", "(", "H&E", ")", "staining", ",", "masson", "trichrome", "(", "Masson", ")", "staining", ",", "and", "periodic", "Schiff", "-", "methenamine", "(", "PASM", ")", "staining", ",", "greatly", "supported", "the", "morphological", "and", "functional", "amelioration", "of", "diabetes", "-", "related", "changes", "in", "mice", "aortas", "after", "kinsenoside", "(", "20", "and", "50μg", "/", "mL", ")", "treatment", ".", "These", "results", "indicated", "that", "kinsenoside", "might", "be", "a", "promising", "agent", "for", "the", "treatment", "of", "diabetic", "vascular", "disease", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
kinsenoside is a CHEMICAL, glucose is a CHEMICAL, kinsenoside is a CHEMICAL, glucose is a CHEMICAL, kinsenoside is a CHEMICAL, glucose is a CHEMICAL, cholesterol is a CHEMICAL, streptozotocin is a CHEMICAL, kinsenoside is a CHEMICAL, nitric oxide is a CHEMICAL, NO is a CHEMICAL, lactic dehydrogenase is a GENE-N, LDH is a GENE-N, superoxide dismutase is a GENE-N, SOD is a GENE-N, catalase is a GENE-Y, CAT is a GENE-Y, glucose is a CHEMICAL, matrix metalloproteinases is a GENE-N, tissue inhibitors of matrix metalloproteinases is a GENE-N, MMP is a GENE-N, kinsenoside is a CHEMICAL, nuclear factor kappa B is a GENE-N, NF - κB is a GENE-N, glucose is a CHEMICAL, hematoxylin is a CHEMICAL, eosin is a CHEMICAL, methenamine is a CHEMICAL, kinsenoside is a CHEMICAL, kinsenoside is a CHEMICAL
12417_task1
Sentence: The vascular protective properties of kinsenoside isolated from Anoectochilus roxburghii under high glucose condition. Anoectochilus roxburghii is a traditional Chinese herb used for the treatment of diabetes and some other diseases. The vascular protective effect of its major active ingredient, kinsenoside, in high glucose conditions was investigated in in vivo and in vitro experiments. In in vivo tests, kinsenoside (50 and 100mg/kg) efficiently lowered blood glucose and cholesterol levels and it enhanced the oxidation resistance of diabetic mice induced by streptozotocin. In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system. The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-κB) mRNA expression levels in high glucose conditions. Moreover, histological examination, including hematoxylin-eosin (H&E) staining, masson trichrome (Masson) staining, and periodic Schiff-methenamine (PASM) staining, greatly supported the morphological and functional amelioration of diabetes-related changes in mice aortas after kinsenoside (20 and 50μg/mL) treatment. These results indicated that kinsenoside might be a promising agent for the treatment of diabetic vascular disease. Instructions: please typing these entity words according to sentence: kinsenoside, glucose, kinsenoside, glucose, kinsenoside, glucose, cholesterol, streptozotocin, kinsenoside, nitric oxide, NO, lactic dehydrogenase, LDH, superoxide dismutase, SOD, catalase, CAT, glucose, matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, MMP, kinsenoside, nuclear factor kappa B, NF - κB, glucose, hematoxylin, eosin, methenamine, kinsenoside, kinsenoside Options: GENE-Y, GENE-N, CHEMICAL
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The vascular protective properties of kinsenoside isolated from Anoectochilus roxburghii under high glucose condition. Anoectochilus roxburghii is a traditional Chinese herb used for the treatment of diabetes and some other diseases. The vascular protective effect of its major active ingredient, kinsenoside, in high glucose conditions was investigated in in vivo and in vitro experiments. In in vivo tests, kinsenoside (50 and 100mg/kg) efficiently lowered blood glucose and cholesterol levels and it enhanced the oxidation resistance of diabetic mice induced by streptozotocin. In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system. The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-κB) mRNA expression levels in high glucose conditions. Moreover, histological examination, including hematoxylin-eosin (H&E) staining, masson trichrome (Masson) staining, and periodic Schiff-methenamine (PASM) staining, greatly supported the morphological and functional amelioration of diabetes-related changes in mice aortas after kinsenoside (20 and 50μg/mL) treatment. These results indicated that kinsenoside might be a promising agent for the treatment of diabetic vascular disease.
[ "The", "vascular", "protective", "properties", "of", "kinsenoside", "isolated", "from", "Anoectochilus", "roxburghii", "under", "high", "glucose", "condition", ".", "\n", "Anoectochilus", "roxburghii", "is", "a", "traditional", "Chinese", "herb", "used", "for", "the", "treatment", "of", "diabetes", "and", "some", "other", "diseases", ".", "The", "vascular", "protective", "effect", "of", "its", "major", "active", "ingredient", ",", "kinsenoside", ",", "in", "high", "glucose", "conditions", "was", "investigated", "in", "in", "vivo", "and", "in", "vitro", "experiments", ".", "In", "in", "vivo", "tests", ",", "kinsenoside", "(", "50", "and", "100mg", "/", "kg", ")", "efficiently", "lowered", "blood", "glucose", "and", "cholesterol", "levels", "and", "it", "enhanced", "the", "oxidation", "resistance", "of", "diabetic", "mice", "induced", "by", "streptozotocin", ".", "In", "the", "in", "vitro", "assay", ",", "kinsenoside", "(", "20", "and", "50μg", "/", "mL", ")", "markedly", "inhibited", "changes", "in", "various", "biochemical", "substances", "(", "nitric", "oxide", "(", "NO", ")", ",", "lactic", "dehydrogenase", "(", "LDH", ")", ",", "superoxide", "dismutase", "(", "SOD", ")", ",", "and", "catalase", "(", "CAT", ")", ")", "in", "human", "umbilical", "vein", "endothelial", "cells", "(", "HUVECs", ")", "damaged", "by", "high", "glucose", "(", "35mM", ")", "and", "restored", "vascular", "endothelial", "structure", "by", "balancing", "the", "matrix", "metalloproteinases", "-", "the", "tissue", "inhibitors", "of", "matrix", "metalloproteinases", "(", "MMP", "-", "TIMP", ")", "system", ".", "The", "vascular", "protective", "effects", "of", "kinsenoside", "were", "speculated", "to", "be", "attributed", "to", "oxidative", "stress", "inhibition", "and", "the", "reduction", "of", "nuclear", "factor", "kappa", "B", "(", "NF", "-", "κB", ")", "mRNA", "expression", "levels", "in", "high", "glucose", "conditions", ".", "Moreover", ",", "histological", "examination", ",", "including", "hematoxylin", "-", "eosin", "(", "H&E", ")", "staining", ",", "masson", "trichrome", "(", "Masson", ")", "staining", ",", "and", "periodic", "Schiff", "-", "methenamine", "(", "PASM", ")", "staining", ",", "greatly", "supported", "the", "morphological", "and", "functional", "amelioration", "of", "diabetes", "-", "related", "changes", "in", "mice", "aortas", "after", "kinsenoside", "(", "20", "and", "50μg", "/", "mL", ")", "treatment", ".", "These", "results", "indicated", "that", "kinsenoside", "might", "be", "a", "promising", "agent", "for", "the", "treatment", "of", "diabetic", "vascular", "disease", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
kinsenoside, glucose, kinsenoside, glucose, kinsenoside, glucose, cholesterol, streptozotocin, kinsenoside, nitric oxide, NO, lactic dehydrogenase, LDH, superoxide dismutase, SOD, catalase, CAT, glucose, matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, MMP, kinsenoside, nuclear factor kappa B, NF - κB, glucose, hematoxylin, eosin, methenamine, kinsenoside, kinsenoside
12417_task2
Sentence: The vascular protective properties of kinsenoside isolated from Anoectochilus roxburghii under high glucose condition. Anoectochilus roxburghii is a traditional Chinese herb used for the treatment of diabetes and some other diseases. The vascular protective effect of its major active ingredient, kinsenoside, in high glucose conditions was investigated in in vivo and in vitro experiments. In in vivo tests, kinsenoside (50 and 100mg/kg) efficiently lowered blood glucose and cholesterol levels and it enhanced the oxidation resistance of diabetic mice induced by streptozotocin. In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system. The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-κB) mRNA expression levels in high glucose conditions. Moreover, histological examination, including hematoxylin-eosin (H&E) staining, masson trichrome (Masson) staining, and periodic Schiff-methenamine (PASM) staining, greatly supported the morphological and functional amelioration of diabetes-related changes in mice aortas after kinsenoside (20 and 50μg/mL) treatment. These results indicated that kinsenoside might be a promising agent for the treatment of diabetic vascular disease. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The vascular protective properties of kinsenoside isolated from Anoectochilus roxburghii under high glucose condition. Anoectochilus roxburghii is a traditional Chinese herb used for the treatment of diabetes and some other diseases. The vascular protective effect of its major active ingredient, kinsenoside, in high glucose conditions was investigated in in vivo and in vitro experiments. In in vivo tests, kinsenoside (50 and 100mg/kg) efficiently lowered blood glucose and cholesterol levels and it enhanced the oxidation resistance of diabetic mice induced by streptozotocin. In the in vitro assay, kinsenoside (20 and 50μg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system. The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-κB) mRNA expression levels in high glucose conditions. Moreover, histological examination, including hematoxylin-eosin (H&E) staining, masson trichrome (Masson) staining, and periodic Schiff-methenamine (PASM) staining, greatly supported the morphological and functional amelioration of diabetes-related changes in mice aortas after kinsenoside (20 and 50μg/mL) treatment. These results indicated that kinsenoside might be a promising agent for the treatment of diabetic vascular disease.
[ "The", "vascular", "protective", "properties", "of", "kinsenoside", "isolated", "from", "Anoectochilus", "roxburghii", "under", "high", "glucose", "condition", ".", "\n", "Anoectochilus", "roxburghii", "is", "a", "traditional", "Chinese", "herb", "used", "for", "the", "treatment", "of", "diabetes", "and", "some", "other", "diseases", ".", "The", "vascular", "protective", "effect", "of", "its", "major", "active", "ingredient", ",", "kinsenoside", ",", "in", "high", "glucose", "conditions", "was", "investigated", "in", "in", "vivo", "and", "in", "vitro", "experiments", ".", "In", "in", "vivo", "tests", ",", "kinsenoside", "(", "50", "and", "100mg", "/", "kg", ")", "efficiently", "lowered", "blood", "glucose", "and", "cholesterol", "levels", "and", "it", "enhanced", "the", "oxidation", "resistance", "of", "diabetic", "mice", "induced", "by", "streptozotocin", ".", "In", "the", "in", "vitro", "assay", ",", "kinsenoside", "(", "20", "and", "50μg", "/", "mL", ")", "markedly", "inhibited", "changes", "in", "various", "biochemical", "substances", "(", "nitric", "oxide", "(", "NO", ")", ",", "lactic", "dehydrogenase", "(", "LDH", ")", ",", "superoxide", "dismutase", "(", "SOD", ")", ",", "and", "catalase", "(", "CAT", ")", ")", "in", "human", "umbilical", "vein", "endothelial", "cells", "(", "HUVECs", ")", "damaged", "by", "high", "glucose", "(", "35mM", ")", "and", "restored", "vascular", "endothelial", "structure", "by", "balancing", "the", "matrix", "metalloproteinases", "-", "the", "tissue", "inhibitors", "of", "matrix", "metalloproteinases", "(", "MMP", "-", "TIMP", ")", "system", ".", "The", "vascular", "protective", "effects", "of", "kinsenoside", "were", "speculated", "to", "be", "attributed", "to", "oxidative", "stress", "inhibition", "and", "the", "reduction", "of", "nuclear", "factor", "kappa", "B", "(", "NF", "-", "κB", ")", "mRNA", "expression", "levels", "in", "high", "glucose", "conditions", ".", "Moreover", ",", "histological", "examination", ",", "including", "hematoxylin", "-", "eosin", "(", "H&E", ")", "staining", ",", "masson", "trichrome", "(", "Masson", ")", "staining", ",", "and", "periodic", "Schiff", "-", "methenamine", "(", "PASM", ")", "staining", ",", "greatly", "supported", "the", "morphological", "and", "functional", "amelioration", "of", "diabetes", "-", "related", "changes", "in", "mice", "aortas", "after", "kinsenoside", "(", "20", "and", "50μg", "/", "mL", ")", "treatment", ".", "These", "results", "indicated", "that", "kinsenoside", "might", "be", "a", "promising", "agent", "for", "the", "treatment", "of", "diabetic", "vascular", "disease", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
MAO inhibitors is a GROUP, antihistamines is a GROUP, antihistamines is a GROUP, alcohol is a DRUG, tricyclic antidepressants is a GROUP, barbiturates is a GROUP, central nervous system depressants is a GROUP, sympathomimetic drugs is a GROUP, monoamine oxidase inhibitors is a GROUP, methyldopa is a DRUG, mecamylamine is a DRUG, reserpine is a DRUG, veratrum alkaloids is a DRUG, sympathomimetics is a GROUP, Beta - adrenergic blocking agents is a GROUP, sympathomimetics is a GROUP, pseudoephedrine is a DRUG, digitalis is a GROUP, Antacids is a GROUP, pseudoephedrine is a DRUG, kaolin is a DRUG
Azatadine_ddi_task0
Sentence: MAO inhibitors prolong and intensify the effects of antihistamines. Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect. When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur. The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics. Beta-adrenergic blocking agents may also interact with sympathomimetics. Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG
[ "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O" ]
MAO inhibitors prolong and intensify the effects of antihistamines. Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect. When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur. The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics. Beta-adrenergic blocking agents may also interact with sympathomimetics. Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
[ "MAO", "inhibitors", "prolong", "and", "intensify", "the", "effects", "of", "antihistamines", ".", "Concomitant", "use", "of", "antihistamines", "with", "alcohol", ",", "tricyclic", "antidepressants", ",", "barbiturates", ",", "or", "other", "central", "nervous", "system", "depressants", "may", "have", "an", "additive", "effect", ".", "When", "sympathomimetic", "drugs", "are", "given", "to", "patients", "receiving", "monoamine", "oxidase", "inhibitors", ",", "hypertensive", "reactions", ",", "including", "hypertensive", "crises", ",", "may", "occur", ".", "The", "antihypertensive", "effects", "of", "methyldopa", ",", "mecamylamine", ",", "reserpine", ",", "and", "veratrum", "alkaloids", "may", "be", "reduced", "by", "sympathomimetics", ".", "Beta", "-", "adrenergic", "blocking", "agents", "may", "also", "interact", "with", "sympathomimetics", ".", "Increased", "ectopic", "pacemaker", "activity", "can", "occur", "when", "pseudoephedrine", "is", "used", "concomitantly", "with", "digitalis", ".", "Antacids", "increase", "the", "rate", "of", "absorption", "of", "pseudoephedrine", ",", "while", "kaolin", "decreases", "it", "." ]
[ "GROUP", "DRUG" ]
MAO inhibitors is a GROUP, antihistamines is a GROUP, antihistamines is a GROUP, alcohol is a DRUG, tricyclic antidepressants is a GROUP, barbiturates is a GROUP, central nervous system depressants is a GROUP, sympathomimetic drugs is a GROUP, monoamine oxidase inhibitors is a GROUP, methyldopa is a DRUG, mecamylamine is a DRUG, reserpine is a DRUG, veratrum alkaloids is a DRUG, sympathomimetics is a GROUP, Beta - adrenergic blocking agents is a GROUP, sympathomimetics is a GROUP, pseudoephedrine is a DRUG, digitalis is a GROUP, Antacids is a GROUP, pseudoephedrine is a DRUG, kaolin is a DRUG
Azatadine_ddi_task1
Sentence: MAO inhibitors prolong and intensify the effects of antihistamines. Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect. When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur. The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics. Beta-adrenergic blocking agents may also interact with sympathomimetics. Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it. Instructions: please typing these entity words according to sentence: MAO inhibitors, antihistamines, antihistamines, alcohol, tricyclic antidepressants, barbiturates, central nervous system depressants, sympathomimetic drugs, monoamine oxidase inhibitors, methyldopa, mecamylamine, reserpine, veratrum alkaloids, sympathomimetics, Beta - adrenergic blocking agents, sympathomimetics, pseudoephedrine, digitalis, Antacids, pseudoephedrine, kaolin Options: GROUP, DRUG
[ "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O" ]
MAO inhibitors prolong and intensify the effects of antihistamines. Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect. When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur. The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics. Beta-adrenergic blocking agents may also interact with sympathomimetics. Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
[ "MAO", "inhibitors", "prolong", "and", "intensify", "the", "effects", "of", "antihistamines", ".", "Concomitant", "use", "of", "antihistamines", "with", "alcohol", ",", "tricyclic", "antidepressants", ",", "barbiturates", ",", "or", "other", "central", "nervous", "system", "depressants", "may", "have", "an", "additive", "effect", ".", "When", "sympathomimetic", "drugs", "are", "given", "to", "patients", "receiving", "monoamine", "oxidase", "inhibitors", ",", "hypertensive", "reactions", ",", "including", "hypertensive", "crises", ",", "may", "occur", ".", "The", "antihypertensive", "effects", "of", "methyldopa", ",", "mecamylamine", ",", "reserpine", ",", "and", "veratrum", "alkaloids", "may", "be", "reduced", "by", "sympathomimetics", ".", "Beta", "-", "adrenergic", "blocking", "agents", "may", "also", "interact", "with", "sympathomimetics", ".", "Increased", "ectopic", "pacemaker", "activity", "can", "occur", "when", "pseudoephedrine", "is", "used", "concomitantly", "with", "digitalis", ".", "Antacids", "increase", "the", "rate", "of", "absorption", "of", "pseudoephedrine", ",", "while", "kaolin", "decreases", "it", "." ]
[ "GROUP", "DRUG" ]
MAO inhibitors, antihistamines, antihistamines, alcohol, tricyclic antidepressants, barbiturates, central nervous system depressants, sympathomimetic drugs, monoamine oxidase inhibitors, methyldopa, mecamylamine, reserpine, veratrum alkaloids, sympathomimetics, Beta - adrenergic blocking agents, sympathomimetics, pseudoephedrine, digitalis, Antacids, pseudoephedrine, kaolin
Azatadine_ddi_task2
Sentence: MAO inhibitors prolong and intensify the effects of antihistamines. Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect. When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur. The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics. Beta-adrenergic blocking agents may also interact with sympathomimetics. Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it. Instructions: please extract entity words from the input sentence
[ "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O" ]
MAO inhibitors prolong and intensify the effects of antihistamines. Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect. When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur. The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics. Beta-adrenergic blocking agents may also interact with sympathomimetics. Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis. Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
[ "MAO", "inhibitors", "prolong", "and", "intensify", "the", "effects", "of", "antihistamines", ".", "Concomitant", "use", "of", "antihistamines", "with", "alcohol", ",", "tricyclic", "antidepressants", ",", "barbiturates", ",", "or", "other", "central", "nervous", "system", "depressants", "may", "have", "an", "additive", "effect", ".", "When", "sympathomimetic", "drugs", "are", "given", "to", "patients", "receiving", "monoamine", "oxidase", "inhibitors", ",", "hypertensive", "reactions", ",", "including", "hypertensive", "crises", ",", "may", "occur", ".", "The", "antihypertensive", "effects", "of", "methyldopa", ",", "mecamylamine", ",", "reserpine", ",", "and", "veratrum", "alkaloids", "may", "be", "reduced", "by", "sympathomimetics", ".", "Beta", "-", "adrenergic", "blocking", "agents", "may", "also", "interact", "with", "sympathomimetics", ".", "Increased", "ectopic", "pacemaker", "activity", "can", "occur", "when", "pseudoephedrine", "is", "used", "concomitantly", "with", "digitalis", ".", "Antacids", "increase", "the", "rate", "of", "absorption", "of", "pseudoephedrine", ",", "while", "kaolin", "decreases", "it", "." ]
[ "GROUP", "DRUG" ]
light is an umlsterm, choice is an umlsterm, treatment is an umlsterm, malformations is an umlsterm, telangiectases is an umlsterm, stains is an umlsterm, hemangiomatous is an umlsterm, malformations is an umlsterm, hypertrichosis is an umlsterm, light is an umlsterm
DerHautarzt.70480886.eng.abstr_task0
Sentence: By varying the light spectrum , impulse length , impulse sequences and fluences , the PhotoDermVL allows a large choice of individual treatment parameters . Superficial as well as deeper localized vascular malformations ( essential telangiectases , port-wine stains , Poikiloderma of Civatte , hemangiomatous malformations ) and cosmetically bothering hypertrichosis can be treated successfully with this high intensity polychromatic pulsed light source . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
By varying the light spectrum , impulse length , impulse sequences and fluences , the PhotoDermVL allows a large choice of individual treatment parameters . Superficial as well as deeper localized vascular malformations ( essential telangiectases , port-wine stains , Poikiloderma of Civatte , hemangiomatous malformations ) and cosmetically bothering hypertrichosis can be treated successfully with this high intensity polychromatic pulsed light source .
[ "By", "varying", "the", "light", "spectrum", ",", "impulse", "length", ",", "impulse", "sequences", "and", "fluences", ",", "the", "PhotoDermVL", "allows", "a", "large", "choice", "of", "individual", "treatment", "parameters", ".", "Superficial", "as", "well", "as", "deeper", "localized", "vascular", "malformations", "(", "essential", "telangiectases", ",", "port", "-", "wine", "stains", ",", "Poikiloderma", "of", "Civatte", ",", "hemangiomatous", "malformations", ")", "and", "cosmetically", "bothering", "hypertrichosis", "can", "be", "treated", "successfully", "with", "this", "high", "intensity", "polychromatic", "pulsed", "light", "source", "." ]
[ "umlsterm" ]
light is an umlsterm, choice is an umlsterm, treatment is an umlsterm, malformations is an umlsterm, telangiectases is an umlsterm, stains is an umlsterm, hemangiomatous is an umlsterm, malformations is an umlsterm, hypertrichosis is an umlsterm, light is an umlsterm
DerHautarzt.70480886.eng.abstr_task1
Sentence: By varying the light spectrum , impulse length , impulse sequences and fluences , the PhotoDermVL allows a large choice of individual treatment parameters . Superficial as well as deeper localized vascular malformations ( essential telangiectases , port-wine stains , Poikiloderma of Civatte , hemangiomatous malformations ) and cosmetically bothering hypertrichosis can be treated successfully with this high intensity polychromatic pulsed light source . Instructions: please typing these entity words according to sentence: light, choice, treatment, malformations, telangiectases, stains, hemangiomatous, malformations, hypertrichosis, light Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
By varying the light spectrum , impulse length , impulse sequences and fluences , the PhotoDermVL allows a large choice of individual treatment parameters . Superficial as well as deeper localized vascular malformations ( essential telangiectases , port-wine stains , Poikiloderma of Civatte , hemangiomatous malformations ) and cosmetically bothering hypertrichosis can be treated successfully with this high intensity polychromatic pulsed light source .
[ "By", "varying", "the", "light", "spectrum", ",", "impulse", "length", ",", "impulse", "sequences", "and", "fluences", ",", "the", "PhotoDermVL", "allows", "a", "large", "choice", "of", "individual", "treatment", "parameters", ".", "Superficial", "as", "well", "as", "deeper", "localized", "vascular", "malformations", "(", "essential", "telangiectases", ",", "port", "-", "wine", "stains", ",", "Poikiloderma", "of", "Civatte", ",", "hemangiomatous", "malformations", ")", "and", "cosmetically", "bothering", "hypertrichosis", "can", "be", "treated", "successfully", "with", "this", "high", "intensity", "polychromatic", "pulsed", "light", "source", "." ]
[ "umlsterm" ]
light, choice, treatment, malformations, telangiectases, stains, hemangiomatous, malformations, hypertrichosis, light
DerHautarzt.70480886.eng.abstr_task2
Sentence: By varying the light spectrum , impulse length , impulse sequences and fluences , the PhotoDermVL allows a large choice of individual treatment parameters . Superficial as well as deeper localized vascular malformations ( essential telangiectases , port-wine stains , Poikiloderma of Civatte , hemangiomatous malformations ) and cosmetically bothering hypertrichosis can be treated successfully with this high intensity polychromatic pulsed light source . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
By varying the light spectrum , impulse length , impulse sequences and fluences , the PhotoDermVL allows a large choice of individual treatment parameters . Superficial as well as deeper localized vascular malformations ( essential telangiectases , port-wine stains , Poikiloderma of Civatte , hemangiomatous malformations ) and cosmetically bothering hypertrichosis can be treated successfully with this high intensity polychromatic pulsed light source .
[ "By", "varying", "the", "light", "spectrum", ",", "impulse", "length", ",", "impulse", "sequences", "and", "fluences", ",", "the", "PhotoDermVL", "allows", "a", "large", "choice", "of", "individual", "treatment", "parameters", ".", "Superficial", "as", "well", "as", "deeper", "localized", "vascular", "malformations", "(", "essential", "telangiectases", ",", "port", "-", "wine", "stains", ",", "Poikiloderma", "of", "Civatte", ",", "hemangiomatous", "malformations", ")", "and", "cosmetically", "bothering", "hypertrichosis", "can", "be", "treated", "successfully", "with", "this", "high", "intensity", "polychromatic", "pulsed", "light", "source", "." ]
[ "umlsterm" ]
Topical PUVA is a Intervention_Pharmacological, etretinate is a Intervention_Pharmacological, combined PUVA and etretinate is a Intervention_Pharmacological, therapeutic efficacy is a Outcome_Other, tonsillar is a Outcome_Physical, Twenty is a Participant_Sample-size, palmoplantar pustulosis ( PPP ) is a Participant_Condition, topical PUVA is a Intervention_Pharmacological, oral etretinate ( Re ) is a Intervention_Pharmacological, combined PUVA and etretinate ( Re - PUVA ) is a Intervention_Pharmacological, sites improved and / or cleared is a Outcome_Physical, Complete clearance is a Outcome_Other, Remission periods is a Outcome_Physical, Tonsillar focal infection ( TFI ) is a Outcome_Physical, dental focal infection ( DFI ) is a Outcome_Physical, focal infection ( FI ) is a Outcome_Physical, complete clearance rates is a Outcome_Physical, remission periods is a Outcome_Physical
51355_task0
Sentence: Topical PUVA , etretinate , and combined PUVA and etretinate for palmoplantar pustulosis : comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections . Twenty patients with palmoplantar pustulosis ( PPP ) were treated with topical PUVA , oral etretinate ( Re ) , or combined PUVA and etretinate ( Re-PUVA ) . Re and Re-PUVA treated sites improved and/or cleared more rapidly than PUVA treated sites . Complete clearance was observed in six of ten sites treated with Re-PUVA , two of ten with Re , and one of ten sites with PUVA within 12 weeks . UVA-control sites failed to be cleared within 12 weeks . Remission periods after stopping the treatment were 1.5 +/- 0.5 weeks ( n = 2 ) with Re , 10.5 +/- 11.4 weeks ( n = 6 ) with Re-PUVA , and one year ( n = 1 ) with PUVA . These results overall suggested that Re-PUVA is the most effective treatment for PPP . Tonsillar focal infection ( TFI ) and dental focal infection ( DFI ) were found in 6/20 and 17/20 patients , respectively . However , the presence of focal infection ( FI ) , TFI and/or DFI , did not appear to interfere with the therapeutic activities of Re and/or PUVA , because the complete clearance rates and remission periods in FI ( + ) patients were comparable with those in FI ( - ) patients . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Topical PUVA , etretinate , and combined PUVA and etretinate for palmoplantar pustulosis : comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections . Twenty patients with palmoplantar pustulosis ( PPP ) were treated with topical PUVA , oral etretinate ( Re ) , or combined PUVA and etretinate ( Re-PUVA ) . Re and Re-PUVA treated sites improved and/or cleared more rapidly than PUVA treated sites . Complete clearance was observed in six of ten sites treated with Re-PUVA , two of ten with Re , and one of ten sites with PUVA within 12 weeks . UVA-control sites failed to be cleared within 12 weeks . Remission periods after stopping the treatment were 1.5 +/- 0.5 weeks ( n = 2 ) with Re , 10.5 +/- 11.4 weeks ( n = 6 ) with Re-PUVA , and one year ( n = 1 ) with PUVA . These results overall suggested that Re-PUVA is the most effective treatment for PPP . Tonsillar focal infection ( TFI ) and dental focal infection ( DFI ) were found in 6/20 and 17/20 patients , respectively . However , the presence of focal infection ( FI ) , TFI and/or DFI , did not appear to interfere with the therapeutic activities of Re and/or PUVA , because the complete clearance rates and remission periods in FI ( + ) patients were comparable with those in FI ( - ) patients .
[ "Topical", "PUVA", ",", "etretinate", ",", "and", "combined", "PUVA", "and", "etretinate", "for", "palmoplantar", "pustulosis", ":", "comparison", "of", "therapeutic", "efficacy", "and", "the", "influences", "of", "tonsillar", "and", "dental", "focal", "infections", ".", "Twenty", "patients", "with", "palmoplantar", "pustulosis", "(", "PPP", ")", "were", "treated", "with", "topical", "PUVA", ",", "oral", "etretinate", "(", "Re", ")", ",", "or", "combined", "PUVA", "and", "etretinate", "(", "Re", "-", "PUVA", ")", ".", "Re", "and", "Re", "-", "PUVA", "treated", "sites", "improved", "and", "/", "or", "cleared", "more", "rapidly", "than", "PUVA", "treated", "sites", ".", "Complete", "clearance", "was", "observed", "in", "six", "of", "ten", "sites", "treated", "with", "Re", "-", "PUVA", ",", "two", "of", "ten", "with", "Re", ",", "and", "one", "of", "ten", "sites", "with", "PUVA", "within", "12", "weeks", ".", "UVA", "-", "control", "sites", "failed", "to", "be", "cleared", "within", "12", "weeks", ".", "Remission", "periods", "after", "stopping", "the", "treatment", "were", "1.5", "+", "/-", "0.5", "weeks", "(", "n", "=", "2", ")", "with", "Re", ",", "10.5", "+", "/-", "11.4", "weeks", "(", "n", "=", "6", ")", "with", "Re", "-", "PUVA", ",", "and", "one", "year", "(", "n", "=", "1", ")", "with", "PUVA", ".", "These", "results", "overall", "suggested", "that", "Re", "-", "PUVA", "is", "the", "most", "effective", "treatment", "for", "PPP", ".", "Tonsillar", "focal", "infection", "(", "TFI", ")", "and", "dental", "focal", "infection", "(", "DFI", ")", "were", "found", "in", "6/20", "and", "17/20", "patients", ",", "respectively", ".", "However", ",", "the", "presence", "of", "focal", "infection", "(", "FI", ")", ",", "TFI", "and", "/", "or", "DFI", ",", "did", "not", "appear", "to", "interfere", "with", "the", "therapeutic", "activities", "of", "Re", "and", "/", "or", "PUVA", ",", "because", "the", "complete", "clearance", "rates", "and", "remission", "periods", "in", "FI", "(", "+", ")", "patients", "were", "comparable", "with", "those", "in", "FI", "(", "-", ")", "patients", "." ]
[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
Topical PUVA is a Intervention_Pharmacological, etretinate is a Intervention_Pharmacological, combined PUVA and etretinate is a Intervention_Pharmacological, therapeutic efficacy is a Outcome_Other, tonsillar is a Outcome_Physical, Twenty is a Participant_Sample-size, palmoplantar pustulosis ( PPP ) is a Participant_Condition, topical PUVA is a Intervention_Pharmacological, oral etretinate ( Re ) is a Intervention_Pharmacological, combined PUVA and etretinate ( Re - PUVA ) is a Intervention_Pharmacological, sites improved and / or cleared is a Outcome_Physical, Complete clearance is a Outcome_Other, Remission periods is a Outcome_Physical, Tonsillar focal infection ( TFI ) is a Outcome_Physical, dental focal infection ( DFI ) is a Outcome_Physical, focal infection ( FI ) is a Outcome_Physical, complete clearance rates is a Outcome_Physical, remission periods is a Outcome_Physical
51355_task1
Sentence: Topical PUVA , etretinate , and combined PUVA and etretinate for palmoplantar pustulosis : comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections . Twenty patients with palmoplantar pustulosis ( PPP ) were treated with topical PUVA , oral etretinate ( Re ) , or combined PUVA and etretinate ( Re-PUVA ) . Re and Re-PUVA treated sites improved and/or cleared more rapidly than PUVA treated sites . Complete clearance was observed in six of ten sites treated with Re-PUVA , two of ten with Re , and one of ten sites with PUVA within 12 weeks . UVA-control sites failed to be cleared within 12 weeks . Remission periods after stopping the treatment were 1.5 +/- 0.5 weeks ( n = 2 ) with Re , 10.5 +/- 11.4 weeks ( n = 6 ) with Re-PUVA , and one year ( n = 1 ) with PUVA . These results overall suggested that Re-PUVA is the most effective treatment for PPP . Tonsillar focal infection ( TFI ) and dental focal infection ( DFI ) were found in 6/20 and 17/20 patients , respectively . However , the presence of focal infection ( FI ) , TFI and/or DFI , did not appear to interfere with the therapeutic activities of Re and/or PUVA , because the complete clearance rates and remission periods in FI ( + ) patients were comparable with those in FI ( - ) patients . Instructions: please typing these entity words according to sentence: Topical PUVA, etretinate, combined PUVA and etretinate, therapeutic efficacy, tonsillar, Twenty, palmoplantar pustulosis ( PPP ), topical PUVA, oral etretinate ( Re ), combined PUVA and etretinate ( Re - PUVA ), sites improved and / or cleared, Complete clearance, Remission periods, Tonsillar focal infection ( TFI ), dental focal infection ( DFI ), focal infection ( FI ), complete clearance rates, remission periods Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Topical PUVA , etretinate , and combined PUVA and etretinate for palmoplantar pustulosis : comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections . Twenty patients with palmoplantar pustulosis ( PPP ) were treated with topical PUVA , oral etretinate ( Re ) , or combined PUVA and etretinate ( Re-PUVA ) . Re and Re-PUVA treated sites improved and/or cleared more rapidly than PUVA treated sites . Complete clearance was observed in six of ten sites treated with Re-PUVA , two of ten with Re , and one of ten sites with PUVA within 12 weeks . UVA-control sites failed to be cleared within 12 weeks . Remission periods after stopping the treatment were 1.5 +/- 0.5 weeks ( n = 2 ) with Re , 10.5 +/- 11.4 weeks ( n = 6 ) with Re-PUVA , and one year ( n = 1 ) with PUVA . These results overall suggested that Re-PUVA is the most effective treatment for PPP . Tonsillar focal infection ( TFI ) and dental focal infection ( DFI ) were found in 6/20 and 17/20 patients , respectively . However , the presence of focal infection ( FI ) , TFI and/or DFI , did not appear to interfere with the therapeutic activities of Re and/or PUVA , because the complete clearance rates and remission periods in FI ( + ) patients were comparable with those in FI ( - ) patients .
[ "Topical", "PUVA", ",", "etretinate", ",", "and", "combined", "PUVA", "and", "etretinate", "for", "palmoplantar", "pustulosis", ":", "comparison", "of", "therapeutic", "efficacy", "and", "the", "influences", "of", "tonsillar", "and", "dental", "focal", "infections", ".", "Twenty", "patients", "with", "palmoplantar", "pustulosis", "(", "PPP", ")", "were", "treated", "with", "topical", "PUVA", ",", "oral", "etretinate", "(", "Re", ")", ",", "or", "combined", "PUVA", "and", "etretinate", "(", "Re", "-", "PUVA", ")", ".", "Re", "and", "Re", "-", "PUVA", "treated", "sites", "improved", "and", "/", "or", "cleared", "more", "rapidly", "than", "PUVA", "treated", "sites", ".", "Complete", "clearance", "was", "observed", "in", "six", "of", "ten", "sites", "treated", "with", "Re", "-", "PUVA", ",", "two", "of", "ten", "with", "Re", ",", "and", "one", "of", "ten", "sites", "with", "PUVA", "within", "12", "weeks", ".", "UVA", "-", "control", "sites", "failed", "to", "be", "cleared", "within", "12", "weeks", ".", "Remission", "periods", "after", "stopping", "the", "treatment", "were", "1.5", "+", "/-", "0.5", "weeks", "(", "n", "=", "2", ")", "with", "Re", ",", "10.5", "+", "/-", "11.4", "weeks", "(", "n", "=", "6", ")", "with", "Re", "-", "PUVA", ",", "and", "one", "year", "(", "n", "=", "1", ")", "with", "PUVA", ".", "These", "results", "overall", "suggested", "that", "Re", "-", "PUVA", "is", "the", "most", "effective", "treatment", "for", "PPP", ".", "Tonsillar", "focal", "infection", "(", "TFI", ")", "and", "dental", "focal", "infection", "(", "DFI", ")", "were", "found", "in", "6/20", "and", "17/20", "patients", ",", "respectively", ".", "However", ",", "the", "presence", "of", "focal", "infection", "(", "FI", ")", ",", "TFI", "and", "/", "or", "DFI", ",", "did", "not", "appear", "to", "interfere", "with", "the", "therapeutic", "activities", "of", "Re", "and", "/", "or", "PUVA", ",", "because", "the", "complete", "clearance", "rates", "and", "remission", "periods", "in", "FI", "(", "+", ")", "patients", "were", "comparable", "with", "those", "in", "FI", "(", "-", ")", "patients", "." ]
[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
Topical PUVA, etretinate, combined PUVA and etretinate, therapeutic efficacy, tonsillar, Twenty, palmoplantar pustulosis ( PPP ), topical PUVA, oral etretinate ( Re ), combined PUVA and etretinate ( Re - PUVA ), sites improved and / or cleared, Complete clearance, Remission periods, Tonsillar focal infection ( TFI ), dental focal infection ( DFI ), focal infection ( FI ), complete clearance rates, remission periods
51355_task2
Sentence: Topical PUVA , etretinate , and combined PUVA and etretinate for palmoplantar pustulosis : comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections . Twenty patients with palmoplantar pustulosis ( PPP ) were treated with topical PUVA , oral etretinate ( Re ) , or combined PUVA and etretinate ( Re-PUVA ) . Re and Re-PUVA treated sites improved and/or cleared more rapidly than PUVA treated sites . Complete clearance was observed in six of ten sites treated with Re-PUVA , two of ten with Re , and one of ten sites with PUVA within 12 weeks . UVA-control sites failed to be cleared within 12 weeks . Remission periods after stopping the treatment were 1.5 +/- 0.5 weeks ( n = 2 ) with Re , 10.5 +/- 11.4 weeks ( n = 6 ) with Re-PUVA , and one year ( n = 1 ) with PUVA . These results overall suggested that Re-PUVA is the most effective treatment for PPP . Tonsillar focal infection ( TFI ) and dental focal infection ( DFI ) were found in 6/20 and 17/20 patients , respectively . However , the presence of focal infection ( FI ) , TFI and/or DFI , did not appear to interfere with the therapeutic activities of Re and/or PUVA , because the complete clearance rates and remission periods in FI ( + ) patients were comparable with those in FI ( - ) patients . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Topical PUVA , etretinate , and combined PUVA and etretinate for palmoplantar pustulosis : comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections . Twenty patients with palmoplantar pustulosis ( PPP ) were treated with topical PUVA , oral etretinate ( Re ) , or combined PUVA and etretinate ( Re-PUVA ) . Re and Re-PUVA treated sites improved and/or cleared more rapidly than PUVA treated sites . Complete clearance was observed in six of ten sites treated with Re-PUVA , two of ten with Re , and one of ten sites with PUVA within 12 weeks . UVA-control sites failed to be cleared within 12 weeks . Remission periods after stopping the treatment were 1.5 +/- 0.5 weeks ( n = 2 ) with Re , 10.5 +/- 11.4 weeks ( n = 6 ) with Re-PUVA , and one year ( n = 1 ) with PUVA . These results overall suggested that Re-PUVA is the most effective treatment for PPP . Tonsillar focal infection ( TFI ) and dental focal infection ( DFI ) were found in 6/20 and 17/20 patients , respectively . However , the presence of focal infection ( FI ) , TFI and/or DFI , did not appear to interfere with the therapeutic activities of Re and/or PUVA , because the complete clearance rates and remission periods in FI ( + ) patients were comparable with those in FI ( - ) patients .
[ "Topical", "PUVA", ",", "etretinate", ",", "and", "combined", "PUVA", "and", "etretinate", "for", "palmoplantar", "pustulosis", ":", "comparison", "of", "therapeutic", "efficacy", "and", "the", "influences", "of", "tonsillar", "and", "dental", "focal", "infections", ".", "Twenty", "patients", "with", "palmoplantar", "pustulosis", "(", "PPP", ")", "were", "treated", "with", "topical", "PUVA", ",", "oral", "etretinate", "(", "Re", ")", ",", "or", "combined", "PUVA", "and", "etretinate", "(", "Re", "-", "PUVA", ")", ".", "Re", "and", "Re", "-", "PUVA", "treated", "sites", "improved", "and", "/", "or", "cleared", "more", "rapidly", "than", "PUVA", "treated", "sites", ".", "Complete", "clearance", "was", "observed", "in", "six", "of", "ten", "sites", "treated", "with", "Re", "-", "PUVA", ",", "two", "of", "ten", "with", "Re", ",", "and", "one", "of", "ten", "sites", "with", "PUVA", "within", "12", "weeks", ".", "UVA", "-", "control", "sites", "failed", "to", "be", "cleared", "within", "12", "weeks", ".", "Remission", "periods", "after", "stopping", "the", "treatment", "were", "1.5", "+", "/-", "0.5", "weeks", "(", "n", "=", "2", ")", "with", "Re", ",", "10.5", "+", "/-", "11.4", "weeks", "(", "n", "=", "6", ")", "with", "Re", "-", "PUVA", ",", "and", "one", "year", "(", "n", "=", "1", ")", "with", "PUVA", ".", "These", "results", "overall", "suggested", "that", "Re", "-", "PUVA", "is", "the", "most", "effective", "treatment", "for", "PPP", ".", "Tonsillar", "focal", "infection", "(", "TFI", ")", "and", "dental", "focal", "infection", "(", "DFI", ")", "were", "found", "in", "6/20", "and", "17/20", "patients", ",", "respectively", ".", "However", ",", "the", "presence", "of", "focal", "infection", "(", "FI", ")", ",", "TFI", "and", "/", "or", "DFI", ",", "did", "not", "appear", "to", "interfere", "with", "the", "therapeutic", "activities", "of", "Re", "and", "/", "or", "PUVA", ",", "because", "the", "complete", "clearance", "rates", "and", "remission", "periods", "in", "FI", "(", "+", ")", "patients", "were", "comparable", "with", "those", "in", "FI", "(", "-", ")", "patients", "." ]
[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
edrophonium is a CHEMICAL, acetylcholinesterase is a GENE-Y, oxime is a CHEMICAL
10421446_task0
Sentence: Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O" ]
Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime.
[ "Role", "of", "edrophonium", "in", "prevention", "of", "the", "re", "-", "inhibition", "of", "acetylcholinesterase", "by", "phosphorylated", "oxime", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
edrophonium is a CHEMICAL, acetylcholinesterase is a GENE-Y, oxime is a CHEMICAL
10421446_task1
Sentence: Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime. Instructions: please typing these entity words according to sentence: edrophonium, acetylcholinesterase, oxime Options: GENE-Y, CHEMICAL
[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O" ]
Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime.
[ "Role", "of", "edrophonium", "in", "prevention", "of", "the", "re", "-", "inhibition", "of", "acetylcholinesterase", "by", "phosphorylated", "oxime", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
edrophonium, acetylcholinesterase, oxime
10421446_task2
Sentence: Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O" ]
Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime.
[ "Role", "of", "edrophonium", "in", "prevention", "of", "the", "re", "-", "inhibition", "of", "acetylcholinesterase", "by", "phosphorylated", "oxime", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Kinder is an umlsterm, Kinder is an umlsterm
KlinischeNeuroradiologie.00100013.ger.abstr_task0
Sentence: Zusammenfassung : Wir beschreiben drei Kinder , bei denen klinisch und laborchemisch ein Leigh-Syndrom diagnostiziert wurde . Bei jedem dieser Kinder lagen in der Bildgebung unterschiedliche Abweichungen von den typischen , bisher beim Leigh-Syndrom berichteten Laesionen in der MRT vor . Die gefundenen Veraenderungen in der MRT passen allerdings sehr gut zu den pathologisch-anatomischen Befunden bei dieser Erkrankung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung : Wir beschreiben drei Kinder , bei denen klinisch und laborchemisch ein Leigh-Syndrom diagnostiziert wurde . Bei jedem dieser Kinder lagen in der Bildgebung unterschiedliche Abweichungen von den typischen , bisher beim Leigh-Syndrom berichteten Laesionen in der MRT vor . Die gefundenen Veraenderungen in der MRT passen allerdings sehr gut zu den pathologisch-anatomischen Befunden bei dieser Erkrankung .
[ "Zusammenfassung", ":", "Wir", "beschreiben", "drei", "Kinder", ",", "bei", "denen", "klinisch", "und", "laborchemisch", "ein", "Leigh", "-", "Syndrom", "diagnostiziert", "wurde", ".", "Bei", "jedem", "dieser", "Kinder", "lagen", "in", "der", "Bildgebung", "unterschiedliche", "Abweichungen", "von", "den", "typischen", ",", "bisher", "beim", "Leigh", "-", "Syndrom", "berichteten", "Laesionen", "in", "der", "MRT", "vor", ".", "Die", "gefundenen", "Veraenderungen", "in", "der", "MRT", "passen", "allerdings", "sehr", "gut", "zu", "den", "pathologisch", "-", "anatomischen", "Befunden", "bei", "dieser", "Erkrankung", "." ]
[ "umlsterm" ]
Kinder is an umlsterm, Kinder is an umlsterm
KlinischeNeuroradiologie.00100013.ger.abstr_task1
Sentence: Zusammenfassung : Wir beschreiben drei Kinder , bei denen klinisch und laborchemisch ein Leigh-Syndrom diagnostiziert wurde . Bei jedem dieser Kinder lagen in der Bildgebung unterschiedliche Abweichungen von den typischen , bisher beim Leigh-Syndrom berichteten Laesionen in der MRT vor . Die gefundenen Veraenderungen in der MRT passen allerdings sehr gut zu den pathologisch-anatomischen Befunden bei dieser Erkrankung . Instructions: please typing these entity words according to sentence: Kinder, Kinder Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung : Wir beschreiben drei Kinder , bei denen klinisch und laborchemisch ein Leigh-Syndrom diagnostiziert wurde . Bei jedem dieser Kinder lagen in der Bildgebung unterschiedliche Abweichungen von den typischen , bisher beim Leigh-Syndrom berichteten Laesionen in der MRT vor . Die gefundenen Veraenderungen in der MRT passen allerdings sehr gut zu den pathologisch-anatomischen Befunden bei dieser Erkrankung .
[ "Zusammenfassung", ":", "Wir", "beschreiben", "drei", "Kinder", ",", "bei", "denen", "klinisch", "und", "laborchemisch", "ein", "Leigh", "-", "Syndrom", "diagnostiziert", "wurde", ".", "Bei", "jedem", "dieser", "Kinder", "lagen", "in", "der", "Bildgebung", "unterschiedliche", "Abweichungen", "von", "den", "typischen", ",", "bisher", "beim", "Leigh", "-", "Syndrom", "berichteten", "Laesionen", "in", "der", "MRT", "vor", ".", "Die", "gefundenen", "Veraenderungen", "in", "der", "MRT", "passen", "allerdings", "sehr", "gut", "zu", "den", "pathologisch", "-", "anatomischen", "Befunden", "bei", "dieser", "Erkrankung", "." ]
[ "umlsterm" ]
Kinder, Kinder
KlinischeNeuroradiologie.00100013.ger.abstr_task2
Sentence: Zusammenfassung : Wir beschreiben drei Kinder , bei denen klinisch und laborchemisch ein Leigh-Syndrom diagnostiziert wurde . Bei jedem dieser Kinder lagen in der Bildgebung unterschiedliche Abweichungen von den typischen , bisher beim Leigh-Syndrom berichteten Laesionen in der MRT vor . Die gefundenen Veraenderungen in der MRT passen allerdings sehr gut zu den pathologisch-anatomischen Befunden bei dieser Erkrankung . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung : Wir beschreiben drei Kinder , bei denen klinisch und laborchemisch ein Leigh-Syndrom diagnostiziert wurde . Bei jedem dieser Kinder lagen in der Bildgebung unterschiedliche Abweichungen von den typischen , bisher beim Leigh-Syndrom berichteten Laesionen in der MRT vor . Die gefundenen Veraenderungen in der MRT passen allerdings sehr gut zu den pathologisch-anatomischen Befunden bei dieser Erkrankung .
[ "Zusammenfassung", ":", "Wir", "beschreiben", "drei", "Kinder", ",", "bei", "denen", "klinisch", "und", "laborchemisch", "ein", "Leigh", "-", "Syndrom", "diagnostiziert", "wurde", ".", "Bei", "jedem", "dieser", "Kinder", "lagen", "in", "der", "Bildgebung", "unterschiedliche", "Abweichungen", "von", "den", "typischen", ",", "bisher", "beim", "Leigh", "-", "Syndrom", "berichteten", "Laesionen", "in", "der", "MRT", "vor", ".", "Die", "gefundenen", "Veraenderungen", "in", "der", "MRT", "passen", "allerdings", "sehr", "gut", "zu", "den", "pathologisch", "-", "anatomischen", "Befunden", "bei", "dieser", "Erkrankung", "." ]
[ "umlsterm" ]
IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, bcr - abl is a Protein, bcr - abl is a Protein, bcr - abl is a Protein, bcr - abl is a Protein, bcr - abl is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein
6_task0
Sentence: Absence of IRF-4 expression in leukemia cells is not due to promoter alterations We have previously demonstrated a lack of IRF-4 expression in leukemia patients and specifically in CML T-cells (3). Here, we demonstrate the absence of IRF-4 expression in various hematopoietic cell lines, such as Jurkat, a T-cell leukemia, CML-T1, a bcr-abl-positive T-cell line, K-562, a bcr-abl-positve erythroleukemia, U-937, a monocytic leukemia, EM-2 and LAMA-84, bcr-abl-positve myeloid leukemia, but not in SD-1, a bcr-abl-positive acute lymphoblastic leukemia (pre B-ALL), RPMI-8226, a multiple myeloma and BV-173, a bcr-abl-positive B-cell line (Figures 1A and 5D). After sequencing of the IRF-4 promoter, it could be excluded that absence of IRF-4 expression in any of the above cell lines was due to genetic aberrations. However, 2 bp changes (nucleotide -1081, T to C and -1068, A to C) could be detected in both the IRF-4-positive BV-173 and the IRF-4-negative LAMA-84, EM-2 and K-562 (Figure 1B). At position -116 an A to C substitution was found in EM-2, K-562 and CML-T1, whereas Jurkat, BV-173 and SD-1 exhibited a mixed A/C sequence and U-937, LAMA-84 and RPMI-8226 no substitution at all (Figure 1B). Consequently, these alterations are unlikely to affect IRF-4 expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]
Absence of IRF-4 expression in leukemia cells is not due to promoter alterations We have previously demonstrated a lack of IRF-4 expression in leukemia patients and specifically in CML T-cells (3). Here, we demonstrate the absence of IRF-4 expression in various hematopoietic cell lines, such as Jurkat, a T-cell leukemia, CML-T1, a bcr-abl-positive T-cell line, K-562, a bcr-abl-positve erythroleukemia, U-937, a monocytic leukemia, EM-2 and LAMA-84, bcr-abl-positve myeloid leukemia, but not in SD-1, a bcr-abl-positive acute lymphoblastic leukemia (pre B-ALL), RPMI-8226, a multiple myeloma and BV-173, a bcr-abl-positive B-cell line (Figures 1A and 5D). After sequencing of the IRF-4 promoter, it could be excluded that absence of IRF-4 expression in any of the above cell lines was due to genetic aberrations. However, 2 bp changes (nucleotide -1081, T to C and -1068, A to C) could be detected in both the IRF-4-positive BV-173 and the IRF-4-negative LAMA-84, EM-2 and K-562 (Figure 1B). At position -116 an A to C substitution was found in EM-2, K-562 and CML-T1, whereas Jurkat, BV-173 and SD-1 exhibited a mixed A/C sequence and U-937, LAMA-84 and RPMI-8226 no substitution at all (Figure 1B). Consequently, these alterations are unlikely to affect IRF-4 expression.
[ "Absence", "of", "IRF-4", "expression", "in", "leukemia", "cells", "is", "not", "due", "to", "promoter", "alterations", "\n", "We", "have", "previously", "demonstrated", "a", "lack", "of", "IRF-4", "expression", "in", "leukemia", "patients", "and", "specifically", "in", "CML", "T", "-", "cells", "(", "3", ")", ".", "Here", ",", "we", "demonstrate", "the", "absence", "of", "IRF-4", "expression", "in", "various", "hematopoietic", "cell", "lines", ",", "such", "as", "Jurkat", ",", "a", "T", "-", "cell", "leukemia", ",", "CML", "-", "T1", ",", "a", "bcr", "-", "abl", "-", "positive", "T", "-", "cell", "line", ",", "K-562", ",", "a", "bcr", "-", "abl", "-", "positve", "erythroleukemia", ",", "U-937", ",", "a", "monocytic", "leukemia", ",", "EM-2", "and", "LAMA-84", ",", "bcr", "-", "abl", "-", "positve", "myeloid", "leukemia", ",", "but", "not", "in", "SD-1", ",", "a", "bcr", "-", "abl", "-", "positive", "acute", "lymphoblastic", "leukemia", "(", "pre", "B", "-", "ALL", ")", ",", "RPMI-8226", ",", "a", "multiple", "myeloma", "and", "BV-173", ",", "a", "bcr", "-", "abl", "-", "positive", "B", "-", "cell", "line", "(", "Figures", "1A", "and", "5D", ")", ".", "After", "sequencing", "of", "the", "IRF-4", "promoter", ",", "it", "could", "be", "excluded", "that", "absence", "of", "IRF-4", "expression", "in", "any", "of", "the", "above", "cell", "lines", "was", "due", "to", "genetic", "aberrations", ".", "However", ",", "2", "bp", "changes", "(", "nucleotide", "-1081", ",", "T", "to", "C", "and", "-1068", ",", "A", "to", "C", ")", "could", "be", "detected", "in", "both", "the", "IRF-4-positive", "BV-173", "and", "the", "IRF-4-negative", "LAMA-84", ",", "EM-2", "and", "K-562", "(", "Figure", "1B", ")", ".", "At", "position", "-116", "an", "A", "to", "C", "substitution", "was", "found", "in", "EM-2", ",", "K-562", "and", "CML", "-", "T1", ",", "whereas", "Jurkat", ",", "BV-173", "and", "SD-1", "exhibited", "a", "mixed", "A", "/", "C", "sequence", "and", "U-937", ",", "LAMA-84", "and", "RPMI-8226", "no", "substitution", "at", "all", "(", "Figure", "1B", ")", ".", "Consequently", ",", "these", "alterations", "are", "unlikely", "to", "affect", "IRF-4", "expression", "." ]
[ "Protein" ]
IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, bcr - abl is a Protein, bcr - abl is a Protein, bcr - abl is a Protein, bcr - abl is a Protein, bcr - abl is a Protein, IRF-4 is a Protein, IRF-4 is a Protein, IRF-4 is a Protein
6_task1
Sentence: Absence of IRF-4 expression in leukemia cells is not due to promoter alterations We have previously demonstrated a lack of IRF-4 expression in leukemia patients and specifically in CML T-cells (3). Here, we demonstrate the absence of IRF-4 expression in various hematopoietic cell lines, such as Jurkat, a T-cell leukemia, CML-T1, a bcr-abl-positive T-cell line, K-562, a bcr-abl-positve erythroleukemia, U-937, a monocytic leukemia, EM-2 and LAMA-84, bcr-abl-positve myeloid leukemia, but not in SD-1, a bcr-abl-positive acute lymphoblastic leukemia (pre B-ALL), RPMI-8226, a multiple myeloma and BV-173, a bcr-abl-positive B-cell line (Figures 1A and 5D). After sequencing of the IRF-4 promoter, it could be excluded that absence of IRF-4 expression in any of the above cell lines was due to genetic aberrations. However, 2 bp changes (nucleotide -1081, T to C and -1068, A to C) could be detected in both the IRF-4-positive BV-173 and the IRF-4-negative LAMA-84, EM-2 and K-562 (Figure 1B). At position -116 an A to C substitution was found in EM-2, K-562 and CML-T1, whereas Jurkat, BV-173 and SD-1 exhibited a mixed A/C sequence and U-937, LAMA-84 and RPMI-8226 no substitution at all (Figure 1B). Consequently, these alterations are unlikely to affect IRF-4 expression. Instructions: please typing these entity words according to sentence: IRF-4, IRF-4, IRF-4, bcr - abl, bcr - abl, bcr - abl, bcr - abl, bcr - abl, IRF-4, IRF-4, IRF-4 Options: Protein
[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]
Absence of IRF-4 expression in leukemia cells is not due to promoter alterations We have previously demonstrated a lack of IRF-4 expression in leukemia patients and specifically in CML T-cells (3). Here, we demonstrate the absence of IRF-4 expression in various hematopoietic cell lines, such as Jurkat, a T-cell leukemia, CML-T1, a bcr-abl-positive T-cell line, K-562, a bcr-abl-positve erythroleukemia, U-937, a monocytic leukemia, EM-2 and LAMA-84, bcr-abl-positve myeloid leukemia, but not in SD-1, a bcr-abl-positive acute lymphoblastic leukemia (pre B-ALL), RPMI-8226, a multiple myeloma and BV-173, a bcr-abl-positive B-cell line (Figures 1A and 5D). After sequencing of the IRF-4 promoter, it could be excluded that absence of IRF-4 expression in any of the above cell lines was due to genetic aberrations. However, 2 bp changes (nucleotide -1081, T to C and -1068, A to C) could be detected in both the IRF-4-positive BV-173 and the IRF-4-negative LAMA-84, EM-2 and K-562 (Figure 1B). At position -116 an A to C substitution was found in EM-2, K-562 and CML-T1, whereas Jurkat, BV-173 and SD-1 exhibited a mixed A/C sequence and U-937, LAMA-84 and RPMI-8226 no substitution at all (Figure 1B). Consequently, these alterations are unlikely to affect IRF-4 expression.
[ "Absence", "of", "IRF-4", "expression", "in", "leukemia", "cells", "is", "not", "due", "to", "promoter", "alterations", "\n", "We", "have", "previously", "demonstrated", "a", "lack", "of", "IRF-4", "expression", "in", "leukemia", "patients", "and", "specifically", "in", "CML", "T", "-", "cells", "(", "3", ")", ".", "Here", ",", "we", "demonstrate", "the", "absence", "of", "IRF-4", "expression", "in", "various", "hematopoietic", "cell", "lines", ",", "such", "as", "Jurkat", ",", "a", "T", "-", "cell", "leukemia", ",", "CML", "-", "T1", ",", "a", "bcr", "-", "abl", "-", "positive", "T", "-", "cell", "line", ",", "K-562", ",", "a", "bcr", "-", "abl", "-", "positve", "erythroleukemia", ",", "U-937", ",", "a", "monocytic", "leukemia", ",", "EM-2", "and", "LAMA-84", ",", "bcr", "-", "abl", "-", "positve", "myeloid", "leukemia", ",", "but", "not", "in", "SD-1", ",", "a", "bcr", "-", "abl", "-", "positive", "acute", "lymphoblastic", "leukemia", "(", "pre", "B", "-", "ALL", ")", ",", "RPMI-8226", ",", "a", "multiple", "myeloma", "and", "BV-173", ",", "a", "bcr", "-", "abl", "-", "positive", "B", "-", "cell", "line", "(", "Figures", "1A", "and", "5D", ")", ".", "After", "sequencing", "of", "the", "IRF-4", "promoter", ",", "it", "could", "be", "excluded", "that", "absence", "of", "IRF-4", "expression", "in", "any", "of", "the", "above", "cell", "lines", "was", "due", "to", "genetic", "aberrations", ".", "However", ",", "2", "bp", "changes", "(", "nucleotide", "-1081", ",", "T", "to", "C", "and", "-1068", ",", "A", "to", "C", ")", "could", "be", "detected", "in", "both", "the", "IRF-4-positive", "BV-173", "and", "the", "IRF-4-negative", "LAMA-84", ",", "EM-2", "and", "K-562", "(", "Figure", "1B", ")", ".", "At", "position", "-116", "an", "A", "to", "C", "substitution", "was", "found", "in", "EM-2", ",", "K-562", "and", "CML", "-", "T1", ",", "whereas", "Jurkat", ",", "BV-173", "and", "SD-1", "exhibited", "a", "mixed", "A", "/", "C", "sequence", "and", "U-937", ",", "LAMA-84", "and", "RPMI-8226", "no", "substitution", "at", "all", "(", "Figure", "1B", ")", ".", "Consequently", ",", "these", "alterations", "are", "unlikely", "to", "affect", "IRF-4", "expression", "." ]
[ "Protein" ]
IRF-4, IRF-4, IRF-4, bcr - abl, bcr - abl, bcr - abl, bcr - abl, bcr - abl, IRF-4, IRF-4, IRF-4
6_task2
Sentence: Absence of IRF-4 expression in leukemia cells is not due to promoter alterations We have previously demonstrated a lack of IRF-4 expression in leukemia patients and specifically in CML T-cells (3). Here, we demonstrate the absence of IRF-4 expression in various hematopoietic cell lines, such as Jurkat, a T-cell leukemia, CML-T1, a bcr-abl-positive T-cell line, K-562, a bcr-abl-positve erythroleukemia, U-937, a monocytic leukemia, EM-2 and LAMA-84, bcr-abl-positve myeloid leukemia, but not in SD-1, a bcr-abl-positive acute lymphoblastic leukemia (pre B-ALL), RPMI-8226, a multiple myeloma and BV-173, a bcr-abl-positive B-cell line (Figures 1A and 5D). After sequencing of the IRF-4 promoter, it could be excluded that absence of IRF-4 expression in any of the above cell lines was due to genetic aberrations. However, 2 bp changes (nucleotide -1081, T to C and -1068, A to C) could be detected in both the IRF-4-positive BV-173 and the IRF-4-negative LAMA-84, EM-2 and K-562 (Figure 1B). At position -116 an A to C substitution was found in EM-2, K-562 and CML-T1, whereas Jurkat, BV-173 and SD-1 exhibited a mixed A/C sequence and U-937, LAMA-84 and RPMI-8226 no substitution at all (Figure 1B). Consequently, these alterations are unlikely to affect IRF-4 expression. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]
Absence of IRF-4 expression in leukemia cells is not due to promoter alterations We have previously demonstrated a lack of IRF-4 expression in leukemia patients and specifically in CML T-cells (3). Here, we demonstrate the absence of IRF-4 expression in various hematopoietic cell lines, such as Jurkat, a T-cell leukemia, CML-T1, a bcr-abl-positive T-cell line, K-562, a bcr-abl-positve erythroleukemia, U-937, a monocytic leukemia, EM-2 and LAMA-84, bcr-abl-positve myeloid leukemia, but not in SD-1, a bcr-abl-positive acute lymphoblastic leukemia (pre B-ALL), RPMI-8226, a multiple myeloma and BV-173, a bcr-abl-positive B-cell line (Figures 1A and 5D). After sequencing of the IRF-4 promoter, it could be excluded that absence of IRF-4 expression in any of the above cell lines was due to genetic aberrations. However, 2 bp changes (nucleotide -1081, T to C and -1068, A to C) could be detected in both the IRF-4-positive BV-173 and the IRF-4-negative LAMA-84, EM-2 and K-562 (Figure 1B). At position -116 an A to C substitution was found in EM-2, K-562 and CML-T1, whereas Jurkat, BV-173 and SD-1 exhibited a mixed A/C sequence and U-937, LAMA-84 and RPMI-8226 no substitution at all (Figure 1B). Consequently, these alterations are unlikely to affect IRF-4 expression.
[ "Absence", "of", "IRF-4", "expression", "in", "leukemia", "cells", "is", "not", "due", "to", "promoter", "alterations", "\n", "We", "have", "previously", "demonstrated", "a", "lack", "of", "IRF-4", "expression", "in", "leukemia", "patients", "and", "specifically", "in", "CML", "T", "-", "cells", "(", "3", ")", ".", "Here", ",", "we", "demonstrate", "the", "absence", "of", "IRF-4", "expression", "in", "various", "hematopoietic", "cell", "lines", ",", "such", "as", "Jurkat", ",", "a", "T", "-", "cell", "leukemia", ",", "CML", "-", "T1", ",", "a", "bcr", "-", "abl", "-", "positive", "T", "-", "cell", "line", ",", "K-562", ",", "a", "bcr", "-", "abl", "-", "positve", "erythroleukemia", ",", "U-937", ",", "a", "monocytic", "leukemia", ",", "EM-2", "and", "LAMA-84", ",", "bcr", "-", "abl", "-", "positve", "myeloid", "leukemia", ",", "but", "not", "in", "SD-1", ",", "a", "bcr", "-", "abl", "-", "positive", "acute", "lymphoblastic", "leukemia", "(", "pre", "B", "-", "ALL", ")", ",", "RPMI-8226", ",", "a", "multiple", "myeloma", "and", "BV-173", ",", "a", "bcr", "-", "abl", "-", "positive", "B", "-", "cell", "line", "(", "Figures", "1A", "and", "5D", ")", ".", "After", "sequencing", "of", "the", "IRF-4", "promoter", ",", "it", "could", "be", "excluded", "that", "absence", "of", "IRF-4", "expression", "in", "any", "of", "the", "above", "cell", "lines", "was", "due", "to", "genetic", "aberrations", ".", "However", ",", "2", "bp", "changes", "(", "nucleotide", "-1081", ",", "T", "to", "C", "and", "-1068", ",", "A", "to", "C", ")", "could", "be", "detected", "in", "both", "the", "IRF-4-positive", "BV-173", "and", "the", "IRF-4-negative", "LAMA-84", ",", "EM-2", "and", "K-562", "(", "Figure", "1B", ")", ".", "At", "position", "-116", "an", "A", "to", "C", "substitution", "was", "found", "in", "EM-2", ",", "K-562", "and", "CML", "-", "T1", ",", "whereas", "Jurkat", ",", "BV-173", "and", "SD-1", "exhibited", "a", "mixed", "A", "/", "C", "sequence", "and", "U-937", ",", "LAMA-84", "and", "RPMI-8226", "no", "substitution", "at", "all", "(", "Figure", "1B", ")", ".", "Consequently", ",", "these", "alterations", "are", "unlikely", "to", "affect", "IRF-4", "expression", "." ]
[ "Protein" ]
Accident & Emergency Department is a Visit, requiring is a Mood, parenteral drug sedation is a Procedure
NCT02380118_inc_task0
Sentence: Accident & Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Mood, Procedure, Visit
[ "B-Visit", "I-Visit", "I-Visit", "I-Visit", "O", "O", "B-Mood", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Accident & Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled.
[ "Accident", "&", "Emergency", "Department", "patients", ",", "requiring", "parenteral", "drug", "sedation", "(", "as", "determined", "by", "an", "emergency", "clinician", ")", "will", "be", "enrolled", ".", "\n" ]
[ "Visit", "Procedure", "Mood" ]
Accident & Emergency Department is a Visit, requiring is a Mood, parenteral drug sedation is a Procedure
NCT02380118_inc_task1
Sentence: Accident & Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled. Instructions: please typing these entity words according to sentence: Accident & Emergency Department, requiring, parenteral drug sedation Options: Mood, Procedure, Visit
[ "B-Visit", "I-Visit", "I-Visit", "I-Visit", "O", "O", "B-Mood", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Accident & Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled.
[ "Accident", "&", "Emergency", "Department", "patients", ",", "requiring", "parenteral", "drug", "sedation", "(", "as", "determined", "by", "an", "emergency", "clinician", ")", "will", "be", "enrolled", ".", "\n" ]
[ "Visit", "Procedure", "Mood" ]
Accident & Emergency Department, requiring, parenteral drug sedation
NCT02380118_inc_task2
Sentence: Accident & Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled. Instructions: please extract entity words from the input sentence
[ "B-Visit", "I-Visit", "I-Visit", "I-Visit", "O", "O", "B-Mood", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Accident & Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled.
[ "Accident", "&", "Emergency", "Department", "patients", ",", "requiring", "parenteral", "drug", "sedation", "(", "as", "determined", "by", "an", "emergency", "clinician", ")", "will", "be", "enrolled", ".", "\n" ]
[ "Visit", "Procedure", "Mood" ]
vulva is an umlsterm, vagina is an umlsterm, gynecological surgery is an umlsterm, surgical is an umlsterm, patient is an umlsterm, techniques is an umlsterm, anatomic is an umlsterm, treatment is an umlsterm
DerGynaekologe.90320121.eng.abstr_task0
Sentence: Reconstruction of the vulva and vagina is mandatory in gynecological surgery . Any gynecologist should be familiar with the different surgical options and should know which center is most appropriate to refer the patient . Careful operative techniques and intensive perioperative management are decisive for good healing results . An optimal anatomic and functional outcome is part of global psychosomatic treatment . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Reconstruction of the vulva and vagina is mandatory in gynecological surgery . Any gynecologist should be familiar with the different surgical options and should know which center is most appropriate to refer the patient . Careful operative techniques and intensive perioperative management are decisive for good healing results . An optimal anatomic and functional outcome is part of global psychosomatic treatment .
[ "Reconstruction", "of", "the", "vulva", "and", "vagina", "is", "mandatory", "in", "gynecological", "surgery", ".", "Any", "gynecologist", "should", "be", "familiar", "with", "the", "different", "surgical", "options", "and", "should", "know", "which", "center", "is", "most", "appropriate", "to", "refer", "the", "patient", ".", "Careful", "operative", "techniques", "and", "intensive", "perioperative", "management", "are", "decisive", "for", "good", "healing", "results", ".", "An", "optimal", "anatomic", "and", "functional", "outcome", "is", "part", "of", "global", "psychosomatic", "treatment", "." ]
[ "umlsterm" ]
vulva is an umlsterm, vagina is an umlsterm, gynecological surgery is an umlsterm, surgical is an umlsterm, patient is an umlsterm, techniques is an umlsterm, anatomic is an umlsterm, treatment is an umlsterm
DerGynaekologe.90320121.eng.abstr_task1
Sentence: Reconstruction of the vulva and vagina is mandatory in gynecological surgery . Any gynecologist should be familiar with the different surgical options and should know which center is most appropriate to refer the patient . Careful operative techniques and intensive perioperative management are decisive for good healing results . An optimal anatomic and functional outcome is part of global psychosomatic treatment . Instructions: please typing these entity words according to sentence: vulva, vagina, gynecological surgery, surgical, patient, techniques, anatomic, treatment Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Reconstruction of the vulva and vagina is mandatory in gynecological surgery . Any gynecologist should be familiar with the different surgical options and should know which center is most appropriate to refer the patient . Careful operative techniques and intensive perioperative management are decisive for good healing results . An optimal anatomic and functional outcome is part of global psychosomatic treatment .
[ "Reconstruction", "of", "the", "vulva", "and", "vagina", "is", "mandatory", "in", "gynecological", "surgery", ".", "Any", "gynecologist", "should", "be", "familiar", "with", "the", "different", "surgical", "options", "and", "should", "know", "which", "center", "is", "most", "appropriate", "to", "refer", "the", "patient", ".", "Careful", "operative", "techniques", "and", "intensive", "perioperative", "management", "are", "decisive", "for", "good", "healing", "results", ".", "An", "optimal", "anatomic", "and", "functional", "outcome", "is", "part", "of", "global", "psychosomatic", "treatment", "." ]
[ "umlsterm" ]
vulva, vagina, gynecological surgery, surgical, patient, techniques, anatomic, treatment
DerGynaekologe.90320121.eng.abstr_task2
Sentence: Reconstruction of the vulva and vagina is mandatory in gynecological surgery . Any gynecologist should be familiar with the different surgical options and should know which center is most appropriate to refer the patient . Careful operative techniques and intensive perioperative management are decisive for good healing results . An optimal anatomic and functional outcome is part of global psychosomatic treatment . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Reconstruction of the vulva and vagina is mandatory in gynecological surgery . Any gynecologist should be familiar with the different surgical options and should know which center is most appropriate to refer the patient . Careful operative techniques and intensive perioperative management are decisive for good healing results . An optimal anatomic and functional outcome is part of global psychosomatic treatment .
[ "Reconstruction", "of", "the", "vulva", "and", "vagina", "is", "mandatory", "in", "gynecological", "surgery", ".", "Any", "gynecologist", "should", "be", "familiar", "with", "the", "different", "surgical", "options", "and", "should", "know", "which", "center", "is", "most", "appropriate", "to", "refer", "the", "patient", ".", "Careful", "operative", "techniques", "and", "intensive", "perioperative", "management", "are", "decisive", "for", "good", "healing", "results", ".", "An", "optimal", "anatomic", "and", "functional", "outcome", "is", "part", "of", "global", "psychosomatic", "treatment", "." ]
[ "umlsterm" ]
Antidepressiva is an umlsterm, Schmerzen is an umlsterm, Noradrenalin is an umlsterm, Serotonin is an umlsterm, Rueckenmark is an umlsterm, Arbeit is an umlsterm, Antidepressiva is an umlsterm, Schmerzen is an umlsterm, Antidepressiva is an umlsterm, Metaanalyse is an umlsterm, Behandlung is an umlsterm, Schmerzen is an umlsterm, Placebo - kontrollierte is an umlsterm, Doppelblindstudien is an umlsterm, Placebo - kontrollierte is an umlsterm, Doppelblindstudien is an umlsterm, Fallberichte is an umlsterm, Verwendung is an umlsterm, Amitriptylin is an umlsterm, Clomipramin is an umlsterm, Desipramin is an umlsterm, Imipramin is an umlsterm, Doxepin is an umlsterm
DerSchmerz.70110213.ger.abstr_task0
Sentence: Sowohl praeklinisch-experimentelle Ueberlegungen als auch klinische Studien sprechen fuer den Einsatz von Antidepressiva bei chronischen Schmerzen . Diese Substanzen beeinflussen die Neurotransmissionen von Noradrenalin ( NA ) und/oder Serotonin ( 5-HT ) ; ihr antinozizeptiver Effekt duerfte sich vor allem im Rueckenmark abspielen . Die vorliegende Arbeit versucht , den wahrscheinlichen analgetischen Wirkmechanismus von Antidepressiva mit den Ergebnissen klinischer Studien zum Einsatz bestimmter Substanzen bei chronischen Schmerzen zu verknuepfen . Experimentell-praeklinisch betrachtet sollten unselektive Monoamin-Wiederaufnahmehemmer anderen Substanzen , die in selektiver Weise nur den Reuptake von NA oder 5-HT blockieren , ueberlegen sein . Ob das pharmakologische und analgetische Profil von Antidepressiva tatsaechlich dieser Erwartung entspricht , wurde in einer Metaanalyse von 57 klinischen Studien zur Behandlung chronischer Schmerzen ueberprueft . Diese Studien wurden entsprechend ihrer wissenschaftlichen Qualitaet in 5 Gruppen unterteilt : [ 1 ] Placebo-kontrollierte Doppelblindstudien mit hoher Trennschaerfe ; [ 2 ] Placebo-kontrollierte Doppelblindstudien mit niederer Trennschaerfe ; [ 3-4 ] offene kontrollierte Studien oder Studien mit historischen Kontrollen ; [ 5 ] Fallberichte . Die wirksamsten Substanzen waren tatsaechlich unselektive Monoamin-Wiederaufnahmehemmer in der folgenden Rangordnung , die der Empfehlung ihrer therapeutischen Verwendung entspricht : Amitriptylin > Clomipramin > = Desipramin > = Imipramin > = Doxepin . Aus den analysierten Studien laesst sich keine allgemein gueltige Dosierungsempfehlung fuer die einzelnen Substanzen ableiten . Dosisfindungsstudien , die auch die entsprechenden Plasmaspiegel erfassen , sind hierzu notwendig . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Sowohl praeklinisch-experimentelle Ueberlegungen als auch klinische Studien sprechen fuer den Einsatz von Antidepressiva bei chronischen Schmerzen . Diese Substanzen beeinflussen die Neurotransmissionen von Noradrenalin ( NA ) und/oder Serotonin ( 5-HT ) ; ihr antinozizeptiver Effekt duerfte sich vor allem im Rueckenmark abspielen . Die vorliegende Arbeit versucht , den wahrscheinlichen analgetischen Wirkmechanismus von Antidepressiva mit den Ergebnissen klinischer Studien zum Einsatz bestimmter Substanzen bei chronischen Schmerzen zu verknuepfen . Experimentell-praeklinisch betrachtet sollten unselektive Monoamin-Wiederaufnahmehemmer anderen Substanzen , die in selektiver Weise nur den Reuptake von NA oder 5-HT blockieren , ueberlegen sein . Ob das pharmakologische und analgetische Profil von Antidepressiva tatsaechlich dieser Erwartung entspricht , wurde in einer Metaanalyse von 57 klinischen Studien zur Behandlung chronischer Schmerzen ueberprueft . Diese Studien wurden entsprechend ihrer wissenschaftlichen Qualitaet in 5 Gruppen unterteilt : [ 1 ] Placebo-kontrollierte Doppelblindstudien mit hoher Trennschaerfe ; [ 2 ] Placebo-kontrollierte Doppelblindstudien mit niederer Trennschaerfe ; [ 3-4 ] offene kontrollierte Studien oder Studien mit historischen Kontrollen ; [ 5 ] Fallberichte . Die wirksamsten Substanzen waren tatsaechlich unselektive Monoamin-Wiederaufnahmehemmer in der folgenden Rangordnung , die der Empfehlung ihrer therapeutischen Verwendung entspricht : Amitriptylin > Clomipramin > = Desipramin > = Imipramin > = Doxepin . Aus den analysierten Studien laesst sich keine allgemein gueltige Dosierungsempfehlung fuer die einzelnen Substanzen ableiten . Dosisfindungsstudien , die auch die entsprechenden Plasmaspiegel erfassen , sind hierzu notwendig .
[ "Sowohl", "praeklinisch", "-", "experimentelle", "Ueberlegungen", "als", "auch", "klinische", "Studien", "sprechen", "fuer", "den", "Einsatz", "von", "Antidepressiva", "bei", "chronischen", "Schmerzen", ".", "Diese", "Substanzen", "beeinflussen", "die", "Neurotransmissionen", "von", "Noradrenalin", "(", "NA", ")", "und", "/", "oder", "Serotonin", "(", "5-HT", ")", ";", "ihr", "antinozizeptiver", "Effekt", "duerfte", "sich", "vor", "allem", "im", "Rueckenmark", "abspielen", ".", "Die", "vorliegende", "Arbeit", "versucht", ",", "den", "wahrscheinlichen", "analgetischen", "Wirkmechanismus", "von", "Antidepressiva", "mit", "den", "Ergebnissen", "klinischer", "Studien", "zum", "Einsatz", "bestimmter", "Substanzen", "bei", "chronischen", "Schmerzen", "zu", "verknuepfen", ".", "Experimentell", "-", "praeklinisch", "betrachtet", "sollten", "unselektive", "Monoamin", "-", "Wiederaufnahmehemmer", "anderen", "Substanzen", ",", "die", "in", "selektiver", "Weise", "nur", "den", "Reuptake", "von", "NA", "oder", "5-HT", "blockieren", ",", "ueberlegen", "sein", ".", "Ob", "das", "pharmakologische", "und", "analgetische", "Profil", "von", "Antidepressiva", "tatsaechlich", "dieser", "Erwartung", "entspricht", ",", "wurde", "in", "einer", "Metaanalyse", "von", "57", "klinischen", "Studien", "zur", "Behandlung", "chronischer", "Schmerzen", "ueberprueft", ".", "Diese", "Studien", "wurden", "entsprechend", "ihrer", "wissenschaftlichen", "Qualitaet", "in", "5", "Gruppen", "unterteilt", ":", "[", "1", "]", "Placebo", "-", "kontrollierte", "Doppelblindstudien", "mit", "hoher", "Trennschaerfe", ";", "[", "2", "]", "Placebo", "-", "kontrollierte", "Doppelblindstudien", "mit", "niederer", "Trennschaerfe", ";", "[", "3", "-", "4", "]", "offene", "kontrollierte", "Studien", "oder", "Studien", "mit", "historischen", "Kontrollen", ";", "[", "5", "]", "Fallberichte", ".", "Die", "wirksamsten", "Substanzen", "waren", "tatsaechlich", "unselektive", "Monoamin", "-", "Wiederaufnahmehemmer", "in", "der", "folgenden", "Rangordnung", ",", "die", "der", "Empfehlung", "ihrer", "therapeutischen", "Verwendung", "entspricht", ":", "Amitriptylin", ">", "Clomipramin", ">", "=", "Desipramin", ">", "=", "Imipramin", ">", "=", "Doxepin", ".", "Aus", "den", "analysierten", "Studien", "laesst", "sich", "keine", "allgemein", "gueltige", "Dosierungsempfehlung", "fuer", "die", "einzelnen", "Substanzen", "ableiten", ".", "Dosisfindungsstudien", ",", "die", "auch", "die", "entsprechenden", "Plasmaspiegel", "erfassen", ",", "sind", "hierzu", "notwendig", "." ]
[ "umlsterm" ]
Antidepressiva is an umlsterm, Schmerzen is an umlsterm, Noradrenalin is an umlsterm, Serotonin is an umlsterm, Rueckenmark is an umlsterm, Arbeit is an umlsterm, Antidepressiva is an umlsterm, Schmerzen is an umlsterm, Antidepressiva is an umlsterm, Metaanalyse is an umlsterm, Behandlung is an umlsterm, Schmerzen is an umlsterm, Placebo - kontrollierte is an umlsterm, Doppelblindstudien is an umlsterm, Placebo - kontrollierte is an umlsterm, Doppelblindstudien is an umlsterm, Fallberichte is an umlsterm, Verwendung is an umlsterm, Amitriptylin is an umlsterm, Clomipramin is an umlsterm, Desipramin is an umlsterm, Imipramin is an umlsterm, Doxepin is an umlsterm
DerSchmerz.70110213.ger.abstr_task1
Sentence: Sowohl praeklinisch-experimentelle Ueberlegungen als auch klinische Studien sprechen fuer den Einsatz von Antidepressiva bei chronischen Schmerzen . Diese Substanzen beeinflussen die Neurotransmissionen von Noradrenalin ( NA ) und/oder Serotonin ( 5-HT ) ; ihr antinozizeptiver Effekt duerfte sich vor allem im Rueckenmark abspielen . Die vorliegende Arbeit versucht , den wahrscheinlichen analgetischen Wirkmechanismus von Antidepressiva mit den Ergebnissen klinischer Studien zum Einsatz bestimmter Substanzen bei chronischen Schmerzen zu verknuepfen . Experimentell-praeklinisch betrachtet sollten unselektive Monoamin-Wiederaufnahmehemmer anderen Substanzen , die in selektiver Weise nur den Reuptake von NA oder 5-HT blockieren , ueberlegen sein . Ob das pharmakologische und analgetische Profil von Antidepressiva tatsaechlich dieser Erwartung entspricht , wurde in einer Metaanalyse von 57 klinischen Studien zur Behandlung chronischer Schmerzen ueberprueft . Diese Studien wurden entsprechend ihrer wissenschaftlichen Qualitaet in 5 Gruppen unterteilt : [ 1 ] Placebo-kontrollierte Doppelblindstudien mit hoher Trennschaerfe ; [ 2 ] Placebo-kontrollierte Doppelblindstudien mit niederer Trennschaerfe ; [ 3-4 ] offene kontrollierte Studien oder Studien mit historischen Kontrollen ; [ 5 ] Fallberichte . Die wirksamsten Substanzen waren tatsaechlich unselektive Monoamin-Wiederaufnahmehemmer in der folgenden Rangordnung , die der Empfehlung ihrer therapeutischen Verwendung entspricht : Amitriptylin > Clomipramin > = Desipramin > = Imipramin > = Doxepin . Aus den analysierten Studien laesst sich keine allgemein gueltige Dosierungsempfehlung fuer die einzelnen Substanzen ableiten . Dosisfindungsstudien , die auch die entsprechenden Plasmaspiegel erfassen , sind hierzu notwendig . Instructions: please typing these entity words according to sentence: Antidepressiva, Schmerzen, Noradrenalin, Serotonin, Rueckenmark, Arbeit, Antidepressiva, Schmerzen, Antidepressiva, Metaanalyse, Behandlung, Schmerzen, Placebo - kontrollierte, Doppelblindstudien, Placebo - kontrollierte, Doppelblindstudien, Fallberichte, Verwendung, Amitriptylin, Clomipramin, Desipramin, Imipramin, Doxepin Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Sowohl praeklinisch-experimentelle Ueberlegungen als auch klinische Studien sprechen fuer den Einsatz von Antidepressiva bei chronischen Schmerzen . Diese Substanzen beeinflussen die Neurotransmissionen von Noradrenalin ( NA ) und/oder Serotonin ( 5-HT ) ; ihr antinozizeptiver Effekt duerfte sich vor allem im Rueckenmark abspielen . Die vorliegende Arbeit versucht , den wahrscheinlichen analgetischen Wirkmechanismus von Antidepressiva mit den Ergebnissen klinischer Studien zum Einsatz bestimmter Substanzen bei chronischen Schmerzen zu verknuepfen . Experimentell-praeklinisch betrachtet sollten unselektive Monoamin-Wiederaufnahmehemmer anderen Substanzen , die in selektiver Weise nur den Reuptake von NA oder 5-HT blockieren , ueberlegen sein . Ob das pharmakologische und analgetische Profil von Antidepressiva tatsaechlich dieser Erwartung entspricht , wurde in einer Metaanalyse von 57 klinischen Studien zur Behandlung chronischer Schmerzen ueberprueft . Diese Studien wurden entsprechend ihrer wissenschaftlichen Qualitaet in 5 Gruppen unterteilt : [ 1 ] Placebo-kontrollierte Doppelblindstudien mit hoher Trennschaerfe ; [ 2 ] Placebo-kontrollierte Doppelblindstudien mit niederer Trennschaerfe ; [ 3-4 ] offene kontrollierte Studien oder Studien mit historischen Kontrollen ; [ 5 ] Fallberichte . Die wirksamsten Substanzen waren tatsaechlich unselektive Monoamin-Wiederaufnahmehemmer in der folgenden Rangordnung , die der Empfehlung ihrer therapeutischen Verwendung entspricht : Amitriptylin > Clomipramin > = Desipramin > = Imipramin > = Doxepin . Aus den analysierten Studien laesst sich keine allgemein gueltige Dosierungsempfehlung fuer die einzelnen Substanzen ableiten . Dosisfindungsstudien , die auch die entsprechenden Plasmaspiegel erfassen , sind hierzu notwendig .
[ "Sowohl", "praeklinisch", "-", "experimentelle", "Ueberlegungen", "als", "auch", "klinische", "Studien", "sprechen", "fuer", "den", "Einsatz", "von", "Antidepressiva", "bei", "chronischen", "Schmerzen", ".", "Diese", "Substanzen", "beeinflussen", "die", "Neurotransmissionen", "von", "Noradrenalin", "(", "NA", ")", "und", "/", "oder", "Serotonin", "(", "5-HT", ")", ";", "ihr", "antinozizeptiver", "Effekt", "duerfte", "sich", "vor", "allem", "im", "Rueckenmark", "abspielen", ".", "Die", "vorliegende", "Arbeit", "versucht", ",", "den", "wahrscheinlichen", "analgetischen", "Wirkmechanismus", "von", "Antidepressiva", "mit", "den", "Ergebnissen", "klinischer", "Studien", "zum", "Einsatz", "bestimmter", "Substanzen", "bei", "chronischen", "Schmerzen", "zu", "verknuepfen", ".", "Experimentell", "-", "praeklinisch", "betrachtet", "sollten", "unselektive", "Monoamin", "-", "Wiederaufnahmehemmer", "anderen", "Substanzen", ",", "die", "in", "selektiver", "Weise", "nur", "den", "Reuptake", "von", "NA", "oder", "5-HT", "blockieren", ",", "ueberlegen", "sein", ".", "Ob", "das", "pharmakologische", "und", "analgetische", "Profil", "von", "Antidepressiva", "tatsaechlich", "dieser", "Erwartung", "entspricht", ",", "wurde", "in", "einer", "Metaanalyse", "von", "57", "klinischen", "Studien", "zur", "Behandlung", "chronischer", "Schmerzen", "ueberprueft", ".", "Diese", "Studien", "wurden", "entsprechend", "ihrer", "wissenschaftlichen", "Qualitaet", "in", "5", "Gruppen", "unterteilt", ":", "[", "1", "]", "Placebo", "-", "kontrollierte", "Doppelblindstudien", "mit", "hoher", "Trennschaerfe", ";", "[", "2", "]", "Placebo", "-", "kontrollierte", "Doppelblindstudien", "mit", "niederer", "Trennschaerfe", ";", "[", "3", "-", "4", "]", "offene", "kontrollierte", "Studien", "oder", "Studien", "mit", "historischen", "Kontrollen", ";", "[", "5", "]", "Fallberichte", ".", "Die", "wirksamsten", "Substanzen", "waren", "tatsaechlich", "unselektive", "Monoamin", "-", "Wiederaufnahmehemmer", "in", "der", "folgenden", "Rangordnung", ",", "die", "der", "Empfehlung", "ihrer", "therapeutischen", "Verwendung", "entspricht", ":", "Amitriptylin", ">", "Clomipramin", ">", "=", "Desipramin", ">", "=", "Imipramin", ">", "=", "Doxepin", ".", "Aus", "den", "analysierten", "Studien", "laesst", "sich", "keine", "allgemein", "gueltige", "Dosierungsempfehlung", "fuer", "die", "einzelnen", "Substanzen", "ableiten", ".", "Dosisfindungsstudien", ",", "die", "auch", "die", "entsprechenden", "Plasmaspiegel", "erfassen", ",", "sind", "hierzu", "notwendig", "." ]
[ "umlsterm" ]
Antidepressiva, Schmerzen, Noradrenalin, Serotonin, Rueckenmark, Arbeit, Antidepressiva, Schmerzen, Antidepressiva, Metaanalyse, Behandlung, Schmerzen, Placebo - kontrollierte, Doppelblindstudien, Placebo - kontrollierte, Doppelblindstudien, Fallberichte, Verwendung, Amitriptylin, Clomipramin, Desipramin, Imipramin, Doxepin
DerSchmerz.70110213.ger.abstr_task2
Sentence: Sowohl praeklinisch-experimentelle Ueberlegungen als auch klinische Studien sprechen fuer den Einsatz von Antidepressiva bei chronischen Schmerzen . Diese Substanzen beeinflussen die Neurotransmissionen von Noradrenalin ( NA ) und/oder Serotonin ( 5-HT ) ; ihr antinozizeptiver Effekt duerfte sich vor allem im Rueckenmark abspielen . Die vorliegende Arbeit versucht , den wahrscheinlichen analgetischen Wirkmechanismus von Antidepressiva mit den Ergebnissen klinischer Studien zum Einsatz bestimmter Substanzen bei chronischen Schmerzen zu verknuepfen . Experimentell-praeklinisch betrachtet sollten unselektive Monoamin-Wiederaufnahmehemmer anderen Substanzen , die in selektiver Weise nur den Reuptake von NA oder 5-HT blockieren , ueberlegen sein . Ob das pharmakologische und analgetische Profil von Antidepressiva tatsaechlich dieser Erwartung entspricht , wurde in einer Metaanalyse von 57 klinischen Studien zur Behandlung chronischer Schmerzen ueberprueft . Diese Studien wurden entsprechend ihrer wissenschaftlichen Qualitaet in 5 Gruppen unterteilt : [ 1 ] Placebo-kontrollierte Doppelblindstudien mit hoher Trennschaerfe ; [ 2 ] Placebo-kontrollierte Doppelblindstudien mit niederer Trennschaerfe ; [ 3-4 ] offene kontrollierte Studien oder Studien mit historischen Kontrollen ; [ 5 ] Fallberichte . Die wirksamsten Substanzen waren tatsaechlich unselektive Monoamin-Wiederaufnahmehemmer in der folgenden Rangordnung , die der Empfehlung ihrer therapeutischen Verwendung entspricht : Amitriptylin > Clomipramin > = Desipramin > = Imipramin > = Doxepin . Aus den analysierten Studien laesst sich keine allgemein gueltige Dosierungsempfehlung fuer die einzelnen Substanzen ableiten . Dosisfindungsstudien , die auch die entsprechenden Plasmaspiegel erfassen , sind hierzu notwendig . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Sowohl praeklinisch-experimentelle Ueberlegungen als auch klinische Studien sprechen fuer den Einsatz von Antidepressiva bei chronischen Schmerzen . Diese Substanzen beeinflussen die Neurotransmissionen von Noradrenalin ( NA ) und/oder Serotonin ( 5-HT ) ; ihr antinozizeptiver Effekt duerfte sich vor allem im Rueckenmark abspielen . Die vorliegende Arbeit versucht , den wahrscheinlichen analgetischen Wirkmechanismus von Antidepressiva mit den Ergebnissen klinischer Studien zum Einsatz bestimmter Substanzen bei chronischen Schmerzen zu verknuepfen . Experimentell-praeklinisch betrachtet sollten unselektive Monoamin-Wiederaufnahmehemmer anderen Substanzen , die in selektiver Weise nur den Reuptake von NA oder 5-HT blockieren , ueberlegen sein . Ob das pharmakologische und analgetische Profil von Antidepressiva tatsaechlich dieser Erwartung entspricht , wurde in einer Metaanalyse von 57 klinischen Studien zur Behandlung chronischer Schmerzen ueberprueft . Diese Studien wurden entsprechend ihrer wissenschaftlichen Qualitaet in 5 Gruppen unterteilt : [ 1 ] Placebo-kontrollierte Doppelblindstudien mit hoher Trennschaerfe ; [ 2 ] Placebo-kontrollierte Doppelblindstudien mit niederer Trennschaerfe ; [ 3-4 ] offene kontrollierte Studien oder Studien mit historischen Kontrollen ; [ 5 ] Fallberichte . Die wirksamsten Substanzen waren tatsaechlich unselektive Monoamin-Wiederaufnahmehemmer in der folgenden Rangordnung , die der Empfehlung ihrer therapeutischen Verwendung entspricht : Amitriptylin > Clomipramin > = Desipramin > = Imipramin > = Doxepin . Aus den analysierten Studien laesst sich keine allgemein gueltige Dosierungsempfehlung fuer die einzelnen Substanzen ableiten . Dosisfindungsstudien , die auch die entsprechenden Plasmaspiegel erfassen , sind hierzu notwendig .
[ "Sowohl", "praeklinisch", "-", "experimentelle", "Ueberlegungen", "als", "auch", "klinische", "Studien", "sprechen", "fuer", "den", "Einsatz", "von", "Antidepressiva", "bei", "chronischen", "Schmerzen", ".", "Diese", "Substanzen", "beeinflussen", "die", "Neurotransmissionen", "von", "Noradrenalin", "(", "NA", ")", "und", "/", "oder", "Serotonin", "(", "5-HT", ")", ";", "ihr", "antinozizeptiver", "Effekt", "duerfte", "sich", "vor", "allem", "im", "Rueckenmark", "abspielen", ".", "Die", "vorliegende", "Arbeit", "versucht", ",", "den", "wahrscheinlichen", "analgetischen", "Wirkmechanismus", "von", "Antidepressiva", "mit", "den", "Ergebnissen", "klinischer", "Studien", "zum", "Einsatz", "bestimmter", "Substanzen", "bei", "chronischen", "Schmerzen", "zu", "verknuepfen", ".", "Experimentell", "-", "praeklinisch", "betrachtet", "sollten", "unselektive", "Monoamin", "-", "Wiederaufnahmehemmer", "anderen", "Substanzen", ",", "die", "in", "selektiver", "Weise", "nur", "den", "Reuptake", "von", "NA", "oder", "5-HT", "blockieren", ",", "ueberlegen", "sein", ".", "Ob", "das", "pharmakologische", "und", "analgetische", "Profil", "von", "Antidepressiva", "tatsaechlich", "dieser", "Erwartung", "entspricht", ",", "wurde", "in", "einer", "Metaanalyse", "von", "57", "klinischen", "Studien", "zur", "Behandlung", "chronischer", "Schmerzen", "ueberprueft", ".", "Diese", "Studien", "wurden", "entsprechend", "ihrer", "wissenschaftlichen", "Qualitaet", "in", "5", "Gruppen", "unterteilt", ":", "[", "1", "]", "Placebo", "-", "kontrollierte", "Doppelblindstudien", "mit", "hoher", "Trennschaerfe", ";", "[", "2", "]", "Placebo", "-", "kontrollierte", "Doppelblindstudien", "mit", "niederer", "Trennschaerfe", ";", "[", "3", "-", "4", "]", "offene", "kontrollierte", "Studien", "oder", "Studien", "mit", "historischen", "Kontrollen", ";", "[", "5", "]", "Fallberichte", ".", "Die", "wirksamsten", "Substanzen", "waren", "tatsaechlich", "unselektive", "Monoamin", "-", "Wiederaufnahmehemmer", "in", "der", "folgenden", "Rangordnung", ",", "die", "der", "Empfehlung", "ihrer", "therapeutischen", "Verwendung", "entspricht", ":", "Amitriptylin", ">", "Clomipramin", ">", "=", "Desipramin", ">", "=", "Imipramin", ">", "=", "Doxepin", ".", "Aus", "den", "analysierten", "Studien", "laesst", "sich", "keine", "allgemein", "gueltige", "Dosierungsempfehlung", "fuer", "die", "einzelnen", "Substanzen", "ableiten", ".", "Dosisfindungsstudien", ",", "die", "auch", "die", "entsprechenden", "Plasmaspiegel", "erfassen", ",", "sind", "hierzu", "notwendig", "." ]
[ "umlsterm" ]
células tumorales malignas is a MORFOLOGIA_NEOPLASIA, CTM is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de pulmón derecho metastásico is a MORFOLOGIA_NEOPLASIA, CTM is a MORFOLOGIA_NEOPLASIA, carcinoma is a MORFOLOGIA_NEOPLASIA, carcinomatosa is a MORFOLOGIA_NEOPLASIA, MC is a MORFOLOGIA_NEOPLASIA, MC is a MORFOLOGIA_NEOPLASIA
87_task0
Sentence: ANAMNESIS Mujer de 66 años de edad, sin alergias medicamentosas conocidas (AMC) ni hábitos tóxicos. Obesa, hipertensa y con artrosis generalizada de años de evolución. Presenta cuadros de hiperreactividad bronquial frecuentes sin haberse filiado patología broncopulmonar previa. La paciente es ama de casa y no presenta antecedentes oncológicos familiares. Está en tratamiento con eprosartán 600 mg al día, un antiinflamatorio dos veces al día por los dolores óseos y un protector del estómago. En el año 2012 (con 63 años) comienza con cuadro de tos persistente y astenia de 4 meses de evolución, por lo que su médico de Atención Primaria solicita radiografía de tórax con hallazgo de condensación basal derecha y nódulos pulmonares múltiples en ambos campos pulmonares. La paciente es derivada al Servicio de Medicina Interna para completar estudio, realizándose una analítica completa con marcadores tumorales, que es normal, además de una tomografía computarizada (TC) toracoabdominopélvica, observándose nódulos pulmonares múltiples de mediano tamaño distribuidos en ambos campos pulmonares (lóbulos superiores, campos medios y lóbulos inferiores), condensación basal derecha y adenopatías mediastínicas macroscópicas en el espacio prevascular y paratraqueales derechas. Tras estos hallazgos se le realizó una fibrobroncoscopia, hallando mucosa de aspecto inflamatorio, sin observarse signos de infiltración, cuya biopsia fue negativa para células tumorales malignas (CTM), pero, en la citología del líquido pleural, se observaron células de hábito epiteloide con núcleos excéntricos, pleomórficos con citoplasma vaculado y con expresión de TTF1+, CK19 y NEGATIVIDAD para P63, mamoglobina, GCDP-15 y RE. Todo esto compatible con adenocarcinoma pulmonar. Se solicitaron las mutaciones EGFR: NATIVO y ALK negativo. Con diagnóstico de adenocarcinoma de pulmón derecho metastásico, inicia 1.ª línea de quimioterapia (QT) con cisplatino (CDDP)-pemetrexed el 31/10/2012. Recibe un total de 4 ciclos CDDP-pemetrexed con enfermedad estable (EE) tras el tercer ciclo, pasando a pemetrexed de mantenimiento el 23/1/2013. Durante el tratamiento con CDDP-pemetrexed presentó episodios de bronquitis. Tras 3 ciclos de pemetrexed de mantenimiento, se realizó una TC, observándose discreta disminución del tamaño de la masa pulmonar, pasando de 7,5 cm a 7 cm y el resto de nódulos pulmonares sin cambios, por lo que se consideró EE y se continuó con tratamiento bien tolerado, hasta diciembre de 2013, presentado en analítica aumento del antígeno carcinoembrionario (CEA) y progresión pulmonar tras 16 ciclos de pemetrexed. En enero de 2014 inicia 2.ª línea con docetaxel (75 mg/m2) a dosis reducidas 15 % por tratamiento previo. Presentando CEA basal: 3.186. Recibe un total de 16 ciclos (último el 19/11/14), con enfermedad estable en TC de control tras 3º., 7.º y 14.º ciclos. Como toxicidad cabe destacar diarrea grado 1 y alopecia grado 3 tras 1.er ciclo. Tras el 2.º y el 4.º ciclos relata astenia y artromialgias los 3 primeros días, bien tolerados a partir del ciclo 6.º, y tras ciclo 14.º, recibió tratamiento con levofloxacino por infeccioó faríngea. La paciente no presentó neurotoxicidad en ninguno de los ciclos. El 10/12/2014 se considera haber conseguido el máximo beneficio tras 16 ciclos de QT de 2.ª línea con docetaxel, por lo que se decide suspender y pasar a seguimiento. Pero en enero de 2015, la paciente presenta aumento de CEA (300) y en la primera TC de control se observa progresión pulmonar, por lo que se decide comenzar 3.ª línea con erlotinib, con indicación en ficha técnica. Inicia erlotinib el 26 de enero 2015 a dosis de 150 mg/ 24 h bien tolerado hasta que comienza con cuadro de mareo inespecífico a las 3 semanas de tratamiento y otalgia, motivo por la que es valorada por Otorrinolaringología, extrayendo un tapón de cerumen, y por Cirugía Maxilofacial, diagnosticando artritis en la articulación mandibular, por lo que se continuó tratamiento con erlotinib sin descanso. Tras 11 semanas de tratamiento, se realiza una TC de extensión el 15 de abril con mejoría radiológica pulmonar, pero persiste el cuadro vertiginoso, por lo que se solicita resonancia magnética (RM) cerebral. El 11 de mayo (15 semanas con erlotinib), la paciente acude a consulta fuera de citación por empeoramiento del cuadro vertiginoso, junto con aparición de parestesias en miembros inferiores (MMII), muslos e hipoestesia en periné, con episodios de incontinencia urinaria y fecal, sin dolor lumbar ni alteración motora. La paciente lo achaca todo al tratamiento con erlotinib, ya que inició esta clínica al poco tiempo de empezar el tratamiento, empeorando progresivamente. Finalmente, se decide suspender erlotinib a la espera del resultado de la RM cerebral. Una semana después, la paciente acude a resultado de la RM cerebral, que es normal, refiriendo que desde el descanso con erlotinb persisten hipoestesias en MMII, siendo menos intensas en muslos, aunque continúa con incontinencia urinaria y fecal, negáado en todo momento dolor de espalda. En este momento, ante resultado negativo de la RM cerebral, se decide ingreso para estudio de médula espinal. Exploración física ECOG 2. Consciente y orientada. Buen estado general. Obesa, normocoloreada, normohidratada, eupneica en reposo. No se palpan adenopatías periféricas. Auscultación cardiopulmonar: tonos cardiacos rítmicos, murmullo vesicular levemente disminuido en hemitórax derecho, sin ruidos patológicos sobreañadidos. Abdomen: globuloso, blando y depresible, no doloroso a la palpación, no se palpan masas ni megalias, ruidos hidroaéreos presentes. MMII: sin edemas ni signos de trombosis venosa profunda. Exploración neurológica: fondo ocular normal. Motilidad ocular extrínseca y resto de pares craneales normales. No hay un claro déficit motor. Reflejos osteotendinosos (ROT) 3+ con ROT vivos algo más izquierdos y arreflexia aquílea con Babinski bilateral. Hipoestesia distal en pies e hipopalestesia hasta últimos arcos costales. No se aprecia nivel en tronco. Marcha tabética con aumento de la base, precisa ayuda de andador, atáxica. Pruebas complementarias » Analítica: bioquímica (BQ) normal, excepto proteinas totales 6,4 g/dL; colesterol 205 mg/dL. CEA 152,7 ng/mL (previo 140); CA 125 8,4 U/mL, resto de BQ normal. Hemograma normal. » RM de columna completa (21/5/2015): se observa alteración de señal hiperintensa en la médula, siendo más marcada en bulbo, región periférica de mesencéfalo y protuberancia con extensión a pedúnculos cerebelosos. Todo ello, probablemente en relación con toxicidad por quimioterapia como primera posibilidad. » Punción lumbar (PL): líquido cefalorraquídeo (LCR) de aspecto claro y transparente, saliendo a una velocidad adecuada. Estudio citobioquímico: células 8; glucorraquia 29; proteínas: 028; hematíes 10 (glucemia tras la PL: 90 preprandial). Estudio microbiológico negativo. Citología: pendiente. Diagnóstico A los pocos días se obtuvieron los resultados de la citología del LCR: positivo para CTM. Sugestivo de afectación por carcinoma. Confirmándose una de las sospechas de polineuropatía secundaria a meningitis carcinomatosa (MC), tras el hallazgo de hipoglucorraquia en el estudio citobioquímico. Se ha solicitado estudio molecular en la citología del LCR, del que estamos pendiente. Tratamiento Al alta, antes de saber el diagnóstico definitivo, se prescribió erlotinib a dosis de 100 mg al día (debido a que presentó respuesta pulmonar y disminución del CEA durante el tratamiento y la a baja probabilidad de que la neurotoxicidad fuera secundaria al inhibidor de la ITK) y una pauta descendente de corticoides. Evolución La paciente se mantuvo estable durante el ingreso hospitalario, mejorando lentamente su clínica neurológica, aunque persistiendo hipoestesia en la parte distal de las extremidades y mejorando progresivamente la incontinencia de esfínteres y la marcha tebética tras el inicio de corticoides y descanso de erlotinib, descartándose compresión medular en la RM de columna. La paciente niega en todo momento cefalea, náuseas o vómitos. El caso fue valorado por parte de Neurología, concluyendo que el perfil temporal y el comportamiento clínico favorecen el diagnóstico de polineuropatía tóxica (PN), sugerido también tras los hallazgos de la RM. Fue dada de alta con diagnóstico de PN tóxica poco probable a erlotinib debido a la infrecuencia del cuadro, sin poder descartar neurotoxicidad tardía a docetaxel (que finalizó en diciembre 2014). En espera de los resultados de la citología para descartar MC del LCR ante el resultado de hipoglucorraquia, sugestivo de consumo en el estudio citobioquímico. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
ANAMNESIS Mujer de 66 años de edad, sin alergias medicamentosas conocidas (AMC) ni hábitos tóxicos. Obesa, hipertensa y con artrosis generalizada de años de evolución. Presenta cuadros de hiperreactividad bronquial frecuentes sin haberse filiado patología broncopulmonar previa. La paciente es ama de casa y no presenta antecedentes oncológicos familiares. Está en tratamiento con eprosartán 600 mg al día, un antiinflamatorio dos veces al día por los dolores óseos y un protector del estómago. En el año 2012 (con 63 años) comienza con cuadro de tos persistente y astenia de 4 meses de evolución, por lo que su médico de Atención Primaria solicita radiografía de tórax con hallazgo de condensación basal derecha y nódulos pulmonares múltiples en ambos campos pulmonares. La paciente es derivada al Servicio de Medicina Interna para completar estudio, realizándose una analítica completa con marcadores tumorales, que es normal, además de una tomografía computarizada (TC) toracoabdominopélvica, observándose nódulos pulmonares múltiples de mediano tamaño distribuidos en ambos campos pulmonares (lóbulos superiores, campos medios y lóbulos inferiores), condensación basal derecha y adenopatías mediastínicas macroscópicas en el espacio prevascular y paratraqueales derechas. Tras estos hallazgos se le realizó una fibrobroncoscopia, hallando mucosa de aspecto inflamatorio, sin observarse signos de infiltración, cuya biopsia fue negativa para células tumorales malignas (CTM), pero, en la citología del líquido pleural, se observaron células de hábito epiteloide con núcleos excéntricos, pleomórficos con citoplasma vaculado y con expresión de TTF1+, CK19 y NEGATIVIDAD para P63, mamoglobina, GCDP-15 y RE. Todo esto compatible con adenocarcinoma pulmonar. Se solicitaron las mutaciones EGFR: NATIVO y ALK negativo. Con diagnóstico de adenocarcinoma de pulmón derecho metastásico, inicia 1.ª línea de quimioterapia (QT) con cisplatino (CDDP)-pemetrexed el 31/10/2012. Recibe un total de 4 ciclos CDDP-pemetrexed con enfermedad estable (EE) tras el tercer ciclo, pasando a pemetrexed de mantenimiento el 23/1/2013. Durante el tratamiento con CDDP-pemetrexed presentó episodios de bronquitis. Tras 3 ciclos de pemetrexed de mantenimiento, se realizó una TC, observándose discreta disminución del tamaño de la masa pulmonar, pasando de 7,5 cm a 7 cm y el resto de nódulos pulmonares sin cambios, por lo que se consideró EE y se continuó con tratamiento bien tolerado, hasta diciembre de 2013, presentado en analítica aumento del antígeno carcinoembrionario (CEA) y progresión pulmonar tras 16 ciclos de pemetrexed. En enero de 2014 inicia 2.ª línea con docetaxel (75 mg/m2) a dosis reducidas 15 % por tratamiento previo. Presentando CEA basal: 3.186. Recibe un total de 16 ciclos (último el 19/11/14), con enfermedad estable en TC de control tras 3º., 7.º y 14.º ciclos. Como toxicidad cabe destacar diarrea grado 1 y alopecia grado 3 tras 1.er ciclo. Tras el 2.º y el 4.º ciclos relata astenia y artromialgias los 3 primeros días, bien tolerados a partir del ciclo 6.º, y tras ciclo 14.º, recibió tratamiento con levofloxacino por infeccioó faríngea. La paciente no presentó neurotoxicidad en ninguno de los ciclos. El 10/12/2014 se considera haber conseguido el máximo beneficio tras 16 ciclos de QT de 2.ª línea con docetaxel, por lo que se decide suspender y pasar a seguimiento. Pero en enero de 2015, la paciente presenta aumento de CEA (300) y en la primera TC de control se observa progresión pulmonar, por lo que se decide comenzar 3.ª línea con erlotinib, con indicación en ficha técnica. Inicia erlotinib el 26 de enero 2015 a dosis de 150 mg/ 24 h bien tolerado hasta que comienza con cuadro de mareo inespecífico a las 3 semanas de tratamiento y otalgia, motivo por la que es valorada por Otorrinolaringología, extrayendo un tapón de cerumen, y por Cirugía Maxilofacial, diagnosticando artritis en la articulación mandibular, por lo que se continuó tratamiento con erlotinib sin descanso. Tras 11 semanas de tratamiento, se realiza una TC de extensión el 15 de abril con mejoría radiológica pulmonar, pero persiste el cuadro vertiginoso, por lo que se solicita resonancia magnética (RM) cerebral. El 11 de mayo (15 semanas con erlotinib), la paciente acude a consulta fuera de citación por empeoramiento del cuadro vertiginoso, junto con aparición de parestesias en miembros inferiores (MMII), muslos e hipoestesia en periné, con episodios de incontinencia urinaria y fecal, sin dolor lumbar ni alteración motora. La paciente lo achaca todo al tratamiento con erlotinib, ya que inició esta clínica al poco tiempo de empezar el tratamiento, empeorando progresivamente. Finalmente, se decide suspender erlotinib a la espera del resultado de la RM cerebral. Una semana después, la paciente acude a resultado de la RM cerebral, que es normal, refiriendo que desde el descanso con erlotinb persisten hipoestesias en MMII, siendo menos intensas en muslos, aunque continúa con incontinencia urinaria y fecal, negáado en todo momento dolor de espalda. En este momento, ante resultado negativo de la RM cerebral, se decide ingreso para estudio de médula espinal. Exploración física ECOG 2. Consciente y orientada. Buen estado general. Obesa, normocoloreada, normohidratada, eupneica en reposo. No se palpan adenopatías periféricas. Auscultación cardiopulmonar: tonos cardiacos rítmicos, murmullo vesicular levemente disminuido en hemitórax derecho, sin ruidos patológicos sobreañadidos. Abdomen: globuloso, blando y depresible, no doloroso a la palpación, no se palpan masas ni megalias, ruidos hidroaéreos presentes. MMII: sin edemas ni signos de trombosis venosa profunda. Exploración neurológica: fondo ocular normal. Motilidad ocular extrínseca y resto de pares craneales normales. No hay un claro déficit motor. Reflejos osteotendinosos (ROT) 3+ con ROT vivos algo más izquierdos y arreflexia aquílea con Babinski bilateral. Hipoestesia distal en pies e hipopalestesia hasta últimos arcos costales. No se aprecia nivel en tronco. Marcha tabética con aumento de la base, precisa ayuda de andador, atáxica. Pruebas complementarias » Analítica: bioquímica (BQ) normal, excepto proteinas totales 6,4 g/dL; colesterol 205 mg/dL. CEA 152,7 ng/mL (previo 140); CA 125 8,4 U/mL, resto de BQ normal. Hemograma normal. » RM de columna completa (21/5/2015): se observa alteración de señal hiperintensa en la médula, siendo más marcada en bulbo, región periférica de mesencéfalo y protuberancia con extensión a pedúnculos cerebelosos. Todo ello, probablemente en relación con toxicidad por quimioterapia como primera posibilidad. » Punción lumbar (PL): líquido cefalorraquídeo (LCR) de aspecto claro y transparente, saliendo a una velocidad adecuada. Estudio citobioquímico: células 8; glucorraquia 29; proteínas: 028; hematíes 10 (glucemia tras la PL: 90 preprandial). Estudio microbiológico negativo. Citología: pendiente. Diagnóstico A los pocos días se obtuvieron los resultados de la citología del LCR: positivo para CTM. Sugestivo de afectación por carcinoma. Confirmándose una de las sospechas de polineuropatía secundaria a meningitis carcinomatosa (MC), tras el hallazgo de hipoglucorraquia en el estudio citobioquímico. Se ha solicitado estudio molecular en la citología del LCR, del que estamos pendiente. Tratamiento Al alta, antes de saber el diagnóstico definitivo, se prescribió erlotinib a dosis de 100 mg al día (debido a que presentó respuesta pulmonar y disminución del CEA durante el tratamiento y la a baja probabilidad de que la neurotoxicidad fuera secundaria al inhibidor de la ITK) y una pauta descendente de corticoides. Evolución La paciente se mantuvo estable durante el ingreso hospitalario, mejorando lentamente su clínica neurológica, aunque persistiendo hipoestesia en la parte distal de las extremidades y mejorando progresivamente la incontinencia de esfínteres y la marcha tebética tras el inicio de corticoides y descanso de erlotinib, descartándose compresión medular en la RM de columna. La paciente niega en todo momento cefalea, náuseas o vómitos. El caso fue valorado por parte de Neurología, concluyendo que el perfil temporal y el comportamiento clínico favorecen el diagnóstico de polineuropatía tóxica (PN), sugerido también tras los hallazgos de la RM. Fue dada de alta con diagnóstico de PN tóxica poco probable a erlotinib debido a la infrecuencia del cuadro, sin poder descartar neurotoxicidad tardía a docetaxel (que finalizó en diciembre 2014). En espera de los resultados de la citología para descartar MC del LCR ante el resultado de hipoglucorraquia, sugestivo de consumo en el estudio citobioquímico.
[ "ANAMNESIS", "\n", "Mujer", "de", "66", "años", "de", "edad", ",", "sin", "alergias", "medicamentosas", "conocidas", "(", "AMC", ")", "ni", "hábitos", "tóxicos", ".", "Obesa", ",", "hipertensa", "y", "con", "artrosis", "generalizada", "de", "años", "de", "evolución", ".", "Presenta", "cuadros", "de", "hiperreactividad", "bronquial", "frecuentes", "sin", "haberse", "filiado", "patología", "broncopulmonar", "previa", ".", "La", "paciente", "es", "ama", "de", "casa", "y", "no", "presenta", "antecedentes", "oncológicos", "familiares", ".", "Está", "en", "tratamiento", "con", "eprosartán", "600", "mg", "al", "día", ",", "un", "antiinflamatorio", "dos", "veces", "al", "día", "por", "los", "dolores", "óseos", "y", "un", "protector", "del", "estómago", ".", "\n\n", "En", "el", "año", "2012", "(", "con", "63", "años", ")", "comienza", "con", "cuadro", "de", "tos", "persistente", "y", "astenia", "de", "4", "meses", "de", "evolución", ",", "por", "lo", "que", "su", "médico", "de", "Atención", "Primaria", "solicita", "radiografía", "de", "tórax", "con", "hallazgo", "de", "condensación", "basal", "derecha", "y", "nódulos", "pulmonares", "múltiples", "en", "ambos", "campos", "pulmonares", ".", "\n\n", "La", "paciente", "es", "derivada", "al", "Servicio", "de", "Medicina", "Interna", "para", "completar", "estudio", ",", "realizándose", "una", "analítica", "completa", "con", "marcadores", "tumorales", ",", "que", "es", "normal", ",", "además", "de", "una", "tomografía", "computarizada", "(", "TC", ")", "toracoabdominopélvica", ",", "observándose", "nódulos", "pulmonares", "múltiples", "de", "mediano", "tamaño", "distribuidos", "en", "ambos", "campos", "pulmonares", "(", "lóbulos", "superiores", ",", "campos", "medios", "y", "lóbulos", "inferiores", ")", ",", "condensación", "basal", "derecha", "y", "adenopatías", "mediastínicas", "macroscópicas", "en", "el", "espacio", "prevascular", "y", "paratraqueales", "derechas", ".", "\n\n", "Tras", "estos", "hallazgos", "se", "le", "realizó", "una", "fibrobroncoscopia", ",", "hallando", "mucosa", "de", "aspecto", "inflamatorio", ",", "sin", "observarse", "signos", "de", "infiltración", ",", "cuya", "biopsia", "fue", "negativa", "para", "células", "tumorales", "malignas", "(", "CTM", ")", ",", "pero", ",", "en", "la", "citología", "del", "líquido", "pleural", ",", "se", "observaron", "células", "de", "hábito", "epiteloide", "con", "núcleos", "excéntricos", ",", "pleomórficos", "con", "citoplasma", "vaculado", "y", "con", "expresión", "de", "TTF1", "+", ",", "CK19", "y", "NEGATIVIDAD", "para", "P63", ",", "mamoglobina", ",", "GCDP-15", "y", "RE", ".", "Todo", "esto", "compatible", "con", "adenocarcinoma", "pulmonar", ".", "Se", "solicitaron", "las", "mutaciones", "EGFR", ":", "NATIVO", "y", "ALK", "negativo", ".", "\n", "Con", "diagnóstico", "de", "adenocarcinoma", "de", "pulmón", "derecho", "metastásico", ",", "inicia", "1.ª", "línea", "de", "quimioterapia", "(", "QT", ")", "con", "cisplatino", "(", "CDDP)-pemetrexed", "el", "31/10/2012", ".", "Recibe", "un", "total", "de", "4", "ciclos", "CDDP", "-", "pemetrexed", "con", "enfermedad", "estable", "(", "EE", ")", "tras", "el", "tercer", "ciclo", ",", "pasando", "a", "pemetrexed", "de", "mantenimiento", "el", "23/1/2013", ".", "\n\n", "Durante", "el", "tratamiento", "con", "CDDP", "-", "pemetrexed", "presentó", "episodios", "de", "bronquitis", ".", "\n\n", "Tras", "3", "ciclos", "de", "pemetrexed", "de", "mantenimiento", ",", "se", "realizó", "una", "TC", ",", "observándose", "discreta", "disminución", "del", "tamaño", "de", "la", "masa", "pulmonar", ",", "pasando", "de", "7,5", "cm", "a", "7", "cm", "y", "el", "resto", "de", "nódulos", "pulmonares", "sin", "cambios", ",", "por", "lo", "que", "se", "consideró", "EE", "y", "se", "continuó", "con", "tratamiento", "bien", "tolerado", ",", "hasta", "diciembre", "de", "2013", ",", "presentado", "en", "analítica", "aumento", "del", "antígeno", "carcinoembrionario", "(", "CEA", ")", "y", "progresión", "pulmonar", "tras", "16", "ciclos", "de", "pemetrexed", ".", "\n\n", "En", "enero", "de", "2014", "inicia", "2.ª", "línea", "con", "docetaxel", "(", "75", "mg", "/", "m2", ")", "a", "dosis", "reducidas", "15", "%", "por", "tratamiento", "previo", ".", "Presentando", "CEA", "basal", ":", "3.186", ".", "Recibe", "un", "total", "de", "16", "ciclos", "(", "último", "el", "19/11/14", ")", ",", "con", "enfermedad", "estable", "en", "TC", "de", "control", "tras", "3º.", ",", "7.º", "y", "14.º", "ciclos", ".", "Como", "toxicidad", "cabe", "destacar", "diarrea", "grado", "1", "y", "alopecia", "grado", "3", "tras", "1.er", "ciclo", ".", "Tras", "el", "2.º", "y", "el", "4.º", "ciclos", "relata", "astenia", "y", "artromialgias", "los", "3", "primeros", "días", ",", "bien", "tolerados", "a", "partir", "del", "ciclo", "6.º", ",", "y", "tras", "ciclo", "14.º", ",", "recibió", "tratamiento", "con", "levofloxacino", "por", "infeccioó", "faríngea", ".", "La", "paciente", "no", "presentó", "neurotoxicidad", "en", "ninguno", "de", "los", "ciclos", ".", "\n\n", "El", "10/12/2014", "se", "considera", "haber", "conseguido", "el", "máximo", "beneficio", "tras", "16", "ciclos", "de", "QT", "de", "2.ª", "línea", "con", "docetaxel", ",", "por", "lo", "que", "se", "decide", "suspender", "y", "pasar", "a", "seguimiento", ".", "Pero", "en", "enero", "de", "2015", ",", "la", "paciente", "presenta", "aumento", "de", "CEA", "(", "300", ")", "y", "en", "la", "primera", "TC", "de", "control", "se", "observa", "progresión", "pulmonar", ",", "por", "lo", "que", "se", "decide", "comenzar", "3.ª", "línea", "con", "erlotinib", ",", "con", "indicación", "en", "ficha", "técnica", ".", "\n\n", "Inicia", "erlotinib", "el", "26", "de", "enero", "2015", "a", "dosis", "de", "150", "mg/", "24", "h", "bien", "tolerado", "hasta", "que", "comienza", "con", "cuadro", "de", "mareo", "inespecífico", "a", "las", "3", "semanas", "de", "tratamiento", "y", "otalgia", ",", "motivo", "por", "la", "que", "es", "valorada", "por", "Otorrinolaringología", ",", "extrayendo", "un", "tapón", "de", "cerumen", ",", "y", "por", "Cirugía", "Maxilofacial", ",", "diagnosticando", "artritis", "en", "la", "articulación", "mandibular", ",", "por", "lo", "que", "se", "continuó", "tratamiento", "con", "erlotinib", "sin", "descanso", ".", "Tras", "11", "semanas", "de", "tratamiento", ",", "se", "realiza", "una", "TC", "de", "extensión", "el", "15", "de", "abril", "con", "mejoría", "radiológica", "pulmonar", ",", "pero", "persiste", "el", "cuadro", "vertiginoso", ",", "por", "lo", "que", "se", "solicita", "resonancia", "magnética", "(", "RM", ")", "cerebral", ".", "\n\n", "El", "11", "de", "mayo", "(", "15", "semanas", "con", "erlotinib", ")", ",", "la", "paciente", "acude", "a", "consulta", "fuera", "de", "citación", "por", "empeoramiento", "del", "cuadro", "vertiginoso", ",", "junto", "con", "aparición", "de", "parestesias", "en", "miembros", "inferiores", "(", "MMII", ")", ",", "muslos", "e", "hipoestesia", "en", "periné", ",", "con", "episodios", "de", "incontinencia", "urinaria", "y", "fecal", ",", "sin", "dolor", "lumbar", "ni", "alteración", "motora", ".", "La", "paciente", "lo", "achaca", "todo", "al", "tratamiento", "con", "erlotinib", ",", "ya", "que", "inició", "esta", "clínica", "al", "poco", "tiempo", "de", "empezar", "el", "tratamiento", ",", "empeorando", "progresivamente", ".", "Finalmente", ",", "se", "decide", "suspender", "erlotinib", "a", "la", "espera", "del", "resultado", "de", "la", "RM", "cerebral", ".", "\n\n", "Una", "semana", "después", ",", "la", "paciente", "acude", "a", "resultado", "de", "la", "RM", "cerebral", ",", "que", "es", "normal", ",", "refiriendo", "que", "desde", "el", "descanso", "con", "erlotinb", "persisten", "hipoestesias", "en", "MMII", ",", "siendo", "menos", "intensas", "en", "muslos", ",", "aunque", "continúa", "con", "incontinencia", "urinaria", "y", "fecal", ",", "negáado", "en", "todo", "momento", "dolor", "de", "espalda", ".", "En", "este", "momento", ",", "ante", "resultado", "negativo", "de", "la", "RM", "cerebral", ",", "se", "decide", "ingreso", "para", "estudio", "de", "médula", "espinal", ".", "\n\n", "Exploración", "física", "\n", "ECOG", "2", ".", "Consciente", "y", "orientada", ".", "Buen", "estado", "general", ".", "Obesa", ",", "normocoloreada", ",", "normohidratada", ",", "eupneica", "en", "reposo", ".", "No", "se", "palpan", "adenopatías", "periféricas", ".", "Auscultación", "cardiopulmonar", ":", "tonos", "cardiacos", "rítmicos", ",", "murmullo", "vesicular", "levemente", "disminuido", "en", "hemitórax", "derecho", ",", "sin", "ruidos", "patológicos", "sobreañadidos", ".", "Abdomen", ":", "globuloso", ",", "blando", "y", "depresible", ",", "no", "doloroso", "a", "la", "palpación", ",", "no", "se", "palpan", "masas", "ni", "megalias", ",", "ruidos", "hidroaéreos", "presentes", ".", "MMII", ":", "sin", "edemas", "ni", "signos", "de", "trombosis", "venosa", "profunda", ".", "\n\n", "Exploración", "neurológica", ":", "fondo", "ocular", "normal", ".", "Motilidad", "ocular", "extrínseca", "y", "resto", "de", "pares", "craneales", "normales", ".", "No", "hay", "un", "claro", "déficit", "motor", ".", "Reflejos", "osteotendinosos", "(", "ROT", ")", "3", "+", "con", "ROT", "vivos", "algo", "más", "izquierdos", "y", "arreflexia", "aquílea", "con", "Babinski", "bilateral", ".", "Hipoestesia", "distal", "en", "pies", "e", "hipopalestesia", "hasta", "últimos", "arcos", "costales", ".", "No", "se", "aprecia", "nivel", "en", "tronco", ".", "Marcha", "tabética", "con", "aumento", "de", "la", "base", ",", "precisa", "ayuda", "de", "andador", ",", "atáxica", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Analítica", ":", "bioquímica", "(", "BQ", ")", "normal", ",", "excepto", "proteinas", "totales", "6,4", "g", "/", "dL", ";", "colesterol", "205", "mg", "/", "dL.", "CEA", "152,7", "ng", "/", "mL", "(", "previo", "140", ")", ";", "CA", "125", "8,4", "U", "/", "mL", ",", "resto", "de", "BQ", "normal", ".", "Hemograma", "normal", ".", "\n", "»", "RM", "de", "columna", "completa", "(", "21/5/2015", "):", "se", "observa", "alteración", "de", "señal", "hiperintensa", "en", "la", "médula", ",", "siendo", "más", "marcada", "en", "bulbo", ",", "región", "periférica", "de", "mesencéfalo", "y", "protuberancia", "con", "extensión", "a", "pedúnculos", "cerebelosos", ".", "Todo", "ello", ",", "probablemente", "en", "relación", "con", "toxicidad", "por", "quimioterapia", "como", "primera", "posibilidad", ".", "\n", "»", "Punción", "lumbar", "(", "PL", "):", "líquido", "cefalorraquídeo", "(", "LCR", ")", "de", "aspecto", "claro", "y", "transparente", ",", "saliendo", "a", "una", "velocidad", "adecuada", ".", "Estudio", "citobioquímico", ":", "células", "8", ";", "glucorraquia", "29", ";", "proteínas", ":", "028", ";", "hematíes", "10", "(", "glucemia", "tras", "la", "PL", ":", "90", "preprandial", ")", ".", "Estudio", "microbiológico", "negativo", ".", "Citología", ":", "pendiente", ".", "\n\n", "Diagnóstico", "\n", "A", "los", "pocos", "días", "se", "obtuvieron", "los", "resultados", "de", "la", "citología", "del", "LCR", ":", "positivo", "para", "CTM", ".", "Sugestivo", "de", "afectación", "por", "carcinoma", ".", "Confirmándose", "una", "de", "las", "sospechas", "de", "polineuropatía", "secundaria", "a", "meningitis", "carcinomatosa", "(", "MC", ")", ",", "tras", "el", "hallazgo", "de", "hipoglucorraquia", "en", "el", "estudio", "citobioquímico", ".", "Se", "ha", "solicitado", "estudio", "molecular", "en", "la", "citología", "del", "LCR", ",", "del", "que", "estamos", "pendiente", ".", "\n\n", "Tratamiento", "\n", "Al", "alta", ",", "antes", "de", "saber", "el", "diagnóstico", "definitivo", ",", "se", "prescribió", "erlotinib", "a", "dosis", "de", "100", "mg", "al", "día", "(", "debido", "a", "que", "presentó", "respuesta", "pulmonar", "y", "disminución", "del", "CEA", "durante", "el", "tratamiento", "y", "la", "a", "baja", "probabilidad", "de", "que", "la", "neurotoxicidad", "fuera", "secundaria", "al", "inhibidor", "de", "la", "ITK", ")", "y", "una", "pauta", "descendente", "de", "corticoides", ".", "\n\n", "Evolución", "\n", "La", "paciente", "se", "mantuvo", "estable", "durante", "el", "ingreso", "hospitalario", ",", "mejorando", "lentamente", "su", "clínica", "neurológica", ",", "aunque", "persistiendo", "hipoestesia", "en", "la", "parte", "distal", "de", "las", "extremidades", "y", "mejorando", "progresivamente", "la", "incontinencia", "de", "esfínteres", "y", "la", "marcha", "tebética", "tras", "el", "inicio", "de", "corticoides", "y", "descanso", "de", "erlotinib", ",", "descartándose", "compresión", "medular", "en", "la", "RM", "de", "columna", ".", "La", "paciente", "niega", "en", "todo", "momento", "cefalea", ",", "náuseas", "o", "vómitos", ".", "\n", "El", "caso", "fue", "valorado", "por", "parte", "de", "Neurología", ",", "concluyendo", "que", "el", "perfil", "temporal", "y", "el", "comportamiento", "clínico", "favorecen", "el", "diagnóstico", "de", "polineuropatía", "tóxica", "(", "PN", ")", ",", "sugerido", "también", "tras", "los", "hallazgos", "de", "la", "RM", ".", "\n", "Fue", "dada", "de", "alta", "con", "diagnóstico", "de", "PN", "tóxica", "poco", "probable", "a", "erlotinib", "debido", "a", "la", "infrecuencia", "del", "cuadro", ",", "sin", "poder", "descartar", "neurotoxicidad", "tardía", "a", "docetaxel", "(", "que", "finalizó", "en", "diciembre", "2014", ")", ".", "En", "espera", "de", "los", "resultados", "de", "la", "citología", "para", "descartar", "MC", "del", "LCR", "ante", "el", "resultado", "de", "hipoglucorraquia", ",", "sugestivo", "de", "consumo", "en", "el", "estudio", "citobioquímico", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
células tumorales malignas is a MORFOLOGIA_NEOPLASIA, CTM is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, adenocarcinoma de pulmón derecho metastásico is a MORFOLOGIA_NEOPLASIA, CTM is a MORFOLOGIA_NEOPLASIA, carcinoma is a MORFOLOGIA_NEOPLASIA, carcinomatosa is a MORFOLOGIA_NEOPLASIA, MC is a MORFOLOGIA_NEOPLASIA, MC is a MORFOLOGIA_NEOPLASIA
87_task1
Sentence: ANAMNESIS Mujer de 66 años de edad, sin alergias medicamentosas conocidas (AMC) ni hábitos tóxicos. Obesa, hipertensa y con artrosis generalizada de años de evolución. Presenta cuadros de hiperreactividad bronquial frecuentes sin haberse filiado patología broncopulmonar previa. La paciente es ama de casa y no presenta antecedentes oncológicos familiares. Está en tratamiento con eprosartán 600 mg al día, un antiinflamatorio dos veces al día por los dolores óseos y un protector del estómago. En el año 2012 (con 63 años) comienza con cuadro de tos persistente y astenia de 4 meses de evolución, por lo que su médico de Atención Primaria solicita radiografía de tórax con hallazgo de condensación basal derecha y nódulos pulmonares múltiples en ambos campos pulmonares. La paciente es derivada al Servicio de Medicina Interna para completar estudio, realizándose una analítica completa con marcadores tumorales, que es normal, además de una tomografía computarizada (TC) toracoabdominopélvica, observándose nódulos pulmonares múltiples de mediano tamaño distribuidos en ambos campos pulmonares (lóbulos superiores, campos medios y lóbulos inferiores), condensación basal derecha y adenopatías mediastínicas macroscópicas en el espacio prevascular y paratraqueales derechas. Tras estos hallazgos se le realizó una fibrobroncoscopia, hallando mucosa de aspecto inflamatorio, sin observarse signos de infiltración, cuya biopsia fue negativa para células tumorales malignas (CTM), pero, en la citología del líquido pleural, se observaron células de hábito epiteloide con núcleos excéntricos, pleomórficos con citoplasma vaculado y con expresión de TTF1+, CK19 y NEGATIVIDAD para P63, mamoglobina, GCDP-15 y RE. Todo esto compatible con adenocarcinoma pulmonar. Se solicitaron las mutaciones EGFR: NATIVO y ALK negativo. Con diagnóstico de adenocarcinoma de pulmón derecho metastásico, inicia 1.ª línea de quimioterapia (QT) con cisplatino (CDDP)-pemetrexed el 31/10/2012. Recibe un total de 4 ciclos CDDP-pemetrexed con enfermedad estable (EE) tras el tercer ciclo, pasando a pemetrexed de mantenimiento el 23/1/2013. Durante el tratamiento con CDDP-pemetrexed presentó episodios de bronquitis. Tras 3 ciclos de pemetrexed de mantenimiento, se realizó una TC, observándose discreta disminución del tamaño de la masa pulmonar, pasando de 7,5 cm a 7 cm y el resto de nódulos pulmonares sin cambios, por lo que se consideró EE y se continuó con tratamiento bien tolerado, hasta diciembre de 2013, presentado en analítica aumento del antígeno carcinoembrionario (CEA) y progresión pulmonar tras 16 ciclos de pemetrexed. En enero de 2014 inicia 2.ª línea con docetaxel (75 mg/m2) a dosis reducidas 15 % por tratamiento previo. Presentando CEA basal: 3.186. Recibe un total de 16 ciclos (último el 19/11/14), con enfermedad estable en TC de control tras 3º., 7.º y 14.º ciclos. Como toxicidad cabe destacar diarrea grado 1 y alopecia grado 3 tras 1.er ciclo. Tras el 2.º y el 4.º ciclos relata astenia y artromialgias los 3 primeros días, bien tolerados a partir del ciclo 6.º, y tras ciclo 14.º, recibió tratamiento con levofloxacino por infeccioó faríngea. La paciente no presentó neurotoxicidad en ninguno de los ciclos. El 10/12/2014 se considera haber conseguido el máximo beneficio tras 16 ciclos de QT de 2.ª línea con docetaxel, por lo que se decide suspender y pasar a seguimiento. Pero en enero de 2015, la paciente presenta aumento de CEA (300) y en la primera TC de control se observa progresión pulmonar, por lo que se decide comenzar 3.ª línea con erlotinib, con indicación en ficha técnica. Inicia erlotinib el 26 de enero 2015 a dosis de 150 mg/ 24 h bien tolerado hasta que comienza con cuadro de mareo inespecífico a las 3 semanas de tratamiento y otalgia, motivo por la que es valorada por Otorrinolaringología, extrayendo un tapón de cerumen, y por Cirugía Maxilofacial, diagnosticando artritis en la articulación mandibular, por lo que se continuó tratamiento con erlotinib sin descanso. Tras 11 semanas de tratamiento, se realiza una TC de extensión el 15 de abril con mejoría radiológica pulmonar, pero persiste el cuadro vertiginoso, por lo que se solicita resonancia magnética (RM) cerebral. El 11 de mayo (15 semanas con erlotinib), la paciente acude a consulta fuera de citación por empeoramiento del cuadro vertiginoso, junto con aparición de parestesias en miembros inferiores (MMII), muslos e hipoestesia en periné, con episodios de incontinencia urinaria y fecal, sin dolor lumbar ni alteración motora. La paciente lo achaca todo al tratamiento con erlotinib, ya que inició esta clínica al poco tiempo de empezar el tratamiento, empeorando progresivamente. Finalmente, se decide suspender erlotinib a la espera del resultado de la RM cerebral. Una semana después, la paciente acude a resultado de la RM cerebral, que es normal, refiriendo que desde el descanso con erlotinb persisten hipoestesias en MMII, siendo menos intensas en muslos, aunque continúa con incontinencia urinaria y fecal, negáado en todo momento dolor de espalda. En este momento, ante resultado negativo de la RM cerebral, se decide ingreso para estudio de médula espinal. Exploración física ECOG 2. Consciente y orientada. Buen estado general. Obesa, normocoloreada, normohidratada, eupneica en reposo. No se palpan adenopatías periféricas. Auscultación cardiopulmonar: tonos cardiacos rítmicos, murmullo vesicular levemente disminuido en hemitórax derecho, sin ruidos patológicos sobreañadidos. Abdomen: globuloso, blando y depresible, no doloroso a la palpación, no se palpan masas ni megalias, ruidos hidroaéreos presentes. MMII: sin edemas ni signos de trombosis venosa profunda. Exploración neurológica: fondo ocular normal. Motilidad ocular extrínseca y resto de pares craneales normales. No hay un claro déficit motor. Reflejos osteotendinosos (ROT) 3+ con ROT vivos algo más izquierdos y arreflexia aquílea con Babinski bilateral. Hipoestesia distal en pies e hipopalestesia hasta últimos arcos costales. No se aprecia nivel en tronco. Marcha tabética con aumento de la base, precisa ayuda de andador, atáxica. Pruebas complementarias » Analítica: bioquímica (BQ) normal, excepto proteinas totales 6,4 g/dL; colesterol 205 mg/dL. CEA 152,7 ng/mL (previo 140); CA 125 8,4 U/mL, resto de BQ normal. Hemograma normal. » RM de columna completa (21/5/2015): se observa alteración de señal hiperintensa en la médula, siendo más marcada en bulbo, región periférica de mesencéfalo y protuberancia con extensión a pedúnculos cerebelosos. Todo ello, probablemente en relación con toxicidad por quimioterapia como primera posibilidad. » Punción lumbar (PL): líquido cefalorraquídeo (LCR) de aspecto claro y transparente, saliendo a una velocidad adecuada. Estudio citobioquímico: células 8; glucorraquia 29; proteínas: 028; hematíes 10 (glucemia tras la PL: 90 preprandial). Estudio microbiológico negativo. Citología: pendiente. Diagnóstico A los pocos días se obtuvieron los resultados de la citología del LCR: positivo para CTM. Sugestivo de afectación por carcinoma. Confirmándose una de las sospechas de polineuropatía secundaria a meningitis carcinomatosa (MC), tras el hallazgo de hipoglucorraquia en el estudio citobioquímico. Se ha solicitado estudio molecular en la citología del LCR, del que estamos pendiente. Tratamiento Al alta, antes de saber el diagnóstico definitivo, se prescribió erlotinib a dosis de 100 mg al día (debido a que presentó respuesta pulmonar y disminución del CEA durante el tratamiento y la a baja probabilidad de que la neurotoxicidad fuera secundaria al inhibidor de la ITK) y una pauta descendente de corticoides. Evolución La paciente se mantuvo estable durante el ingreso hospitalario, mejorando lentamente su clínica neurológica, aunque persistiendo hipoestesia en la parte distal de las extremidades y mejorando progresivamente la incontinencia de esfínteres y la marcha tebética tras el inicio de corticoides y descanso de erlotinib, descartándose compresión medular en la RM de columna. La paciente niega en todo momento cefalea, náuseas o vómitos. El caso fue valorado por parte de Neurología, concluyendo que el perfil temporal y el comportamiento clínico favorecen el diagnóstico de polineuropatía tóxica (PN), sugerido también tras los hallazgos de la RM. Fue dada de alta con diagnóstico de PN tóxica poco probable a erlotinib debido a la infrecuencia del cuadro, sin poder descartar neurotoxicidad tardía a docetaxel (que finalizó en diciembre 2014). En espera de los resultados de la citología para descartar MC del LCR ante el resultado de hipoglucorraquia, sugestivo de consumo en el estudio citobioquímico. Instructions: please typing these entity words according to sentence: células tumorales malignas, CTM, adenocarcinoma, adenocarcinoma de pulmón derecho metastásico, CTM, carcinoma, carcinomatosa, MC, MC Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
ANAMNESIS Mujer de 66 años de edad, sin alergias medicamentosas conocidas (AMC) ni hábitos tóxicos. Obesa, hipertensa y con artrosis generalizada de años de evolución. Presenta cuadros de hiperreactividad bronquial frecuentes sin haberse filiado patología broncopulmonar previa. La paciente es ama de casa y no presenta antecedentes oncológicos familiares. Está en tratamiento con eprosartán 600 mg al día, un antiinflamatorio dos veces al día por los dolores óseos y un protector del estómago. En el año 2012 (con 63 años) comienza con cuadro de tos persistente y astenia de 4 meses de evolución, por lo que su médico de Atención Primaria solicita radiografía de tórax con hallazgo de condensación basal derecha y nódulos pulmonares múltiples en ambos campos pulmonares. La paciente es derivada al Servicio de Medicina Interna para completar estudio, realizándose una analítica completa con marcadores tumorales, que es normal, además de una tomografía computarizada (TC) toracoabdominopélvica, observándose nódulos pulmonares múltiples de mediano tamaño distribuidos en ambos campos pulmonares (lóbulos superiores, campos medios y lóbulos inferiores), condensación basal derecha y adenopatías mediastínicas macroscópicas en el espacio prevascular y paratraqueales derechas. Tras estos hallazgos se le realizó una fibrobroncoscopia, hallando mucosa de aspecto inflamatorio, sin observarse signos de infiltración, cuya biopsia fue negativa para células tumorales malignas (CTM), pero, en la citología del líquido pleural, se observaron células de hábito epiteloide con núcleos excéntricos, pleomórficos con citoplasma vaculado y con expresión de TTF1+, CK19 y NEGATIVIDAD para P63, mamoglobina, GCDP-15 y RE. Todo esto compatible con adenocarcinoma pulmonar. Se solicitaron las mutaciones EGFR: NATIVO y ALK negativo. Con diagnóstico de adenocarcinoma de pulmón derecho metastásico, inicia 1.ª línea de quimioterapia (QT) con cisplatino (CDDP)-pemetrexed el 31/10/2012. Recibe un total de 4 ciclos CDDP-pemetrexed con enfermedad estable (EE) tras el tercer ciclo, pasando a pemetrexed de mantenimiento el 23/1/2013. Durante el tratamiento con CDDP-pemetrexed presentó episodios de bronquitis. Tras 3 ciclos de pemetrexed de mantenimiento, se realizó una TC, observándose discreta disminución del tamaño de la masa pulmonar, pasando de 7,5 cm a 7 cm y el resto de nódulos pulmonares sin cambios, por lo que se consideró EE y se continuó con tratamiento bien tolerado, hasta diciembre de 2013, presentado en analítica aumento del antígeno carcinoembrionario (CEA) y progresión pulmonar tras 16 ciclos de pemetrexed. En enero de 2014 inicia 2.ª línea con docetaxel (75 mg/m2) a dosis reducidas 15 % por tratamiento previo. Presentando CEA basal: 3.186. Recibe un total de 16 ciclos (último el 19/11/14), con enfermedad estable en TC de control tras 3º., 7.º y 14.º ciclos. Como toxicidad cabe destacar diarrea grado 1 y alopecia grado 3 tras 1.er ciclo. Tras el 2.º y el 4.º ciclos relata astenia y artromialgias los 3 primeros días, bien tolerados a partir del ciclo 6.º, y tras ciclo 14.º, recibió tratamiento con levofloxacino por infeccioó faríngea. La paciente no presentó neurotoxicidad en ninguno de los ciclos. El 10/12/2014 se considera haber conseguido el máximo beneficio tras 16 ciclos de QT de 2.ª línea con docetaxel, por lo que se decide suspender y pasar a seguimiento. Pero en enero de 2015, la paciente presenta aumento de CEA (300) y en la primera TC de control se observa progresión pulmonar, por lo que se decide comenzar 3.ª línea con erlotinib, con indicación en ficha técnica. Inicia erlotinib el 26 de enero 2015 a dosis de 150 mg/ 24 h bien tolerado hasta que comienza con cuadro de mareo inespecífico a las 3 semanas de tratamiento y otalgia, motivo por la que es valorada por Otorrinolaringología, extrayendo un tapón de cerumen, y por Cirugía Maxilofacial, diagnosticando artritis en la articulación mandibular, por lo que se continuó tratamiento con erlotinib sin descanso. Tras 11 semanas de tratamiento, se realiza una TC de extensión el 15 de abril con mejoría radiológica pulmonar, pero persiste el cuadro vertiginoso, por lo que se solicita resonancia magnética (RM) cerebral. El 11 de mayo (15 semanas con erlotinib), la paciente acude a consulta fuera de citación por empeoramiento del cuadro vertiginoso, junto con aparición de parestesias en miembros inferiores (MMII), muslos e hipoestesia en periné, con episodios de incontinencia urinaria y fecal, sin dolor lumbar ni alteración motora. La paciente lo achaca todo al tratamiento con erlotinib, ya que inició esta clínica al poco tiempo de empezar el tratamiento, empeorando progresivamente. Finalmente, se decide suspender erlotinib a la espera del resultado de la RM cerebral. Una semana después, la paciente acude a resultado de la RM cerebral, que es normal, refiriendo que desde el descanso con erlotinb persisten hipoestesias en MMII, siendo menos intensas en muslos, aunque continúa con incontinencia urinaria y fecal, negáado en todo momento dolor de espalda. En este momento, ante resultado negativo de la RM cerebral, se decide ingreso para estudio de médula espinal. Exploración física ECOG 2. Consciente y orientada. Buen estado general. Obesa, normocoloreada, normohidratada, eupneica en reposo. No se palpan adenopatías periféricas. Auscultación cardiopulmonar: tonos cardiacos rítmicos, murmullo vesicular levemente disminuido en hemitórax derecho, sin ruidos patológicos sobreañadidos. Abdomen: globuloso, blando y depresible, no doloroso a la palpación, no se palpan masas ni megalias, ruidos hidroaéreos presentes. MMII: sin edemas ni signos de trombosis venosa profunda. Exploración neurológica: fondo ocular normal. Motilidad ocular extrínseca y resto de pares craneales normales. No hay un claro déficit motor. Reflejos osteotendinosos (ROT) 3+ con ROT vivos algo más izquierdos y arreflexia aquílea con Babinski bilateral. Hipoestesia distal en pies e hipopalestesia hasta últimos arcos costales. No se aprecia nivel en tronco. Marcha tabética con aumento de la base, precisa ayuda de andador, atáxica. Pruebas complementarias » Analítica: bioquímica (BQ) normal, excepto proteinas totales 6,4 g/dL; colesterol 205 mg/dL. CEA 152,7 ng/mL (previo 140); CA 125 8,4 U/mL, resto de BQ normal. Hemograma normal. » RM de columna completa (21/5/2015): se observa alteración de señal hiperintensa en la médula, siendo más marcada en bulbo, región periférica de mesencéfalo y protuberancia con extensión a pedúnculos cerebelosos. Todo ello, probablemente en relación con toxicidad por quimioterapia como primera posibilidad. » Punción lumbar (PL): líquido cefalorraquídeo (LCR) de aspecto claro y transparente, saliendo a una velocidad adecuada. Estudio citobioquímico: células 8; glucorraquia 29; proteínas: 028; hematíes 10 (glucemia tras la PL: 90 preprandial). Estudio microbiológico negativo. Citología: pendiente. Diagnóstico A los pocos días se obtuvieron los resultados de la citología del LCR: positivo para CTM. Sugestivo de afectación por carcinoma. Confirmándose una de las sospechas de polineuropatía secundaria a meningitis carcinomatosa (MC), tras el hallazgo de hipoglucorraquia en el estudio citobioquímico. Se ha solicitado estudio molecular en la citología del LCR, del que estamos pendiente. Tratamiento Al alta, antes de saber el diagnóstico definitivo, se prescribió erlotinib a dosis de 100 mg al día (debido a que presentó respuesta pulmonar y disminución del CEA durante el tratamiento y la a baja probabilidad de que la neurotoxicidad fuera secundaria al inhibidor de la ITK) y una pauta descendente de corticoides. Evolución La paciente se mantuvo estable durante el ingreso hospitalario, mejorando lentamente su clínica neurológica, aunque persistiendo hipoestesia en la parte distal de las extremidades y mejorando progresivamente la incontinencia de esfínteres y la marcha tebética tras el inicio de corticoides y descanso de erlotinib, descartándose compresión medular en la RM de columna. La paciente niega en todo momento cefalea, náuseas o vómitos. El caso fue valorado por parte de Neurología, concluyendo que el perfil temporal y el comportamiento clínico favorecen el diagnóstico de polineuropatía tóxica (PN), sugerido también tras los hallazgos de la RM. Fue dada de alta con diagnóstico de PN tóxica poco probable a erlotinib debido a la infrecuencia del cuadro, sin poder descartar neurotoxicidad tardía a docetaxel (que finalizó en diciembre 2014). En espera de los resultados de la citología para descartar MC del LCR ante el resultado de hipoglucorraquia, sugestivo de consumo en el estudio citobioquímico.
[ "ANAMNESIS", "\n", "Mujer", "de", "66", "años", "de", "edad", ",", "sin", "alergias", "medicamentosas", "conocidas", "(", "AMC", ")", "ni", "hábitos", "tóxicos", ".", "Obesa", ",", "hipertensa", "y", "con", "artrosis", "generalizada", "de", "años", "de", "evolución", ".", "Presenta", "cuadros", "de", "hiperreactividad", "bronquial", "frecuentes", "sin", "haberse", "filiado", "patología", "broncopulmonar", "previa", ".", "La", "paciente", "es", "ama", "de", "casa", "y", "no", "presenta", "antecedentes", "oncológicos", "familiares", ".", "Está", "en", "tratamiento", "con", "eprosartán", "600", "mg", "al", "día", ",", "un", "antiinflamatorio", "dos", "veces", "al", "día", "por", "los", "dolores", "óseos", "y", "un", "protector", "del", "estómago", ".", "\n\n", "En", "el", "año", "2012", "(", "con", "63", "años", ")", "comienza", "con", "cuadro", "de", "tos", "persistente", "y", "astenia", "de", "4", "meses", "de", "evolución", ",", "por", "lo", "que", "su", "médico", "de", "Atención", "Primaria", "solicita", "radiografía", "de", "tórax", "con", "hallazgo", "de", "condensación", "basal", "derecha", "y", "nódulos", "pulmonares", "múltiples", "en", "ambos", "campos", "pulmonares", ".", "\n\n", "La", "paciente", "es", "derivada", "al", "Servicio", "de", "Medicina", "Interna", "para", "completar", "estudio", ",", "realizándose", "una", "analítica", "completa", "con", "marcadores", "tumorales", ",", "que", "es", "normal", ",", "además", "de", "una", "tomografía", "computarizada", "(", "TC", ")", "toracoabdominopélvica", ",", "observándose", "nódulos", "pulmonares", "múltiples", "de", "mediano", "tamaño", "distribuidos", "en", "ambos", "campos", "pulmonares", "(", "lóbulos", "superiores", ",", "campos", "medios", "y", "lóbulos", "inferiores", ")", ",", "condensación", "basal", "derecha", "y", "adenopatías", "mediastínicas", "macroscópicas", "en", "el", "espacio", "prevascular", "y", "paratraqueales", "derechas", ".", "\n\n", "Tras", "estos", "hallazgos", "se", "le", "realizó", "una", "fibrobroncoscopia", ",", "hallando", "mucosa", "de", "aspecto", "inflamatorio", ",", "sin", "observarse", "signos", "de", "infiltración", ",", "cuya", "biopsia", "fue", "negativa", "para", "células", "tumorales", "malignas", "(", "CTM", ")", ",", "pero", ",", "en", "la", "citología", "del", "líquido", "pleural", ",", "se", "observaron", "células", "de", "hábito", "epiteloide", "con", "núcleos", "excéntricos", ",", "pleomórficos", "con", "citoplasma", "vaculado", "y", "con", "expresión", "de", "TTF1", "+", ",", "CK19", "y", "NEGATIVIDAD", "para", "P63", ",", "mamoglobina", ",", "GCDP-15", "y", "RE", ".", "Todo", "esto", "compatible", "con", "adenocarcinoma", "pulmonar", ".", "Se", "solicitaron", "las", "mutaciones", "EGFR", ":", "NATIVO", "y", "ALK", "negativo", ".", "\n", "Con", "diagnóstico", "de", "adenocarcinoma", "de", "pulmón", "derecho", "metastásico", ",", "inicia", "1.ª", "línea", "de", "quimioterapia", "(", "QT", ")", "con", "cisplatino", "(", "CDDP)-pemetrexed", "el", "31/10/2012", ".", "Recibe", "un", "total", "de", "4", "ciclos", "CDDP", "-", "pemetrexed", "con", "enfermedad", "estable", "(", "EE", ")", "tras", "el", "tercer", "ciclo", ",", "pasando", "a", "pemetrexed", "de", "mantenimiento", "el", "23/1/2013", ".", "\n\n", "Durante", "el", "tratamiento", "con", "CDDP", "-", "pemetrexed", "presentó", "episodios", "de", "bronquitis", ".", "\n\n", "Tras", "3", "ciclos", "de", "pemetrexed", "de", "mantenimiento", ",", "se", "realizó", "una", "TC", ",", "observándose", "discreta", "disminución", "del", "tamaño", "de", "la", "masa", "pulmonar", ",", "pasando", "de", "7,5", "cm", "a", "7", "cm", "y", "el", "resto", "de", "nódulos", "pulmonares", "sin", "cambios", ",", "por", "lo", "que", "se", "consideró", "EE", "y", "se", "continuó", "con", "tratamiento", "bien", "tolerado", ",", "hasta", "diciembre", "de", "2013", ",", "presentado", "en", "analítica", "aumento", "del", "antígeno", "carcinoembrionario", "(", "CEA", ")", "y", "progresión", "pulmonar", "tras", "16", "ciclos", "de", "pemetrexed", ".", "\n\n", "En", "enero", "de", "2014", "inicia", "2.ª", "línea", "con", "docetaxel", "(", "75", "mg", "/", "m2", ")", "a", "dosis", "reducidas", "15", "%", "por", "tratamiento", "previo", ".", "Presentando", "CEA", "basal", ":", "3.186", ".", "Recibe", "un", "total", "de", "16", "ciclos", "(", "último", "el", "19/11/14", ")", ",", "con", "enfermedad", "estable", "en", "TC", "de", "control", "tras", "3º.", ",", "7.º", "y", "14.º", "ciclos", ".", "Como", "toxicidad", "cabe", "destacar", "diarrea", "grado", "1", "y", "alopecia", "grado", "3", "tras", "1.er", "ciclo", ".", "Tras", "el", "2.º", "y", "el", "4.º", "ciclos", "relata", "astenia", "y", "artromialgias", "los", "3", "primeros", "días", ",", "bien", "tolerados", "a", "partir", "del", "ciclo", "6.º", ",", "y", "tras", "ciclo", "14.º", ",", "recibió", "tratamiento", "con", "levofloxacino", "por", "infeccioó", "faríngea", ".", "La", "paciente", "no", "presentó", "neurotoxicidad", "en", "ninguno", "de", "los", "ciclos", ".", "\n\n", "El", "10/12/2014", "se", "considera", "haber", "conseguido", "el", "máximo", "beneficio", "tras", "16", "ciclos", "de", "QT", "de", "2.ª", "línea", "con", "docetaxel", ",", "por", "lo", "que", "se", "decide", "suspender", "y", "pasar", "a", "seguimiento", ".", "Pero", "en", "enero", "de", "2015", ",", "la", "paciente", "presenta", "aumento", "de", "CEA", "(", "300", ")", "y", "en", "la", "primera", "TC", "de", "control", "se", "observa", "progresión", "pulmonar", ",", "por", "lo", "que", "se", "decide", "comenzar", "3.ª", "línea", "con", "erlotinib", ",", "con", "indicación", "en", "ficha", "técnica", ".", "\n\n", "Inicia", "erlotinib", "el", "26", "de", "enero", "2015", "a", "dosis", "de", "150", "mg/", "24", "h", "bien", "tolerado", "hasta", "que", "comienza", "con", "cuadro", "de", "mareo", "inespecífico", "a", "las", "3", "semanas", "de", "tratamiento", "y", "otalgia", ",", "motivo", "por", "la", "que", "es", "valorada", "por", "Otorrinolaringología", ",", "extrayendo", "un", "tapón", "de", "cerumen", ",", "y", "por", "Cirugía", "Maxilofacial", ",", "diagnosticando", "artritis", "en", "la", "articulación", "mandibular", ",", "por", "lo", "que", "se", "continuó", "tratamiento", "con", "erlotinib", "sin", "descanso", ".", "Tras", "11", "semanas", "de", "tratamiento", ",", "se", "realiza", "una", "TC", "de", "extensión", "el", "15", "de", "abril", "con", "mejoría", "radiológica", "pulmonar", ",", "pero", "persiste", "el", "cuadro", "vertiginoso", ",", "por", "lo", "que", "se", "solicita", "resonancia", "magnética", "(", "RM", ")", "cerebral", ".", "\n\n", "El", "11", "de", "mayo", "(", "15", "semanas", "con", "erlotinib", ")", ",", "la", "paciente", "acude", "a", "consulta", "fuera", "de", "citación", "por", "empeoramiento", "del", "cuadro", "vertiginoso", ",", "junto", "con", "aparición", "de", "parestesias", "en", "miembros", "inferiores", "(", "MMII", ")", ",", "muslos", "e", "hipoestesia", "en", "periné", ",", "con", "episodios", "de", "incontinencia", "urinaria", "y", "fecal", ",", "sin", "dolor", "lumbar", "ni", "alteración", "motora", ".", "La", "paciente", "lo", "achaca", "todo", "al", "tratamiento", "con", "erlotinib", ",", "ya", "que", "inició", "esta", "clínica", "al", "poco", "tiempo", "de", "empezar", "el", "tratamiento", ",", "empeorando", "progresivamente", ".", "Finalmente", ",", "se", "decide", "suspender", "erlotinib", "a", "la", "espera", "del", "resultado", "de", "la", "RM", "cerebral", ".", "\n\n", "Una", "semana", "después", ",", "la", "paciente", "acude", "a", "resultado", "de", "la", "RM", "cerebral", ",", "que", "es", "normal", ",", "refiriendo", "que", "desde", "el", "descanso", "con", "erlotinb", "persisten", "hipoestesias", "en", "MMII", ",", "siendo", "menos", "intensas", "en", "muslos", ",", "aunque", "continúa", "con", "incontinencia", "urinaria", "y", "fecal", ",", "negáado", "en", "todo", "momento", "dolor", "de", "espalda", ".", "En", "este", "momento", ",", "ante", "resultado", "negativo", "de", "la", "RM", "cerebral", ",", "se", "decide", "ingreso", "para", "estudio", "de", "médula", "espinal", ".", "\n\n", "Exploración", "física", "\n", "ECOG", "2", ".", "Consciente", "y", "orientada", ".", "Buen", "estado", "general", ".", "Obesa", ",", "normocoloreada", ",", "normohidratada", ",", "eupneica", "en", "reposo", ".", "No", "se", "palpan", "adenopatías", "periféricas", ".", "Auscultación", "cardiopulmonar", ":", "tonos", "cardiacos", "rítmicos", ",", "murmullo", "vesicular", "levemente", "disminuido", "en", "hemitórax", "derecho", ",", "sin", "ruidos", "patológicos", "sobreañadidos", ".", "Abdomen", ":", "globuloso", ",", "blando", "y", "depresible", ",", "no", "doloroso", "a", "la", "palpación", ",", "no", "se", "palpan", "masas", "ni", "megalias", ",", "ruidos", "hidroaéreos", "presentes", ".", "MMII", ":", "sin", "edemas", "ni", "signos", "de", "trombosis", "venosa", "profunda", ".", "\n\n", "Exploración", "neurológica", ":", "fondo", "ocular", "normal", ".", "Motilidad", "ocular", "extrínseca", "y", "resto", "de", "pares", "craneales", "normales", ".", "No", "hay", "un", "claro", "déficit", "motor", ".", "Reflejos", "osteotendinosos", "(", "ROT", ")", "3", "+", "con", "ROT", "vivos", "algo", "más", "izquierdos", "y", "arreflexia", "aquílea", "con", "Babinski", "bilateral", ".", "Hipoestesia", "distal", "en", "pies", "e", "hipopalestesia", "hasta", "últimos", "arcos", "costales", ".", "No", "se", "aprecia", "nivel", "en", "tronco", ".", "Marcha", "tabética", "con", "aumento", "de", "la", "base", ",", "precisa", "ayuda", "de", "andador", ",", "atáxica", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Analítica", ":", "bioquímica", "(", "BQ", ")", "normal", ",", "excepto", "proteinas", "totales", "6,4", "g", "/", "dL", ";", "colesterol", "205", "mg", "/", "dL.", "CEA", "152,7", "ng", "/", "mL", "(", "previo", "140", ")", ";", "CA", "125", "8,4", "U", "/", "mL", ",", "resto", "de", "BQ", "normal", ".", "Hemograma", "normal", ".", "\n", "»", "RM", "de", "columna", "completa", "(", "21/5/2015", "):", "se", "observa", "alteración", "de", "señal", "hiperintensa", "en", "la", "médula", ",", "siendo", "más", "marcada", "en", "bulbo", ",", "región", "periférica", "de", "mesencéfalo", "y", "protuberancia", "con", "extensión", "a", "pedúnculos", "cerebelosos", ".", "Todo", "ello", ",", "probablemente", "en", "relación", "con", "toxicidad", "por", "quimioterapia", "como", "primera", "posibilidad", ".", "\n", "»", "Punción", "lumbar", "(", "PL", "):", "líquido", "cefalorraquídeo", "(", "LCR", ")", "de", "aspecto", "claro", "y", "transparente", ",", "saliendo", "a", "una", "velocidad", "adecuada", ".", "Estudio", "citobioquímico", ":", "células", "8", ";", "glucorraquia", "29", ";", "proteínas", ":", "028", ";", "hematíes", "10", "(", "glucemia", "tras", "la", "PL", ":", "90", "preprandial", ")", ".", "Estudio", "microbiológico", "negativo", ".", "Citología", ":", "pendiente", ".", "\n\n", "Diagnóstico", "\n", "A", "los", "pocos", "días", "se", "obtuvieron", "los", "resultados", "de", "la", "citología", "del", "LCR", ":", "positivo", "para", "CTM", ".", "Sugestivo", "de", "afectación", "por", "carcinoma", ".", "Confirmándose", "una", "de", "las", "sospechas", "de", "polineuropatía", "secundaria", "a", "meningitis", "carcinomatosa", "(", "MC", ")", ",", "tras", "el", "hallazgo", "de", "hipoglucorraquia", "en", "el", "estudio", "citobioquímico", ".", "Se", "ha", "solicitado", "estudio", "molecular", "en", "la", "citología", "del", "LCR", ",", "del", "que", "estamos", "pendiente", ".", "\n\n", "Tratamiento", "\n", "Al", "alta", ",", "antes", "de", "saber", "el", "diagnóstico", "definitivo", ",", "se", "prescribió", "erlotinib", "a", "dosis", "de", "100", "mg", "al", "día", "(", "debido", "a", "que", "presentó", "respuesta", "pulmonar", "y", "disminución", "del", "CEA", "durante", "el", "tratamiento", "y", "la", "a", "baja", "probabilidad", "de", "que", "la", "neurotoxicidad", "fuera", "secundaria", "al", "inhibidor", "de", "la", "ITK", ")", "y", "una", "pauta", "descendente", "de", "corticoides", ".", "\n\n", "Evolución", "\n", "La", "paciente", "se", "mantuvo", "estable", "durante", "el", "ingreso", "hospitalario", ",", "mejorando", "lentamente", "su", "clínica", "neurológica", ",", "aunque", "persistiendo", "hipoestesia", "en", "la", "parte", "distal", "de", "las", "extremidades", "y", "mejorando", "progresivamente", "la", "incontinencia", "de", "esfínteres", "y", "la", "marcha", "tebética", "tras", "el", "inicio", "de", "corticoides", "y", "descanso", "de", "erlotinib", ",", "descartándose", "compresión", "medular", "en", "la", "RM", "de", "columna", ".", "La", "paciente", "niega", "en", "todo", "momento", "cefalea", ",", "náuseas", "o", "vómitos", ".", "\n", "El", "caso", "fue", "valorado", "por", "parte", "de", "Neurología", ",", "concluyendo", "que", "el", "perfil", "temporal", "y", "el", "comportamiento", "clínico", "favorecen", "el", "diagnóstico", "de", "polineuropatía", "tóxica", "(", "PN", ")", ",", "sugerido", "también", "tras", "los", "hallazgos", "de", "la", "RM", ".", "\n", "Fue", "dada", "de", "alta", "con", "diagnóstico", "de", "PN", "tóxica", "poco", "probable", "a", "erlotinib", "debido", "a", "la", "infrecuencia", "del", "cuadro", ",", "sin", "poder", "descartar", "neurotoxicidad", "tardía", "a", "docetaxel", "(", "que", "finalizó", "en", "diciembre", "2014", ")", ".", "En", "espera", "de", "los", "resultados", "de", "la", "citología", "para", "descartar", "MC", "del", "LCR", "ante", "el", "resultado", "de", "hipoglucorraquia", ",", "sugestivo", "de", "consumo", "en", "el", "estudio", "citobioquímico", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
células tumorales malignas, CTM, adenocarcinoma, adenocarcinoma de pulmón derecho metastásico, CTM, carcinoma, carcinomatosa, MC, MC
87_task2
Sentence: ANAMNESIS Mujer de 66 años de edad, sin alergias medicamentosas conocidas (AMC) ni hábitos tóxicos. Obesa, hipertensa y con artrosis generalizada de años de evolución. Presenta cuadros de hiperreactividad bronquial frecuentes sin haberse filiado patología broncopulmonar previa. La paciente es ama de casa y no presenta antecedentes oncológicos familiares. Está en tratamiento con eprosartán 600 mg al día, un antiinflamatorio dos veces al día por los dolores óseos y un protector del estómago. En el año 2012 (con 63 años) comienza con cuadro de tos persistente y astenia de 4 meses de evolución, por lo que su médico de Atención Primaria solicita radiografía de tórax con hallazgo de condensación basal derecha y nódulos pulmonares múltiples en ambos campos pulmonares. La paciente es derivada al Servicio de Medicina Interna para completar estudio, realizándose una analítica completa con marcadores tumorales, que es normal, además de una tomografía computarizada (TC) toracoabdominopélvica, observándose nódulos pulmonares múltiples de mediano tamaño distribuidos en ambos campos pulmonares (lóbulos superiores, campos medios y lóbulos inferiores), condensación basal derecha y adenopatías mediastínicas macroscópicas en el espacio prevascular y paratraqueales derechas. Tras estos hallazgos se le realizó una fibrobroncoscopia, hallando mucosa de aspecto inflamatorio, sin observarse signos de infiltración, cuya biopsia fue negativa para células tumorales malignas (CTM), pero, en la citología del líquido pleural, se observaron células de hábito epiteloide con núcleos excéntricos, pleomórficos con citoplasma vaculado y con expresión de TTF1+, CK19 y NEGATIVIDAD para P63, mamoglobina, GCDP-15 y RE. Todo esto compatible con adenocarcinoma pulmonar. Se solicitaron las mutaciones EGFR: NATIVO y ALK negativo. Con diagnóstico de adenocarcinoma de pulmón derecho metastásico, inicia 1.ª línea de quimioterapia (QT) con cisplatino (CDDP)-pemetrexed el 31/10/2012. Recibe un total de 4 ciclos CDDP-pemetrexed con enfermedad estable (EE) tras el tercer ciclo, pasando a pemetrexed de mantenimiento el 23/1/2013. Durante el tratamiento con CDDP-pemetrexed presentó episodios de bronquitis. Tras 3 ciclos de pemetrexed de mantenimiento, se realizó una TC, observándose discreta disminución del tamaño de la masa pulmonar, pasando de 7,5 cm a 7 cm y el resto de nódulos pulmonares sin cambios, por lo que se consideró EE y se continuó con tratamiento bien tolerado, hasta diciembre de 2013, presentado en analítica aumento del antígeno carcinoembrionario (CEA) y progresión pulmonar tras 16 ciclos de pemetrexed. En enero de 2014 inicia 2.ª línea con docetaxel (75 mg/m2) a dosis reducidas 15 % por tratamiento previo. Presentando CEA basal: 3.186. Recibe un total de 16 ciclos (último el 19/11/14), con enfermedad estable en TC de control tras 3º., 7.º y 14.º ciclos. Como toxicidad cabe destacar diarrea grado 1 y alopecia grado 3 tras 1.er ciclo. Tras el 2.º y el 4.º ciclos relata astenia y artromialgias los 3 primeros días, bien tolerados a partir del ciclo 6.º, y tras ciclo 14.º, recibió tratamiento con levofloxacino por infeccioó faríngea. La paciente no presentó neurotoxicidad en ninguno de los ciclos. El 10/12/2014 se considera haber conseguido el máximo beneficio tras 16 ciclos de QT de 2.ª línea con docetaxel, por lo que se decide suspender y pasar a seguimiento. Pero en enero de 2015, la paciente presenta aumento de CEA (300) y en la primera TC de control se observa progresión pulmonar, por lo que se decide comenzar 3.ª línea con erlotinib, con indicación en ficha técnica. Inicia erlotinib el 26 de enero 2015 a dosis de 150 mg/ 24 h bien tolerado hasta que comienza con cuadro de mareo inespecífico a las 3 semanas de tratamiento y otalgia, motivo por la que es valorada por Otorrinolaringología, extrayendo un tapón de cerumen, y por Cirugía Maxilofacial, diagnosticando artritis en la articulación mandibular, por lo que se continuó tratamiento con erlotinib sin descanso. Tras 11 semanas de tratamiento, se realiza una TC de extensión el 15 de abril con mejoría radiológica pulmonar, pero persiste el cuadro vertiginoso, por lo que se solicita resonancia magnética (RM) cerebral. El 11 de mayo (15 semanas con erlotinib), la paciente acude a consulta fuera de citación por empeoramiento del cuadro vertiginoso, junto con aparición de parestesias en miembros inferiores (MMII), muslos e hipoestesia en periné, con episodios de incontinencia urinaria y fecal, sin dolor lumbar ni alteración motora. La paciente lo achaca todo al tratamiento con erlotinib, ya que inició esta clínica al poco tiempo de empezar el tratamiento, empeorando progresivamente. Finalmente, se decide suspender erlotinib a la espera del resultado de la RM cerebral. Una semana después, la paciente acude a resultado de la RM cerebral, que es normal, refiriendo que desde el descanso con erlotinb persisten hipoestesias en MMII, siendo menos intensas en muslos, aunque continúa con incontinencia urinaria y fecal, negáado en todo momento dolor de espalda. En este momento, ante resultado negativo de la RM cerebral, se decide ingreso para estudio de médula espinal. Exploración física ECOG 2. Consciente y orientada. Buen estado general. Obesa, normocoloreada, normohidratada, eupneica en reposo. No se palpan adenopatías periféricas. Auscultación cardiopulmonar: tonos cardiacos rítmicos, murmullo vesicular levemente disminuido en hemitórax derecho, sin ruidos patológicos sobreañadidos. Abdomen: globuloso, blando y depresible, no doloroso a la palpación, no se palpan masas ni megalias, ruidos hidroaéreos presentes. MMII: sin edemas ni signos de trombosis venosa profunda. Exploración neurológica: fondo ocular normal. Motilidad ocular extrínseca y resto de pares craneales normales. No hay un claro déficit motor. Reflejos osteotendinosos (ROT) 3+ con ROT vivos algo más izquierdos y arreflexia aquílea con Babinski bilateral. Hipoestesia distal en pies e hipopalestesia hasta últimos arcos costales. No se aprecia nivel en tronco. Marcha tabética con aumento de la base, precisa ayuda de andador, atáxica. Pruebas complementarias » Analítica: bioquímica (BQ) normal, excepto proteinas totales 6,4 g/dL; colesterol 205 mg/dL. CEA 152,7 ng/mL (previo 140); CA 125 8,4 U/mL, resto de BQ normal. Hemograma normal. » RM de columna completa (21/5/2015): se observa alteración de señal hiperintensa en la médula, siendo más marcada en bulbo, región periférica de mesencéfalo y protuberancia con extensión a pedúnculos cerebelosos. Todo ello, probablemente en relación con toxicidad por quimioterapia como primera posibilidad. » Punción lumbar (PL): líquido cefalorraquídeo (LCR) de aspecto claro y transparente, saliendo a una velocidad adecuada. Estudio citobioquímico: células 8; glucorraquia 29; proteínas: 028; hematíes 10 (glucemia tras la PL: 90 preprandial). Estudio microbiológico negativo. Citología: pendiente. Diagnóstico A los pocos días se obtuvieron los resultados de la citología del LCR: positivo para CTM. Sugestivo de afectación por carcinoma. Confirmándose una de las sospechas de polineuropatía secundaria a meningitis carcinomatosa (MC), tras el hallazgo de hipoglucorraquia en el estudio citobioquímico. Se ha solicitado estudio molecular en la citología del LCR, del que estamos pendiente. Tratamiento Al alta, antes de saber el diagnóstico definitivo, se prescribió erlotinib a dosis de 100 mg al día (debido a que presentó respuesta pulmonar y disminución del CEA durante el tratamiento y la a baja probabilidad de que la neurotoxicidad fuera secundaria al inhibidor de la ITK) y una pauta descendente de corticoides. Evolución La paciente se mantuvo estable durante el ingreso hospitalario, mejorando lentamente su clínica neurológica, aunque persistiendo hipoestesia en la parte distal de las extremidades y mejorando progresivamente la incontinencia de esfínteres y la marcha tebética tras el inicio de corticoides y descanso de erlotinib, descartándose compresión medular en la RM de columna. La paciente niega en todo momento cefalea, náuseas o vómitos. El caso fue valorado por parte de Neurología, concluyendo que el perfil temporal y el comportamiento clínico favorecen el diagnóstico de polineuropatía tóxica (PN), sugerido también tras los hallazgos de la RM. Fue dada de alta con diagnóstico de PN tóxica poco probable a erlotinib debido a la infrecuencia del cuadro, sin poder descartar neurotoxicidad tardía a docetaxel (que finalizó en diciembre 2014). En espera de los resultados de la citología para descartar MC del LCR ante el resultado de hipoglucorraquia, sugestivo de consumo en el estudio citobioquímico. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
ANAMNESIS Mujer de 66 años de edad, sin alergias medicamentosas conocidas (AMC) ni hábitos tóxicos. Obesa, hipertensa y con artrosis generalizada de años de evolución. Presenta cuadros de hiperreactividad bronquial frecuentes sin haberse filiado patología broncopulmonar previa. La paciente es ama de casa y no presenta antecedentes oncológicos familiares. Está en tratamiento con eprosartán 600 mg al día, un antiinflamatorio dos veces al día por los dolores óseos y un protector del estómago. En el año 2012 (con 63 años) comienza con cuadro de tos persistente y astenia de 4 meses de evolución, por lo que su médico de Atención Primaria solicita radiografía de tórax con hallazgo de condensación basal derecha y nódulos pulmonares múltiples en ambos campos pulmonares. La paciente es derivada al Servicio de Medicina Interna para completar estudio, realizándose una analítica completa con marcadores tumorales, que es normal, además de una tomografía computarizada (TC) toracoabdominopélvica, observándose nódulos pulmonares múltiples de mediano tamaño distribuidos en ambos campos pulmonares (lóbulos superiores, campos medios y lóbulos inferiores), condensación basal derecha y adenopatías mediastínicas macroscópicas en el espacio prevascular y paratraqueales derechas. Tras estos hallazgos se le realizó una fibrobroncoscopia, hallando mucosa de aspecto inflamatorio, sin observarse signos de infiltración, cuya biopsia fue negativa para células tumorales malignas (CTM), pero, en la citología del líquido pleural, se observaron células de hábito epiteloide con núcleos excéntricos, pleomórficos con citoplasma vaculado y con expresión de TTF1+, CK19 y NEGATIVIDAD para P63, mamoglobina, GCDP-15 y RE. Todo esto compatible con adenocarcinoma pulmonar. Se solicitaron las mutaciones EGFR: NATIVO y ALK negativo. Con diagnóstico de adenocarcinoma de pulmón derecho metastásico, inicia 1.ª línea de quimioterapia (QT) con cisplatino (CDDP)-pemetrexed el 31/10/2012. Recibe un total de 4 ciclos CDDP-pemetrexed con enfermedad estable (EE) tras el tercer ciclo, pasando a pemetrexed de mantenimiento el 23/1/2013. Durante el tratamiento con CDDP-pemetrexed presentó episodios de bronquitis. Tras 3 ciclos de pemetrexed de mantenimiento, se realizó una TC, observándose discreta disminución del tamaño de la masa pulmonar, pasando de 7,5 cm a 7 cm y el resto de nódulos pulmonares sin cambios, por lo que se consideró EE y se continuó con tratamiento bien tolerado, hasta diciembre de 2013, presentado en analítica aumento del antígeno carcinoembrionario (CEA) y progresión pulmonar tras 16 ciclos de pemetrexed. En enero de 2014 inicia 2.ª línea con docetaxel (75 mg/m2) a dosis reducidas 15 % por tratamiento previo. Presentando CEA basal: 3.186. Recibe un total de 16 ciclos (último el 19/11/14), con enfermedad estable en TC de control tras 3º., 7.º y 14.º ciclos. Como toxicidad cabe destacar diarrea grado 1 y alopecia grado 3 tras 1.er ciclo. Tras el 2.º y el 4.º ciclos relata astenia y artromialgias los 3 primeros días, bien tolerados a partir del ciclo 6.º, y tras ciclo 14.º, recibió tratamiento con levofloxacino por infeccioó faríngea. La paciente no presentó neurotoxicidad en ninguno de los ciclos. El 10/12/2014 se considera haber conseguido el máximo beneficio tras 16 ciclos de QT de 2.ª línea con docetaxel, por lo que se decide suspender y pasar a seguimiento. Pero en enero de 2015, la paciente presenta aumento de CEA (300) y en la primera TC de control se observa progresión pulmonar, por lo que se decide comenzar 3.ª línea con erlotinib, con indicación en ficha técnica. Inicia erlotinib el 26 de enero 2015 a dosis de 150 mg/ 24 h bien tolerado hasta que comienza con cuadro de mareo inespecífico a las 3 semanas de tratamiento y otalgia, motivo por la que es valorada por Otorrinolaringología, extrayendo un tapón de cerumen, y por Cirugía Maxilofacial, diagnosticando artritis en la articulación mandibular, por lo que se continuó tratamiento con erlotinib sin descanso. Tras 11 semanas de tratamiento, se realiza una TC de extensión el 15 de abril con mejoría radiológica pulmonar, pero persiste el cuadro vertiginoso, por lo que se solicita resonancia magnética (RM) cerebral. El 11 de mayo (15 semanas con erlotinib), la paciente acude a consulta fuera de citación por empeoramiento del cuadro vertiginoso, junto con aparición de parestesias en miembros inferiores (MMII), muslos e hipoestesia en periné, con episodios de incontinencia urinaria y fecal, sin dolor lumbar ni alteración motora. La paciente lo achaca todo al tratamiento con erlotinib, ya que inició esta clínica al poco tiempo de empezar el tratamiento, empeorando progresivamente. Finalmente, se decide suspender erlotinib a la espera del resultado de la RM cerebral. Una semana después, la paciente acude a resultado de la RM cerebral, que es normal, refiriendo que desde el descanso con erlotinb persisten hipoestesias en MMII, siendo menos intensas en muslos, aunque continúa con incontinencia urinaria y fecal, negáado en todo momento dolor de espalda. En este momento, ante resultado negativo de la RM cerebral, se decide ingreso para estudio de médula espinal. Exploración física ECOG 2. Consciente y orientada. Buen estado general. Obesa, normocoloreada, normohidratada, eupneica en reposo. No se palpan adenopatías periféricas. Auscultación cardiopulmonar: tonos cardiacos rítmicos, murmullo vesicular levemente disminuido en hemitórax derecho, sin ruidos patológicos sobreañadidos. Abdomen: globuloso, blando y depresible, no doloroso a la palpación, no se palpan masas ni megalias, ruidos hidroaéreos presentes. MMII: sin edemas ni signos de trombosis venosa profunda. Exploración neurológica: fondo ocular normal. Motilidad ocular extrínseca y resto de pares craneales normales. No hay un claro déficit motor. Reflejos osteotendinosos (ROT) 3+ con ROT vivos algo más izquierdos y arreflexia aquílea con Babinski bilateral. Hipoestesia distal en pies e hipopalestesia hasta últimos arcos costales. No se aprecia nivel en tronco. Marcha tabética con aumento de la base, precisa ayuda de andador, atáxica. Pruebas complementarias » Analítica: bioquímica (BQ) normal, excepto proteinas totales 6,4 g/dL; colesterol 205 mg/dL. CEA 152,7 ng/mL (previo 140); CA 125 8,4 U/mL, resto de BQ normal. Hemograma normal. » RM de columna completa (21/5/2015): se observa alteración de señal hiperintensa en la médula, siendo más marcada en bulbo, región periférica de mesencéfalo y protuberancia con extensión a pedúnculos cerebelosos. Todo ello, probablemente en relación con toxicidad por quimioterapia como primera posibilidad. » Punción lumbar (PL): líquido cefalorraquídeo (LCR) de aspecto claro y transparente, saliendo a una velocidad adecuada. Estudio citobioquímico: células 8; glucorraquia 29; proteínas: 028; hematíes 10 (glucemia tras la PL: 90 preprandial). Estudio microbiológico negativo. Citología: pendiente. Diagnóstico A los pocos días se obtuvieron los resultados de la citología del LCR: positivo para CTM. Sugestivo de afectación por carcinoma. Confirmándose una de las sospechas de polineuropatía secundaria a meningitis carcinomatosa (MC), tras el hallazgo de hipoglucorraquia en el estudio citobioquímico. Se ha solicitado estudio molecular en la citología del LCR, del que estamos pendiente. Tratamiento Al alta, antes de saber el diagnóstico definitivo, se prescribió erlotinib a dosis de 100 mg al día (debido a que presentó respuesta pulmonar y disminución del CEA durante el tratamiento y la a baja probabilidad de que la neurotoxicidad fuera secundaria al inhibidor de la ITK) y una pauta descendente de corticoides. Evolución La paciente se mantuvo estable durante el ingreso hospitalario, mejorando lentamente su clínica neurológica, aunque persistiendo hipoestesia en la parte distal de las extremidades y mejorando progresivamente la incontinencia de esfínteres y la marcha tebética tras el inicio de corticoides y descanso de erlotinib, descartándose compresión medular en la RM de columna. La paciente niega en todo momento cefalea, náuseas o vómitos. El caso fue valorado por parte de Neurología, concluyendo que el perfil temporal y el comportamiento clínico favorecen el diagnóstico de polineuropatía tóxica (PN), sugerido también tras los hallazgos de la RM. Fue dada de alta con diagnóstico de PN tóxica poco probable a erlotinib debido a la infrecuencia del cuadro, sin poder descartar neurotoxicidad tardía a docetaxel (que finalizó en diciembre 2014). En espera de los resultados de la citología para descartar MC del LCR ante el resultado de hipoglucorraquia, sugestivo de consumo en el estudio citobioquímico.
[ "ANAMNESIS", "\n", "Mujer", "de", "66", "años", "de", "edad", ",", "sin", "alergias", "medicamentosas", "conocidas", "(", "AMC", ")", "ni", "hábitos", "tóxicos", ".", "Obesa", ",", "hipertensa", "y", "con", "artrosis", "generalizada", "de", "años", "de", "evolución", ".", "Presenta", "cuadros", "de", "hiperreactividad", "bronquial", "frecuentes", "sin", "haberse", "filiado", "patología", "broncopulmonar", "previa", ".", "La", "paciente", "es", "ama", "de", "casa", "y", "no", "presenta", "antecedentes", "oncológicos", "familiares", ".", "Está", "en", "tratamiento", "con", "eprosartán", "600", "mg", "al", "día", ",", "un", "antiinflamatorio", "dos", "veces", "al", "día", "por", "los", "dolores", "óseos", "y", "un", "protector", "del", "estómago", ".", "\n\n", "En", "el", "año", "2012", "(", "con", "63", "años", ")", "comienza", "con", "cuadro", "de", "tos", "persistente", "y", "astenia", "de", "4", "meses", "de", "evolución", ",", "por", "lo", "que", "su", "médico", "de", "Atención", "Primaria", "solicita", "radiografía", "de", "tórax", "con", "hallazgo", "de", "condensación", "basal", "derecha", "y", "nódulos", "pulmonares", "múltiples", "en", "ambos", "campos", "pulmonares", ".", "\n\n", "La", "paciente", "es", "derivada", "al", "Servicio", "de", "Medicina", "Interna", "para", "completar", "estudio", ",", "realizándose", "una", "analítica", "completa", "con", "marcadores", "tumorales", ",", "que", "es", "normal", ",", "además", "de", "una", "tomografía", "computarizada", "(", "TC", ")", "toracoabdominopélvica", ",", "observándose", "nódulos", "pulmonares", "múltiples", "de", "mediano", "tamaño", "distribuidos", "en", "ambos", "campos", "pulmonares", "(", "lóbulos", "superiores", ",", "campos", "medios", "y", "lóbulos", "inferiores", ")", ",", "condensación", "basal", "derecha", "y", "adenopatías", "mediastínicas", "macroscópicas", "en", "el", "espacio", "prevascular", "y", "paratraqueales", "derechas", ".", "\n\n", "Tras", "estos", "hallazgos", "se", "le", "realizó", "una", "fibrobroncoscopia", ",", "hallando", "mucosa", "de", "aspecto", "inflamatorio", ",", "sin", "observarse", "signos", "de", "infiltración", ",", "cuya", "biopsia", "fue", "negativa", "para", "células", "tumorales", "malignas", "(", "CTM", ")", ",", "pero", ",", "en", "la", "citología", "del", "líquido", "pleural", ",", "se", "observaron", "células", "de", "hábito", "epiteloide", "con", "núcleos", "excéntricos", ",", "pleomórficos", "con", "citoplasma", "vaculado", "y", "con", "expresión", "de", "TTF1", "+", ",", "CK19", "y", "NEGATIVIDAD", "para", "P63", ",", "mamoglobina", ",", "GCDP-15", "y", "RE", ".", "Todo", "esto", "compatible", "con", "adenocarcinoma", "pulmonar", ".", "Se", "solicitaron", "las", "mutaciones", "EGFR", ":", "NATIVO", "y", "ALK", "negativo", ".", "\n", "Con", "diagnóstico", "de", "adenocarcinoma", "de", "pulmón", "derecho", "metastásico", ",", "inicia", "1.ª", "línea", "de", "quimioterapia", "(", "QT", ")", "con", "cisplatino", "(", "CDDP)-pemetrexed", "el", "31/10/2012", ".", "Recibe", "un", "total", "de", "4", "ciclos", "CDDP", "-", "pemetrexed", "con", "enfermedad", "estable", "(", "EE", ")", "tras", "el", "tercer", "ciclo", ",", "pasando", "a", "pemetrexed", "de", "mantenimiento", "el", "23/1/2013", ".", "\n\n", "Durante", "el", "tratamiento", "con", "CDDP", "-", "pemetrexed", "presentó", "episodios", "de", "bronquitis", ".", "\n\n", "Tras", "3", "ciclos", "de", "pemetrexed", "de", "mantenimiento", ",", "se", "realizó", "una", "TC", ",", "observándose", "discreta", "disminución", "del", "tamaño", "de", "la", "masa", "pulmonar", ",", "pasando", "de", "7,5", "cm", "a", "7", "cm", "y", "el", "resto", "de", "nódulos", "pulmonares", "sin", "cambios", ",", "por", "lo", "que", "se", "consideró", "EE", "y", "se", "continuó", "con", "tratamiento", "bien", "tolerado", ",", "hasta", "diciembre", "de", "2013", ",", "presentado", "en", "analítica", "aumento", "del", "antígeno", "carcinoembrionario", "(", "CEA", ")", "y", "progresión", "pulmonar", "tras", "16", "ciclos", "de", "pemetrexed", ".", "\n\n", "En", "enero", "de", "2014", "inicia", "2.ª", "línea", "con", "docetaxel", "(", "75", "mg", "/", "m2", ")", "a", "dosis", "reducidas", "15", "%", "por", "tratamiento", "previo", ".", "Presentando", "CEA", "basal", ":", "3.186", ".", "Recibe", "un", "total", "de", "16", "ciclos", "(", "último", "el", "19/11/14", ")", ",", "con", "enfermedad", "estable", "en", "TC", "de", "control", "tras", "3º.", ",", "7.º", "y", "14.º", "ciclos", ".", "Como", "toxicidad", "cabe", "destacar", "diarrea", "grado", "1", "y", "alopecia", "grado", "3", "tras", "1.er", "ciclo", ".", "Tras", "el", "2.º", "y", "el", "4.º", "ciclos", "relata", "astenia", "y", "artromialgias", "los", "3", "primeros", "días", ",", "bien", "tolerados", "a", "partir", "del", "ciclo", "6.º", ",", "y", "tras", "ciclo", "14.º", ",", "recibió", "tratamiento", "con", "levofloxacino", "por", "infeccioó", "faríngea", ".", "La", "paciente", "no", "presentó", "neurotoxicidad", "en", "ninguno", "de", "los", "ciclos", ".", "\n\n", "El", "10/12/2014", "se", "considera", "haber", "conseguido", "el", "máximo", "beneficio", "tras", "16", "ciclos", "de", "QT", "de", "2.ª", "línea", "con", "docetaxel", ",", "por", "lo", "que", "se", "decide", "suspender", "y", "pasar", "a", "seguimiento", ".", "Pero", "en", "enero", "de", "2015", ",", "la", "paciente", "presenta", "aumento", "de", "CEA", "(", "300", ")", "y", "en", "la", "primera", "TC", "de", "control", "se", "observa", "progresión", "pulmonar", ",", "por", "lo", "que", "se", "decide", "comenzar", "3.ª", "línea", "con", "erlotinib", ",", "con", "indicación", "en", "ficha", "técnica", ".", "\n\n", "Inicia", "erlotinib", "el", "26", "de", "enero", "2015", "a", "dosis", "de", "150", "mg/", "24", "h", "bien", "tolerado", "hasta", "que", "comienza", "con", "cuadro", "de", "mareo", "inespecífico", "a", "las", "3", "semanas", "de", "tratamiento", "y", "otalgia", ",", "motivo", "por", "la", "que", "es", "valorada", "por", "Otorrinolaringología", ",", "extrayendo", "un", "tapón", "de", "cerumen", ",", "y", "por", "Cirugía", "Maxilofacial", ",", "diagnosticando", "artritis", "en", "la", "articulación", "mandibular", ",", "por", "lo", "que", "se", "continuó", "tratamiento", "con", "erlotinib", "sin", "descanso", ".", "Tras", "11", "semanas", "de", "tratamiento", ",", "se", "realiza", "una", "TC", "de", "extensión", "el", "15", "de", "abril", "con", "mejoría", "radiológica", "pulmonar", ",", "pero", "persiste", "el", "cuadro", "vertiginoso", ",", "por", "lo", "que", "se", "solicita", "resonancia", "magnética", "(", "RM", ")", "cerebral", ".", "\n\n", "El", "11", "de", "mayo", "(", "15", "semanas", "con", "erlotinib", ")", ",", "la", "paciente", "acude", "a", "consulta", "fuera", "de", "citación", "por", "empeoramiento", "del", "cuadro", "vertiginoso", ",", "junto", "con", "aparición", "de", "parestesias", "en", "miembros", "inferiores", "(", "MMII", ")", ",", "muslos", "e", "hipoestesia", "en", "periné", ",", "con", "episodios", "de", "incontinencia", "urinaria", "y", "fecal", ",", "sin", "dolor", "lumbar", "ni", "alteración", "motora", ".", "La", "paciente", "lo", "achaca", "todo", "al", "tratamiento", "con", "erlotinib", ",", "ya", "que", "inició", "esta", "clínica", "al", "poco", "tiempo", "de", "empezar", "el", "tratamiento", ",", "empeorando", "progresivamente", ".", "Finalmente", ",", "se", "decide", "suspender", "erlotinib", "a", "la", "espera", "del", "resultado", "de", "la", "RM", "cerebral", ".", "\n\n", "Una", "semana", "después", ",", "la", "paciente", "acude", "a", "resultado", "de", "la", "RM", "cerebral", ",", "que", "es", "normal", ",", "refiriendo", "que", "desde", "el", "descanso", "con", "erlotinb", "persisten", "hipoestesias", "en", "MMII", ",", "siendo", "menos", "intensas", "en", "muslos", ",", "aunque", "continúa", "con", "incontinencia", "urinaria", "y", "fecal", ",", "negáado", "en", "todo", "momento", "dolor", "de", "espalda", ".", "En", "este", "momento", ",", "ante", "resultado", "negativo", "de", "la", "RM", "cerebral", ",", "se", "decide", "ingreso", "para", "estudio", "de", "médula", "espinal", ".", "\n\n", "Exploración", "física", "\n", "ECOG", "2", ".", "Consciente", "y", "orientada", ".", "Buen", "estado", "general", ".", "Obesa", ",", "normocoloreada", ",", "normohidratada", ",", "eupneica", "en", "reposo", ".", "No", "se", "palpan", "adenopatías", "periféricas", ".", "Auscultación", "cardiopulmonar", ":", "tonos", "cardiacos", "rítmicos", ",", "murmullo", "vesicular", "levemente", "disminuido", "en", "hemitórax", "derecho", ",", "sin", "ruidos", "patológicos", "sobreañadidos", ".", "Abdomen", ":", "globuloso", ",", "blando", "y", "depresible", ",", "no", "doloroso", "a", "la", "palpación", ",", "no", "se", "palpan", "masas", "ni", "megalias", ",", "ruidos", "hidroaéreos", "presentes", ".", "MMII", ":", "sin", "edemas", "ni", "signos", "de", "trombosis", "venosa", "profunda", ".", "\n\n", "Exploración", "neurológica", ":", "fondo", "ocular", "normal", ".", "Motilidad", "ocular", "extrínseca", "y", "resto", "de", "pares", "craneales", "normales", ".", "No", "hay", "un", "claro", "déficit", "motor", ".", "Reflejos", "osteotendinosos", "(", "ROT", ")", "3", "+", "con", "ROT", "vivos", "algo", "más", "izquierdos", "y", "arreflexia", "aquílea", "con", "Babinski", "bilateral", ".", "Hipoestesia", "distal", "en", "pies", "e", "hipopalestesia", "hasta", "últimos", "arcos", "costales", ".", "No", "se", "aprecia", "nivel", "en", "tronco", ".", "Marcha", "tabética", "con", "aumento", "de", "la", "base", ",", "precisa", "ayuda", "de", "andador", ",", "atáxica", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "Analítica", ":", "bioquímica", "(", "BQ", ")", "normal", ",", "excepto", "proteinas", "totales", "6,4", "g", "/", "dL", ";", "colesterol", "205", "mg", "/", "dL.", "CEA", "152,7", "ng", "/", "mL", "(", "previo", "140", ")", ";", "CA", "125", "8,4", "U", "/", "mL", ",", "resto", "de", "BQ", "normal", ".", "Hemograma", "normal", ".", "\n", "»", "RM", "de", "columna", "completa", "(", "21/5/2015", "):", "se", "observa", "alteración", "de", "señal", "hiperintensa", "en", "la", "médula", ",", "siendo", "más", "marcada", "en", "bulbo", ",", "región", "periférica", "de", "mesencéfalo", "y", "protuberancia", "con", "extensión", "a", "pedúnculos", "cerebelosos", ".", "Todo", "ello", ",", "probablemente", "en", "relación", "con", "toxicidad", "por", "quimioterapia", "como", "primera", "posibilidad", ".", "\n", "»", "Punción", "lumbar", "(", "PL", "):", "líquido", "cefalorraquídeo", "(", "LCR", ")", "de", "aspecto", "claro", "y", "transparente", ",", "saliendo", "a", "una", "velocidad", "adecuada", ".", "Estudio", "citobioquímico", ":", "células", "8", ";", "glucorraquia", "29", ";", "proteínas", ":", "028", ";", "hematíes", "10", "(", "glucemia", "tras", "la", "PL", ":", "90", "preprandial", ")", ".", "Estudio", "microbiológico", "negativo", ".", "Citología", ":", "pendiente", ".", "\n\n", "Diagnóstico", "\n", "A", "los", "pocos", "días", "se", "obtuvieron", "los", "resultados", "de", "la", "citología", "del", "LCR", ":", "positivo", "para", "CTM", ".", "Sugestivo", "de", "afectación", "por", "carcinoma", ".", "Confirmándose", "una", "de", "las", "sospechas", "de", "polineuropatía", "secundaria", "a", "meningitis", "carcinomatosa", "(", "MC", ")", ",", "tras", "el", "hallazgo", "de", "hipoglucorraquia", "en", "el", "estudio", "citobioquímico", ".", "Se", "ha", "solicitado", "estudio", "molecular", "en", "la", "citología", "del", "LCR", ",", "del", "que", "estamos", "pendiente", ".", "\n\n", "Tratamiento", "\n", "Al", "alta", ",", "antes", "de", "saber", "el", "diagnóstico", "definitivo", ",", "se", "prescribió", "erlotinib", "a", "dosis", "de", "100", "mg", "al", "día", "(", "debido", "a", "que", "presentó", "respuesta", "pulmonar", "y", "disminución", "del", "CEA", "durante", "el", "tratamiento", "y", "la", "a", "baja", "probabilidad", "de", "que", "la", "neurotoxicidad", "fuera", "secundaria", "al", "inhibidor", "de", "la", "ITK", ")", "y", "una", "pauta", "descendente", "de", "corticoides", ".", "\n\n", "Evolución", "\n", "La", "paciente", "se", "mantuvo", "estable", "durante", "el", "ingreso", "hospitalario", ",", "mejorando", "lentamente", "su", "clínica", "neurológica", ",", "aunque", "persistiendo", "hipoestesia", "en", "la", "parte", "distal", "de", "las", "extremidades", "y", "mejorando", "progresivamente", "la", "incontinencia", "de", "esfínteres", "y", "la", "marcha", "tebética", "tras", "el", "inicio", "de", "corticoides", "y", "descanso", "de", "erlotinib", ",", "descartándose", "compresión", "medular", "en", "la", "RM", "de", "columna", ".", "La", "paciente", "niega", "en", "todo", "momento", "cefalea", ",", "náuseas", "o", "vómitos", ".", "\n", "El", "caso", "fue", "valorado", "por", "parte", "de", "Neurología", ",", "concluyendo", "que", "el", "perfil", "temporal", "y", "el", "comportamiento", "clínico", "favorecen", "el", "diagnóstico", "de", "polineuropatía", "tóxica", "(", "PN", ")", ",", "sugerido", "también", "tras", "los", "hallazgos", "de", "la", "RM", ".", "\n", "Fue", "dada", "de", "alta", "con", "diagnóstico", "de", "PN", "tóxica", "poco", "probable", "a", "erlotinib", "debido", "a", "la", "infrecuencia", "del", "cuadro", ",", "sin", "poder", "descartar", "neurotoxicidad", "tardía", "a", "docetaxel", "(", "que", "finalizó", "en", "diciembre", "2014", ")", ".", "En", "espera", "de", "los", "resultados", "de", "la", "citología", "para", "descartar", "MC", "del", "LCR", "ante", "el", "resultado", "de", "hipoglucorraquia", ",", "sugestivo", "de", "consumo", "en", "el", "estudio", "citobioquímico", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
radionuclide is an umlsterm, method is an umlsterm, evaluation is an umlsterm, urinary tract is an umlsterm, aim is an umlsterm, diuresis is an umlsterm, function is an umlsterm
MonatsschriftKinderheilkunde.81460850.eng.abstr_task0
Sentence: Background : The dynamic radionuclide nephrography ( Tc99m-MAG3) is an important method in the evaluation of obstruction of the upper urinary tract . The aim of the present study was to assess whether radionuclid nephrography under standardized conditions with adequate hydration and Furosemid induced diuresis can reliably detect a significant obstruction at the pelvi-ureteric junction . We therefore tested whether minimal tracer washout ( 10-25% ) in the presence of normal renal function could justity a non-operative managment . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : The dynamic radionuclide nephrography ( Tc99m-MAG3) is an important method in the evaluation of obstruction of the upper urinary tract . The aim of the present study was to assess whether radionuclid nephrography under standardized conditions with adequate hydration and Furosemid induced diuresis can reliably detect a significant obstruction at the pelvi-ureteric junction . We therefore tested whether minimal tracer washout ( 10-25% ) in the presence of normal renal function could justity a non-operative managment .
[ "Background", ":", "The", "dynamic", "radionuclide", "nephrography", "(", "Tc99m", "-", "MAG3", ")", "is", "an", "important", "method", "in", "the", "evaluation", "of", "obstruction", "of", "the", "upper", "urinary", "tract", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "assess", "whether", "radionuclid", "nephrography", "under", "standardized", "conditions", "with", "adequate", "hydration", "and", "Furosemid", "induced", "diuresis", "can", "reliably", "detect", "a", "significant", "obstruction", "at", "the", "pelvi", "-", "ureteric", "junction", ".", "We", "therefore", "tested", "whether", "minimal", "tracer", "washout", "(", "10", "-", "25", "%", ")", "in", "the", "presence", "of", "normal", "renal", "function", "could", "justity", "a", "non", "-", "operative", "managment", "." ]
[ "umlsterm" ]
radionuclide is an umlsterm, method is an umlsterm, evaluation is an umlsterm, urinary tract is an umlsterm, aim is an umlsterm, diuresis is an umlsterm, function is an umlsterm
MonatsschriftKinderheilkunde.81460850.eng.abstr_task1
Sentence: Background : The dynamic radionuclide nephrography ( Tc99m-MAG3) is an important method in the evaluation of obstruction of the upper urinary tract . The aim of the present study was to assess whether radionuclid nephrography under standardized conditions with adequate hydration and Furosemid induced diuresis can reliably detect a significant obstruction at the pelvi-ureteric junction . We therefore tested whether minimal tracer washout ( 10-25% ) in the presence of normal renal function could justity a non-operative managment . Instructions: please typing these entity words according to sentence: radionuclide, method, evaluation, urinary tract, aim, diuresis, function Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : The dynamic radionuclide nephrography ( Tc99m-MAG3) is an important method in the evaluation of obstruction of the upper urinary tract . The aim of the present study was to assess whether radionuclid nephrography under standardized conditions with adequate hydration and Furosemid induced diuresis can reliably detect a significant obstruction at the pelvi-ureteric junction . We therefore tested whether minimal tracer washout ( 10-25% ) in the presence of normal renal function could justity a non-operative managment .
[ "Background", ":", "The", "dynamic", "radionuclide", "nephrography", "(", "Tc99m", "-", "MAG3", ")", "is", "an", "important", "method", "in", "the", "evaluation", "of", "obstruction", "of", "the", "upper", "urinary", "tract", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "assess", "whether", "radionuclid", "nephrography", "under", "standardized", "conditions", "with", "adequate", "hydration", "and", "Furosemid", "induced", "diuresis", "can", "reliably", "detect", "a", "significant", "obstruction", "at", "the", "pelvi", "-", "ureteric", "junction", ".", "We", "therefore", "tested", "whether", "minimal", "tracer", "washout", "(", "10", "-", "25", "%", ")", "in", "the", "presence", "of", "normal", "renal", "function", "could", "justity", "a", "non", "-", "operative", "managment", "." ]
[ "umlsterm" ]
radionuclide, method, evaluation, urinary tract, aim, diuresis, function
MonatsschriftKinderheilkunde.81460850.eng.abstr_task2
Sentence: Background : The dynamic radionuclide nephrography ( Tc99m-MAG3) is an important method in the evaluation of obstruction of the upper urinary tract . The aim of the present study was to assess whether radionuclid nephrography under standardized conditions with adequate hydration and Furosemid induced diuresis can reliably detect a significant obstruction at the pelvi-ureteric junction . We therefore tested whether minimal tracer washout ( 10-25% ) in the presence of normal renal function could justity a non-operative managment . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : The dynamic radionuclide nephrography ( Tc99m-MAG3) is an important method in the evaluation of obstruction of the upper urinary tract . The aim of the present study was to assess whether radionuclid nephrography under standardized conditions with adequate hydration and Furosemid induced diuresis can reliably detect a significant obstruction at the pelvi-ureteric junction . We therefore tested whether minimal tracer washout ( 10-25% ) in the presence of normal renal function could justity a non-operative managment .
[ "Background", ":", "The", "dynamic", "radionuclide", "nephrography", "(", "Tc99m", "-", "MAG3", ")", "is", "an", "important", "method", "in", "the", "evaluation", "of", "obstruction", "of", "the", "upper", "urinary", "tract", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "assess", "whether", "radionuclid", "nephrography", "under", "standardized", "conditions", "with", "adequate", "hydration", "and", "Furosemid", "induced", "diuresis", "can", "reliably", "detect", "a", "significant", "obstruction", "at", "the", "pelvi", "-", "ureteric", "junction", ".", "We", "therefore", "tested", "whether", "minimal", "tracer", "washout", "(", "10", "-", "25", "%", ")", "in", "the", "presence", "of", "normal", "renal", "function", "could", "justity", "a", "non", "-", "operative", "managment", "." ]
[ "umlsterm" ]
anti - phospholipase A2 antibody is a Intervention_Pharmacological, performance , feed efficiency , in vitro fermentation , and the acute - phase response of growing beef calves . is a Outcome_Other, 70 is a Participant_Sample-size, low - concentrate ( LC ) growing diet is a Intervention_Pharmacological, either no additional supplement is a Intervention_Control, receive a supplement of anti - phospholipase A2 antibody ( aPLA2 is a Intervention_Pharmacological, concentrations of plasma ceruloplasmin and haptoglobin . is a Outcome_Physical, BW is a Outcome_Physical
69675_task0
Sentence: Inclusion of anti-phospholipase A2 antibody to backgrounding diets on performance , feed efficiency , in vitro fermentation , and the acute-phase response of growing beef calves . In Exp . 1 , individual performance and daily DMI was measured on 70 crossbred weaned calves during a 70-d period using a GrowSafe system ( GrowSafe Systems Ltd. , Airdrie , AB , Canada ) at the University of Florida North Florida Research and Education Center Feed Efficiency Facility ( FEF ) . Calves were fed a low-concentrate ( LC ) growing diet , blocked by weight and sex , and then randomly assigned to pens to receive either no additional supplement ( CON ; n = 35 ) or receive a supplement of anti-phospholipase A2 antibody ( aPLA2 ) at an inclusion rate of 0.6 % of the diet DM ( n = 35 ) . After the 70-d feed efficiency ( FE ) trial ( Phase 1 ) , calves were loaded into a commercial livestock trailer and were driven for approximately 1,600 km during 24 h. Upon return to the FEF ( Phase 2 ) , calves were relocated to the same pens and groups and received the same diets and treatments for 28 d. Blood samples from each calf were collected on d 0 , 1 , 3 , 5 , 7 , 14 , 21 , and 28 relative to initiation of transportation and were analyzed for determination of concentrations of plasma ceruloplasmin and haptoglobin . In Phase 1 , initial BW ( 242.0 ± 3.7 kg ; P = 0.92 ) , BW at d 70 ( 313.0 ± 4.1 kg ; P = 0.79 ) , and ADG ( 1.01 ± 0.02 kg ; P = 0.95 ) were similar between treatments . However , daily DMI was greater ( P = 0.01 ) for CON ( 9.18 ± 0.15 kg ) than aPLA2 ( 8.53 ± 0.15 kg ) . In addition , residual feed intake was greater ( P = 0.002 ) for CON ( 0.389 ± 0.110 kg/d ) than aPLA2 calves ( -0.272 ± 0.110 kg/d ) . In Phase 2 , after transportation , there were no differences between treatments on BW loss due to transportation shrink ( 26.0 ± 0.6 kg ; P = 0.86 ) , BW at d 28 ( 339.0 ± 4.1 kg ; P = 0.72 ) , ADG ( 1.28 ± 0.03 kg/d ; P = 0.72 ) , G : F ( 0.164 ± 0.004 ; P = 0.83 ) , and concentrations of plasma haptoglobin ( 0.08 ± 0.02 mg/mL ; P = 0.41 ) . However , concentrations of plasma ceruloplasmin were greater ( P < 0.001 ) for CON calves ( 14.3 ± 0.3 mg/dL ) compared to aPLA2 calves ( 13.0 ± 0.3 mg/dL ) . In Exp . 2 , the effects of aPLA2 inclusion on LC and high-concentrate ( HC ) substrates on in vitro fermentation parameters were assessed . Addition of aPLA2 had no effects on in vitro fermentation parameters of LC and HC substrates . In conclusion , supplementation of aPLA2 improved FE of growing beef calves when fed LC diets in Phase 1 and addition of aPLA2 had no effect on fermentation parameters of LC and HC substrates . In addition , calves supplemented with aPLA2 had reduced concentrations of plasma ceruloplasmin after 24 h of transportation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Inclusion of anti-phospholipase A2 antibody to backgrounding diets on performance , feed efficiency , in vitro fermentation , and the acute-phase response of growing beef calves . In Exp . 1 , individual performance and daily DMI was measured on 70 crossbred weaned calves during a 70-d period using a GrowSafe system ( GrowSafe Systems Ltd. , Airdrie , AB , Canada ) at the University of Florida North Florida Research and Education Center Feed Efficiency Facility ( FEF ) . Calves were fed a low-concentrate ( LC ) growing diet , blocked by weight and sex , and then randomly assigned to pens to receive either no additional supplement ( CON ; n = 35 ) or receive a supplement of anti-phospholipase A2 antibody ( aPLA2 ) at an inclusion rate of 0.6 % of the diet DM ( n = 35 ) . After the 70-d feed efficiency ( FE ) trial ( Phase 1 ) , calves were loaded into a commercial livestock trailer and were driven for approximately 1,600 km during 24 h. Upon return to the FEF ( Phase 2 ) , calves were relocated to the same pens and groups and received the same diets and treatments for 28 d. Blood samples from each calf were collected on d 0 , 1 , 3 , 5 , 7 , 14 , 21 , and 28 relative to initiation of transportation and were analyzed for determination of concentrations of plasma ceruloplasmin and haptoglobin . In Phase 1 , initial BW ( 242.0 ± 3.7 kg ; P = 0.92 ) , BW at d 70 ( 313.0 ± 4.1 kg ; P = 0.79 ) , and ADG ( 1.01 ± 0.02 kg ; P = 0.95 ) were similar between treatments . However , daily DMI was greater ( P = 0.01 ) for CON ( 9.18 ± 0.15 kg ) than aPLA2 ( 8.53 ± 0.15 kg ) . In addition , residual feed intake was greater ( P = 0.002 ) for CON ( 0.389 ± 0.110 kg/d ) than aPLA2 calves ( -0.272 ± 0.110 kg/d ) . In Phase 2 , after transportation , there were no differences between treatments on BW loss due to transportation shrink ( 26.0 ± 0.6 kg ; P = 0.86 ) , BW at d 28 ( 339.0 ± 4.1 kg ; P = 0.72 ) , ADG ( 1.28 ± 0.03 kg/d ; P = 0.72 ) , G : F ( 0.164 ± 0.004 ; P = 0.83 ) , and concentrations of plasma haptoglobin ( 0.08 ± 0.02 mg/mL ; P = 0.41 ) . However , concentrations of plasma ceruloplasmin were greater ( P < 0.001 ) for CON calves ( 14.3 ± 0.3 mg/dL ) compared to aPLA2 calves ( 13.0 ± 0.3 mg/dL ) . In Exp . 2 , the effects of aPLA2 inclusion on LC and high-concentrate ( HC ) substrates on in vitro fermentation parameters were assessed . Addition of aPLA2 had no effects on in vitro fermentation parameters of LC and HC substrates . In conclusion , supplementation of aPLA2 improved FE of growing beef calves when fed LC diets in Phase 1 and addition of aPLA2 had no effect on fermentation parameters of LC and HC substrates . In addition , calves supplemented with aPLA2 had reduced concentrations of plasma ceruloplasmin after 24 h of transportation .
[ "Inclusion", "of", "anti", "-", "phospholipase", "A2", "antibody", "to", "backgrounding", "diets", "on", "performance", ",", "feed", "efficiency", ",", "in", "vitro", "fermentation", ",", "and", "the", "acute", "-", "phase", "response", "of", "growing", "beef", "calves", ".", "In", "Exp", ".", "1", ",", "individual", "performance", "and", "daily", "DMI", "was", "measured", "on", "70", "crossbred", "weaned", "calves", "during", "a", "70-d", "period", "using", "a", "GrowSafe", "system", "(", "GrowSafe", "Systems", "Ltd", ".", ",", "Airdrie", ",", "AB", ",", "Canada", ")", "at", "the", "University", "of", "Florida", "North", "Florida", "Research", "and", "Education", "Center", "Feed", "Efficiency", "Facility", "(", "FEF", ")", ".", "Calves", "were", "fed", "a", "low", "-", "concentrate", "(", "LC", ")", "growing", "diet", ",", "blocked", "by", "weight", "and", "sex", ",", "and", "then", "randomly", "assigned", "to", "pens", "to", "receive", "either", "no", "additional", "supplement", "(", "CON", ";", "n", "=", "35", ")", "or", "receive", "a", "supplement", "of", "anti", "-", "phospholipase", "A2", "antibody", "(", "aPLA2", ")", "at", "an", "inclusion", "rate", "of", "0.6", "%", "of", "the", "diet", "DM", "(", "n", "=", "35", ")", ".", "After", "the", "70-d", "feed", "efficiency", "(", "FE", ")", "trial", "(", "Phase", "1", ")", ",", "calves", "were", "loaded", "into", "a", "commercial", "livestock", "trailer", "and", "were", "driven", "for", "approximately", "1,600", "km", "during", "24", "h.", "Upon", "return", "to", "the", "FEF", "(", "Phase", "2", ")", ",", "calves", "were", "relocated", "to", "the", "same", "pens", "and", "groups", "and", "received", "the", "same", "diets", "and", "treatments", "for", "28", "d.", "Blood", "samples", "from", "each", "calf", "were", "collected", "on", "d", "0", ",", "1", ",", "3", ",", "5", ",", "7", ",", "14", ",", "21", ",", "and", "28", "relative", "to", "initiation", "of", "transportation", "and", "were", "analyzed", "for", "determination", "of", "concentrations", "of", "plasma", "ceruloplasmin", "and", "haptoglobin", ".", "In", "Phase", "1", ",", "initial", "BW", "(", "242.0", "±", "3.7", "kg", ";", "P", "=", "0.92", ")", ",", "BW", "at", "d", "70", "(", "313.0", "±", "4.1", "kg", ";", "P", "=", "0.79", ")", ",", "and", "ADG", "(", "1.01", "±", "0.02", "kg", ";", "P", "=", "0.95", ")", "were", "similar", "between", "treatments", ".", "However", ",", "daily", "DMI", "was", "greater", "(", "P", "=", "0.01", ")", "for", "CON", "(", "9.18", "±", "0.15", "kg", ")", "than", "aPLA2", "(", "8.53", "±", "0.15", "kg", ")", ".", "In", "addition", ",", "residual", "feed", "intake", "was", "greater", "(", "P", "=", "0.002", ")", "for", "CON", "(", "0.389", "±", "0.110", "kg", "/", "d", ")", "than", "aPLA2", "calves", "(", "-0.272", "±", "0.110", "kg", "/", "d", ")", ".", "In", "Phase", "2", ",", "after", "transportation", ",", "there", "were", "no", "differences", "between", "treatments", "on", "BW", "loss", "due", "to", "transportation", "shrink", "(", "26.0", "±", "0.6", "kg", ";", "P", "=", "0.86", ")", ",", "BW", "at", "d", "28", "(", "339.0", "±", "4.1", "kg", ";", "P", "=", "0.72", ")", ",", "ADG", "(", "1.28", "±", "0.03", "kg", "/", "d", ";", "P", "=", "0.72", ")", ",", "G", ":", "F", "(", "0.164", "±", "0.004", ";", "P", "=", "0.83", ")", ",", "and", "concentrations", "of", "plasma", "haptoglobin", "(", "0.08", "±", "0.02", "mg", "/", "mL", ";", "P", "=", "0.41", ")", ".", "However", ",", "concentrations", "of", "plasma", "ceruloplasmin", "were", "greater", "(", "P", "<", "0.001", ")", "for", "CON", "calves", "(", "14.3", "±", "0.3", "mg", "/", "dL", ")", "compared", "to", "aPLA2", "calves", "(", "13.0", "±", "0.3", "mg", "/", "dL", ")", ".", "In", "Exp", ".", "2", ",", "the", "effects", "of", "aPLA2", "inclusion", "on", "LC", "and", "high", "-", "concentrate", "(", "HC", ")", "substrates", "on", "in", "vitro", "fermentation", "parameters", "were", "assessed", ".", "Addition", "of", "aPLA2", "had", "no", "effects", "on", "in", "vitro", "fermentation", "parameters", "of", "LC", "and", "HC", "substrates", ".", "In", "conclusion", ",", "supplementation", "of", "aPLA2", "improved", "FE", "of", "growing", "beef", "calves", "when", "fed", "LC", "diets", "in", "Phase", "1", "and", "addition", "of", "aPLA2", "had", "no", "effect", "on", "fermentation", "parameters", "of", "LC", "and", "HC", "substrates", ".", "In", "addition", ",", "calves", "supplemented", "with", "aPLA2", "had", "reduced", "concentrations", "of", "plasma", "ceruloplasmin", "after", "24", "h", "of", "transportation", "." ]
[ "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
anti - phospholipase A2 antibody is a Intervention_Pharmacological, performance , feed efficiency , in vitro fermentation , and the acute - phase response of growing beef calves . is a Outcome_Other, 70 is a Participant_Sample-size, low - concentrate ( LC ) growing diet is a Intervention_Pharmacological, either no additional supplement is a Intervention_Control, receive a supplement of anti - phospholipase A2 antibody ( aPLA2 is a Intervention_Pharmacological, concentrations of plasma ceruloplasmin and haptoglobin . is a Outcome_Physical, BW is a Outcome_Physical
69675_task1
Sentence: Inclusion of anti-phospholipase A2 antibody to backgrounding diets on performance , feed efficiency , in vitro fermentation , and the acute-phase response of growing beef calves . In Exp . 1 , individual performance and daily DMI was measured on 70 crossbred weaned calves during a 70-d period using a GrowSafe system ( GrowSafe Systems Ltd. , Airdrie , AB , Canada ) at the University of Florida North Florida Research and Education Center Feed Efficiency Facility ( FEF ) . Calves were fed a low-concentrate ( LC ) growing diet , blocked by weight and sex , and then randomly assigned to pens to receive either no additional supplement ( CON ; n = 35 ) or receive a supplement of anti-phospholipase A2 antibody ( aPLA2 ) at an inclusion rate of 0.6 % of the diet DM ( n = 35 ) . After the 70-d feed efficiency ( FE ) trial ( Phase 1 ) , calves were loaded into a commercial livestock trailer and were driven for approximately 1,600 km during 24 h. Upon return to the FEF ( Phase 2 ) , calves were relocated to the same pens and groups and received the same diets and treatments for 28 d. Blood samples from each calf were collected on d 0 , 1 , 3 , 5 , 7 , 14 , 21 , and 28 relative to initiation of transportation and were analyzed for determination of concentrations of plasma ceruloplasmin and haptoglobin . In Phase 1 , initial BW ( 242.0 ± 3.7 kg ; P = 0.92 ) , BW at d 70 ( 313.0 ± 4.1 kg ; P = 0.79 ) , and ADG ( 1.01 ± 0.02 kg ; P = 0.95 ) were similar between treatments . However , daily DMI was greater ( P = 0.01 ) for CON ( 9.18 ± 0.15 kg ) than aPLA2 ( 8.53 ± 0.15 kg ) . In addition , residual feed intake was greater ( P = 0.002 ) for CON ( 0.389 ± 0.110 kg/d ) than aPLA2 calves ( -0.272 ± 0.110 kg/d ) . In Phase 2 , after transportation , there were no differences between treatments on BW loss due to transportation shrink ( 26.0 ± 0.6 kg ; P = 0.86 ) , BW at d 28 ( 339.0 ± 4.1 kg ; P = 0.72 ) , ADG ( 1.28 ± 0.03 kg/d ; P = 0.72 ) , G : F ( 0.164 ± 0.004 ; P = 0.83 ) , and concentrations of plasma haptoglobin ( 0.08 ± 0.02 mg/mL ; P = 0.41 ) . However , concentrations of plasma ceruloplasmin were greater ( P < 0.001 ) for CON calves ( 14.3 ± 0.3 mg/dL ) compared to aPLA2 calves ( 13.0 ± 0.3 mg/dL ) . In Exp . 2 , the effects of aPLA2 inclusion on LC and high-concentrate ( HC ) substrates on in vitro fermentation parameters were assessed . Addition of aPLA2 had no effects on in vitro fermentation parameters of LC and HC substrates . In conclusion , supplementation of aPLA2 improved FE of growing beef calves when fed LC diets in Phase 1 and addition of aPLA2 had no effect on fermentation parameters of LC and HC substrates . In addition , calves supplemented with aPLA2 had reduced concentrations of plasma ceruloplasmin after 24 h of transportation . Instructions: please typing these entity words according to sentence: anti - phospholipase A2 antibody, performance , feed efficiency , in vitro fermentation , and the acute - phase response of growing beef calves ., 70, low - concentrate ( LC ) growing diet, either no additional supplement, receive a supplement of anti - phospholipase A2 antibody ( aPLA2, concentrations of plasma ceruloplasmin and haptoglobin ., BW Options: Intervention_Pharmacological, Intervention_Control, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Inclusion of anti-phospholipase A2 antibody to backgrounding diets on performance , feed efficiency , in vitro fermentation , and the acute-phase response of growing beef calves . In Exp . 1 , individual performance and daily DMI was measured on 70 crossbred weaned calves during a 70-d period using a GrowSafe system ( GrowSafe Systems Ltd. , Airdrie , AB , Canada ) at the University of Florida North Florida Research and Education Center Feed Efficiency Facility ( FEF ) . Calves were fed a low-concentrate ( LC ) growing diet , blocked by weight and sex , and then randomly assigned to pens to receive either no additional supplement ( CON ; n = 35 ) or receive a supplement of anti-phospholipase A2 antibody ( aPLA2 ) at an inclusion rate of 0.6 % of the diet DM ( n = 35 ) . After the 70-d feed efficiency ( FE ) trial ( Phase 1 ) , calves were loaded into a commercial livestock trailer and were driven for approximately 1,600 km during 24 h. Upon return to the FEF ( Phase 2 ) , calves were relocated to the same pens and groups and received the same diets and treatments for 28 d. Blood samples from each calf were collected on d 0 , 1 , 3 , 5 , 7 , 14 , 21 , and 28 relative to initiation of transportation and were analyzed for determination of concentrations of plasma ceruloplasmin and haptoglobin . In Phase 1 , initial BW ( 242.0 ± 3.7 kg ; P = 0.92 ) , BW at d 70 ( 313.0 ± 4.1 kg ; P = 0.79 ) , and ADG ( 1.01 ± 0.02 kg ; P = 0.95 ) were similar between treatments . However , daily DMI was greater ( P = 0.01 ) for CON ( 9.18 ± 0.15 kg ) than aPLA2 ( 8.53 ± 0.15 kg ) . In addition , residual feed intake was greater ( P = 0.002 ) for CON ( 0.389 ± 0.110 kg/d ) than aPLA2 calves ( -0.272 ± 0.110 kg/d ) . In Phase 2 , after transportation , there were no differences between treatments on BW loss due to transportation shrink ( 26.0 ± 0.6 kg ; P = 0.86 ) , BW at d 28 ( 339.0 ± 4.1 kg ; P = 0.72 ) , ADG ( 1.28 ± 0.03 kg/d ; P = 0.72 ) , G : F ( 0.164 ± 0.004 ; P = 0.83 ) , and concentrations of plasma haptoglobin ( 0.08 ± 0.02 mg/mL ; P = 0.41 ) . However , concentrations of plasma ceruloplasmin were greater ( P < 0.001 ) for CON calves ( 14.3 ± 0.3 mg/dL ) compared to aPLA2 calves ( 13.0 ± 0.3 mg/dL ) . In Exp . 2 , the effects of aPLA2 inclusion on LC and high-concentrate ( HC ) substrates on in vitro fermentation parameters were assessed . Addition of aPLA2 had no effects on in vitro fermentation parameters of LC and HC substrates . In conclusion , supplementation of aPLA2 improved FE of growing beef calves when fed LC diets in Phase 1 and addition of aPLA2 had no effect on fermentation parameters of LC and HC substrates . In addition , calves supplemented with aPLA2 had reduced concentrations of plasma ceruloplasmin after 24 h of transportation .
[ "Inclusion", "of", "anti", "-", "phospholipase", "A2", "antibody", "to", "backgrounding", "diets", "on", "performance", ",", "feed", "efficiency", ",", "in", "vitro", "fermentation", ",", "and", "the", "acute", "-", "phase", "response", "of", "growing", "beef", "calves", ".", "In", "Exp", ".", "1", ",", "individual", "performance", "and", "daily", "DMI", "was", "measured", "on", "70", "crossbred", "weaned", "calves", "during", "a", "70-d", "period", "using", "a", "GrowSafe", "system", "(", "GrowSafe", "Systems", "Ltd", ".", ",", "Airdrie", ",", "AB", ",", "Canada", ")", "at", "the", "University", "of", "Florida", "North", "Florida", "Research", "and", "Education", "Center", "Feed", "Efficiency", "Facility", "(", "FEF", ")", ".", "Calves", "were", "fed", "a", "low", "-", "concentrate", "(", "LC", ")", "growing", "diet", ",", "blocked", "by", "weight", "and", "sex", ",", "and", "then", "randomly", "assigned", "to", "pens", "to", "receive", "either", "no", "additional", "supplement", "(", "CON", ";", "n", "=", "35", ")", "or", "receive", "a", "supplement", "of", "anti", "-", "phospholipase", "A2", "antibody", "(", "aPLA2", ")", "at", "an", "inclusion", "rate", "of", "0.6", "%", "of", "the", "diet", "DM", "(", "n", "=", "35", ")", ".", "After", "the", "70-d", "feed", "efficiency", "(", "FE", ")", "trial", "(", "Phase", "1", ")", ",", "calves", "were", "loaded", "into", "a", "commercial", "livestock", "trailer", "and", "were", "driven", "for", "approximately", "1,600", "km", "during", "24", "h.", "Upon", "return", "to", "the", "FEF", "(", "Phase", "2", ")", ",", "calves", "were", "relocated", "to", "the", "same", "pens", "and", "groups", "and", "received", "the", "same", "diets", "and", "treatments", "for", "28", "d.", "Blood", "samples", "from", "each", "calf", "were", "collected", "on", "d", "0", ",", "1", ",", "3", ",", "5", ",", "7", ",", "14", ",", "21", ",", "and", "28", "relative", "to", "initiation", "of", "transportation", "and", "were", "analyzed", "for", "determination", "of", "concentrations", "of", "plasma", "ceruloplasmin", "and", "haptoglobin", ".", "In", "Phase", "1", ",", "initial", "BW", "(", "242.0", "±", "3.7", "kg", ";", "P", "=", "0.92", ")", ",", "BW", "at", "d", "70", "(", "313.0", "±", "4.1", "kg", ";", "P", "=", "0.79", ")", ",", "and", "ADG", "(", "1.01", "±", "0.02", "kg", ";", "P", "=", "0.95", ")", "were", "similar", "between", "treatments", ".", "However", ",", "daily", "DMI", "was", "greater", "(", "P", "=", "0.01", ")", "for", "CON", "(", "9.18", "±", "0.15", "kg", ")", "than", "aPLA2", "(", "8.53", "±", "0.15", "kg", ")", ".", "In", "addition", ",", "residual", "feed", "intake", "was", "greater", "(", "P", "=", "0.002", ")", "for", "CON", "(", "0.389", "±", "0.110", "kg", "/", "d", ")", "than", "aPLA2", "calves", "(", "-0.272", "±", "0.110", "kg", "/", "d", ")", ".", "In", "Phase", "2", ",", "after", "transportation", ",", "there", "were", "no", "differences", "between", "treatments", "on", "BW", "loss", "due", "to", "transportation", "shrink", "(", "26.0", "±", "0.6", "kg", ";", "P", "=", "0.86", ")", ",", "BW", "at", "d", "28", "(", "339.0", "±", "4.1", "kg", ";", "P", "=", "0.72", ")", ",", "ADG", "(", "1.28", "±", "0.03", "kg", "/", "d", ";", "P", "=", "0.72", ")", ",", "G", ":", "F", "(", "0.164", "±", "0.004", ";", "P", "=", "0.83", ")", ",", "and", "concentrations", "of", "plasma", "haptoglobin", "(", "0.08", "±", "0.02", "mg", "/", "mL", ";", "P", "=", "0.41", ")", ".", "However", ",", "concentrations", "of", "plasma", "ceruloplasmin", "were", "greater", "(", "P", "<", "0.001", ")", "for", "CON", "calves", "(", "14.3", "±", "0.3", "mg", "/", "dL", ")", "compared", "to", "aPLA2", "calves", "(", "13.0", "±", "0.3", "mg", "/", "dL", ")", ".", "In", "Exp", ".", "2", ",", "the", "effects", "of", "aPLA2", "inclusion", "on", "LC", "and", "high", "-", "concentrate", "(", "HC", ")", "substrates", "on", "in", "vitro", "fermentation", "parameters", "were", "assessed", ".", "Addition", "of", "aPLA2", "had", "no", "effects", "on", "in", "vitro", "fermentation", "parameters", "of", "LC", "and", "HC", "substrates", ".", "In", "conclusion", ",", "supplementation", "of", "aPLA2", "improved", "FE", "of", "growing", "beef", "calves", "when", "fed", "LC", "diets", "in", "Phase", "1", "and", "addition", "of", "aPLA2", "had", "no", "effect", "on", "fermentation", "parameters", "of", "LC", "and", "HC", "substrates", ".", "In", "addition", ",", "calves", "supplemented", "with", "aPLA2", "had", "reduced", "concentrations", "of", "plasma", "ceruloplasmin", "after", "24", "h", "of", "transportation", "." ]
[ "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
anti - phospholipase A2 antibody, performance , feed efficiency , in vitro fermentation , and the acute - phase response of growing beef calves ., 70, low - concentrate ( LC ) growing diet, either no additional supplement, receive a supplement of anti - phospholipase A2 antibody ( aPLA2, concentrations of plasma ceruloplasmin and haptoglobin ., BW
69675_task2
Sentence: Inclusion of anti-phospholipase A2 antibody to backgrounding diets on performance , feed efficiency , in vitro fermentation , and the acute-phase response of growing beef calves . In Exp . 1 , individual performance and daily DMI was measured on 70 crossbred weaned calves during a 70-d period using a GrowSafe system ( GrowSafe Systems Ltd. , Airdrie , AB , Canada ) at the University of Florida North Florida Research and Education Center Feed Efficiency Facility ( FEF ) . Calves were fed a low-concentrate ( LC ) growing diet , blocked by weight and sex , and then randomly assigned to pens to receive either no additional supplement ( CON ; n = 35 ) or receive a supplement of anti-phospholipase A2 antibody ( aPLA2 ) at an inclusion rate of 0.6 % of the diet DM ( n = 35 ) . After the 70-d feed efficiency ( FE ) trial ( Phase 1 ) , calves were loaded into a commercial livestock trailer and were driven for approximately 1,600 km during 24 h. Upon return to the FEF ( Phase 2 ) , calves were relocated to the same pens and groups and received the same diets and treatments for 28 d. Blood samples from each calf were collected on d 0 , 1 , 3 , 5 , 7 , 14 , 21 , and 28 relative to initiation of transportation and were analyzed for determination of concentrations of plasma ceruloplasmin and haptoglobin . In Phase 1 , initial BW ( 242.0 ± 3.7 kg ; P = 0.92 ) , BW at d 70 ( 313.0 ± 4.1 kg ; P = 0.79 ) , and ADG ( 1.01 ± 0.02 kg ; P = 0.95 ) were similar between treatments . However , daily DMI was greater ( P = 0.01 ) for CON ( 9.18 ± 0.15 kg ) than aPLA2 ( 8.53 ± 0.15 kg ) . In addition , residual feed intake was greater ( P = 0.002 ) for CON ( 0.389 ± 0.110 kg/d ) than aPLA2 calves ( -0.272 ± 0.110 kg/d ) . In Phase 2 , after transportation , there were no differences between treatments on BW loss due to transportation shrink ( 26.0 ± 0.6 kg ; P = 0.86 ) , BW at d 28 ( 339.0 ± 4.1 kg ; P = 0.72 ) , ADG ( 1.28 ± 0.03 kg/d ; P = 0.72 ) , G : F ( 0.164 ± 0.004 ; P = 0.83 ) , and concentrations of plasma haptoglobin ( 0.08 ± 0.02 mg/mL ; P = 0.41 ) . However , concentrations of plasma ceruloplasmin were greater ( P < 0.001 ) for CON calves ( 14.3 ± 0.3 mg/dL ) compared to aPLA2 calves ( 13.0 ± 0.3 mg/dL ) . In Exp . 2 , the effects of aPLA2 inclusion on LC and high-concentrate ( HC ) substrates on in vitro fermentation parameters were assessed . Addition of aPLA2 had no effects on in vitro fermentation parameters of LC and HC substrates . In conclusion , supplementation of aPLA2 improved FE of growing beef calves when fed LC diets in Phase 1 and addition of aPLA2 had no effect on fermentation parameters of LC and HC substrates . In addition , calves supplemented with aPLA2 had reduced concentrations of plasma ceruloplasmin after 24 h of transportation . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Inclusion of anti-phospholipase A2 antibody to backgrounding diets on performance , feed efficiency , in vitro fermentation , and the acute-phase response of growing beef calves . In Exp . 1 , individual performance and daily DMI was measured on 70 crossbred weaned calves during a 70-d period using a GrowSafe system ( GrowSafe Systems Ltd. , Airdrie , AB , Canada ) at the University of Florida North Florida Research and Education Center Feed Efficiency Facility ( FEF ) . Calves were fed a low-concentrate ( LC ) growing diet , blocked by weight and sex , and then randomly assigned to pens to receive either no additional supplement ( CON ; n = 35 ) or receive a supplement of anti-phospholipase A2 antibody ( aPLA2 ) at an inclusion rate of 0.6 % of the diet DM ( n = 35 ) . After the 70-d feed efficiency ( FE ) trial ( Phase 1 ) , calves were loaded into a commercial livestock trailer and were driven for approximately 1,600 km during 24 h. Upon return to the FEF ( Phase 2 ) , calves were relocated to the same pens and groups and received the same diets and treatments for 28 d. Blood samples from each calf were collected on d 0 , 1 , 3 , 5 , 7 , 14 , 21 , and 28 relative to initiation of transportation and were analyzed for determination of concentrations of plasma ceruloplasmin and haptoglobin . In Phase 1 , initial BW ( 242.0 ± 3.7 kg ; P = 0.92 ) , BW at d 70 ( 313.0 ± 4.1 kg ; P = 0.79 ) , and ADG ( 1.01 ± 0.02 kg ; P = 0.95 ) were similar between treatments . However , daily DMI was greater ( P = 0.01 ) for CON ( 9.18 ± 0.15 kg ) than aPLA2 ( 8.53 ± 0.15 kg ) . In addition , residual feed intake was greater ( P = 0.002 ) for CON ( 0.389 ± 0.110 kg/d ) than aPLA2 calves ( -0.272 ± 0.110 kg/d ) . In Phase 2 , after transportation , there were no differences between treatments on BW loss due to transportation shrink ( 26.0 ± 0.6 kg ; P = 0.86 ) , BW at d 28 ( 339.0 ± 4.1 kg ; P = 0.72 ) , ADG ( 1.28 ± 0.03 kg/d ; P = 0.72 ) , G : F ( 0.164 ± 0.004 ; P = 0.83 ) , and concentrations of plasma haptoglobin ( 0.08 ± 0.02 mg/mL ; P = 0.41 ) . However , concentrations of plasma ceruloplasmin were greater ( P < 0.001 ) for CON calves ( 14.3 ± 0.3 mg/dL ) compared to aPLA2 calves ( 13.0 ± 0.3 mg/dL ) . In Exp . 2 , the effects of aPLA2 inclusion on LC and high-concentrate ( HC ) substrates on in vitro fermentation parameters were assessed . Addition of aPLA2 had no effects on in vitro fermentation parameters of LC and HC substrates . In conclusion , supplementation of aPLA2 improved FE of growing beef calves when fed LC diets in Phase 1 and addition of aPLA2 had no effect on fermentation parameters of LC and HC substrates . In addition , calves supplemented with aPLA2 had reduced concentrations of plasma ceruloplasmin after 24 h of transportation .
[ "Inclusion", "of", "anti", "-", "phospholipase", "A2", "antibody", "to", "backgrounding", "diets", "on", "performance", ",", "feed", "efficiency", ",", "in", "vitro", "fermentation", ",", "and", "the", "acute", "-", "phase", "response", "of", "growing", "beef", "calves", ".", "In", "Exp", ".", "1", ",", "individual", "performance", "and", "daily", "DMI", "was", "measured", "on", "70", "crossbred", "weaned", "calves", "during", "a", "70-d", "period", "using", "a", "GrowSafe", "system", "(", "GrowSafe", "Systems", "Ltd", ".", ",", "Airdrie", ",", "AB", ",", "Canada", ")", "at", "the", "University", "of", "Florida", "North", "Florida", "Research", "and", "Education", "Center", "Feed", "Efficiency", "Facility", "(", "FEF", ")", ".", "Calves", "were", "fed", "a", "low", "-", "concentrate", "(", "LC", ")", "growing", "diet", ",", "blocked", "by", "weight", "and", "sex", ",", "and", "then", "randomly", "assigned", "to", "pens", "to", "receive", "either", "no", "additional", "supplement", "(", "CON", ";", "n", "=", "35", ")", "or", "receive", "a", "supplement", "of", "anti", "-", "phospholipase", "A2", "antibody", "(", "aPLA2", ")", "at", "an", "inclusion", "rate", "of", "0.6", "%", "of", "the", "diet", "DM", "(", "n", "=", "35", ")", ".", "After", "the", "70-d", "feed", "efficiency", "(", "FE", ")", "trial", "(", "Phase", "1", ")", ",", "calves", "were", "loaded", "into", "a", "commercial", "livestock", "trailer", "and", "were", "driven", "for", "approximately", "1,600", "km", "during", "24", "h.", "Upon", "return", "to", "the", "FEF", "(", "Phase", "2", ")", ",", "calves", "were", "relocated", "to", "the", "same", "pens", "and", "groups", "and", "received", "the", "same", "diets", "and", "treatments", "for", "28", "d.", "Blood", "samples", "from", "each", "calf", "were", "collected", "on", "d", "0", ",", "1", ",", "3", ",", "5", ",", "7", ",", "14", ",", "21", ",", "and", "28", "relative", "to", "initiation", "of", "transportation", "and", "were", "analyzed", "for", "determination", "of", "concentrations", "of", "plasma", "ceruloplasmin", "and", "haptoglobin", ".", "In", "Phase", "1", ",", "initial", "BW", "(", "242.0", "±", "3.7", "kg", ";", "P", "=", "0.92", ")", ",", "BW", "at", "d", "70", "(", "313.0", "±", "4.1", "kg", ";", "P", "=", "0.79", ")", ",", "and", "ADG", "(", "1.01", "±", "0.02", "kg", ";", "P", "=", "0.95", ")", "were", "similar", "between", "treatments", ".", "However", ",", "daily", "DMI", "was", "greater", "(", "P", "=", "0.01", ")", "for", "CON", "(", "9.18", "±", "0.15", "kg", ")", "than", "aPLA2", "(", "8.53", "±", "0.15", "kg", ")", ".", "In", "addition", ",", "residual", "feed", "intake", "was", "greater", "(", "P", "=", "0.002", ")", "for", "CON", "(", "0.389", "±", "0.110", "kg", "/", "d", ")", "than", "aPLA2", "calves", "(", "-0.272", "±", "0.110", "kg", "/", "d", ")", ".", "In", "Phase", "2", ",", "after", "transportation", ",", "there", "were", "no", "differences", "between", "treatments", "on", "BW", "loss", "due", "to", "transportation", "shrink", "(", "26.0", "±", "0.6", "kg", ";", "P", "=", "0.86", ")", ",", "BW", "at", "d", "28", "(", "339.0", "±", "4.1", "kg", ";", "P", "=", "0.72", ")", ",", "ADG", "(", "1.28", "±", "0.03", "kg", "/", "d", ";", "P", "=", "0.72", ")", ",", "G", ":", "F", "(", "0.164", "±", "0.004", ";", "P", "=", "0.83", ")", ",", "and", "concentrations", "of", "plasma", "haptoglobin", "(", "0.08", "±", "0.02", "mg", "/", "mL", ";", "P", "=", "0.41", ")", ".", "However", ",", "concentrations", "of", "plasma", "ceruloplasmin", "were", "greater", "(", "P", "<", "0.001", ")", "for", "CON", "calves", "(", "14.3", "±", "0.3", "mg", "/", "dL", ")", "compared", "to", "aPLA2", "calves", "(", "13.0", "±", "0.3", "mg", "/", "dL", ")", ".", "In", "Exp", ".", "2", ",", "the", "effects", "of", "aPLA2", "inclusion", "on", "LC", "and", "high", "-", "concentrate", "(", "HC", ")", "substrates", "on", "in", "vitro", "fermentation", "parameters", "were", "assessed", ".", "Addition", "of", "aPLA2", "had", "no", "effects", "on", "in", "vitro", "fermentation", "parameters", "of", "LC", "and", "HC", "substrates", ".", "In", "conclusion", ",", "supplementation", "of", "aPLA2", "improved", "FE", "of", "growing", "beef", "calves", "when", "fed", "LC", "diets", "in", "Phase", "1", "and", "addition", "of", "aPLA2", "had", "no", "effect", "on", "fermentation", "parameters", "of", "LC", "and", "HC", "substrates", ".", "In", "addition", ",", "calves", "supplemented", "with", "aPLA2", "had", "reduced", "concentrations", "of", "plasma", "ceruloplasmin", "after", "24", "h", "of", "transportation", "." ]
[ "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Control", "Participant_Condition", "Participant_Age", "Participant_Sample-size" ]
online continuing medical education seminars : is a Intervention_Educational, online continuing medical education ( CME ) seminars is a Intervention_Educational, improve quality of care . is a Outcome_Other, Primary care physicians ( 113 ) participated in a randomized controlled trial to evaluate an online CME series . is a Participant_Sample-size, seminar about type 2 diabetes is a Intervention_Educational, seminar about systolic heart failure is a Intervention_Educational, recommend guideline - consistent care is a Outcome_Mental, order an eye exam for diabetes patients is a Outcome_Mental, online CME programs is a Intervention_Educational, improve physician clinical practice . is a Outcome_Other
37903_task0
Sentence: Evaluating online continuing medical education seminars : evidence for improving clinical practices . The purpose of this study was to evaluate the potential for online continuing medical education ( CME ) seminars to improve quality of care . Primary care physicians ( 113 ) participated in a randomized controlled trial to evaluate an online CME series . Physicians were randomized to view either a seminar about type 2 diabetes or a seminar about systolic heart failure . Following the seminar , physicians were presented with 4 clinical vignettes and asked to describe what tests , treatments , counseling , or referrals they would recommend . Physicians who viewed the seminars were significantly more likely to recommend guideline-consistent care to patients in the vignettes . For example , physicians who viewed the diabetes seminar were significantly more likely to order an eye exam for diabetes patients ( 63 % ) compared with physicians in the control group ( 27 % ) . For some guidelines there were no group differences . These results provide early evidence of the effectiveness of online CME programs to improve physician clinical practice . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Educational, Outcome_Other, Outcome_Mental, Participant_Sample-size
[ "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other" ]
Evaluating online continuing medical education seminars : evidence for improving clinical practices . The purpose of this study was to evaluate the potential for online continuing medical education ( CME ) seminars to improve quality of care . Primary care physicians ( 113 ) participated in a randomized controlled trial to evaluate an online CME series . Physicians were randomized to view either a seminar about type 2 diabetes or a seminar about systolic heart failure . Following the seminar , physicians were presented with 4 clinical vignettes and asked to describe what tests , treatments , counseling , or referrals they would recommend . Physicians who viewed the seminars were significantly more likely to recommend guideline-consistent care to patients in the vignettes . For example , physicians who viewed the diabetes seminar were significantly more likely to order an eye exam for diabetes patients ( 63 % ) compared with physicians in the control group ( 27 % ) . For some guidelines there were no group differences . These results provide early evidence of the effectiveness of online CME programs to improve physician clinical practice .
[ "Evaluating", "online", "continuing", "medical", "education", "seminars", ":", "evidence", "for", "improving", "clinical", "practices", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "potential", "for", "online", "continuing", "medical", "education", "(", "CME", ")", "seminars", "to", "improve", "quality", "of", "care", ".", "Primary", "care", "physicians", "(", "113", ")", "participated", "in", "a", "randomized", "controlled", "trial", "to", "evaluate", "an", "online", "CME", "series", ".", "Physicians", "were", "randomized", "to", "view", "either", "a", "seminar", "about", "type", "2", "diabetes", "or", "a", "seminar", "about", "systolic", "heart", "failure", ".", "Following", "the", "seminar", ",", "physicians", "were", "presented", "with", "4", "clinical", "vignettes", "and", "asked", "to", "describe", "what", "tests", ",", "treatments", ",", "counseling", ",", "or", "referrals", "they", "would", "recommend", ".", "Physicians", "who", "viewed", "the", "seminars", "were", "significantly", "more", "likely", "to", "recommend", "guideline", "-", "consistent", "care", "to", "patients", "in", "the", "vignettes", ".", "For", "example", ",", "physicians", "who", "viewed", "the", "diabetes", "seminar", "were", "significantly", "more", "likely", "to", "order", "an", "eye", "exam", "for", "diabetes", "patients", "(", "63", "%", ")", "compared", "with", "physicians", "in", "the", "control", "group", "(", "27", "%", ")", ".", "For", "some", "guidelines", "there", "were", "no", "group", "differences", ".", "These", "results", "provide", "early", "evidence", "of", "the", "effectiveness", "of", "online", "CME", "programs", "to", "improve", "physician", "clinical", "practice", "." ]
[ "Participant_Sample-size", "Intervention_Educational", "Outcome_Mental", "Outcome_Other", "Participant_Condition" ]
online continuing medical education seminars : is a Intervention_Educational, online continuing medical education ( CME ) seminars is a Intervention_Educational, improve quality of care . is a Outcome_Other, Primary care physicians ( 113 ) participated in a randomized controlled trial to evaluate an online CME series . is a Participant_Sample-size, seminar about type 2 diabetes is a Intervention_Educational, seminar about systolic heart failure is a Intervention_Educational, recommend guideline - consistent care is a Outcome_Mental, order an eye exam for diabetes patients is a Outcome_Mental, online CME programs is a Intervention_Educational, improve physician clinical practice . is a Outcome_Other
37903_task1
Sentence: Evaluating online continuing medical education seminars : evidence for improving clinical practices . The purpose of this study was to evaluate the potential for online continuing medical education ( CME ) seminars to improve quality of care . Primary care physicians ( 113 ) participated in a randomized controlled trial to evaluate an online CME series . Physicians were randomized to view either a seminar about type 2 diabetes or a seminar about systolic heart failure . Following the seminar , physicians were presented with 4 clinical vignettes and asked to describe what tests , treatments , counseling , or referrals they would recommend . Physicians who viewed the seminars were significantly more likely to recommend guideline-consistent care to patients in the vignettes . For example , physicians who viewed the diabetes seminar were significantly more likely to order an eye exam for diabetes patients ( 63 % ) compared with physicians in the control group ( 27 % ) . For some guidelines there were no group differences . These results provide early evidence of the effectiveness of online CME programs to improve physician clinical practice . Instructions: please typing these entity words according to sentence: online continuing medical education seminars :, online continuing medical education ( CME ) seminars, improve quality of care ., Primary care physicians ( 113 ) participated in a randomized controlled trial to evaluate an online CME series ., seminar about type 2 diabetes, seminar about systolic heart failure, recommend guideline - consistent care, order an eye exam for diabetes patients, online CME programs, improve physician clinical practice . Options: Intervention_Educational, Outcome_Other, Outcome_Mental, Participant_Sample-size
[ "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other" ]
Evaluating online continuing medical education seminars : evidence for improving clinical practices . The purpose of this study was to evaluate the potential for online continuing medical education ( CME ) seminars to improve quality of care . Primary care physicians ( 113 ) participated in a randomized controlled trial to evaluate an online CME series . Physicians were randomized to view either a seminar about type 2 diabetes or a seminar about systolic heart failure . Following the seminar , physicians were presented with 4 clinical vignettes and asked to describe what tests , treatments , counseling , or referrals they would recommend . Physicians who viewed the seminars were significantly more likely to recommend guideline-consistent care to patients in the vignettes . For example , physicians who viewed the diabetes seminar were significantly more likely to order an eye exam for diabetes patients ( 63 % ) compared with physicians in the control group ( 27 % ) . For some guidelines there were no group differences . These results provide early evidence of the effectiveness of online CME programs to improve physician clinical practice .
[ "Evaluating", "online", "continuing", "medical", "education", "seminars", ":", "evidence", "for", "improving", "clinical", "practices", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "potential", "for", "online", "continuing", "medical", "education", "(", "CME", ")", "seminars", "to", "improve", "quality", "of", "care", ".", "Primary", "care", "physicians", "(", "113", ")", "participated", "in", "a", "randomized", "controlled", "trial", "to", "evaluate", "an", "online", "CME", "series", ".", "Physicians", "were", "randomized", "to", "view", "either", "a", "seminar", "about", "type", "2", "diabetes", "or", "a", "seminar", "about", "systolic", "heart", "failure", ".", "Following", "the", "seminar", ",", "physicians", "were", "presented", "with", "4", "clinical", "vignettes", "and", "asked", "to", "describe", "what", "tests", ",", "treatments", ",", "counseling", ",", "or", "referrals", "they", "would", "recommend", ".", "Physicians", "who", "viewed", "the", "seminars", "were", "significantly", "more", "likely", "to", "recommend", "guideline", "-", "consistent", "care", "to", "patients", "in", "the", "vignettes", ".", "For", "example", ",", "physicians", "who", "viewed", "the", "diabetes", "seminar", "were", "significantly", "more", "likely", "to", "order", "an", "eye", "exam", "for", "diabetes", "patients", "(", "63", "%", ")", "compared", "with", "physicians", "in", "the", "control", "group", "(", "27", "%", ")", ".", "For", "some", "guidelines", "there", "were", "no", "group", "differences", ".", "These", "results", "provide", "early", "evidence", "of", "the", "effectiveness", "of", "online", "CME", "programs", "to", "improve", "physician", "clinical", "practice", "." ]
[ "Participant_Sample-size", "Intervention_Educational", "Outcome_Mental", "Outcome_Other", "Participant_Condition" ]
online continuing medical education seminars :, online continuing medical education ( CME ) seminars, improve quality of care ., Primary care physicians ( 113 ) participated in a randomized controlled trial to evaluate an online CME series ., seminar about type 2 diabetes, seminar about systolic heart failure, recommend guideline - consistent care, order an eye exam for diabetes patients, online CME programs, improve physician clinical practice .
37903_task2
Sentence: Evaluating online continuing medical education seminars : evidence for improving clinical practices . The purpose of this study was to evaluate the potential for online continuing medical education ( CME ) seminars to improve quality of care . Primary care physicians ( 113 ) participated in a randomized controlled trial to evaluate an online CME series . Physicians were randomized to view either a seminar about type 2 diabetes or a seminar about systolic heart failure . Following the seminar , physicians were presented with 4 clinical vignettes and asked to describe what tests , treatments , counseling , or referrals they would recommend . Physicians who viewed the seminars were significantly more likely to recommend guideline-consistent care to patients in the vignettes . For example , physicians who viewed the diabetes seminar were significantly more likely to order an eye exam for diabetes patients ( 63 % ) compared with physicians in the control group ( 27 % ) . For some guidelines there were no group differences . These results provide early evidence of the effectiveness of online CME programs to improve physician clinical practice . Instructions: please extract entity words from the input sentence
[ "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other" ]
Evaluating online continuing medical education seminars : evidence for improving clinical practices . The purpose of this study was to evaluate the potential for online continuing medical education ( CME ) seminars to improve quality of care . Primary care physicians ( 113 ) participated in a randomized controlled trial to evaluate an online CME series . Physicians were randomized to view either a seminar about type 2 diabetes or a seminar about systolic heart failure . Following the seminar , physicians were presented with 4 clinical vignettes and asked to describe what tests , treatments , counseling , or referrals they would recommend . Physicians who viewed the seminars were significantly more likely to recommend guideline-consistent care to patients in the vignettes . For example , physicians who viewed the diabetes seminar were significantly more likely to order an eye exam for diabetes patients ( 63 % ) compared with physicians in the control group ( 27 % ) . For some guidelines there were no group differences . These results provide early evidence of the effectiveness of online CME programs to improve physician clinical practice .
[ "Evaluating", "online", "continuing", "medical", "education", "seminars", ":", "evidence", "for", "improving", "clinical", "practices", ".", "The", "purpose", "of", "this", "study", "was", "to", "evaluate", "the", "potential", "for", "online", "continuing", "medical", "education", "(", "CME", ")", "seminars", "to", "improve", "quality", "of", "care", ".", "Primary", "care", "physicians", "(", "113", ")", "participated", "in", "a", "randomized", "controlled", "trial", "to", "evaluate", "an", "online", "CME", "series", ".", "Physicians", "were", "randomized", "to", "view", "either", "a", "seminar", "about", "type", "2", "diabetes", "or", "a", "seminar", "about", "systolic", "heart", "failure", ".", "Following", "the", "seminar", ",", "physicians", "were", "presented", "with", "4", "clinical", "vignettes", "and", "asked", "to", "describe", "what", "tests", ",", "treatments", ",", "counseling", ",", "or", "referrals", "they", "would", "recommend", ".", "Physicians", "who", "viewed", "the", "seminars", "were", "significantly", "more", "likely", "to", "recommend", "guideline", "-", "consistent", "care", "to", "patients", "in", "the", "vignettes", ".", "For", "example", ",", "physicians", "who", "viewed", "the", "diabetes", "seminar", "were", "significantly", "more", "likely", "to", "order", "an", "eye", "exam", "for", "diabetes", "patients", "(", "63", "%", ")", "compared", "with", "physicians", "in", "the", "control", "group", "(", "27", "%", ")", ".", "For", "some", "guidelines", "there", "were", "no", "group", "differences", ".", "These", "results", "provide", "early", "evidence", "of", "the", "effectiveness", "of", "online", "CME", "programs", "to", "improve", "physician", "clinical", "practice", "." ]
[ "Participant_Sample-size", "Intervention_Educational", "Outcome_Mental", "Outcome_Other", "Participant_Condition" ]
PPARs is a protein, glucose is a compound
DS.d1034_task0
Sentence: Despite their inhibitory effects on inflammatory gene expression, loss of PPARs or LXRs in macrophages did not exert major effects on obesity or glucose tolerance induced by a high-fat diet. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Despite their inhibitory effects on inflammatory gene expression, loss of PPARs or LXRs in macrophages did not exert major effects on obesity or glucose tolerance induced by a high-fat diet.
[ "Despite", "their", "inhibitory", "effects", "on", "inflammatory", "gene", "expression", ",", "loss", "of", "PPARs", "or", "LXRs", "in", "macrophages", "did", "not", "exert", "major", "effects", "on", "obesity", "or", "glucose", "tolerance", "induced", "by", "a", "high", "-", "fat", "diet", "." ]
[ "compound", "protein" ]
PPARs is a protein, glucose is a compound
DS.d1034_task1
Sentence: Despite their inhibitory effects on inflammatory gene expression, loss of PPARs or LXRs in macrophages did not exert major effects on obesity or glucose tolerance induced by a high-fat diet. Instructions: please typing these entity words according to sentence: PPARs, glucose Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Despite their inhibitory effects on inflammatory gene expression, loss of PPARs or LXRs in macrophages did not exert major effects on obesity or glucose tolerance induced by a high-fat diet.
[ "Despite", "their", "inhibitory", "effects", "on", "inflammatory", "gene", "expression", ",", "loss", "of", "PPARs", "or", "LXRs", "in", "macrophages", "did", "not", "exert", "major", "effects", "on", "obesity", "or", "glucose", "tolerance", "induced", "by", "a", "high", "-", "fat", "diet", "." ]
[ "compound", "protein" ]
PPARs, glucose
DS.d1034_task2
Sentence: Despite their inhibitory effects on inflammatory gene expression, loss of PPARs or LXRs in macrophages did not exert major effects on obesity or glucose tolerance induced by a high-fat diet. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Despite their inhibitory effects on inflammatory gene expression, loss of PPARs or LXRs in macrophages did not exert major effects on obesity or glucose tolerance induced by a high-fat diet.
[ "Despite", "their", "inhibitory", "effects", "on", "inflammatory", "gene", "expression", ",", "loss", "of", "PPARs", "or", "LXRs", "in", "macrophages", "did", "not", "exert", "major", "effects", "on", "obesity", "or", "glucose", "tolerance", "induced", "by", "a", "high", "-", "fat", "diet", "." ]
[ "compound", "protein" ]
Zeit is an umlsterm, Notfall is an umlsterm, Selbst is an umlsterm, Kurvenlicht is an umlsterm, Infrarottechnik is an umlsterm, Personen is an umlsterm, ACC is an umlsterm, Licht is an umlsterm, Mensch - Maschine - Schnittstelle is an umlsterm, Faehigkeiten is an umlsterm
ZfuerGerontologie+Geriatrie.00330178.ger.abstr_task0
Sentence: Zunaechst werden die Mobilitaetsbeduerfnisse und -erfordernisse Aelterer , sowie ihre Probleme beim Zugang und der Nutzung oeffentlicher Verkehrsmittel dargestellt . Im Bereich des motorisierten Strassenverkehrs existieren fuer Aeltere eine Reihe von Leistungsdefiziten , die sie momentan durch veraendertes Fahrverhalten bzw. durch Einschraenkungen der Mobilitaet kompensieren . Fahrerassistenz-Systeme , die eben auf den Markt kommen oder in absehbarer Zeit verfuegbar sind , werden in ihrer technischen Funktion dargestellt und bezueglich ihrer Auswirkungen auf aeltere Kraftfahrer untersucht . Aufgrund einer Expertenbewertung zaehlen zur Gruppe der besonders wichtigen Systeme : Notrufsysteme Systeme , zur Verbesserung der Sicht und Einparkhilfen . Mit Notrufsystemen koennen Rettungsfahrzeuge im Notfall verstaendigt und direkt zum Einsatzort gelotst werden . Selbst auferlegte Einschraenkungen bezueglich Nachtfahrten Aelterer koennen durch Kurvenlicht und automatische Leuchtweitenregelung teilweise kompensiert werden . Einparkhilfen , die mit Kameras oder Infrarottechnik arbeiten , sind fuer Personen mit Bewegungseinschraenkungen hilfreich . Zur Gruppe der hilfreichen , aber nicht so zentralen Fahrerassistenz-Systeme zaehlen zunaechst solche , die den Fahrer bei der Laengs- und Querfuehrung des Fahrzeugs entlasten . Sie umfassen Automatische Abstandsregelung zu vorausfahrenden Fahrzeugen ( Autonomous Cruise Control - ACC Antiblockiersysteme ( ) , ABS ) und elektronische Stabilitaetshilfen ( ESP ) . Die Auswirkungen der Unterstuetzungssysteme zur Fahrdynamik werden im Licht der Risikohomoeosthase-Theorie beleuchtet . Entlastung und Mobilitaetserleichterung fuer Aeltere versprechen schliesslich Navigations-Systeme , falls sie nutzergerecht gestaltet sind . Der Artikel erlaeutert die besondere Bedeutung der Gestaltung der Mensch-Maschine-Schnittstelle unter Beruecksichtigung der Faehigkeiten und Beduerfnisse aelterer Kraftfahrer . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Zunaechst werden die Mobilitaetsbeduerfnisse und -erfordernisse Aelterer , sowie ihre Probleme beim Zugang und der Nutzung oeffentlicher Verkehrsmittel dargestellt . Im Bereich des motorisierten Strassenverkehrs existieren fuer Aeltere eine Reihe von Leistungsdefiziten , die sie momentan durch veraendertes Fahrverhalten bzw. durch Einschraenkungen der Mobilitaet kompensieren . Fahrerassistenz-Systeme , die eben auf den Markt kommen oder in absehbarer Zeit verfuegbar sind , werden in ihrer technischen Funktion dargestellt und bezueglich ihrer Auswirkungen auf aeltere Kraftfahrer untersucht . Aufgrund einer Expertenbewertung zaehlen zur Gruppe der besonders wichtigen Systeme : Notrufsysteme Systeme , zur Verbesserung der Sicht und Einparkhilfen . Mit Notrufsystemen koennen Rettungsfahrzeuge im Notfall verstaendigt und direkt zum Einsatzort gelotst werden . Selbst auferlegte Einschraenkungen bezueglich Nachtfahrten Aelterer koennen durch Kurvenlicht und automatische Leuchtweitenregelung teilweise kompensiert werden . Einparkhilfen , die mit Kameras oder Infrarottechnik arbeiten , sind fuer Personen mit Bewegungseinschraenkungen hilfreich . Zur Gruppe der hilfreichen , aber nicht so zentralen Fahrerassistenz-Systeme zaehlen zunaechst solche , die den Fahrer bei der Laengs- und Querfuehrung des Fahrzeugs entlasten . Sie umfassen Automatische Abstandsregelung zu vorausfahrenden Fahrzeugen ( Autonomous Cruise Control - ACC Antiblockiersysteme ( ) , ABS ) und elektronische Stabilitaetshilfen ( ESP ) . Die Auswirkungen der Unterstuetzungssysteme zur Fahrdynamik werden im Licht der Risikohomoeosthase-Theorie beleuchtet . Entlastung und Mobilitaetserleichterung fuer Aeltere versprechen schliesslich Navigations-Systeme , falls sie nutzergerecht gestaltet sind . Der Artikel erlaeutert die besondere Bedeutung der Gestaltung der Mensch-Maschine-Schnittstelle unter Beruecksichtigung der Faehigkeiten und Beduerfnisse aelterer Kraftfahrer .
[ "Zunaechst", "werden", "die", "Mobilitaetsbeduerfnisse", "und", "-erfordernisse", "Aelterer", ",", "sowie", "ihre", "Probleme", "beim", "Zugang", "und", "der", "Nutzung", "oeffentlicher", "Verkehrsmittel", "dargestellt", ".", "Im", "Bereich", "des", "motorisierten", "Strassenverkehrs", "existieren", "fuer", "Aeltere", "eine", "Reihe", "von", "Leistungsdefiziten", ",", "die", "sie", "momentan", "durch", "veraendertes", "Fahrverhalten", "bzw", ".", "durch", "Einschraenkungen", "der", "Mobilitaet", "kompensieren", ".", "Fahrerassistenz", "-", "Systeme", ",", "die", "eben", "auf", "den", "Markt", "kommen", "oder", "in", "absehbarer", "Zeit", "verfuegbar", "sind", ",", "werden", "in", "ihrer", "technischen", "Funktion", "dargestellt", "und", "bezueglich", "ihrer", "Auswirkungen", "auf", "aeltere", "Kraftfahrer", "untersucht", ".", "Aufgrund", "einer", "Expertenbewertung", "zaehlen", "zur", "Gruppe", "der", "besonders", "wichtigen", "Systeme", ":", "Notrufsysteme", "Systeme", ",", "zur", "Verbesserung", "der", "Sicht", "und", "Einparkhilfen", ".", "Mit", "Notrufsystemen", "koennen", "Rettungsfahrzeuge", "im", "Notfall", "verstaendigt", "und", "direkt", "zum", "Einsatzort", "gelotst", "werden", ".", "Selbst", "auferlegte", "Einschraenkungen", "bezueglich", "Nachtfahrten", "Aelterer", "koennen", "durch", "Kurvenlicht", "und", "automatische", "Leuchtweitenregelung", "teilweise", "kompensiert", "werden", ".", "Einparkhilfen", ",", "die", "mit", "Kameras", "oder", "Infrarottechnik", "arbeiten", ",", "sind", "fuer", "Personen", "mit", "Bewegungseinschraenkungen", "hilfreich", ".", "Zur", "Gruppe", "der", "hilfreichen", ",", "aber", "nicht", "so", "zentralen", "Fahrerassistenz", "-", "Systeme", "zaehlen", "zunaechst", "solche", ",", "die", "den", "Fahrer", "bei", "der", "Laengs-", "und", "Querfuehrung", "des", "Fahrzeugs", "entlasten", ".", "Sie", "umfassen", "Automatische", "Abstandsregelung", "zu", "vorausfahrenden", "Fahrzeugen", "(", "Autonomous", "Cruise", "Control", "-", "ACC", "Antiblockiersysteme", "(", ")", ",", "ABS", ")", "und", "elektronische", "Stabilitaetshilfen", "(", "ESP", ")", ".", "Die", "Auswirkungen", "der", "Unterstuetzungssysteme", "zur", "Fahrdynamik", "werden", "im", "Licht", "der", "Risikohomoeosthase", "-", "Theorie", "beleuchtet", ".", "Entlastung", "und", "Mobilitaetserleichterung", "fuer", "Aeltere", "versprechen", "schliesslich", "Navigations", "-", "Systeme", ",", "falls", "sie", "nutzergerecht", "gestaltet", "sind", ".", "Der", "Artikel", "erlaeutert", "die", "besondere", "Bedeutung", "der", "Gestaltung", "der", "Mensch", "-", "Maschine", "-", "Schnittstelle", "unter", "Beruecksichtigung", "der", "Faehigkeiten", "und", "Beduerfnisse", "aelterer", "Kraftfahrer", "." ]
[ "umlsterm" ]
Zeit is an umlsterm, Notfall is an umlsterm, Selbst is an umlsterm, Kurvenlicht is an umlsterm, Infrarottechnik is an umlsterm, Personen is an umlsterm, ACC is an umlsterm, Licht is an umlsterm, Mensch - Maschine - Schnittstelle is an umlsterm, Faehigkeiten is an umlsterm
ZfuerGerontologie+Geriatrie.00330178.ger.abstr_task1
Sentence: Zunaechst werden die Mobilitaetsbeduerfnisse und -erfordernisse Aelterer , sowie ihre Probleme beim Zugang und der Nutzung oeffentlicher Verkehrsmittel dargestellt . Im Bereich des motorisierten Strassenverkehrs existieren fuer Aeltere eine Reihe von Leistungsdefiziten , die sie momentan durch veraendertes Fahrverhalten bzw. durch Einschraenkungen der Mobilitaet kompensieren . Fahrerassistenz-Systeme , die eben auf den Markt kommen oder in absehbarer Zeit verfuegbar sind , werden in ihrer technischen Funktion dargestellt und bezueglich ihrer Auswirkungen auf aeltere Kraftfahrer untersucht . Aufgrund einer Expertenbewertung zaehlen zur Gruppe der besonders wichtigen Systeme : Notrufsysteme Systeme , zur Verbesserung der Sicht und Einparkhilfen . Mit Notrufsystemen koennen Rettungsfahrzeuge im Notfall verstaendigt und direkt zum Einsatzort gelotst werden . Selbst auferlegte Einschraenkungen bezueglich Nachtfahrten Aelterer koennen durch Kurvenlicht und automatische Leuchtweitenregelung teilweise kompensiert werden . Einparkhilfen , die mit Kameras oder Infrarottechnik arbeiten , sind fuer Personen mit Bewegungseinschraenkungen hilfreich . Zur Gruppe der hilfreichen , aber nicht so zentralen Fahrerassistenz-Systeme zaehlen zunaechst solche , die den Fahrer bei der Laengs- und Querfuehrung des Fahrzeugs entlasten . Sie umfassen Automatische Abstandsregelung zu vorausfahrenden Fahrzeugen ( Autonomous Cruise Control - ACC Antiblockiersysteme ( ) , ABS ) und elektronische Stabilitaetshilfen ( ESP ) . Die Auswirkungen der Unterstuetzungssysteme zur Fahrdynamik werden im Licht der Risikohomoeosthase-Theorie beleuchtet . Entlastung und Mobilitaetserleichterung fuer Aeltere versprechen schliesslich Navigations-Systeme , falls sie nutzergerecht gestaltet sind . Der Artikel erlaeutert die besondere Bedeutung der Gestaltung der Mensch-Maschine-Schnittstelle unter Beruecksichtigung der Faehigkeiten und Beduerfnisse aelterer Kraftfahrer . Instructions: please typing these entity words according to sentence: Zeit, Notfall, Selbst, Kurvenlicht, Infrarottechnik, Personen, ACC, Licht, Mensch - Maschine - Schnittstelle, Faehigkeiten Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Zunaechst werden die Mobilitaetsbeduerfnisse und -erfordernisse Aelterer , sowie ihre Probleme beim Zugang und der Nutzung oeffentlicher Verkehrsmittel dargestellt . Im Bereich des motorisierten Strassenverkehrs existieren fuer Aeltere eine Reihe von Leistungsdefiziten , die sie momentan durch veraendertes Fahrverhalten bzw. durch Einschraenkungen der Mobilitaet kompensieren . Fahrerassistenz-Systeme , die eben auf den Markt kommen oder in absehbarer Zeit verfuegbar sind , werden in ihrer technischen Funktion dargestellt und bezueglich ihrer Auswirkungen auf aeltere Kraftfahrer untersucht . Aufgrund einer Expertenbewertung zaehlen zur Gruppe der besonders wichtigen Systeme : Notrufsysteme Systeme , zur Verbesserung der Sicht und Einparkhilfen . Mit Notrufsystemen koennen Rettungsfahrzeuge im Notfall verstaendigt und direkt zum Einsatzort gelotst werden . Selbst auferlegte Einschraenkungen bezueglich Nachtfahrten Aelterer koennen durch Kurvenlicht und automatische Leuchtweitenregelung teilweise kompensiert werden . Einparkhilfen , die mit Kameras oder Infrarottechnik arbeiten , sind fuer Personen mit Bewegungseinschraenkungen hilfreich . Zur Gruppe der hilfreichen , aber nicht so zentralen Fahrerassistenz-Systeme zaehlen zunaechst solche , die den Fahrer bei der Laengs- und Querfuehrung des Fahrzeugs entlasten . Sie umfassen Automatische Abstandsregelung zu vorausfahrenden Fahrzeugen ( Autonomous Cruise Control - ACC Antiblockiersysteme ( ) , ABS ) und elektronische Stabilitaetshilfen ( ESP ) . Die Auswirkungen der Unterstuetzungssysteme zur Fahrdynamik werden im Licht der Risikohomoeosthase-Theorie beleuchtet . Entlastung und Mobilitaetserleichterung fuer Aeltere versprechen schliesslich Navigations-Systeme , falls sie nutzergerecht gestaltet sind . Der Artikel erlaeutert die besondere Bedeutung der Gestaltung der Mensch-Maschine-Schnittstelle unter Beruecksichtigung der Faehigkeiten und Beduerfnisse aelterer Kraftfahrer .
[ "Zunaechst", "werden", "die", "Mobilitaetsbeduerfnisse", "und", "-erfordernisse", "Aelterer", ",", "sowie", "ihre", "Probleme", "beim", "Zugang", "und", "der", "Nutzung", "oeffentlicher", "Verkehrsmittel", "dargestellt", ".", "Im", "Bereich", "des", "motorisierten", "Strassenverkehrs", "existieren", "fuer", "Aeltere", "eine", "Reihe", "von", "Leistungsdefiziten", ",", "die", "sie", "momentan", "durch", "veraendertes", "Fahrverhalten", "bzw", ".", "durch", "Einschraenkungen", "der", "Mobilitaet", "kompensieren", ".", "Fahrerassistenz", "-", "Systeme", ",", "die", "eben", "auf", "den", "Markt", "kommen", "oder", "in", "absehbarer", "Zeit", "verfuegbar", "sind", ",", "werden", "in", "ihrer", "technischen", "Funktion", "dargestellt", "und", "bezueglich", "ihrer", "Auswirkungen", "auf", "aeltere", "Kraftfahrer", "untersucht", ".", "Aufgrund", "einer", "Expertenbewertung", "zaehlen", "zur", "Gruppe", "der", "besonders", "wichtigen", "Systeme", ":", "Notrufsysteme", "Systeme", ",", "zur", "Verbesserung", "der", "Sicht", "und", "Einparkhilfen", ".", "Mit", "Notrufsystemen", "koennen", "Rettungsfahrzeuge", "im", "Notfall", "verstaendigt", "und", "direkt", "zum", "Einsatzort", "gelotst", "werden", ".", "Selbst", "auferlegte", "Einschraenkungen", "bezueglich", "Nachtfahrten", "Aelterer", "koennen", "durch", "Kurvenlicht", "und", "automatische", "Leuchtweitenregelung", "teilweise", "kompensiert", "werden", ".", "Einparkhilfen", ",", "die", "mit", "Kameras", "oder", "Infrarottechnik", "arbeiten", ",", "sind", "fuer", "Personen", "mit", "Bewegungseinschraenkungen", "hilfreich", ".", "Zur", "Gruppe", "der", "hilfreichen", ",", "aber", "nicht", "so", "zentralen", "Fahrerassistenz", "-", "Systeme", "zaehlen", "zunaechst", "solche", ",", "die", "den", "Fahrer", "bei", "der", "Laengs-", "und", "Querfuehrung", "des", "Fahrzeugs", "entlasten", ".", "Sie", "umfassen", "Automatische", "Abstandsregelung", "zu", "vorausfahrenden", "Fahrzeugen", "(", "Autonomous", "Cruise", "Control", "-", "ACC", "Antiblockiersysteme", "(", ")", ",", "ABS", ")", "und", "elektronische", "Stabilitaetshilfen", "(", "ESP", ")", ".", "Die", "Auswirkungen", "der", "Unterstuetzungssysteme", "zur", "Fahrdynamik", "werden", "im", "Licht", "der", "Risikohomoeosthase", "-", "Theorie", "beleuchtet", ".", "Entlastung", "und", "Mobilitaetserleichterung", "fuer", "Aeltere", "versprechen", "schliesslich", "Navigations", "-", "Systeme", ",", "falls", "sie", "nutzergerecht", "gestaltet", "sind", ".", "Der", "Artikel", "erlaeutert", "die", "besondere", "Bedeutung", "der", "Gestaltung", "der", "Mensch", "-", "Maschine", "-", "Schnittstelle", "unter", "Beruecksichtigung", "der", "Faehigkeiten", "und", "Beduerfnisse", "aelterer", "Kraftfahrer", "." ]
[ "umlsterm" ]
Zeit, Notfall, Selbst, Kurvenlicht, Infrarottechnik, Personen, ACC, Licht, Mensch - Maschine - Schnittstelle, Faehigkeiten
ZfuerGerontologie+Geriatrie.00330178.ger.abstr_task2
Sentence: Zunaechst werden die Mobilitaetsbeduerfnisse und -erfordernisse Aelterer , sowie ihre Probleme beim Zugang und der Nutzung oeffentlicher Verkehrsmittel dargestellt . Im Bereich des motorisierten Strassenverkehrs existieren fuer Aeltere eine Reihe von Leistungsdefiziten , die sie momentan durch veraendertes Fahrverhalten bzw. durch Einschraenkungen der Mobilitaet kompensieren . Fahrerassistenz-Systeme , die eben auf den Markt kommen oder in absehbarer Zeit verfuegbar sind , werden in ihrer technischen Funktion dargestellt und bezueglich ihrer Auswirkungen auf aeltere Kraftfahrer untersucht . Aufgrund einer Expertenbewertung zaehlen zur Gruppe der besonders wichtigen Systeme : Notrufsysteme Systeme , zur Verbesserung der Sicht und Einparkhilfen . Mit Notrufsystemen koennen Rettungsfahrzeuge im Notfall verstaendigt und direkt zum Einsatzort gelotst werden . Selbst auferlegte Einschraenkungen bezueglich Nachtfahrten Aelterer koennen durch Kurvenlicht und automatische Leuchtweitenregelung teilweise kompensiert werden . Einparkhilfen , die mit Kameras oder Infrarottechnik arbeiten , sind fuer Personen mit Bewegungseinschraenkungen hilfreich . Zur Gruppe der hilfreichen , aber nicht so zentralen Fahrerassistenz-Systeme zaehlen zunaechst solche , die den Fahrer bei der Laengs- und Querfuehrung des Fahrzeugs entlasten . Sie umfassen Automatische Abstandsregelung zu vorausfahrenden Fahrzeugen ( Autonomous Cruise Control - ACC Antiblockiersysteme ( ) , ABS ) und elektronische Stabilitaetshilfen ( ESP ) . Die Auswirkungen der Unterstuetzungssysteme zur Fahrdynamik werden im Licht der Risikohomoeosthase-Theorie beleuchtet . Entlastung und Mobilitaetserleichterung fuer Aeltere versprechen schliesslich Navigations-Systeme , falls sie nutzergerecht gestaltet sind . Der Artikel erlaeutert die besondere Bedeutung der Gestaltung der Mensch-Maschine-Schnittstelle unter Beruecksichtigung der Faehigkeiten und Beduerfnisse aelterer Kraftfahrer . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Zunaechst werden die Mobilitaetsbeduerfnisse und -erfordernisse Aelterer , sowie ihre Probleme beim Zugang und der Nutzung oeffentlicher Verkehrsmittel dargestellt . Im Bereich des motorisierten Strassenverkehrs existieren fuer Aeltere eine Reihe von Leistungsdefiziten , die sie momentan durch veraendertes Fahrverhalten bzw. durch Einschraenkungen der Mobilitaet kompensieren . Fahrerassistenz-Systeme , die eben auf den Markt kommen oder in absehbarer Zeit verfuegbar sind , werden in ihrer technischen Funktion dargestellt und bezueglich ihrer Auswirkungen auf aeltere Kraftfahrer untersucht . Aufgrund einer Expertenbewertung zaehlen zur Gruppe der besonders wichtigen Systeme : Notrufsysteme Systeme , zur Verbesserung der Sicht und Einparkhilfen . Mit Notrufsystemen koennen Rettungsfahrzeuge im Notfall verstaendigt und direkt zum Einsatzort gelotst werden . Selbst auferlegte Einschraenkungen bezueglich Nachtfahrten Aelterer koennen durch Kurvenlicht und automatische Leuchtweitenregelung teilweise kompensiert werden . Einparkhilfen , die mit Kameras oder Infrarottechnik arbeiten , sind fuer Personen mit Bewegungseinschraenkungen hilfreich . Zur Gruppe der hilfreichen , aber nicht so zentralen Fahrerassistenz-Systeme zaehlen zunaechst solche , die den Fahrer bei der Laengs- und Querfuehrung des Fahrzeugs entlasten . Sie umfassen Automatische Abstandsregelung zu vorausfahrenden Fahrzeugen ( Autonomous Cruise Control - ACC Antiblockiersysteme ( ) , ABS ) und elektronische Stabilitaetshilfen ( ESP ) . Die Auswirkungen der Unterstuetzungssysteme zur Fahrdynamik werden im Licht der Risikohomoeosthase-Theorie beleuchtet . Entlastung und Mobilitaetserleichterung fuer Aeltere versprechen schliesslich Navigations-Systeme , falls sie nutzergerecht gestaltet sind . Der Artikel erlaeutert die besondere Bedeutung der Gestaltung der Mensch-Maschine-Schnittstelle unter Beruecksichtigung der Faehigkeiten und Beduerfnisse aelterer Kraftfahrer .
[ "Zunaechst", "werden", "die", "Mobilitaetsbeduerfnisse", "und", "-erfordernisse", "Aelterer", ",", "sowie", "ihre", "Probleme", "beim", "Zugang", "und", "der", "Nutzung", "oeffentlicher", "Verkehrsmittel", "dargestellt", ".", "Im", "Bereich", "des", "motorisierten", "Strassenverkehrs", "existieren", "fuer", "Aeltere", "eine", "Reihe", "von", "Leistungsdefiziten", ",", "die", "sie", "momentan", "durch", "veraendertes", "Fahrverhalten", "bzw", ".", "durch", "Einschraenkungen", "der", "Mobilitaet", "kompensieren", ".", "Fahrerassistenz", "-", "Systeme", ",", "die", "eben", "auf", "den", "Markt", "kommen", "oder", "in", "absehbarer", "Zeit", "verfuegbar", "sind", ",", "werden", "in", "ihrer", "technischen", "Funktion", "dargestellt", "und", "bezueglich", "ihrer", "Auswirkungen", "auf", "aeltere", "Kraftfahrer", "untersucht", ".", "Aufgrund", "einer", "Expertenbewertung", "zaehlen", "zur", "Gruppe", "der", "besonders", "wichtigen", "Systeme", ":", "Notrufsysteme", "Systeme", ",", "zur", "Verbesserung", "der", "Sicht", "und", "Einparkhilfen", ".", "Mit", "Notrufsystemen", "koennen", "Rettungsfahrzeuge", "im", "Notfall", "verstaendigt", "und", "direkt", "zum", "Einsatzort", "gelotst", "werden", ".", "Selbst", "auferlegte", "Einschraenkungen", "bezueglich", "Nachtfahrten", "Aelterer", "koennen", "durch", "Kurvenlicht", "und", "automatische", "Leuchtweitenregelung", "teilweise", "kompensiert", "werden", ".", "Einparkhilfen", ",", "die", "mit", "Kameras", "oder", "Infrarottechnik", "arbeiten", ",", "sind", "fuer", "Personen", "mit", "Bewegungseinschraenkungen", "hilfreich", ".", "Zur", "Gruppe", "der", "hilfreichen", ",", "aber", "nicht", "so", "zentralen", "Fahrerassistenz", "-", "Systeme", "zaehlen", "zunaechst", "solche", ",", "die", "den", "Fahrer", "bei", "der", "Laengs-", "und", "Querfuehrung", "des", "Fahrzeugs", "entlasten", ".", "Sie", "umfassen", "Automatische", "Abstandsregelung", "zu", "vorausfahrenden", "Fahrzeugen", "(", "Autonomous", "Cruise", "Control", "-", "ACC", "Antiblockiersysteme", "(", ")", ",", "ABS", ")", "und", "elektronische", "Stabilitaetshilfen", "(", "ESP", ")", ".", "Die", "Auswirkungen", "der", "Unterstuetzungssysteme", "zur", "Fahrdynamik", "werden", "im", "Licht", "der", "Risikohomoeosthase", "-", "Theorie", "beleuchtet", ".", "Entlastung", "und", "Mobilitaetserleichterung", "fuer", "Aeltere", "versprechen", "schliesslich", "Navigations", "-", "Systeme", ",", "falls", "sie", "nutzergerecht", "gestaltet", "sind", ".", "Der", "Artikel", "erlaeutert", "die", "besondere", "Bedeutung", "der", "Gestaltung", "der", "Mensch", "-", "Maschine", "-", "Schnittstelle", "unter", "Beruecksichtigung", "der", "Faehigkeiten", "und", "Beduerfnisse", "aelterer", "Kraftfahrer", "." ]
[ "umlsterm" ]
nuclear factor of activated T cells is a protein_molecule
81172_task0
Sentence: Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_molecule
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells.
[ "Analysis", "of", "the", "preexisting", "and", "nuclear", "forms", "of", "nuclear", "factor", "of", "activated", "T", "cells", "." ]
[ "protein_subunit", "protein_molecule", "other_organic_compound", "polynucleotide", "protein_complex", "DNA_domain_or_region", "protein_family_or_group", "cell_component", "cell_type", "other_name", "DNA_N/A" ]
nuclear factor of activated T cells is a protein_molecule
81172_task1
Sentence: Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. Instructions: please typing these entity words according to sentence: nuclear factor of activated T cells Options: protein_molecule
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells.
[ "Analysis", "of", "the", "preexisting", "and", "nuclear", "forms", "of", "nuclear", "factor", "of", "activated", "T", "cells", "." ]
[ "protein_subunit", "protein_molecule", "other_organic_compound", "polynucleotide", "protein_complex", "DNA_domain_or_region", "protein_family_or_group", "cell_component", "cell_type", "other_name", "DNA_N/A" ]
nuclear factor of activated T cells
81172_task2
Sentence: Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells.
[ "Analysis", "of", "the", "preexisting", "and", "nuclear", "forms", "of", "nuclear", "factor", "of", "activated", "T", "cells", "." ]
[ "protein_subunit", "protein_molecule", "other_organic_compound", "polynucleotide", "protein_complex", "DNA_domain_or_region", "protein_family_or_group", "cell_component", "cell_type", "other_name", "DNA_N/A" ]
PRP9 is a Individual_protein, PRP11 is a Individual_protein
146_task0
Sentence: Biochemical complementation experiments also indicate that the PRP9 and PRP11 proteins interact. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein
[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O" ]
Biochemical complementation experiments also indicate that the PRP9 and PRP11 proteins interact.
[ "Biochemical", "complementation", "experiments", "also", "indicate", "that", "the", "PRP9", "and", "PRP11", "proteins", "interact", "." ]
[ "Individual_protein" ]
PRP9 is a Individual_protein, PRP11 is a Individual_protein
146_task1
Sentence: Biochemical complementation experiments also indicate that the PRP9 and PRP11 proteins interact. Instructions: please typing these entity words according to sentence: PRP9, PRP11 Options: Individual_protein
[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O" ]
Biochemical complementation experiments also indicate that the PRP9 and PRP11 proteins interact.
[ "Biochemical", "complementation", "experiments", "also", "indicate", "that", "the", "PRP9", "and", "PRP11", "proteins", "interact", "." ]
[ "Individual_protein" ]
PRP9, PRP11
146_task2
Sentence: Biochemical complementation experiments also indicate that the PRP9 and PRP11 proteins interact. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O" ]
Biochemical complementation experiments also indicate that the PRP9 and PRP11 proteins interact.
[ "Biochemical", "complementation", "experiments", "also", "indicate", "that", "the", "PRP9", "and", "PRP11", "proteins", "interact", "." ]
[ "Individual_protein" ]
IKK1 is a protein_molecule, IKK2 is a protein_molecule, lipopolysaccharide signaling is an other_name, human monocytic cells is a cell_type
77211_task0
Sentence: Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, other_name, protein_molecule
[ "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]
Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells.
[ "Role", "of", "IKK1", "and", "IKK2", "in", "lipopolysaccharide", "signaling", "in", "human", "monocytic", "cells", "." ]
[ "other_name", "protein_family_or_group", "(AND other_name other_name)", "protein_molecule", "lipid", "cell_type", "cell_line", "", "protein_complex" ]
IKK1 is a protein_molecule, IKK2 is a protein_molecule, lipopolysaccharide signaling is an other_name, human monocytic cells is a cell_type
77211_task1
Sentence: Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. Instructions: please typing these entity words according to sentence: IKK1, IKK2, lipopolysaccharide signaling, human monocytic cells Options: cell_type, other_name, protein_molecule
[ "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]
Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells.
[ "Role", "of", "IKK1", "and", "IKK2", "in", "lipopolysaccharide", "signaling", "in", "human", "monocytic", "cells", "." ]
[ "other_name", "protein_family_or_group", "(AND other_name other_name)", "protein_molecule", "lipid", "cell_type", "cell_line", "", "protein_complex" ]
IKK1, IKK2, lipopolysaccharide signaling, human monocytic cells
77211_task2
Sentence: Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-protein_molecule", "O", "B-protein_molecule", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]
Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells.
[ "Role", "of", "IKK1", "and", "IKK2", "in", "lipopolysaccharide", "signaling", "in", "human", "monocytic", "cells", "." ]
[ "other_name", "protein_family_or_group", "(AND other_name other_name)", "protein_molecule", "lipid", "cell_type", "cell_line", "", "protein_complex" ]